Document:

EX 10.1

 Exhibit 10.1 
 Execution Version 
     Confidential 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 
 DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY
AGREEMENT 
 between 
 ASTRAZENECA UK LIMITED 
 and 

Impax LABORATORIES, INC. 
 Dated as of January 31, 2012 

 TABLE OF CONTENTS 

 

				September 30,	
	 Article 1 Definitions
	    	 	2	  
		
	 Article 2 Governance
	    	 	24	  
		
	 2.1 Joint Steering Committee
	    	 	24	  
	 2.2 Joint Operating Committee
	    	 	25	  
	 2.3. General Provisions Applicable to Joint Committees
	    	 	26	  
	 2.4. Discontinuation of Participation on a Joint Committee
	    	 	27	  
	 2.5. Alliance Managers
	    	 	28	  
		
	 Article 3 Commercialization
	    	 	28	  
		
	 3.1. Impax Obligations
	    	 	28	  
	 3.2. Transition Plan
	    	 	28	  
	 3.3. Commercialization Plan
	    	 	29	  
	 3.4. Commercialization Reporting
	    	 	29	  
	 3.5. Diligence
	    	 	30	  
	 3.6. No Implied Obligations
	    	 	30	  
	 3.7. Compliance
	    	 	30	  
	 3.8. Compliance Books and Records
	    	 	35	  
	 3.9. No Parallel Imports
	    	 	36	  
	 3.10. Distribution Matters
	    	 	36	  
	 3.11. Managed Market Segments and Other Government Program Responsibilities
	    	 	37	  
	 3.12. NDC Number
	    	 	37	  
	 3.13. Sales Force and Training
	    	 	37	  
	 3.14. Samples of Licensed Products
	    	 	39	  
	 3.15. Marketing Materials
	    	 	40	  
	 3.16. Product Trademarks
	    	 	42	  
	 3.17. Product Online Assets
	    	 	43	  
	 3.18. AstraZeneca Patient Assistance Program
	    	 	44	  
	 3.19. Commercialization Subcontracting
	    	 	44	  
		
	 Article 4 Development Activities
	    	 	44	  
		
	 4.1. Licensed Product Studies
	    	 	44	  
	 4.2. Development Costs
	    	 	46	  
	 4.3. Records
	    	 	46	  
	 4.4. Disclosure of AstraZeneca Regulatory Documentation
	    	 	47	  
	 4.5. New AstraZeneca Studies
	    	 	47	  
		
	 Article 5 Regulatory Matters
	    	 	48	  
		
	 5.1. Ownership of Regulatory Documentation
	    	 	48	  
	 5.2. Regulatory Responsibilities
	    	 	48	  
	 5.3. Violation of Law
	    	 	51	  

  
 i 

				September 30,	
	 5.4. Pharmacovigilance
	    	 	51	  
	 5.5. Medical Affairs Activities
	    	 	51	  
		
	 Article 6 Grant of Rights
	    	 	51	  
		
	 6.1. Grants to Impax
	    	 	51	  
	 6.2. Grants to AstraZeneca
	    	 	54	  
	 6.3. Impax Sublicenses
	    	 	55	  
	 6.4. [***] Compliance
	    	 	55	  
	 6.5. Authorized Generics
	    	 	56	  
	 6.6. Reservation of Rights
	    	 	57	  
	 6.7. Non-Compete Covenants
	    	 	58	  
	 6.8. [***]
	    	 	58	  
	 6.9. [***]
	    	 	58	  
	 6.10. [***] Products
	    	 	58	  
	 6.11. Certain Licenses to Impax Study Data and Impax Regulatory Documentation
	    	 	59	  
		
	 Article 7 Payments and Records
	    	 	59	  
		
	 7.1. Lump Sum Payments
	    	 	59	  
	 7.2. Royalties
	    	 	59	  
	 7.3. Payments and Reports
	    	 	62	  
	 7.4. Mode of Payment
	    	 	62	  
	 7.5. Taxes
	    	 	62	  
	 7.6. Interest on Late Payments
	    	 	63	  
	 7.7. Financial Records
	    	 	63	  
	 7.8. Payment Audit
	    	 	63	  
	 7.9. No Setoff; Offset
	    	 	64	  
		
	 Article 8 Supply
	    	 	64	  
		
	 8.1. Supply Obligations
	    	 	64	  
	 8.2. Supply Term
	    	 	65	  
	 8.3. Supplied Products Packaging
	    	 	65	  
	 8.4. Additional Product Supply
	    	 	66	  
	 8.5. Impax Generic Version
	    	 	66	  
	 8.6. Forecasts and Orders
	    	 	66	  
	 8.7. Purchase Orders
	    	 	67	  
	 8.8. Conformity to Planning Forecasts
	    	 	68	  
	 8.9. Limit on Obligation to Supply
	    	 	68	  
	 8.10. Shortfall
	    	 	68	  
	 8.11. Monthly Deliveries by AstraZeneca
	    	 	69	  
	 8.12. Expiration Dating
	    	 	69	  
	 8.13. Delivery Terms; Title Passage
	    	 	69	  
	 8.14. Suspension of Shipment; Payments in Event of Default
	    	 	69	  
	 8.15. Supply Price
	    	 	69	  

  
 ii 

				September 30,	
	 8.16. Change to Specifications
	    	 	72	  
	 8.17. Failure or Inability to Supply
	    	 	72	  
	 8.18. Right of Impax to Visit Premises
	    	 	73	  
	 8.19. Manufacturing Technology Transfer and Manufacturing License
	    	 	74	  
	 8.20. Supplied Product Storage and Distribution
	    	 	75	  
	 8.21. Quality Assurance Agreement
	    	 	76	  
	 8.22. Number of Facilities and Suppliers
	    	 	76	  
	 8.23. Third Party Contract Manufacturers
	    	 	76	  
	 8.24. Product Representations and Warranties
	    	 	77	  
		
	 Article 9 Recalls
	    	 	78	  
		
	 9.1. Notification and Recall
	    	 	78	  
	 9.2. Recall Expenses
	    	 	78	  
	 9.3. Commercialization Records
	    	 	78	  
		
	 Article 10 Intellectual Property
	    	 	79	  
		
	 10.1. Ownership of Intellectual Property
	    	 	79	  
	 10.2. Maintenance and Prosecution of Patents
	    	 	79	  
	 10.3. Enforcement of Patents
	    	 	80	  
	 10.4. Infringement Claims by Third Parties
	    	 	81	  
	 10.5. Invalidity or Unenforceability Defenses or Actions
	    	 	82	  
	 10.6. Third Party Licenses
	    	 	83	  
	 10.7. Product Trademarks
	    	 	84	  
		
	 Article 11 Confidentiality, Non-Disclosure, Securities Matters
	    	 	85	  
		
	 11.1. Confidentiality Obligations
	    	 	85	  
	 11.2. Permitted Disclosures
	    	 	86	  
	 11.3. Third Party Confidentiality Obligations
	    	 	87	  
	 11.4. Use of Name
	    	 	87	  
	 11.5. Public Announcements
	    	 	87	  
	 11.6. Publications
	    	 	88	  
	 11.7. Return of Confidential Information
	    	 	89	  
	 11.8. Disclosure Required by Applicable Law
	    	 	89	  
	 11.9. Securities Laws
	    	 	89	  
		
	 Article 12 Representations and Warranties
	    	 	90	  
		
	 12.1. Mutual Representations and Warranties
	    	 	90	  
	 12.2. Additional Representations and Warranties of AstraZeneca
	    	 	90	  
	 12.3. Additional Representations and Warranties of Impax
	    	 	93	  
	 12.4. DISCLAIMER OF WARRANTIES
	    	 	94	  
		
	 Article 13 Indemnity
	    	 	95	  
		
	 13.1. Indemnification of AstraZeneca
	    	 	95	  

  
 iii

				September 30,	
	 13.2. Indemnification of Impax
	    	 	96	  
	 13.3. Notice of Claim
	    	 	97	  
	 13.4. Control of Defense
	    	 	97	  
	 13.5. LIMITATIONS OF LIABILITY
	    	 	99	  
	 13.6. Insurance
	    	 	101	  
		
	 Article 14 Term, Termination and Other Remedies
	    	 	102	  
		
	 14.1. Term
	    	 	102	  
	 14.2. Mutual Termination Rights
	    	 	102	  
	 14.3. Additional Termination by Impax
	    	 	102	  
	 14.4. Additional Termination by AstraZeneca
	    	 	103	  
	 14.5. Termination for Insolvency
	    	 	103	  
	 14.6. Rights in Bankruptcy
	    	 	103	  
	 14.7. Effect of Termination
	    	 	103	  
	 14.8. Remedies
	    	 	109	  
	 14.9. Accrued Rights; Surviving Obligations
	    	 	109	  
		
	 Article 15 Miscellaneous
	    	 	110	  
		
	 15.1. Force Majeure
	    	 	110	  
	 15.2. Export Control
	    	 	110	  
	 15.3. Assignment
	    	 	110	  
	 15.4. Severability
	    	 	111	  
	 15.5. Governing Law, Jurisdiction and Service
	    	 	111	  
	 15.6. Notices
	    	 	112	  
	 15.7. Entire Agreement
	    	 	113	  
	 15.8. English Language
	    	 	113	  
	 15.9. Expenses
	    	 	113	  
	 15.10. Equitable Relief
	    	 	114	  
	 15.11. Waiver and Non-Exclusion of Remedies
	    	 	114	  
	 15.12. No Benefit to Third Parties
	    	 	114	  
	 15.13. Further Assurance
	    	 	114	  
	 15.14. Amendments
	    	 	114	  
	 15.15. Relationship of the Parties
	    	 	114	  
	 15.16. Counterparts; Facsimile Execution
	    	 	115	  
	 15.17. References
	    	 	115	  
	 15.18. Schedules
	    	 	115	  
	 15.19. Construction
	    	 	115	  

  
 iv 

 DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT 

This Distribution, License, Development and Supply Agreement (the “Agreement”) is made and entered into effective as of
January 31, 2012 (the “Effective Date”) by and between AstraZeneca UK Limited, a company incorporated in England under no. 3674842 whose registered office is at 2 Kingdom Street, London, W2 6BD, England
(“AstraZeneca”), and Impax Laboratories, Inc., a Delaware corporation located at 30831 Huntwood Avenue, Hayward, CA 94544 (“Impax”). AstraZeneca and Impax are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, AstraZeneca controls rights to certain pharmaceutical products containing zolmitriptan, which are
currently being sold by AstraZeneca throughout the world under the Trademark (as defined below) Zomig®;

 WHEREAS, Impax has experience in the distribution and sale of pharmaceutical products in the Territory (as defined
below); 
 WHEREAS, AstraZeneca desires to grant to Impax the right to distribute and sell Existing Products (as defined
below) in the Territory, to seek regulatory approval for one or more New Indications (as defined below) with respect to such Existing Products, to develop one or more Additional Products (as defined below) for Commercialization (as defined below) in
the Territory, and other related rights described herein, and Impax desires to receive such rights, in each case in accordance with the terms and conditions set forth below; 

WHEREAS, AstraZeneca will retain rights to the Licensed Compound (as defined below) and products containing
the Licensed Compound outside the Territory and accordingly has a significant on-going commercial interest in the Licensed Compound, pharmaceutical products containing the Licensed Compound and the Trademark Zomig®; 
 WHEREAS, AstraZeneca will, itself or through one or more of its Affiliates (as defined below), continue to be the holder of the NDAs (as defined below) for the Existing Products in the Territory
and will continue to have certain ongoing obligations with respect thereto, including the completion of the Selected Mandated Studies (as defined below); 
 WHEREAS, AstraZeneca and Impax have agreed to coordinate to effect the transfer from AstraZeneca to Impax of certain Commercialization activities with respect to Existing Products in the Territory
in accordance with the terms and conditions of the Transition Plan (as defined below); 
 WHEREAS, in furtherance of
these arrangements, AstraZeneca is willing to supply to Impax its requirements of the Existing Products for distribution and sale in the Territory, and Impax desires to exclusively purchase such supply from AstraZeneca, in each case during a
specified Supply Term (as defined below) with respect to each Existing Product and in accordance with the terms and conditions set forth below; and 

  

 NOW, THEREFORE, in consideration of the premises and the mutual promises and
conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

Article 1 

DEFINITIONS 
 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 
 1.1. “A/B Rated” means “therapeutically equivalent” as evaluated by the FDA, applying the definition of “therapeutically equivalent” set forth in the preface to
the Orange Book. 
 1.2. “Acquisition” means, with respect to a Party, a merger, acquisition (whether of
all of the stock or all or substantially all of the assets of a Person or any operating or business division of a Person) or similar material transaction by or with the Party, other than a Change in Control of the Party. 

1.3. “Additional Product” means any prescription pharmaceutical product, other than any Existing Product or any
Restricted Product, that contains the Licensed Compound, whether alone or in combination with one or more other active ingredients, in any and all forms, modes of administration, delivery systems and dosages (references to more than one Additional
Product or all Additional Products, as applicable, “Additional Products”). 
 1.4. “Affected
Party” has the meaning set forth in Section 3.8.3. 
 1.5. “Affiliate” means, with respect
to a Party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, “control” and, with correlative meanings, the
terms “controlled by” and “under common control with” means (i) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting
securities, by contract relating to voting rights or corporate governance, or otherwise; or (ii) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a business
entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). 

1.6. “Agreement” has the meaning set forth in the preamble hereto. 

1.7. “Alliance Manager” has the meaning set forth in Section 2.5. 

1.8. “Ancillary Agreements” means the Quality Assurance Agreement and the Safety Agreement. 

1.9. “Anticipated Generic Date” means, with respect to each Existing Product mode of administration and dosage
strength, either (i) if no Paragraph IV Notice has been 

  
 2 

 
received by a Party, the latest expiration date of any issued AstraZeneca Patent or a [***] Patent listed in the Orange Book with respect to such Existing Product, or the expiration date of any
statutory exclusivity, if later, or (ii) if a Paragraph IV Notice has been received by a Party, the date of the last expiring statutory exclusivity or stay of approval provided under 21 U.S.C. Section 355(j)(5)(B) with respect to the
corresponding ANDA for a Third Party Generic Version, provided, however, that in the event the Parties enter into a settlement agreement as provided under Section 10.3 pursuant to which a Third Party has the right to launch commercially a Third
Party Generic Version corresponding to such Existing Product mode of administration and dosage strength on a fixed date, then the Anticipated Generic Date for such Existing Product shall be such fixed date. 

1.10. “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010,
as amended, any other applicable anti-corruption laws, and laws for the prevention of fraud, racketeering, money laundering or terrorism. 
 1.11. “Anti-Corruption Policies” means (i) collectively, the Anti-Bribery and Anti-Corruption Policy and the External Interactions Policy each of which applies to AstraZeneca
and are attached as Schedules 1.11A and 1.11B, respectively, to this Agreement and as the same may be amended, modified or supplemented from time to time as notified by AstraZeneca to Impax, or (ii) a policy of Impax similar in scope and
substance to the policies described in the foregoing clause (i) that is reasonably acceptable to AstraZeneca pursuant to Section 3.7.7. 
 1.12. “Applicable Law” means all supra-national, national, federal, state and local laws, and the rules, regulations, directives, guidance, guidelines and requirements of all
Regulatory Authorities, in effect from time to time, including those applicable to the Exploitation or Manufacture of pharmaceutical products, including the FFDCA, the PDMA, federal and state anti-kickback statutes, false claim statutes, statutes
that govern price reporting, reimbursement and monetary disclosure and the Office of Inspector General’s Compliance Program Guidance for Pharmaceutical Manufacturers. “Applicable Law” shall be deemed to include (i) the
American Medical Association Guidelines on Gifts to Physicians from Industry, and (ii) the PhRMA Code on Interactions with Healthcare Professionals. 
 1.13. “Approved Indication” means, with respect to an Existing Product, an indication for which such Existing Product has been approved by the FDA as of the Effective Date.

 1.14. “[***]” has the meaning set forth in Section 4.1.3(iv). 

1.15. “Arbitrator” has the meaning set forth in Section 7.8.2. 

1.16. “AstraZeneca” has the meaning set forth in the preamble hereto. 

1.17. “AstraZeneca CIA” means the Corporate Integrity Agreement between the Office of Inspector General of the
U.S. Department of Health and Human Services and AstraZeneca Pharmaceuticals LP and AstraZeneca LP dated April 27, 2010 to which AstraZeneca and its Affiliates are subject, as it may be amended from time to time. 

  
 3 

 1.18. “AstraZeneca Controlled Infringement” has the meaning set
forth in Section 10.3.1. 
 1.19. “AstraZeneca Improvement” means any inventions, discoveries,
developments or modifications with respect to any Licensed Product or the Exploitation of the foregoing conceived, discovered, reduced to practice or otherwise made by or on behalf of AstraZeneca or its Affiliates during the Term, provided that
“AstraZeneca Improvements” shall exclude inventions, discoveries, developments or modifications with respect to any active ingredient other than the Licensed Compound that may be included in a Licensed Product or in any product
containing the Licensed Compound. 
 1.20. “AstraZeneca Improvement Patents” means any Patent Controlled
by AstraZeneca or its Affiliates in the Territory during the Term to the extent claiming or covering any AstraZeneca Improvement; provided that “AstraZeneca Improvement Patent” shall exclude any Patents Controlled by any Affiliate
of AstraZeneca that becomes an Affiliate after the Effective Date solely to the extent such Patents claim AstraZeneca Improvements that are conceived, discovered, reduced to practice or otherwise made (i) by or for such Affiliate, or by a Third
Party and licensed to such Affiliate, (ii) prior to the date such Affiliate Controlling such Patent becomes an Affiliate and (iii) without access to or use of any Confidential Information of Impax or any of its Affiliates. 

1.21. “AstraZeneca Indemnified Parties” has the meaning set forth in Section 13.1. 

1.22. “AstraZeneca Net Sales” has the meaning set forth in the Transition Plan. 

1.23. “AstraZeneca Patents” means Patents Controlled by AstraZeneca or its Affiliates (i) that (a) are
set forth on Schedule 1.23 and that claim any of the Existing Products as of the Effective Date or during the Term or (b) that are foreign equivalents of such Patents covered by clause (i)(a) or (ii) that are (a) patent applications
filed either from Patents covered by clause (i) or from an application claiming priority from the same patent application(s) as the Patents covered by clause (i), including divisionals, continuations, continuations-in-part, provisionals,
converted provisionals and continued prosecution applications; (b) Patents that have issued or in the future issue from the foregoing patent applications ((i) and (ii)(a)), including utility models and design patents and certificates of
invention; or (c) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions of the foregoing Patents ((i), (ii)(a) and (ii)(b)).

 1.24. “AstraZeneca Regulatory Documentation” has the meaning set forth in Section 5.1.1.

 1.25. “AstraZeneca Regulatory Responsibilities” has the meaning set forth in Section 5.2.1(i).

 1.26. “AstraZeneca Related Termination” means any termination of this Agreement in its entirety
[***]. 

  
 4 

 1.27. “AstraZeneca Study” has the meaning set forth in
Section 4.5.1. 
 1.28. “AstraZeneca U.S. Patents” means those AstraZeneca Patents issued or
pending in the U.S. 
 1.29. “Attack Pack Dispensers” means those certain dispensers in the form made
available in the Territory by AstraZeneca and its Affiliates as of the Effective Date for patients to carry Zomig Tablets or Zomig-ZMT. 
 1.30. “AZAP Review Process” means AstraZeneca’s and its Affiliates’ process for reviewing Marketing Materials and training materials as set forth in Schedule 1.30, as it
may be amended from time to time by AstraZeneca and its Affiliates, in their sole discretion, to conform to AstraZeneca’s and its Affiliates’ then-current internal review procedures for similar materials for pharmaceutical products
marketed by AstraZeneca and its Affiliates in the Territory. 
 1.31. “[***] Agreement” means any [***]
agreement entered into between the Parties or their Affiliates pursuant to which Impax is the [***] and AstraZeneca is the [***], and which includes terms and conditions relating to the [***]. 

1.32. “[***] Product” means any Supplied Product consisting of an Impax Generic Version that is [***] pursuant to
[***] Agreement, including, to the extent applicable, any such Supplied Product that is additionally subject to [***]. 

1.33. “Board of Directors” has the meaning set forth in the definition of “Change in Control.”

 1.34. “Breaching Party” has the meaning set forth in Section 14.2. 

1.35. “Business Day” means a day other than a Saturday or Sunday on which banking institutions in New York, New
York are open for business. 
 1.36. “Business Policies” means those Impax policies and procedures
(including any applicable codes of conduct) relating to the marketing and Promotion of pharmaceutical products and the conduct of related activities, subject to Sections 3.7.6 and 3.7.7, as may be amended by Impax from time to time. 

1.37. “Calendar Quarter” means each successive period of three (3) calendar months commencing on
January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of
January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 
 1.38. “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar
Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on
the last day of the Term. 

  
 5 

 1.39. “Change in Control,” means, with respect to a Party, the
occurrence of any of the following after the Effective Date: 
 1.39.1. any “person” or “group” (as
such terms are defined below) (i) is or becomes the “beneficial owner” (as defined below), directly or indirectly, of shares of Voting Stock of such Party (or such controlling Affiliate) representing more than fifty percent
(50%) of the total voting power of all outstanding classes of Voting Stock of such Party (or such Party’s controlling Affiliate) or (ii) has the power, directly or indirectly, to elect a majority of the members of the Party’s (or
such controlling Affiliate’s) board of directors, or similar governing body (“Board of Directors”); 

1.39.2. such Party (or such controlling Affiliate) enters into a merger, consolidation or similar transaction with another Person
(whether or not such Party (or such controlling Affiliate) is the surviving entity) and as a result of such merger, consolidation or similar transaction (i) the members of the Board of Directors of such Party (or such controlling Affiliate)
immediately prior to such transaction constitute less than a majority of the members of the Board of Directors of such Party (or such controlling Affiliate) or such surviving Person immediately following such transaction or (ii) the Persons
that beneficially owned, directly or indirectly, the shares of Voting Stock of such Party (or such controlling Affiliate) immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party
(or such controlling Affiliate) representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving Person in substantially the same proportions as their ownership of Voting Stock of such Party (or
such controlling Affiliate) immediately prior to such transaction; 
 1.39.3. such Party sells or transfers to any Third
Party, in one or more related transactions, properties or assets representing all or substantially all of such Party’s consolidated total assets to which this Agreement relates; or 

1.39.4. the holders of Voting Stock of such Party (or such controlling Affiliate) approve a plan or proposal for the liquidation
or dissolution of such Party (or such controlling Affiliate). 
 For the purpose of this definition of Change in Control,
(i) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934, and the term “group” includes any group acting for the purpose of
acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the said Act; (ii) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the aforesaid Act; and (iii) the terms
“beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” 
 1.40. “[***]” means [***], Inc. and its successors and assigns pursuant to the [***] License Agreement or [***] Supply Agreement, as applicable. 

1.41. “[***] License Agreement” means that certain License Agreement dated [***] between [***] and IPR
Pharmaceuticals, Inc., as amended. 

  
 6 

 1.42. “[***] Patents” means those Patents licensed from [***]
pursuant to the [***] License Agreement that would, but for the license granted by [***] in the [***] License Agreement, be infringed by the Exploitation of Zomig-ZMT by AstraZeneca or any of its Affiliates or (sub)licensees. 

1.43. “[***] Supply Agreement” means that certain Supply Agreement dated [***] between [***] and AstraZeneca UK
Limited, as amended. 
 1.44. “Class I Situation” means a situation, as defined in 21 C.F.R. §
7.3(m)(1), in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. 
 1.45. “Commercialization” means any and all activities directed to the preparation for sale of, offering for sale of, or sale of a Licensed Product, including activities related to
marketing, selling, offering for sale, Promoting, Detailing, distributing, warehousing and importing such Licensed Product, provided that “Commercialization” excludes Manufacturing. When used as a verb, “to
Commercialize” and “Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning. 
 1.46. “[***]” means (i) with respect to any day occurring after the Effective Date and on or prior to [***], that such day is a [***] with respect to [***], and (ii) with
respect to any day after [***], that such day is a [***] with respect to [***], in each case ((i) and (ii)) caused by (a) any breach or failure to perform any of the provisions of this Agreement or any Ancillary Agreement by AstraZeneca or any
of its Affiliates, or (b) any intentional or willful misconduct of AstraZeneca or any of its Affiliates. 
 1.47.
“Commercialization Plan” has the meaning set forth in Section 3.3.1. 
 1.48. “Commercially
Reasonable Efforts” means, with respect to the performance by a Party of activities with respect to the Licensed Compound or a Licensed Product or other activities pursuant to this Agreement, the carrying out of such activities using
efforts and resources comparable to the efforts and resources [***] for compounds or products of similar market potential at a similar stage in their lifecycle; provided, however, that with respect to AstraZeneca’s performance of its
obligations with respect to the Existing Products pursuant to the Transition Plan, “Commercially Reasonable Efforts” shall mean carrying out such activities [***], and in no event shall such efforts require AstraZeneca to Promote any
Existing Product during the Transition Period. In determining whether Commercially Reasonable Efforts were satisfied, the fact that Impax is required to make any payments to AstraZeneca under this Agreement shall not diminish the level of effort
expended by Impax. 
 1.49. “Commitment Date” means, with respect to each of Zomig-ZMT, Zomig Nasal
Spray and Zomig Tablets, the earlier to occur of (i) [***] and (ii) the first date on which [***]. 
 1.50.
“Competing Product” means any product other than a Licensed Product that (i) [***] and (ii) [***] (iii) [***], and (iv) [***]. 

  
 7 

 1.51. “Competitor” means any Person that is commercializing a
Competing Product. 
 1.52. “Compliance Officers” shall mean the chief legal officer and chief
compliance officer of a Party and each of its Affiliates or, if those positions do not exist, such other persons who are responsible for compliance matters with respect to such Party and each of its Affiliates. 

1.53. “Confidential Information” has the meaning set forth in Section 11.1. 

1.54. “Control” means, with respect to any item of Information, Regulatory Documentation, material, Patent, or
other intellectual property right, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise (other than by operation of the license and other grants by one Party to the other in this Agreement,
including in Sections 6.1 or 6.2), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent, or other intellectual property
right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 
 1.55. “Corporate Names” means (i) in the case of AstraZeneca, the Trademark AstraZeneca® and the AstraZeneca corporate logo or such other names and logos used generally by AstraZeneca in its business (and not relating to a specific product or technology)
as AstraZeneca may designate in writing from time to time, and (ii) in the case of Impax, the Trademark
Impax® and the Impax corporate logo or such other names and logos used generally by Impax in its business (and
not relating to a specific product or technology) as Impax may designate in writing from time to time, in each case ((i) and (ii)), together with any variations and derivatives thereof. 

1.56. “Credit Note” means a credit memo issued by AstraZeneca to Impax and usable by Impax as an offset against
amounts payable to AstraZeneca by Impax or, if no such amounts are outstanding at the time of termination of this Agreement or later, for a refund from AstraZeneca to Impax which AstraZeneca shall pay to Impax no later than [***] after any such
termination. 
 1.57. “Current Quarter” has the meaning set forth in Section 8.6.2. 

1.58. “Default Notice” has the meaning set forth in Section 14.2. 

1.59. “Detail” means that part of an in person, face-to-face sales call during which a Representative, who is
trained and knowledgeable with respect to the applicable Licensed Product, including its Product Labels and Inserts and the use of the Marketing Materials, makes an appropriate presentation of the Licensed Product to a physician or other medical
professional with prescribing authority (including in a group practice setting), such that the relevant characteristics of the Licensed Product are described by the Representative in a manner consistent with the requirements of this Agreement and
Applicable Law and in a manner that is customary in the industry for the purpose of Promoting a prescription pharmaceutical product. For the avoidance of doubt, the following shall not constitute a “Detail”: (i) any activities
performed by medical information scientists, market development specialists, managed 

  
 8 

 
care account directors and other personnel who are not conducting face-to-face sales calls; (ii) E-details; or (iii) a mere delivery of Licensed Product samples without discussion with
a physician or other medical professional with prescribing authority about the Licensed Product. When used as a verb, “Detail” means to perform a Detail. 
 1.60. “Development” means, with respect to the Licensed Compound or a Licensed Product, all pre-clinical, non-clinical and clinical research activities, and related regulatory
activities, that are necessary or useful to obtain and maintain approval by the FDA of a Drug Approval Application as required to market and sell such product for the applicable indication, provided that “Development” excludes
Manufacturing. “Develop” and “Developing” shall be interpreted accordingly. 
 1.61.
“Dollars” or “$” means United States Dollars. 
 1.62. “Drug Approval
Application” means a New Drug Application (an “NDA”), or other application required to market a drug product, as defined in the FFDCA and the regulations promulgated thereunder (including all additions, supplements,
extensions, and modifications thereto), or any corresponding foreign application. 
 1.63. “Effective
Date” means the effective date of this Agreement as set forth in the preamble hereto. 
 1.64. “Electing
Party” has the meaning set forth in Section 3.8.3. 
 1.65. “Election Date” has the
meaning set forth in Section 3.15.5. 
 1.66. “Equivalent Product” has the meaning set forth in
Section 8.23.2. 
 1.67. “Existing Product” means each of (i) Zomig oral tablets (referred to
herein as “Zomig Tablets”), (ii) Zomig nasal spray (referred to herein as “Zomig Nasal Spray”) and (iii) Zomig orally disintegrating tablets (referred to herein as “Zomig-ZMT”), in each
case ((i), (ii) and (iii)), in each of (a) the forms approved by the FDA in the Territory as of the Effective Date and (b) the dosage strengths approved by the FDA in the Territory as of the Effective Date or thereafter during the
Term (including [***]) (references to more than one Existing Product or all Existing Products, as applicable, the “Existing Products”). For clarity, each dosage strength of the same Existing Product mode of administration
(i.e., oral tablet, nasal spray or orally disintegrating tablet) in the Territory shall constitute the same Existing Product, regardless of whether such dosage strength is offered for sale by AstraZeneca as of the Effective Date. 

1.68. “Existing Regulatory Documentation” means the AstraZeneca Regulatory Documentation identified on Schedule
1.68. 
 1.69. “Exploit” means to make (including Manufacture), have made (including have Manufactured),
import, use, sell, or offer for sale, including to research, develop (including to Develop), commercialize (including to Commercialize), register, hold, or keep (whether for disposal or otherwise), have used, export, transport, distribute, Promote,
market, or have sold or otherwise dispose of. 

  
 9 

 1.70. “Exploitation” means the act of Exploiting a compound,
product, or process. 
 1.71. “FDA” means the United States Food and Drug Administration and any
successor agency thereto. 
 1.72. “FFDCA” means the United States Food, Drug, and Cosmetic Act, as
amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). 

1.73. “Field” means the diagnosis, treatment or prevention of any condition or indication in humans, excluding
[***]. 
 1.74. “First Commercial Sale” means, with respect to a Licensed Product, the first sale by
Impax, its Affiliates or Sublicensees for monetary value of such Licensed Product in the Territory to a Third Party; provided that, as used in Section 6.5, “First Commercial Sale” includes a sale to any Person, including an Affiliate
or Sublicensee. 
 1.75. “Fixed Payment” and “Fixed Payments” have the meanings set
forth in Section 7.1. 
 1.76. “FSS” means the Federal Supply Schedule, which is the listing of
prices published by the United States General Services Administration at which a product is sold to eligible federal government agencies pursuant to 48 C.F.R. 538 et seq., as in effect from time–to-time. 

1.77. “GAAP” means United States generally accepted accounting principles consistently applied. 

1.78. “Generic Launch Date” means, with respect to any Impax Generic Version, [***]. 

1.79. “Generic Version” means, with respect to a particular mode of administration and dosage strength of an
Existing Product, any other prescription pharmaceutical product that has the same mode of administration and dosage strength as such Existing Product that (i) contains the Licensed Compound as an active ingredient and (ii) is A/B Rated
with respect to such mode of administration and dosage strength of such Existing Product. 
 1.80. “GMP”
means the current good manufacturing practices applicable to the Manufacturing, handling, storage and distribution of the Licensed Products pursuant to Applicable Law, including the FFDCA and the regulations of the FDA, as from time to time in
effect. 
 1.81. “Government Health Care Program” means the Medicare Part D Coverage Gap Discount
program (as defined in 42 U.S.C. 1395w-114A, as amended), the Medicaid program (Title XIX of the Social Security Act), the Department of Veterans Affairs Federal Supply Schedule Program, TRICARE, and the Public Health Service 340B Program, and any
mandatory federal, state, and local governmental health care plans and programs. 

  
 10 

 1.82. “Government Official” means any Person employed by or acting
on behalf of a government, government-controlled entity or public international organization; any political party, party official or candidate; any person who holds or performs the duties of an appointment, office or position created by custom or
convention; and any Person who holds himself out to be the authorized intermediary of any of the foregoing. 
 1.83.
“Gross Profit” means, with respect to a given Impax Generic Version in a Calendar Quarter, the positive excess, if any, of (i) Net Sales of such Impax Generic Version in the Territory minus (ii) the Supply Price paid for
such Impax Generic Version which is a Supplied Product supplied by AstraZeneca, minus (iii) Impax’ cost of goods sold determined in accordance with GAAP for such Impax Generic Version that is not a Supplied Product supplied by AstraZeneca
(for clarity, if and to the extent that Impax has the right to make or have made by a Third Party such Impax Generic Version in accordance with the terms and conditions of this Agreement), and minus (iv) [***] as an allowance for transportation
costs and distribution expenses with respect to such Impax Generic Version, including related insurance charges. 
 1.84.
“Hatch-Waxman Act” means the Drug Price Competition and Patent Term Restoration Act of 1984, as amended. 

1.85. “Healthcare Reform Excise Fees” means that portion of the annual fee on prescription drug manufacturers
imposed by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as amended) and reasonably allocable to sales of Licensed Products. 
 1.86. “Impax” has the meaning set forth in the preamble hereto. 
 1.87. “Impax Commercialization Date” has the meaning set forth in the Transition Plan. 
 1.88. “Impax Generic Version” means, with respect to a particular mode of administration and dosage strength of an Existing Product being sold in the Territory, any version of such
pharmaceutical product having the same mode of administration and dosage strength that (i) is sold by or on behalf of Impax or any of its Affiliates or Sublicensees under the NDA for such Existing Product, (ii) is sold under a different
Trademark than any Product Trademark (or under no Trademark), and (iii) has a NDC number that differs from the NDC number for such Existing Product. 
 1.89. “Impax Generic Version Payments” has the meaning set forth in Section 7.2.2. 
 1.90. “Impax Improvement” means any inventions, discoveries, developments or improvements with respect to any Licensed Product or any product containing the Licensed Compound or
the Exploitation of the foregoing conceived, discovered, reduced to practice or otherwise made by or on behalf of Impax or its Affiliates or Sublicensees during the Term, provided that “Impax Improvements” shall exclude inventions,
discoveries, developments or modifications with respect to any active ingredient other than the Licensed Compound that may be included in a Licensed Product or in any product that includes the Licensed Compound. 

  
 11 

 1.91. “Impax Improvement Patent” means any Patents Controlled by
Impax or its Affiliates or Sublicensees during the Term to the extent claiming or covering any Impax Improvement; provided that “Impax Improvement Patent” shall exclude any Patents Controlled by (i) any Affiliate of Impax that
becomes an Affiliate after the Effective Date or (ii) any licensee of Impax, in each case ((i) and (ii)) solely to the extent such Patents claim Impax Improvements that are conceived, discovered, reduced to practice or otherwise made
(a) by or for such Affiliate or licensee, or by a Third Party and licensed to such Affiliate or licensee, (b) prior to (x) in the case of any such Affiliate, the date such Affiliate Controlling such Patent becomes an Affiliate, and
(y) in the case of any licensee, the effective date of any license granted by Impax to such licensee, and (c) without access to or use of any Confidential Information of AstraZeneca or any of its Affiliates. 

1.92. “Impax Indemnified Parties” has the meaning set forth in Section 13.2. 

1.93. “Impax Know-How” means all Information Controlled by Impax or any of its Affiliates as of the Effective
Date or during the Term that is not generally known and is reasonably necessary or useful for the Development, Manufacture, or Commercialization of the Licensed Compound or a Licensed Product. 

1.94. “Impax NDC” has the meaning set forth in Section 3.12. 

1.95. “Impax Patents” means all of the Patents Controlled by Impax or any of its Affiliates as of the Effective
Date or during the Term that are reasonably necessary or useful (or, with respect to patent applications, would be reasonably necessary or useful if such patent applications were to issue as Patents) for the Development, Manufacture, or
Commercialization of the Licensed Compound or a Licensed Product. 
 1.96. “Impax Policies” has the
meaning set forth in Section 3.7.7(i). 
 1.97. “Impax Primary Regulatory Responsibilities” has the
meaning set forth in Section 5.2.2(i). 
 1.98. “Impax Related Termination” means any termination
of this Agreement in its entirety by [***]. 
 1.99. “Impax Regulatory Documentation” has the meaning
set forth in Section 5.1.2. 
 1.100. “Impax Study” has the meaning set forth in
Section 4.1.2(ii). 
 1.101. “Impax Study Data” has the meaning set forth in Section 4.1.5.

 1.102. “Impax Supporting Regulatory Responsibilities” has the meaning set forth in
Section 5.2.2(ii). 
 1.103. “IND” means (i) an investigational new drug application filed
with the FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions, and (ii) all supplements and amendments that may be filed with respect to the foregoing. 

  
 12 

 1.104. “Indemnification Claim Notice” has the meaning set forth in
Section 13.3. 
 1.105. “Indemnified Party” means a Party, its Affiliates or its or their
respective directors, officers, employees and agents seeking to recover a Loss under Sections 13.1 or 13.2. 
 1.106.
“Indemnifying Party” means a Party from whom recovery of a Loss is sought under Sections 13.1 or 13.2. 

1.107. “Independent Auditor” has the meaning set forth in Section 7.8.1. 

1.108. “Independent Expert” means a mutually acceptable, disinterested, conflict-of-interest-free Person not
affiliated with either Party with such scientific, technical and regulatory experience as is necessary to resolve a given dispute. The Independent Expert shall not be or have been at any time an Affiliate, employee, consultant, officer or director
of either Party or any of its Affiliates. 
 1.109. “Indirect Taxes” means value added taxes, sales
taxes, consumption taxes and other similar taxes. 
 1.110. “Industrial Funding Fee” means the
industrial funding fee payable to the United States Department of Veterans Affairs in connection with the sale of the Licensed Products to the United States Department of Veterans Affairs under the FSS, as in effect from time to time. 

1.111. “Information” means all technical, scientific, and other know-how and information, trade secrets,
knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data, results and other material,
including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols; assays; and
biological methodology; in each case (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed, excluding Regulatory Documentation. 

1.112. “Inspected Party” has the meaning set forth in Section 3.8.2. 

1.113. “Inspecting Party” has the meaning set forth in Section 3.8.2. 

1.114. “IRB” has the meaning set forth in Section 14.7.6. 

1.115. “ISS” means investigator sponsored studies or trials conducted prior to or following Regulatory Approval,
in which a qualified individual investigator assumes the responsibilities of a drug product Sponsor-Investigator in accordance with FDCA and related FDA regulations and guidelines. 

  
 13 

 1.116. “Joint Committees” has the meaning set forth in
Section 2.2.1. 
 1.117. “Joint Operating Committee” or “JOC” has the meaning set
forth in Section 2.2.1. 
 1.118. “Joint Steering Committee” or “JSC” has the
meaning set forth in Section 2.1.1. 
 1.119. “Knowledge” means the actual knowledge without any
duty to conduct any investigation with respect to such facts and information of any person who (i) in the case of AstraZeneca, is as of the Effective Date (a) an officer of AstraZeneca or any of its Affiliates, (b) a Compliance
Officer of AstraZeneca or any of its Affiliates, or (c) an employee of AstraZeneca or any of its Affiliates with a title or functional responsibility of director or above and whose responsibilities include or have included Existing Products,
and (ii) in the case of Impax, a Person who is as of the Effective Date (a) an officer of Impax or any of its Affiliates, (b) a Compliance Officer of Impax or any of its Affiliates, or (c) an employee of Impax or any of its
Affiliates with a title or functional responsibility of director or above. 
 1.120. “Liability Cap” has
the meaning set forth in Section 13.5.2. 
 1.121. “LIBOR” means the London Interbank Offered Rate
for deposits in United States Dollars having a maturity of one month published by the British Bankers’ Association, as adjusted from time to time on the first London business day of each month. 

1.122. “Licensed Compound” means the pharmaceutical compound zolmitriptan. 

1.123. “Licensed Product” means any Existing Product or Additional Product, as applicable, and “Licensed
Products” means more than one, or all, Existing Products or Additional Products, as applicable. For clarity, each Impax Generic Version is a “Licensed Product.” 
 1.124. “Losses” has the meaning set forth in Section 13.1. 
 1.125. “Major Markets” means [***]. 
 1.126.
“Managed Market Contract” means, with respect to a Licensed Product, an agreement with a managed care organization or other Third Party providing for a discount or rebate other than an agreement with respect to a Government Health
Care Program. 
 1.127. “Manufacture” and “Manufacturing” means all activities related
to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of the Licensed Compound, any Licensed Product, or any intermediate thereof, including process development, formulation, process qualification
and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control. 

  
 14 

 1.128. “Manufacturing Cost” means, with respect to any Supplied
Product, AstraZeneca’s and its Affiliates’ (i) costs incurred by AstraZeneca or its Affiliates in support of Manufacture of the Supplied Product as determined under [***] as per GAAP, and (ii) costs with respect to
AstraZeneca’s and its Affiliates’ [***]. 
 1.129. “Manufacturing Know-How” has the meaning
set forth in Section 8.19.1. 
 1.130. “Manufacturing Split” has the meaning set forth in
Section 8.23.2. 
 1.131. “Marketing Materials” means all materials used by Impax to Commercialize
the Licensed Products, including advertisements, brochures and other written material, audio and video material, computer based material, web sites, display panels, medically relevant give-aways, press/media communications and training and briefing
materials for Representatives or any other marketing materials aimed at physicians, patients, customers, or organized customer groups. 
 1.132. “Marketing Material Copyrights” means copyrights on all Marketing Materials developed by or on behalf of Impax. 

1.133. “Material AstraZeneca Regulatory Documentation” means any AstraZeneca Regulatory Documentation that is
Material Regulatory Documentation. 
 1.134. “Material Impax Regulatory Documentation” means any Impax
Regulatory Documentation that is Material Regulatory Documentation. 
 1.135. “Material Regulatory
Documentation” means all material Regulatory Documentation, including INDs, Drug Approval Applications, Regulatory Approvals, annual reports to the FDA, official FDA meeting minutes, draft and final Product Labels and Inserts, FDA briefing
documents, investigator brochures, clinical study reports, clinical protocols, clinical and non-clinical draft and high level summaries submitted to the FDA, PSURs, FDA approval letters, general product summary updates (such as new efficacy or
safety data), FDA advance notices that have a material effect on the safety or efficacy profile of a Licensed Product and any equivalent materials filed with or received from FDA or a Regulatory Authority outside the Territory. 

1.136. “Material Supply Failure” means, with respect to each Supplied Product, the failure by AstraZeneca to
deliver to Impax for [***], at least [***] of the aggregate quantity of such Supplied Product that complies with Section 8.24 and is required to be delivered by AstraZeneca to Impax in such period based on Purchase Orders for such Supplied
Product submitted by Impax in accordance with the terms and conditions of Article 8, [***]; provided that a Material Supply Failure shall be deemed not to have occurred if the primary cause of such Material Supply Failure was (i) a force
majeure event described in Section 15.1 or (ii) [***]. For clarity, [***]. 
 1.137. “Minimum PDE
Requirements” has the meaning set forth in Section 3.5. 

  
 15 

 1.138. “Minimum Promotional Spend Requirements” has the meaning set
forth in Section 3.5. 
 1.139. “Minimum Requirements” means, collectively, the Minimum Promotional
Spend Requirements, Minimum PDE Requirements and Minimum Sampling Requirements. 
 1.140. “Minimum Sampling
Requirements” has the meaning set forth in Section 3.5. 
 1.141. “NDA” has the meaning
set forth in the definition of “Drug Approval Application.” 
 1.142. “NDC” means National
Drug Code. 
 1.143. “Net Sales” means, with respect to a Licensed Product, excluding Transition
Product, for any period, the total amount billed or invoiced on sales of such Licensed Product during such period by Impax, its Affiliates or Sublicensees in the Territory, less the following normal and customary deductions with respect to such
sales: 
 (i) trade, cash and quantity discounts, including discount on shipments or off-invoice discounts; 

(ii) discounts to end-customers granted pursuant to consumer savings or coupon programs; 

(iii) price reductions or rebates, retroactive or otherwise, and administrative fees imposed by, negotiated with or otherwise paid to
governmental authorities; 
 (iv) service fees paid under any distribution services agreement; 

(v) taxes on sales (such as sales, value added, or use taxes) to the extent added to the sale price and set forth separately as such in
the total amount invoiced; 
 (vi) amounts repaid or credited by reason of rejections, defects, recalls or returns, or because
of retroactive price reductions, including rebates or wholesaler charge backs; 
 (vii) the portion of administrative fees
(which fees shall be consistent with the requirements set forth in 42 C.F.R. 1001.952(j) or any successor regulation) paid during the relevant time period to pharmaceutical benefit managers relating specifically to such Licensed Product; and

 (viii) Healthcare Reform Excise Fees (for clarity, whether or not taken as a reduction from revenue under GAAP). 

  
 16 

 Net Sales shall not include: (a) transfers or dispositions for charitable, pre-clinical, clinical,
regulatory, or governmental purposes; or (b) sales between or among Impax, its Affiliates or Sublicensees. Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and procedures of Impax, its
Affiliates, or Sublicensees, which must be in accordance with GAAP. 
 1.144. “New Indication” means any
indication for an Existing Product in the Territory other than an Approved Indication. 
 1.145. “Non-Breaching
Party” has the meaning set forth in Section 14.2.1. 
 1.146. “Ongoing Adolescent Trial”
has the meaning set forth in Section 4.1.1. 
 1.147. “OPDP” means the Office of Prescription Drug
Promotion of the FDA and any successor agency thereto. 
 1.148. “OTC Field” means the offer for sale or
sale of a pharmaceutical product directly to consumers without a prescription from a physician or other healthcare provider with prescribing authority, including pharmaceutical products designated as over-the-counter or behind-the-counter or
semi-ethical. 
 1.149. “Paragraph IV Notice” has the meaning set forth in Section 12.2.2(iii).

 1.150. “Party” and “Parties” has the meaning set forth in the preamble hereto.

 1.151. “Party Members” has the meaning set forth in Section 3.7.2. 

1.152. “Patents” means (i) all national, regional and international patents and patent applications,
including provisional patent applications; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from the foregoing patent applications ((i) and (ii)),
including utility models, petty patents and design patents and certificates of invention; (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations
and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((i), (ii), and (iii)); and (v) any similar rights, including so-called pipeline protection or any importation,
revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents. 
 1.153. “Payment” has the meaning set forth in Section 7.5. 
 1.154. “Payment Period” has the meaning set forth in Section 7.1. 
 1.155. “PDE” means a Primary Detail equivalent for an Existing Product where (i) a Primary Detail has a value of 1.0 (one) primary Detail equivalent, and (ii) a Secondary
Detail has the value of [***] primary Detail equivalents. 

  
 17 

 1.156. “PDMA” means the Prescription Drug Marketing Act of 1987, as
amended, and the rules, regulations and guidelines promulgated thereunder and in effect from time to time. 
 1.157.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. 
 1.158. “Phase IV Study” means a post-marketing human clinical study for a Licensed Product with respect to any indication for which Regulatory Approval has been received.

 1.159. “Planning Forecast” has the meaning set forth in Section 8.6.2. 

1.160. “PREA” means the Pediatric Research Equity Act, as amended from time to time. 

1.161. “Primary Detail” means a Detail during a sales call in which [***] and an Existing Product [***] and the
[***]. 
 1.162. “Product Infringement” has the meaning set forth in Section 10.3.1. 

1.163. “Product Labels and Inserts” means (i) any display of written, printed or graphic matter affixed upon
the immediate container, outside container, wrapper or other packaging of any Licensed Product or (ii) any written, printed or graphic material on or within the package from which any Licensed Product is to be dispensed, including the package
insert and full prescribing information with respect to the Licensed Product. 
 1.164. “Product Online
Assets” means the domain name www.Zomig.com, and if and to the extent agreed by the Parties in writing after the Effective Date, such other domain names Controlled by AstraZeneca in the Territory that contain a variation or misspelling of
“Zomig”, in each case solely to the extent utilized with respect to the Existing Products in the Territory (and for audiences in the Territory). 
 1.165. “Product Trademarks” means (i) the Trademark
Zomig® and the registrations thereof and any associated trade dress, (ii) any other Trademarks relating to
an Existing Product used in the Field in the Territory by AstraZeneca prior to or as of the Effective Date and the registrations thereof and any associated trade dress, (iii) any future Trademark that may be approved by AstraZeneca pursuant to
Section 3.16.1, the applications for registration thereof and the registrations thereof and any associated trade dress, (iv) any unregistered Trademark rights relating to an Existing Product for use in the Field in the Territory as may
exist through use in the Territory prior to or as of the Effective Date and (v) any current or future variants or derivatives of any of the foregoing Trademarks that may be approved by AstraZeneca pursuant to Section 3.16.1, in each case
((i), (ii), (iii), (iv) and (v)), excluding Corporate Names of AstraZeneca or any of its Affiliates or Impax or any of its Affiliates. For the avoidance of doubt, “Product Trademarks” shall exclude any Trademarks used solely in
connection with the Impax Generic Versions. 

  
 18 

 1.166. “Promotion” means those activities normally undertaken by a
pharmaceutical company’s sales force to implement marketing plans and strategies aimed at encouraging the appropriate use of a particular prescription or other pharmaceutical product, including Detail activities. When used as a verb,
“Promote” means to engage in such activities. 
 1.167. “Promotion Commencement
Date” means [***], or such earlier date determined by Impax. 
 1.168. “Promotional
Spend” means all out-of-pocket costs and expenses directly related to the Existing Products that are paid to Third Parties by Impax (other than the costs and expenses of a Third Party sales force and for purchase of Existing Product
samples) in connection with the Commercialization of the Existing Products under this Agreement, including: (i) local marketing and marketing research costs; (ii) non-personal Promotion and advertising costs (including costs of
direct-to-consumer advertising, journal advertising, Marketing Materials, direct mail, reminder promotions, coupons and discount cards and web-based promotions); and (iii) public relations. Promotional Spend excludes salaries and other variable
costs of Detailing the Existing Products and the other Sales Force costs. For the avoidance of doubt, Promotional Spend excludes all costs and expenses for acquisition of Existing Product samples for distribution.  

1.169. “Proration Election” has the meaning set forth in Section 7.1. 

1.170. “Purchase Order” means a written purchase order based on a form reasonably acceptable to AstraZeneca that
sets forth, with respect to the month covered thereby, the quantities of each Supplied Product to be delivered by AstraZeneca. Any form of Purchase Order set forth in Schedule 8.6.1 shall be deemed to be reasonably acceptable to AstraZeneca.

 1.171. “Quality Assurance Agreement” means the quality assurance agreement between the Parties of
even date herewith, a copy of which is attached as Schedule 1.171, as the same may be amended from time to time. 

1.172. “Recall Termination” means any termination of this Agreement by either Party with respect to a particular
Terminated Product(s) pursuant to Section 14.2.2. 
 1.173. “Regulatory Approval” means, with
respect to a country, any and all approvals (including Drug Approval Applications), licenses, registrations, or authorizations of any Regulatory Authority necessary to commercially distribute, sell, or market a product that contains the Licensed
Compound in such country, including, where applicable, (i) pricing or reimbursement approval in such country, (ii) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related
thereto), and (iii) labeling approval. 
 1.174. “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the Exploitation or
Manufacture of the Licensed Compound or a product that contains the Licensed Compound. 

  
 19 

 1.175. “Regulatory Documentation” means all (i) applications
(including all INDs and Drug Approval Applications), registrations, licenses, authorizations, and approvals (including Regulatory Approvals); (ii) correspondence and reports submitted to or received from Regulatory Authorities (including
minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files; and (iii) clinical and other data
contained or relied upon in any of the foregoing, in each case ((i), (ii), and (iii)) relating to the Licensed Compound or a Licensed Product. 
 1.176. “Representative” means a sales representative employed or engaged by Impax (either directly or through a contract sales organization), its Affiliates or Sublicensees in
compliance with the terms hereof to Promote the Licensed Products in the Territory. 
 1.177. “Restricted
Product” means a [***]; provided, however, that the definition of Restricted Product shall be deemed to be a null set of no products, formulations or compounds beginning on the first date on which [***]. 

1.178. “Royalty Nasal Offset Amount” has the meaning set forth in Section 8.15.1(iii). 

1.179. “Royalty Payments” means the payments due from Impax to AstraZeneca based on a percentage of Net Sales
pursuant to Section 7.2. 
 1.180. “Royalty Tablet Offset Amount” has the meaning set forth in
Section 8.15.1(i). 
 1.181. “Royalty Term” has the meaning set forth in Section 7.2.7.

 1.182. “Royalty ZMT Offset Amount” has the meaning set forth in Section 8.15.1(ii). 

1.183. “Safety Agreement” means the safety agreement between the Parties of even date herewith, a copy of which
is attached as Schedule 1.183, as the same may be amended from time to time. 
 1.184. “Sales Force”
means the full set of Representatives, field sales managers, district sales managers, regional sales managers, national sales managers, trainers, market development specialists, managed care account directors and other members customarily comprising
a pharmaceutical company’s sales force. For clarity, a Sales Force shall not include medical information scientists or medical science liaisons. 
 1.185. “Secondary Detail” means a Detail during a sales call in which [***] and an Existing Product [***] and the [***]. 

  
 20 

 1.186. “Selected Additional Product” means any Additional Product
that is [***]. 
 1.187. “Selected Mandated Studies” has the meaning set forth in Section 4.1.1.

 1.188. “Selected Manufacturing Activities” means those categories of Manufacturing activities with
respect to any Existing Product that, as of the Effective Date, are carried out by AstraZeneca or one or more of its Affiliates at the applicable sites in [***] and are described in Schedule 1.188. 

1.189. “Selected Manufacturing Costs” means, with respect to any Supplied Product, AstraZeneca’s and its
Affiliates’ [***]. 
 1.190. “Senior Officer” means, with respect to AstraZeneca, an executive
officer of AstraZeneca, and with respect to Impax, the President of its branded pharmaceuticals business. 
 1.191.
“[***]” means, with respect to the applicable Supplied Product (i.e., until [***], for Zomig Tablets, and thereafter, Zomig Nasal Spray) on any day that (i) there are [***] by Impax or any of its Affiliates or
Sublicensees, or its or their wholesalers, or, during the Transition Period, by AstraZeneca or any of its Affiliates or its or their wholesalers; (ii) Impax is in compliance with [***]; (iii) Impax reasonably demonstrates that Impax has
reasonably [***] for the period commencing [***] prior to the alleged [***] (or, as applicable, such shorter period as may occur between the Impax Commercialization Date with respect to such Supplied Product and the alleged [***]) as evidenced by
reasonable documentation, including [***]; provided, however, that “[***]” excludes in each case ((i) through (iii)), any such event caused by (x) [***] or (y) [***]. 

1.192. “[***]” means each day on which a [***] occurs. 

1.193. “Study” means any clinical study or other study in humans related to the Licensed Compound or any Licensed
Product, including a Phase IV Study or an ISS. 
 1.194. “Study Data” means all data and information
with respect to the Licensed Compound or any Licensed Product that are made, collected, or otherwise generated under or in connection with any Studies, including any clinical data, reports, adverse event information, and other information with
respect thereto. 
 1.195. “Subcontractor” means, with respect to any Party, a Third Party that is
granted a subcontract by such Party to perform obligations hereunder on behalf of such Party. Any Third Party Manufacturer shall also be a Subcontractor with respect to AstraZeneca. 

1.196. “Subject Party” has the meaning set forth in Section 6.8. 

1.197. “Sublicensee” means with respect to Impax, an Affiliate or a Third Party that is granted a sublicense
(except for any sublicense granted pursuant to a settlement agreement under Section 10.3.2) by Impax under the grants in Section 6.1 as provided in Section 6.3. 

  
 21 

 1.198. “Supplied Product” means (i) (a) each Existing
Product in the dosage strengths and forms approved by the FDA in the Territory as of the Effective Date and (b) Zomig Nasal Spray [***], and (ii) each Impax Generic Version of the Existing Products described in the foregoing clause (i),
and (iii) any other Additional Products or dosage strengths that AstraZeneca agrees to produce under Section 8.4 (references to more than one, or all Supplied Products, as applicable, the “Supplied Products”). For clarity,
any dosage strength of any Existing Product that is approved by the FDA after the Effective Date ([***]) shall not constitute a Supplied Product unless AstraZeneca agrees to produce it under Section 8.4. 

1.199. “Supply Failure” means, with respect to any Supplied Product, any failure by AstraZeneca to supply and
deliver such Supplied Product to Impax in accordance with the terms and conditions of this Agreement and each Ancillary Agreement, including as a result of (i) any breach or failure to perform any of the provisions of this Agreement or any
Ancillary Agreement by AstraZeneca or any of its Affiliates or (ii) any intentional or willful misconduct of AstraZeneca or any of its Affiliates. 
 1.200. “Supply Price” has the meaning set forth in Section 8.15.1. 
 1.201. “Supply Term” has the meaning set forth in Section 8.2.1. 
 1.202. “Term” has the meaning set forth in Section 14.1. 
 1.203. “Terminated Product” means, in the case of any termination of this Agreement in its entirety, any and all Licensed Products hereunder, and, in the case of any termination of
this Agreement by either Party pursuant to Section 14.2.2 with respect to one or more but fewer than all Licensed Products, the Licensed Product(s) with respect to which this Agreement is terminated pursuant to Section 14.2.2. 

1.204. “Territory” means the fifty (50) states of the United States of America, the District of Columbia and
the Commonwealth of Puerto Rico. 
 1.205. “Testing Laboratory” has the meaning set forth in
Section 8.17.3. 
 1.206. “Third Party” means any Person other than AstraZeneca, Impax and their
respective Affiliates. 
 1.207. “Third Party [***] Agreement” means any [***] agreement entered into
between Impax and one or more [***], or, additionally in the case of an Impax Generic Version of [***] (and any other Impax Generic Version for which the Parties agree pursuant to Section 6.5.2(iii) that Impax will be permitted to conduct such
[***] activities), [***], as applicable, pursuant to which Impax is the [***] and the [***] is the [***] relating to the [***]. 

1.208. “Third Party Claims” has the meaning set forth in Section 13.1. 

1.209. “Third Party Generic Version” means, with respect to a particular mode of administration and dosage
strength of an Existing Product being sold in the Territory, any Generic Version of such Existing Product that is sold by or on behalf of a Third Party in the Territory. 

  
 22 

 1.210. “Third Party License” has the meaning set forth in
Section 10.6. 
 1.211. “Third Party Manufacturer” means any Third Party contract manufacturer that
AstraZeneca designates to Manufacture the Supplied Products (excluding any Third Party contract manufacturer approved by AstraZeneca pursuant to Section 8.19.2). 
 1.212. “Third Party Personnel” has the meaning set forth in the AstraZeneca CIA. 
 1.213. “Tier 2 PIR Support Level” means the level of support and services set forth in Schedule 1.213, as amended from time to time by AstraZeneca in the ordinary course of
business. 
 1.214. “Trademark” means any word, name, symbol, color, designation or device or any
combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered. 

1.215. “Training Materials” has the meaning set forth in Section 3.13.2. 

1.216. “Transition Period” has the meaning set forth in the Transition Plan. 

1.217. “Transition Plan” means the transition plan for Existing Products attached hereto as Schedule 1.217.

 1.218. “Transition Product” has the meaning set forth in the Transition Plan. 

1.219. “TRICARE” means the military healthcare program for the uniformed services, available to certain retirees,
active-duty members, and their dependents, as authorized under 10 U.S.C. Chapter 55. 
 1.220. “United
States” or “U.S.” means the United States of America. 
 1.221. “Valid Claim”
means (i) a claim of any issued and unexpired Patent whose validity, enforceability, or patentability has not been affected by any of the following: (a) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer;
or (b) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding,
or decision being final and unappealable or unappealed within the time allowed for appeal; or (ii) a claim of a pending Patent application that was filed and is being prosecuted in good faith and has not been abandoned or finally disallowed
without the possibility of appeal or re-filing of the application. 
 1.222. “Voting Stock” means, with
respect to any Person (i) shares of common stock or other voting securities, or any other securities convertible into, exchangeable for or exercisable for common stock or other voting securities, of such Person and (ii) any securities of
such Person entitled to vote generally for the election of directors of such Person that the holders of Voting Stock shall receive or, as a matter of right be entitled to receive, as a result of (a) any

  
 23 

 
capital reorganization, recapitalization or reclassification of the capital stock of such Person or (b) any merger, consolidation or other form of business combination, share exchange or
similar extraordinary transaction of such Person with another entity in which such Person survives after such merger, consolidation or other form of business combination, share exchange or similar extraordinary transaction. 

1.223. “Zomig Nasal Spray” has the meaning set forth in the definition of “Existing Product.”

 1.224. “Zomig Tablets” has the meaning set forth in the definition of “Existing Product.”

 1.225. “Zomig-ZMT” has the meaning set forth in the definition of “Existing Product.”

 Article 2 
 GOVERNANCE 
 2.1. Joint Steering Committee.

 2.1.1. Formation. Within fifteen (15) days after the Effective Date, the Parties shall establish a joint
steering committee (the “Joint Steering Committee” or “JSC”). The JSC shall consist of three (3) representatives from each of the Parties, each with the requisite experience and seniority to enable such person
to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JSC. No representative of a Party that serves on the JOC or that will act as a Senior Officer under this Agreement may serve on the JSC. At
least one (1) representative from each Party shall have a commercialization background and at least one (1) representative from each Party shall have a regulatory affairs background. From time to time, each Party may substitute one or more
of its representatives to the JSC on written notice to the other Party. Impax shall select from its representatives the chairperson for the JSC. From time to time, Impax may change the representative who shall serve as chairperson on written notice
to AstraZeneca. 
 2.1.2. Specific Responsibilities. The JSC shall (i) oversee at a high level the work of
the JOC and periodically receive reports and other information submitted by the JOC; (ii) resolve all disputes referred to the JSC by the JOC; and (iii) make such other decisions as may be delegated to the JSC pursuant to this Agreement or
by written agreement of the Parties. 
 2.1.3. Dispute Resolution. 

(i) Each Party’s representatives on the JSC shall use reasonable efforts to reach consensus with the other Party’s
representatives on all matters within the jurisdiction of the JSC. If consensus on a particular matter cannot be reached by the JSC within a period of [***] or such shorter period as the subject matter of the dispute requires, either Party may, upon
written notice, refer such dispute to the Senior Officers of the Parties for discussion and resolution. Subject to Section 14.2.1, in the event the Senior Officers of the Parties cannot agree on a resolution to such dispute within [***], [***]
shall resolve the dispute 

  
 24 

 giving good faith consideration to the issues raised by [***], subject to the principles set forth in
Section 2.1.3(ii). Unless agreed to in advance by the Parties or otherwise provided for pursuant to this Agreement, in no event shall the failure to reach an agreement under this Section 2.1.3(i) enable either Party to terminate this
Agreement. 
 (ii) Notwithstanding the foregoing or any other term or condition of this Agreement to the contrary, neither the
JSC nor any Senior Officer, as applicable, shall have the right or authority (a) to exercise any decision-making with respect to an alleged breach of this Agreement or any Ancillary Agreement; (b) to exercise any decision-making with
respect to a matter for which this Agreement explicitly requires the approval of, or otherwise reserves decision-making to, one Party or requires the mutual agreement of both Parties; (c) to modify or amend this Agreement, or make any decision
that is inconsistent with a Party’s rights or obligations under this Agreement, including the Minimum Requirements to which Impax is subject pursuant to Section 3.5; or (d) to take any action over the objection of AstraZeneca that is
reasonably likely to affect adversely the Exploitation of the Licensed Products in the Territory or outside the Territory. 

2.2. Joint Operating Committee. 
 2.2.1. Formation. Within fifteen (15) days after the Effective Date, the Parties shall establish a joint operating committee (the “Joint Operating Committee” or
“JOC” and collectively with the JSC, the “Joint Committees”). The JOC shall consist of three (3) representatives from each of the Parties, each with the requisite experience and seniority to enable such person
to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JOC. At least one (1) representative from each Party shall have a commercialization background and at least one (1) representative
from each Party shall have a regulatory affairs background. From time to time, each Party may substitute one (1) or more of its representatives to the JOC on written notice to the other Party. Impax shall select from its representatives the
chairperson for the JOC. From time to time, Impax may change the representative who shall serve as chairperson on written notice to AstraZeneca. 
 2.2.2. Specific Responsibilities. The JOC shall serve as a general consultative forum to (i) review and discuss (a) the Commercialization of the Licensed Products in the Field in
the Territory by Impax, including Impax’ performance as compared to each applicable annual Commercialization Plan, (b) Impax’ plans for Development of Licensed Products for Commercialization in the Field in the Territory, and
(c) the preparation and submission of Material Regulatory Documentation to Regulatory Authorities in connection with obtaining and maintaining Regulatory Approvals for Licensed Products in the Field in the Territory, and (ii) facilitate
the discussion and exchange by the Parties of information required hereunder with respect to the foregoing activities. In particular, the JOC shall serve as a forum for: 
 (i) discussing and periodically reviewing Commercialization Plans prepared by Impax and amendments and updates thereto; 
 (ii) discussing, reviewing and receiving updates regarding the Commercialization activities with respect to Licensed Products in the Field in the Territory; 

  
 25 

 (iii) discussing, reviewing and receiving updates regarding Impax’ Development of
Licensed Products for Commercialization in the Field in the Territory; 
 (iv) making such other decisions as may be delegated
to the JOC pursuant to this Agreement or by written agreement of the Parties; 
 (v) establishing other working groups to
implement the foregoing responsibilities, which working groups shall have such responsibilities and be comprised of such equal number of employees from each of the Parties with such expertise and seniority, as the JOC may direct from time to time,
and supervise and direct the activities of such working groups and accept reports and recommendations from such working groups; 
 (vi) discussing, reviewing and receiving updates regarding Manufacturing activities under this Agreement; and 
 (vii) providing updates on the Selected Mandated Studies to Impax. 

2.2.3. Dispute Resolution. Each Party’s representatives on the JOC shall use reasonable efforts to reach consensus
with the other Party’s representatives on all matters within the jurisdiction of the JOC. If the JOC cannot, or does not, reach consensus on an issue at a meeting (or within such other period as the Parties may mutually agree), then either
Party shall have the right to refer the dispute to the JSC for resolution and a special meeting of the JSC shall be called for such purpose. 
 2.3. General Provisions Applicable to Joint Committees. 

2.3.1. Meetings and Minutes. The JSC shall meet semi-annually (or such more frequent time as is required to resolve
disputes referred by the JOC in accordance with Section 2.2.3) and the JOC shall meet quarterly, or in each case as otherwise agreed to by the Parties, with the location of such meetings alternating between locations designated by AstraZeneca
and locations designated by Impax. The chairperson of the applicable Joint Committee shall be responsible for calling meetings on no less than fifteen (15) Business Days’ notice. Each Party shall make all proposals for agenda items and
shall provide all appropriate information with respect to such proposed items at least five (5) Business Days in advance of the applicable meeting; provided that under exigent circumstances requiring input by the Joint Committee, a Party may
provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition of such
agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld, conditioned or delayed. The chairperson of the Joint Committee shall prepare and circulate for review and approval of the Parties
minutes of each meeting within fifteen (15) days after the meeting. Each Joint Committee member shall have the opportunity to provide comments on the draft minutes, which comments shall be provided to all Joint Committee members as soon as
practicable after circulation of the draft minutes. The minutes shall be deemed approved upon the approval of such minutes by at least one representative appointed by each Party and the Parties shall use good faith efforts to approve minutes within
thirty (30) days 

  
 26 

 following the applicable meeting; provided that minutes for such meeting may reflect a lack of consensus on
an issue-by-issue basis, the person(s) responsible for resolving such matter and by what date such matter shall be resolved. Upon approval, final minutes shall be circulated to the members of the Joint Committee by the chairperson. 

2.3.2. Procedural Rules. Each Joint Committee shall have the right to adopt such standing rules as shall be necessary for
its work, to the extent that such rules are not inconsistent with this Agreement. A quorum of the Joint Committee shall exist whenever there is present at a meeting at least one (1) representative appointed by each Party. Representatives of the
Parties on a Joint Committee may attend a meeting either in person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants; provided, however, that at least
annually with respect to the JSC and at least two (2) times per Calendar Year with respect to the JOC, the Representatives shall meet in person at a location in the Territory to be mutually agreed by the Parties. Representation by proxy shall
be allowed. Subject to Sections 2.1.3 and 2.2.3, each Joint Committee shall take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having a single vote irrespective of the number of
representatives of such Party in attendance, or by a written resolution signed by at least one (1) representative appointed by each Party. Employees or consultants of either Party that are not representatives of the Parties on a Joint Committee
may attend meetings of such Joint Committee; provided, however, that such attendees (i) shall not vote or otherwise participate in the decision-making process of the Joint Committee, and (ii) are bound by obligations of confidentiality and
non-disclosure equivalent to those set forth in Article 11. 
 2.3.3. Expenses. Each Party shall bear all costs
of its representatives on a Joint Committee related to their participation on the Joint Committee and attendance at Joint Committee meetings. 
 2.3.4. Limitations on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement and no such rights, powers, or discretion shall be delegated to
or vested in a Joint Committee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. No Joint Committee shall have the power to amend, modify, or waive compliance with
this Agreement, which may only be amended or modified as provided in Section 15.14 or compliance with which may only be waived as provided in Section 15.11. 
 2.4. Discontinuation of Participation on a Joint Committee. Each Joint Committee shall continue to exist until the Parties mutually agree to disband such Joint Committee. For the avoidance
of doubt, (i) following termination of a Joint Committee, each Party’s Alliance Manager shall be deemed the point of contact for all matters that were within the responsibilities of the applicable Joint Committee and (ii) the
termination shall in no manner enable any Party to exercise any decision-making with respect to the matters set forth in Section 2.1.3(ii). 

  
 27 

 2.5. Alliance Managers. 

2.5.1. Each of the Parties shall appoint a single individual to act as a single point of contact between the Parties to assure a
successful collaboration (each, an “Alliance Manager”). Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily
perform the functions of that Alliance Manager by written notice to the other Party. 
 2.5.2. The Alliance Managers
shall attend all Joint Committee meetings and support the representatives of each Joint Committee in the discharge of their responsibilities. Alliance Managers shall be nonvoting participants in such Joint Committee meetings, unless they are also
appointed members of such Joint Committee pursuant to Sections 2.1.1 or 2.2.1; provided, however, that an Alliance Manager may bring any matter to the attention of any Joint Committee if such Alliance Manager reasonably believes that such matter
warrants such attention. Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within and among the Joint Committee. In addition, each Alliance Manager: (i) shall be the point of first referral in
all matters of conflict resolution; (ii) shall provide a single point of communication for seeking consensus both internally within the respective Parties’ organizations and between the Parties; (iii) shall identify and bring disputes
to the attention of the appropriate Joint Committee in a timely manner; (iv) shall plan and coordinate cooperative efforts and internal and external communications; (v) shall take responsibility for ensuring the sharing of relevant
Commercialization and Development materials between the Parties in accordance with this Agreement; and (vi) shall take responsibility for ensuring that governance activities, such as the conduct of required Joint Committee meetings and
production of meeting minutes, occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 

Article 3 

COMMERCIALIZATION 
 3.1. Impax Obligations. Except as may be otherwise provided in the Transition Plan, Impax shall have the sole and exclusive (even as to AstraZeneca and its Affiliates) right and
responsibility for the Commercialization of Licensed Products in the Field in the Territory during the Term in accordance with the terms and conditions of this Agreement. For clarity, this obligation includes the responsibility to Commercialize each
dosage strength of each Existing Product approved by the FDA. Impax shall bear all costs and expenses arising out of its Commercialization activities. For clarity, the foregoing sentence shall not limit Impax’ ability to deduct normal and
customary deductions from the definition of Net Sales, as specified in Section 1.143. Notwithstanding any other term or condition of this Agreement to the contrary, Impax shall not sell or distribute any Existing Product prior to the Impax
Commercialization Date with respect to such Existing Product as determined pursuant to the Transition Plan. 
 3.2.
Transition Plan. During the Transition Period, AstraZeneca and Impax shall cooperate to transition the Commercialization of Licensed Products in the Field in the Territory, and related administrative activities, from AstraZeneca to Impax and
to ensure that Impax commences the performance of such activities hereunder with the least disruption to customers, in each case, in accordance with and to the extent provided for in the Transition Plan and the other terms and conditions of this
Agreement. To effectuate this transition, each Party shall use Commercially Reasonable Efforts to perform its respective obligations under the Transition Plan attached as Schedule 1.217. 

  
 28 

 3.3. Commercialization Plan. 

3.3.1. In General. Impax’ Commercialization of the Licensed Products in the Field in the Territory shall be conducted
pursuant to annual commercialization plans and budgets (the “Commercialization Plan”). The initial Commercialization Plan will be prepared by Impax and provided to the JOC for review and discussion within [***] of the Effective
Date. Impax shall update the Commercialization Plan in good faith at least once per Calendar Year through December 31, 2021. The JOC shall review and discuss the Commercialization Plan (and each annual update thereto) within thirty [***] after
receiving such Commercialization Plan or update, and Impax shall consider in good faith any comments made by AstraZeneca thereon. For the avoidance of doubt, except with respect to the Minimum Requirements, the Commercialization Plan shall not be
binding on Impax. 
 3.3.2. Contents of Commercialization Plan. The Commercialization Plan shall include, with
respect to the Commercialization of Licensed Products in the Field in the Territory during the applicable Calendar Year: (i) general plans and strategies for the Commercialization of the Licensed Products; (ii) the nature of advertising,
sampling and promotional activities anticipated; and (iii) non-binding summary-level market and sales forecasts for the Licensed Products. The Commercialization Plan shall cover the following areas: 

(i) a [***] with respect to the Licensed Products; 
 (ii) a [***] expenses to be incurred by Impax; 
 (iii) a [***] by Calendar
Quarter; 
 (iv) a [***] on a Calendar Quarter basis, including: (a) [***]; and (b) [***]; 

(v) a [***] describes on a Calendar Quarter and Licensed Product-by-Licensed Product basis: (a) the [***]; (b) the [***];
(c) compliance guidelines and other objectives to maintain compliance with Applicable Law and associated reporting requirements; and (d) such other matters related to Licensed Product [***] as the JOC deem necessary or appropriate;

 (vi) a [***]; and 
 (vii) such other plans relating to the [***] of the Licensed Products in the Field in the Territory as the JOC deems necessary or appropriate. 

3.4. Commercialization Reporting. Impax shall provide to AstraZeneca not later than [***] after [***], a report setting
forth in reasonable detail the Commercialization activities it has performed, or caused to be performed, during the applicable reporting period evaluating the work performed in relation to the applicable Commercialization Plan, including [***].

  
 29 

 3.5. Diligence. Impax shall Promote the Existing Products in the Field in the
Territory commencing on the Promotion Commencement Date, provided that such Promotion obligation shall terminate with respect to each Existing Product as of the applicable Commitment Date with respect to such Existing Product. Impax shall fulfill
the Minimum Requirements with respect to the Existing Products for each applicable Calendar Year as set forth in Schedule 3.5 through the last Commitment Date to occur for any Existing Product, including the obligations to [***]. For clarity, the
Minimum Requirements shall cease to apply to all dosage strengths of Zomig Nasal Spray, Zomig-ZMT or Zomig Tablets, as applicable, on an Existing Product-by-Existing Product basis, in each case, on the Commitment Date for the applicable Existing
Product, but Impax shall continue to fulfill the Minimum Requirements (without reduction in the aggregate amount of such Minimum Requirements set forth in Schedule 3.5) with respect to all other Existing Products for which the Commitment Date has
not occurred until the last Commitment Date to occur for any Existing Product. After the last Commitment Date has passed with respect to each Existing Product, Impax shall use Commercially Reasonable Efforts to continue Commercializing such Existing
Product in the Field in the Territory during the Term. 
 3.6. No Implied Obligations. Impax shall have no
obligation to Exploit any Additional Products, New Indications, or Impax Generic Versions hereunder. In the event that Impax elects to Exploit any Additional Products, New Indications, or Impax Generic Versions hereunder, such Exploitation shall be
subject to the terms and conditions of this Agreement. 
 3.7. Compliance 

3.7.1. General. Each Party shall, and shall cause its Affiliates and its and their officers, directors, employees, agents
and representatives to, comply with (i) Applicable Law, and (ii) the terms and conditions of this Agreement, in each case ((i) and (ii)) in performing its obligations and exercising its rights under this Agreement and in relation to
the Commercialization of Licensed Products in the Field in the Territory. 
 3.7.2. Anti-Corruption Covenants.
Without limitation of Section 3.7.1, each Party agrees, on behalf of itself, its Affiliates who perform obligations hereunder and its and their respective officers, directors, employees, agents and representatives, in each case, who perform
obligations hereunder (together with such Party, the “Party Members”), that, in connection with the matters that are the subject of this Agreement, and the performance of its obligations hereunder: 

(i) The Party Members shall comply with the Anti-Corruption Laws and the Anti-Corruption Policies, and shall not take any action that
will, or would reasonably be expected to, cause (a) the other Party or its Affiliates to be in violation of any such laws or policies or (b) the performance by the other Party or its Affiliates of their obligations under this Agreement to
violate any such laws or policies. 

  
 30 

 (ii) The Party Members shall not, directly or indirectly, pay, offer or promise to pay, or
authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to: 

(a) any Government Official in order to influence official action; 

(b) any Person (whether or not a Government Official) (i) to influence such Person to act in breach of a duty of good faith,
impartiality or trust (“acting improperly”), (ii) to reward such Person for acting improperly, or (iii) where such Person would be acting improperly by receiving the money or other thing of value; or 

(c) any other Person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid,
offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement, or the performance of their
respective obligations under this Agreement or to any Person to influence such Person to act improperly. 
 (iii) The Party
Members shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws or the Anti-Corruption Policies. 

3.7.3. Anti-Corruption Representations. Each Party, on behalf of itself and its other Party Members, represents and
warrants to the other Party that: 
 (i) To the best of such Party’s and its Affiliates’ Knowledge, no Party Member
has, directly or indirectly, (a) paid, offered or promised to pay, or authorized the payment of any money, (b) given, offered or promised to give, or authorized the giving of anything else of value or (c) solicited, received or agreed
to accept any payment of money or anything else of value, in each case ((a), (b) and (c)), in violation of the Anti-Corruption Laws during the [***] preceding the Effective Date in connection with the matters that are the subject of this
Agreement. 
 (ii) Neither it nor, to the best of such Party’s and its Affiliates’ Knowledge, any of its Affiliates
is wholly owned or otherwise controlled by any Government Official in a position to take or influence official action for or against either Party in connection with the matters that are the subject of this Agreement, or the performance of their
respective obligations under this Agreement, and to the best of such Party’s and its Affiliates’ Knowledge, none of its officers, directors, employees, or, with respect to each of the Parties, their respective five percent (5%) or
greater shareholders, is or expects to become a Government Official in a position to take or influence official action for or against either Party in connection with the matters that are the subject of this Agreement, or the performance of their
respective obligations under this Agreement during the Term. 
 (iii) To the best of (a) AstraZeneca’s and its
Affiliates’ Knowledge, none of the AstraZeneca Patents, Product Trademarks, Regulatory Approvals, contracts, licenses or other assets that are the subject of this Agreement were or will be procured

  
 31 

 
in violation of any Anti-Corruption Laws and (b) Impax’ and its Affiliates’ Knowledge, none of the Impax Patents, Regulatory Approvals, contracts, licenses or other assets that are
the subject of this Agreement were or will be procured in violation of any Anti-Corruption Laws. 
 3.7.4. Other
Anti-Corruption Provisions. 
 (i) Each Party shall deliver to the other Party annually a certificate executed by an
authorized officer of such Party, substantially in the form of Schedule 3.7.4, certifying compliance by such Party and its other Party Members with the representations, warranties and undertakings set forth in Sections 3.7.2 and 3.7.3. 

(ii) Each Party shall promptly notify the other Party upon becoming aware of any breach or violation by the notifying Party (including
through any of its other Party Members) of any representation, warranty, or undertaking set forth in Sections 3.7.2 and 3.7.3. If a Party becomes aware that any of its or any of its other Party Members’ officers, directors or employees becomes
during the Term a Government Official in a position to take or influence official action for or against either Party in connection with the matters that are the subject of this Agreement, or the performance of their respective obligations under this
Agreement, such Party shall promptly notify the other Party and shall take such steps as the Parties may reasonably agree to avoid a potential violation of the Anti-Corruption Laws or a violation or breach of the representations, warranties and
undertakings set forth in Sections 3.7.2 and 3.7.3. 
 (iii) Each Party shall be responsible for any breach of the provisions
of Sections 3.7.2 and 3.7.3 by any of its other Party Members. 
 (iv) If the Non-Breaching Party determines in good faith
based on the advice of counsel, whether or not through an inspection, that the Breaching Party (including through any of its other Party Members) is or will imminently become in breach or violation of any representation, warranty or undertaking in
Sections 3.7.2 and 3.7.3 or the Anti-Corruption Laws, the Non-Breaching Party shall have the right, in addition to any other rights or remedies under this Agreement or to which the Non-Breaching Party may be entitled in law of equity, to take such
steps as are reasonably necessary in order to avoid a potential violation or continuing violation of the Anti-Corruption Laws and to ensure that the Non-Breaching Party does not suffer or incur any Losses resulting from or arising out of or in
connection with any violation, including by requesting such additional representations, warranties, undertakings and other provisions as it believes in good faith are reasonably necessary. 

(v) Each Party acknowledges and agrees that no Party Member of the other Party is authorized to waive compliance with any of the
representations, warranties or undertakings set forth in Sections 3.7.2 and 3.7.3 and that such first Party shall be solely responsible for its compliance with such Sections and the Anti-Corruption Laws irrespective of any act or omission of such
other Party or any of its other Party Members. 
 3.7.5. AstraZeneca CIA. For the term of the AstraZeneca CIA,
Impax shall, and shall cause its Affiliates and its and their officers, directors, employees, agents and representatives to, comply with the AstraZeneca CIA insofar as it applies to Third Party

  
 32 

 
Personnel, in each case solely to the extent that Impax’ obligations as Third Party Personnel under the AstraZeneca CIA are satisfied by compliance with the Business Policies, the
Anti-Corruption Policies or otherwise by compliance with an interpretation of the AstraZeneca CIA in writing by AstraZeneca or one of its Affiliates and delivered to Impax, and in each case solely to the extent of performing Impax’ obligations
and exercising its rights under this Agreement and in relation to the Commercialization of Licensed Products in the Field in the Territory. Promptly after the Effective Date and annually thereafter during the term of the AstraZeneca CIA, AstraZeneca
shall deliver to Impax a copy of a Third Party Personnel Notification Letter substantially in the form of Schedule 3.7.5A. In response to each such Third Party Personnel Notification Letter, Impax shall deliver a Third Party Response Form
substantially in the form of Schedule 3.7.5B that has been completed and executed by an authorized officer of Impax. 

3.7.6. Business Policies 
 (i) Impax shall, and shall cause its Affiliates and its and their officers, directors, employees, agents and representatives to, comply with the Business Policies, in performing Impax’ obligations
and exercising its rights under this Agreement and in relation to the Commercialization of Licensed Products in the Field in the Territory. Promptly after the Effective Date, but in any event in advance of the Promotion Commencement Date, a
compliance officer designated by Impax and a compliance officer designated by AstraZeneca shall discuss and agree upon any amendments that such compliance officers determine should be made to the Business Policies in relation to the
Commercialization of Licensed Products in the Field in the Territory. 
 (ii) Impax shall maintain a corporate compliance
program that will include compliance monitoring focused on specific risk areas, including off-label promotion, fraud and abuse and false claims, to assess whether Impax’ policies and procedures are being followed. Within [***] after the end of
each [***] during the Term, Impax shall report to AstraZeneca all allegations it has received or investigations it has commenced with respect to the alleged failure by a member of the Sales Force to comply with the requirements set forth in
Section 3.7.1 or Section 3.7.6(i) (or a statement that no such allegations have been received or investigations commenced) and what action, if any, was taken by Impax as a result. 

(iii) Impax shall maintain a corporate compliance program that shall include a mechanism for its and its Affiliates’ employees to
report, anonymously if they choose, any concerns about potential illegal activity with respect to the Details performed under this Agreement, and Impax shall investigate any such reports. Within [***] after the end of each [***] during the Term and
before reporting any such activity to any Regulatory Authority, unless Impax concludes that doing so would violate Applicable Law or would compromise Impax’ ability to complete an appropriate investigation, Impax shall notify AstraZeneca of the
substance of any such report that relates to the subject of this Agreement. Impax shall in any case promptly inform AstraZeneca of the result of the investigation and any action taken by Impax as a result thereof. 

  
 33 

 (iv) Impax shall report any material violation by any member of the Sales Force of
Applicable Law in performing activities under this Agreement to AstraZeneca promptly after Impax learns of such violation. 

(v) Impax shall notify AstraZeneca in writing of any amendments to the Business Policies as soon as practicable and, with respect to any
amendment that would cause the Business Policies to be less restrictive than the agreed Business Policies in effect as of the Promotion Commencement Date, prior to the implementation thereof. Prior to Impax implementing any amendment that would
cause the Business Policies to be less restrictive than the agreed Business Policies in effect as of the Promotion Commencement Date, the Parties shall negotiate in good faith a mutually acceptable resolution with respect thereto. No amendment to
the Business Policies that would cause them to be less restrictive than the agreed Business Policies in effect as of the Promotion Commencement Date shall be effective for the purposes of this Agreement unless and until the Parties agree upon a
resolution with respect thereto in accordance with this Section 3.7.6(v). 
 3.7.7. Use of Impax Policies.

 (i) In the event Impax reasonably believes that it may satisfy compliance with all or a portion of the requirements of
the Anti-Corruption Policies or the AstraZeneca CIA, as required pursuant to this Section 3.7, by complying with Impax’ internal written policies (the “Impax Policies”), Impax may [***], and Impax shall provide AstraZeneca
a copy of the applicable Impax Policies with such notification. AstraZeneca shall [***]. [***]. 
 (ii) If at any time
thereafter, the Anti-Corruption Policies or the AstraZeneca CIA are amended, revised or restated and [***], AstraZeneca shall promptly notify Impax, and Impax shall thereafter be required to [***], as required pursuant to this Section 3.7. For
the avoidance of doubt, if at any time thereafter Impax revises the Impax Policies such that [***]as required pursuant to this Section 3.7[***]in accordance with Section 3.7.7(i). 

(iii) If at any time, Impax [***] AstraZeneca shall [***] as required pursuant to this Section 3.7 and shall [***] pursuant to
Section 3.7.8(ii). [***]. 
 3.7.8. Changes to Anti-Corruption Policies or AstraZeneca CIA. 

(i) AstraZeneca shall notify Impax in writing of any substantive changes to the Anti-Corruption Policies or the AstraZeneca CIA to the
extent impacting Impax’ obligations under this Agreement and provide, at its cost, Impax with a copy of such changes and a compliance officer designated by AstraZeneca shall discuss with a compliance officer designated by Impax any such
substantive changes to the Anti-Corruption Policies or the AstraZeneca CIA and the application of such changes with respect to this Agreement and the Licensed Products. Within [***] after AstraZeneca provides the copies and the respective compliance
officers of the Parties discuss the substantive changes, [***], as required pursuant to this Section 3.7. 
 (ii) If
AstraZeneca [***], as applicable, pursuant to Section 3.7.7, Impax shall notify AstraZeneca in writing [***]. 

  
 34 

 3.8. Compliance Books and Records. 

3.8.1. Until the later of (i) [***] after the end of the period to which the applicable books and records pertain and
(ii) the expiration of the applicable statute of limitations (or any extension thereof), each Party shall keep or cause to be kept accurate financial and other books and records in connection with the performance of its obligations under, and
payments made in connection with, this Agreement, including its compliance with Applicable Law, the representations, warranties and undertakings set forth in Sections 3.7.2 and 3.7.3, the Business Policies (in the case of Impax), the Anti-Corruption
Policies and the AstraZeneca CIA, as required pursuant to Section 3.7, for each Calendar Year during the Term. 

3.8.2. During the Term and for [***] thereafter, in the event that a Party (the “Inspecting Party”) in good
faith believes that the other Party (the “Inspected Party”) (including through any of its other Party Members) is not in compliance with the representations, warranties and undertakings set forth in Sections 3.7.2 and 3.7.3, upon
the written request of the Inspecting Party, the Inspected Party shall, and shall cause its other Party Members, as applicable, to, permit an Independent Auditor designated by the Inspecting Party that is reasonably acceptable to the Inspected
Party, to, during regular business hours and no more than once a Calendar Year, inspect all or any part of the Inspected Party’s and its other Party Members’, as applicable, books and records that are related to this Agreement and the
performance hereunder and have access to the Inspected Party’s and its other Party Members’, as applicable, relevant personnel as necessary to determine compliance with the representations, warranties and undertakings set forth in Sections
3.7.2 and 3.7.3; provided, however, that the Inspecting Party shall have the right to have such Independent Auditor perform additional inspections and have additional access to relevant personnel during a Calendar Year if a previous inspection
during such Calendar Year revealed an issue with respect to the Inspected Party’s (including through any of its other Party Members’) compliance with the representations, warranties and undertakings set forth in Sections 3.7.2 and 3.7.3 or
if the Inspecting Party otherwise has a good faith reason to believe that the Inspected Party (including through any of its other Party Members) has breached or violated any representation, warranty or undertaking set forth in Sections 3.7.2 and
3.7.3. The results of any inspection under this Section 3.8.2 shall (i) disclose only the nature and circumstances of any breach or failure; (ii) report any findings in a manner that does not disclose the identity of the applicable
officers, directors, employees, agents or representatives to the extent permitted by Applicable Law; and (iii) be made available to both Parties. Any Independent Auditor designated by the Inspecting Party shall enter into appropriate
obligations with the Inspected Party to treat all information it receives during its inspection in confidence. The Inspected Party shall cooperate and provide such information and assistance as the Independent Auditor may reasonably require in
connection with such an inspection. The costs of any inspection shall be paid by the Inspecting Party, except that if an inspection reveals any breach or violation by the Inspected Party (including through any of its other Party Members) of any
representation, warranty or undertaking set forth in Sections 3.7.2 and 3.7.3, the costs of such inspection shall be paid by the Inspected Party. 
 3.8.3. If (i) an inspection reveals an issue with respect to a Party’s (the “Affected Party”) (including through any of its other Party Members’) compliance with the
representations, warranties and undertakings set forth in Sections 3.7.2 and 3.7.3 or (ii) the other Party (the “Electing Party”) otherwise has reason to believe that the Affected Party (including

  
 35 

 
through any of its other Party Members) has breached or violated any representation, warranty or undertaking set forth in Sections 3.7.2 and 3.7.3, the Electing Party shall have the right to take
such steps as are reasonably necessary in order to avoid a potential violation or continuing violation of the Anti-Corruption Laws by the Affected Party (including through any of its other Party Members) in accordance with Section 3.7.4(iv).

 3.9. No Parallel Imports.  
 3.9.1. Impax (i) shall not, and shall cause its Affiliates and shall use Commercially Reasonable Efforts to cause its Sublicensees not to, Commercialize any product containing the Licensed
Compound outside the Territory or outside the Field inside the Territory, (ii) shall use Commercially Reasonable Efforts to cause any distributors to which Impax or any of its Affiliates or Sublicensees transfers or sells any product containing
the Licensed Compound to refrain from Commercializing such product outside the Territory or outside the Field inside the Territory, provided, however, that if Impax or any of its Affiliates or Sublicensees engages in any such conduct, Impax shall
promptly notify AstraZeneca in writing upon becoming aware of such circumstances and, whether or not Impax has fulfilled its notice obligations, in the event that any Sublicensee of Impax engages in any such conduct, AstraZeneca shall have the right
to terminate such Sublicensee’s sublicense or right of reference, as applicable, and [***], effective automatically upon AstraZeneca’s providing notice thereof to Impax. If Impax or its Affiliates, or if Impax becomes aware that any
Sublicensees, receive any orders for any Licensed Product outside the Territory or for distribution or sale outside the Territory, Impax promptly shall refer such orders to AstraZeneca. 

3.9.2. AstraZeneca (i) shall not, and shall cause its Affiliates not to, Commercialize any product containing the Licensed
Compound in the Field in the Territory, and (ii) shall cause any distributors to which AstraZeneca or any of its Affiliates transfers or sells any product containing the Licensed Compound to refrain from Commercializing such product in the
Field in the Territory, except in each case ((i) and (ii)) in connection with the performance of AstraZeneca’s obligations under this Agreement, including the Transition Plan. If AstraZeneca or its Affiliates receive any orders for any product
containing the Licensed Compound inside the Field in the Territory or for distribution or sale inside the Field in the Territory, AstraZeneca promptly shall refer such orders to Impax, except as otherwise contemplated in the Transition Plan. Nothing
in this Section 3.9.2 shall be construed as limiting or prejudicing [***]. 
 3.10. Distribution Matters.

 3.10.1. Except as may be otherwise provided in the Transition Plan or with respect to Transition Product, and
without limitation to Section 3.1, Impax shall have the sole right and responsibility with respect to Licensed Products for use in the Field in the Territory to invoice and book sales, establish all terms of sale (including pricing and
discounts), warehouse and distribute and perform or cause to be performed all related services, including the handling of all returns (and related refunds and credits), order processing, invoicing, collection and inventory management with respect to
such Licensed Products. Any changes after the Effective Date to Impax’ order fulfillment and supply chain practices (including with respect to handling returns) must be reasonably acceptable to AstraZeneca, and Impax shall provide AstraZeneca
with reasonable information requested by AstraZeneca from time to time to enable AstraZeneca to review Impax’ order fulfillment and supply chain practices. 

  
 36 

 3.10.2. Without limitation to the other terms and conditions of this Agreement, in
connection with Impax’ Commercialization of Zomig Tablets and Zomig-ZMT in the Field in the Territory, Impax shall offer patients a reasonable opportunity to obtain Attack Pack Dispensers [***] as may be reasonably required to comply with
Applicable Law and the applicable Regulatory Approval. Following the Transition Period with respect to Zomig Tablets and Zomig-ZMT, AstraZeneca and Impax shall coordinate with respect to the transfer by AstraZeneca to Impax of any remaining
inventories of Attack Pack Dispensers then held by AstraZeneca, at no cost to Impax, and AstraZeneca will provide to Impax the information necessary for Impax to obtain future supplies of Attack Pack Dispensers. 

3.11. Managed Market Segments and Other Government Program Responsibilities. 

3.11.1. Except as may otherwise be provided in the Transition Plan or with respect to Transition Product, and without limitation
to Section 3.1, Impax shall be solely responsible for managing necessary responsibilities with respect to the Licensed Product for use in the Field across all managed care market segments in the Territory and shall have exclusive responsibility
(including administrative and financial) for: (i) contract strategy; (ii) contract creation; (iii) price reporting, rebate and Industrial Funding Fee processing and payment, coverage gap discount processing and payment, and related
responsibilities with respect to all Government Health Care Programs, including the calculation and reporting of all required pricing for such programs; (iv) contract compliance, monitoring and audits; and (v) contract administration and
claims processing, including with respect to any such contracts, rebates, discounts or other fees. 
 3.11.2. Except as
may otherwise be provided in the Transition Plan, and without limitation to Section 3.1, Impax shall be solely responsible for any government reporting obligations required with respect to the Healthcare Reform Excise Fees and Impax shall be
solely responsible for the payment of the Healthcare Reform Excise Fees. 
 3.12. NDC Number. As set forth in the
Transition Plan, Impax shall use its Commercially Reasonable Efforts to obtain and provide to AstraZeneca the ten (10) digit NDC number for each mode of administration and dosage strength for each Existing Product (each an “Impax
NDC”) no later than two (2) weeks after the Effective Date in order to facilitate the conversion of the packaging and trade dress in a timely and effective manner. Except as otherwise provided in this Agreement, AstraZeneca shall
include the Impax NDC on the packaging of the Supplied Product supplied to Impax pursuant to Article 8. 
 3.13. Sales
Force and Training. 
 3.13.1. Impax shall be responsible, at its sole cost and expense, for establishing and
maintaining an appropriate Sales Force for the Promotion of the Licensed Products in the Field in the Territory during the Term. Impax shall ensure that its Sales Force personnel engaged in the Promotion of the Licensed Products are appropriately
qualified, including by ensuring that each such individual (i) to the knowledge of Impax after reasonable inquiry, has graduated from an accredited four-year college and (ii) has satisfactorily completed the Licensed Product sales training
program. 

  
 37 

 3.13.2. No later than [***] after the Effective Date, AstraZeneca shall provide to
Impax copies of the most recent AstraZeneca training materials related to the Existing Products, which materials Impax may use in connection with creating and developing its training materials for the Licensed Products. Prior to their first use,
Impax shall submit to AstraZeneca all training materials created and developed by Impax (including any modified forms of the training materials initially provided by AstraZeneca) relating to the Existing Products (the “Training
Materials”), and Impax shall not use any such Training Materials unless [***]. [***]. Impax acknowledges and agrees that, notwithstanding any [***], or AstraZeneca’s having provided training materials to Impax for use in connection
with this Agreement, AstraZeneca shall have no liability whatsoever to Impax or any of its Affiliates or Sublicensees in connection with Training Materials created or used by Impax or any of its Affiliates or Sublicensees, and Impax shall indemnify
AstraZeneca Indemnified Parties with respect to such Training Materials pursuant to Section 13.1.4. 
 3.13.3.
During the Transition Period, AstraZeneca shall provide initial training for Impax’ Sales Force trainers at AstraZeneca’s offices in Wilmington, Delaware, at a time reasonably designated by AstraZeneca, for a training period not to exceed
five [***]. For such initial training by AstraZeneca, each Party shall bear all travel and living expenses for its respective trainers, including airfare, hotels and meals. Impax shall be responsible for all other initial and ongoing training of its
Sales Force trainers and all other members of its Sales Force. 
 3.13.4. Subject to Sections 3.13.2 and 3.13.3, Impax
shall, at is sole cost and expense, provide appropriate training materials and in-person trainings for its Sales Force and other Representatives engaged in the Promotion of Licensed Products to ensure that such Persons are able to carry out their
responsibilities in compliance with Applicable Law and the applicable terms and conditions of this Agreement. The quality and frequency of such trainings by Impax shall be of a commercially reasonable standard to ensure that the Sales Force and
other Representatives involved in the Promotion of the Licensed Products are able to carry out their responsibilities in compliance with Applicable Law and the applicable terms and conditions of this Agreement. 

3.13.5. Impax shall use Commercially Reasonable Efforts to ensure that all members of its Sales Force and other Representatives
engaged in the Promotion of Licensed Products in the Territory or in performing Impax’ obligations under this Agreement comply with the requirements of Section 3.7. 
 3.13.6. As requested by AstraZeneca, but in no event more than [***], Impax shall make available to AstraZeneca [***], and such information shall be subject to Article 11. 

3.13.7. Subject to Section 3.19, Impax may use contract sales force personnel to fulfill its obligations under this
Agreement, provided that Impax shall be required to ensure and demonstrate to AstraZeneca compliance by such contract sales force with the applicable terms and conditions of this Agreement. 

  
 38 

 3.13.8. In order to help facilitate the success of the Parties pursuant to this
Agreement, Impax shall permit AstraZeneca from time to time to observe certain Commercialization activities and meetings related to the Licensed Products, as described below: 
 (i) Impax shall permit AstraZeneca’s personnel designated by the AstraZeneca Alliance Manager, at AstraZeneca’s expense, to [***]. 

(ii) Impax shall permit AstraZeneca personnel to [***], at AstraZeneca’s expense, [***]. This shall include (a) the [***],
(b) [***] and (c) [***], but in any event AstraZeneca personnel shall not have any right to [***] in any Calendar Quarter. 
 (iii) AstraZeneca’s observation of such meetings and other activities pursuant to this Section 3.13.8 shall be subject to reasonable advance notice requirements and other guidelines (to be
established and mutually agreed upon by the Parties’ Alliance Managers) in order to minimize any disruption to Impax’ operations and to limit or prohibit access by AstraZeneca to meetings or information relating to Impax’ other
products and business operations other than Commercialization of the Licensed Products. AstraZeneca may only attend those portions of meetings specific to the Licensed Products. AstraZeneca shall not disclose (either internally within AstraZeneca or
to any Affiliate or Third Party) or use any information obtained or based on the above activities other than for the purposes of this Agreement. All such information and any reports and other information obtained or based on the above activities
shall be subject to Article 11. 
 3.14. Samples of Licensed Products. 

3.14.1. Impax shall distribute samples of Existing Products and shall have discretion regarding the number of samples to
distribute for each of the Existing Products, provided that [***]. Impax shall commence distribution of samples of Existing Products beginning upon the Promotion Commencement Date and shall continue sampling with respect to each Existing Product
through the Commitment Date for such Existing Product. At the time of commencement of sampling activities, Impax shall ensure that it has appropriate systems in place with respect to the Existing Products and sampling to ensure compliance with
Applicable Law, the requirements of Section 3.7 and appropriate reporting. Impax may distribute Existing Product samples directly to its Representatives or ship samples of the Existing Products directly to prescribers who have submitted a
product sample request form to its Representatives. 
 3.14.2. During the Supply Term with respect to each Supplied
Product, AstraZeneca shall supply to Impax its requirements of samples of such Supplied Product in accordance with the terms and conditions of Article 8 and the Transition Plan and Impax shall pay to AstraZeneca the applicable Supply Price with
respect thereto. Subject to the other terms and conditions of this Agreement, including the Transition Plan, Impax may utilize any samples bearing the AstraZeneca Corporate Names and NDC until they are exhausted or expire. 

 

  
 39 

 3.14.3. Impax shall (i) comply with all requirements of the Product Labels and
Inserts, the PDMA and any other Applicable Law in connection with the storage, handling, transport and distribution of Licensed Product samples; (ii) maintain its own investigation, corrective and preventive action program for the handling of
samples of the Licensed Products in accordance with its internal policies and procedures; (iii) maintain its own monitoring and auditing programs capable of detecting losses, potential diversion and falsification of records related to samples
of the Licensed Product; (iv) implement its own processes for the inventory, distribution reconciliation and storage of samples of the Licensed Products; and (v) review with AstraZeneca its practices with respect to its contacts and
communications with Regulatory Authorities with respect to matters relating to compliance with Applicable Law with respect to Licensed Product sampling activities. 
 3.14.4. Impax shall notify the FDA of falsification of drug sample records, diversion, significant loss and theft of drug samples according to its standard operating procedures and in compliance
with Applicable Laws. If the falsification, diversion, significant loss or theft involves samples of the Existing Products, Impax shall notify AstraZeneca by providing copies of all correspondence with the FDA regarding the event within forty-eight
(48) hours after delivery of the notification to the FDA. 
 3.14.5. Upon reasonable advance notice to Impax and
not more than once during any Calendar Year, AstraZeneca shall be entitled, at AstraZeneca’s expense, to conduct an inspection and audit of Impax’ inventory of Existing Product samples (including samples held by Impax’
Representatives), documents, records, and policies and procedures, to ensure compliance with the provisions of this Agreement. 

3.15. Marketing Materials 
 3.15.1. Impax shall create and develop, at its sole expense, appropriate Marketing Materials for use in Commercializing the Licensed Products in the Field in the Territory. All such Marketing
Materials shall comply with the requirements set forth in this Section 3.15 and all Applicable Law, including the FFDCA and FDA regulations and requirements applicable to drug advertising and promotion, and shall be consistent with the
applicable Regulatory Approvals for the Licensed Products. 
 3.15.2. AstraZeneca shall provide to Impax for its use, at
its option, samples of or source files for the most current marketing materials maintained and previously approved for use as of the Effective Date by AstraZeneca with respect to the Existing Products, provided that Impax shall be responsible for
updating such materials as appropriate after the Effective Date, [***] in accordance with Section 3.15.3. AstraZeneca shall have the right to use such materials and any updated materials developed by or on behalf of Impax in developing
marketing materials for use in Commercializing the Licensed Products outside the Territory. 
 3.15.3. Impax shall not
use any Marketing Materials for the Licensed Products in the Territory unless and until [***] All such Marketing Materials [***] shall comply with the requirements set forth in this Section 3.15 and all Applicable Law, including the FFDCA and FDA
regulations and requirements applicable to drug advertising and promotion, and shall be consistent with the applicable Regulatory Approvals for the Licensed Products. Impax acknowledges and agrees that, notwithstanding [***], or AstraZeneca’s
having provided materials to Impax for use pursuant to Section 3.15.2 or otherwise in connection with this 

  
 40 

 
Agreement, AstraZeneca shall have no liability whatsoever to Impax or any of its Affiliates or Sublicensees in connection with Marketing Materials created or used by Impax or any of its
Affiliates or Sublicensees, and Impax shall indemnify AstraZeneca Indemnified Parties with respect to such Marketing Materials pursuant to Section 13.1.4. 
 3.15.4. With respect to any Marketing Materials that are in use by Impax, AstraZeneca may, at any time when it has reasonably determined that any such Marketing Materials are not in compliance with
the Regulatory Approvals for the Licensed Products in the Territory, the most recent prescribing information for the Licensed Products as approved by the Regulatory Authorities, any Applicable Law or the AstraZeneca CIA, as required pursuant to
Section 3.7, provide notice to Impax of such determination and [***]. Any such notice shall provide an explanation for any such determination that AstraZeneca may have reached. Promptly upon its receipt of any such notice from AstraZeneca (but
in no event more than [***] after receipt of such notice from AstraZeneca or such lesser period as may be required by the FDA or pursuant to Applicable Law), Impax shall [***]. Any replacement Marketing Materials that Impax may prepare to replace
the withdrawn Marketing Materials shall [***] as provided in Section 3.15.3. In the event of any discontinuation of [***] Marketing Materials requested by AstraZeneca pursuant to the provisions of this Section 3.15.4 other than as a result
of (i) any change in requirements of a Regulatory Approval with respect to any Licensed Product, (ii) any change in Applicable Law or (iii) any change in the prescribing information for any Licensed Product as approved by a Regulatory
Authority, Impax shall be entitled to submit to AstraZeneca a statement of the reasonable out-of-pocket costs incurred by Impax in connection with the withdrawal of the Marketing Materials in question and the development of replacement Marketing
Materials (any such statement to be accompanied by reasonable documentary support for the costs reflected thereon). AstraZeneca shall reimburse Impax for such costs within [***] of receipt of such statement. 

3.15.5. Prior to the Election Date, following [***] in accordance with Section 3.15.3 and prior to first use thereof in the
Territory, AstraZeneca shall be responsible for timely submission to the FDA and OPDP, pursuant to 21 C.F.R. 314.81(b)(3)(i), of such Marketing Materials with respect to the Licensed Products for use in the Field in the Territory, in each case to
the extent required by Applicable Law. Impax shall provide to AstraZeneca, not later than [***] prior to such first use, five (5) copies of all Marketing Materials. At either Party’s election, beginning on the first anniversary of the
Effective Date or any time thereafter (such date of election, if any, the “Election Date”), [***] in accordance with Section 3.15.3 and prior to first use thereof in the Territory, Impax shall be responsible for timely
submission to the FDA and OPDP, pursuant to 21 C.F.R. 314.81(b)(3)(i), of such Marketing Materials with respect to the Licensed Products for use in the Field in the Territory, in each case to the extent required by Applicable Law; provided that
neither Party shall be entitled to make such election unless and until Impax has reasonably demonstrated to AstraZeneca that it is capable of making such submissions in an appropriate and timely manner. AstraZeneca shall have no further
responsibility for submissions of Marketing Materials pursuant to this Section 3.15.5 from and after the Election Date, but, for clarity, AstraZeneca shall [***] pursuant to Section 3.15.3. 

  
 41 

 3.15.6. Copyrights on all Marketing Materials developed by or on behalf of Impax
shall be owned by Impax. 
 3.15.7. Any Marketing Materials for the Licensed Products in the Field in the Territory
shall identify Impax as the distributor of the Licensed Products in the Territory and may contain the Impax Corporate Name. Except as may be required by Applicable Law, Impax shall not make any reference to AstraZeneca or its Affiliates in any
Marketing Materials or otherwise in connection with Commercializing the Licensed Product except to include the AstraZeneca Corporate Names in the Product Labels and Inserts as approved by AstraZeneca, such approval not to be unreasonably withheld,
conditioned or delayed, or as otherwise permitted herein or approved by AstraZeneca in writing. 
 3.16. Product Trademarks.

 3.16.1. Except as provided in Section 6.5 with respect to Impax Generic Versions, Impax shall use the
Product Trademarks on all Licensed Products Commercialized by Impax in the Territory. No other Trademark, other than Impax’ Corporate Names, shall be used by Impax or any of its Affiliates or Sublicensees or distributors in connection with the
Commercialization of the Licensed Products in the Territory unless and until AstraZeneca approves such Trademark for use in connection with the Commercialization of the Licensed Products in writing. Any such approval shall not be unreasonably
withheld, conditioned or delayed. All goodwill from the use of the Product Trademarks shall inure to the sole benefit of AstraZeneca. Except as granted under this Agreement (including under Sections 6.1.8 and 6.1.9), to the extent that Impax
acquires any right, title or interest in or to any Product Trademarks used by Impax in connection with the Exploitation of the Licensed Products, Impax hereby assigns such rights to AstraZeneca. 

3.16.2. Each Party shall not during the Term or thereafter adopt or seek to register any Trademark confusingly similar to the
Product Trademarks or the other Party’s Corporate Names. Each Party shall not, and shall not permit its Affiliates to, (i) use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with
respect to or that dilutes any (or any part) of the Corporate Names of the other Party or the Product Trademarks, or (ii) do any act which endangers, destroys, or similarly affects, in any material respect, the value of the goodwill pertaining
to such other Party’s Corporate Names or the Product Trademarks. Each Party agrees, and shall cause its Affiliates and, in the case of Impax, Sublicensees to conform (a) to the customary industry standards for the protection of the other
Party’s Corporate Names and the Product Trademarks, and (b) to maintain the quality standards of the other Party with respect to the goods sold and services provided in connection with such other Party’s Corporate Names and the
Product Trademarks and any guidelines with respect to such other Party’s Corporate Names provided by such other Party and the Product Trademarks provided by AstraZeneca from time to time. Each Party shall not, and shall cause its Affiliates
and, in the case of Impax, shall use Commercially Reasonable Efforts to cause its Sublicensees not to, do any act which endangers, destroys, or similarly affects, in any material respect, the value of the goodwill pertaining to such other
Party’s Corporate Names or the Product Trademarks. Each Party shall not, and shall cause its Affiliates and, in the case of Impax, shall use Commercially Reasonable Efforts to cause its Sublicensees and distributors not to, attack, dispute, or
contest the validity of or ownership of the other Party’s Corporate Names or the Product Trademarks or any registrations issued or issuing with respect thereto. Each Party agrees to promptly cease and to cause its Affiliates and, in the case of
Impax, use Commercially Reasonable Efforts to cause its Sublicensees and distributors to cease, any use of the Product 

  
 42 

 
Trademarks or the other Party’s Corporate Names in the event such other Party determines that such use of the Product Trademarks or such other Party’s Corporate Names by such first
Party or its Affiliates or Sublicensees is in breach of this Section 3.16. At the request of the other Party, each Party shall provide to the other Party an opportunity to review samples of the use of Trademarks owned by the requesting Party.
If Impax or an Impax Sublicensee or distributor engages in conduct that violates this Section 3.16.2 or otherwise fails to comply with the provisions of this Section 3.16.2, Impax shall promptly notify AstraZeneca in writing upon becoming
aware of any such non-compliance. Whether or not Impax has fulfilled its notice obligations, AstraZeneca shall have the right (x) in the case of any such non-compliance by a distributor, to require that Impax terminate such distributor’s
right to distribute Licensed Products, and (y) in the case of any such non-compliance by a Sublicensee, to terminate such Sublicensee’s sublicense or right of reference, as applicable, and [***], in each case ((x) and (y)) effective
automatically upon AstraZeneca’s providing notice thereof to Impax. 
 3.17. Product Online Assets. During a
reasonable transition period following the Effective Date and in any event no longer than [***], AstraZeneca at its cost shall continue to host, on Impax’ behalf, the Product Online Assets and shall use in connection with such hosting content
that AstraZeneca determines in its reasonable discretion to be appropriate for the Existing Products, it being understood that AstraZeneca shall have the right but not the obligation to use content used in connection with the Product Online Assets
in the Territory as of the Effective Date and expressly reserves the right to (i) remove content that is not specific to Existing Products or (ii) modify content as may be appropriate to include information regarding Impax’
Commercialization of Existing Products in the Territory. Impax shall pay to AstraZeneca [***] for each month that AstraZeneca agrees to host the Product Online Assets after such transition period; provided that AstraZeneca shall not be obligated to
host the Product Online Assets after such transition period. Included in such monthly fee are the web site hosting, updates, maintenance and ongoing technical support [***]. Fees for technical support hours (as requested by Impax in writing) in
excess of [***] shall be billed at [***] per hour. All invoices for web site support and hosting shall be submitted to Impax on a Calendar Quarter basis. Impax shall pay in full each invoice within [***] of the invoice date. Impax shall provide
AstraZeneca with [***] advance written notice prior to the date that Impax intends to move the web site hosting for the www.Zomig.com domain name in the Territory from AstraZeneca, and in the event that AstraZeneca has agreed to extend its hosting
beyond the initial [***] period, AstraZeneca shall provide Impax with [***] advance written notice prior to the date that AstraZeneca intends to cease web site hosting on behalf of Impax. Once AstraZeneca ceases hosting in accordance with this
Section 3.17, Impax shall be solely responsible for hosting the Product Online Assets and, subject to the terms and conditions of this Agreement, for providing content therefor. The Parties shall coordinate in good faith to carry out the
transition in an orderly manner. There shall be no refunds or credits for partial month hosting or technical support hours not used. All domain names which are registered for the Licensed Products shall be the sole property of AstraZeneca. Impax is
permitted to use the www.Zomig.com domain name in accordance with this Section 3.17 and for the Commercialization of the Licensed Products in accordance with this Agreement. The Licensed Products website for the Territory shall be operated and
maintained by the applicable Party in accordance with Applicable Law. Notwithstanding the foregoing, except with respect to the rights of use provided to Impax, AstraZeneca shall continue to own all right, title and interest in and to Product Online
Assets and content utilized by AstraZeneca during any period in which AstraZeneca has hosted the Product Online Assets, and shall retain the right to use Product Online Assets and such content. 

  
 43 

 3.18. AstraZeneca Patient Assistance Program. AstraZeneca shall have the right
for [***] after the Effective Date to supply Licensed Product through its patient assistance program, at its own cost. After such [***] period, Impax shall have the right but not the obligation to establish a patient assistance program to supply
Licensed Product, at its own cost, and AstraZeneca shall at Impax’ request reasonably cooperate with Impax in Impax’ efforts to establish a patient assistance program for the Existing Products with the Third Party that AstraZeneca is
currently utilizing to manage AstraZeneca’s patient assistance program for the Existing Products in the Territory. 

3.19. Commercialization Subcontracting. Subject to the terms and conditions of this Section 3.19 and Section 6.3,
Impax may subcontract with one or more Third Parties to perform certain Commercialization obligations of Impax hereunder in its reasonable discretion, including to engage a contract sales force organization to provide Representatives on Impax’
Sales Force, provided that (i) Impax shall continue to control and direct such Subcontractor and shall ensure compliance by such Subcontractor with this Agreement, (ii) no such permitted Subcontracting shall relieve Impax of any liability
or obligation hereunder except to the extent satisfactorily performed by such Subcontractor and (iii) the agreement pursuant to which Impax engages any Third Party Subcontractor must (a) be consistent in all material respects with this
Agreement, (b) contain terms obligating such Subcontractor to comply with the confidentiality, intellectual property, and all other relevant provisions of this Agreement, including Section 3.7 to the extent applicable to the activities to
be performed by such Subcontractor and (c) contain terms obligating such Subcontractor to permit AstraZeneca rights of inspection, access, and audit substantially similar to those provided by Impax to AstraZeneca in this Agreement.
Notwithstanding the foregoing, Impax shall not have the right, without obtaining AstraZeneca’s prior written consent (which shall not be unreasonably withheld, conditioned or delayed) to subcontract with any Third Party (w) in any
circumstance involving the grant of a sublicense or similar rights under the licenses or rights of cross-reference or reference granted to Impax in Section 6.1, (x) in any circumstance involving [***], (y) in circumstances involving
[***], or (z) for services with respect to [***]; provided that no consent shall be necessary for Impax to subcontract with [***] for the services described in clause (z). Further, notwithstanding clause (x) or (y), Impax shall have the
right, without obtaining AstraZeneca’s consent, to subcontract with [***] to [***], provided that the grant of a sublicense or similar rights as provided in clause (w) shall require AstraZeneca’s consent. 

Article 4 

DEVELOPMENT ACTIVITIES 
 4.1. Licensed Product Studies. 
 4.1.1. AstraZeneca
Obligations. AstraZeneca shall conduct, at its expense, the current PREA commitment studies in the U.S. evaluating Zomig Nasal Spray in adolescents as required pursuant to that certain [***] (the “Ongoing Adolescent Trial”), and
any currently outstanding and deferred post-marketing commitments required by the FDA in connection therewith that are contained on Schedule 4.1.1 (excluding any safety studies), and 

  
 44 

 
any current or future PREA commitment studies that the FDA requires with respect to Existing Products as a result of the Ongoing Adolescent Trial (excluding any safety studies) (together with the
Ongoing Adolescent Trial, the “Selected Mandated Studies”). Except with respect to the Selected Mandated Studies, AstraZeneca shall not have any further obligation to conduct, fund or otherwise support any Studies (including any
investigator sponsored studies) or other Development activities with respect to the Licensed Products or the Licensed Compound in the Territory (or outside the Territory as a result of this Agreement), including any Development activities which may
be required to obtain Regulatory Approval for any Licensed Product or New Indications. 
 4.1.2. Impax Rights and
Obligations. 
 (i) Impax shall not, and shall cause its Affiliates not to, (a) conduct any Study or
(b) authorize, support or assist any Third Party to conduct any Study, including by providing funding or supplies of any Licensed Product, in each case ((a) and (b)) unless [***]. If [***], Impax shall conduct such Study, or shall cause such
Study to be conducted in accordance with [***] and otherwise in accordance with Section 4.1.4. 
 (ii) Subject to
Section 4.1.2(i) and 4.1.3, Impax shall have the right, but not the obligation, to conduct (or, in the case of an ISS, support), at its expense, one or more Studies (each such Study conducted, or in the case of an ISS, supported by Impax, a
“Impax Study”), including (a) Studies to support Regulatory Approval for (1) one or more New Indications for any Existing Product, or (2) any Additional Product, (b) Phase IV Studies, or (c) an ISS for the
Licensed Products, in each case ((a), (b) and (c)) in the Field in the Territory. For the avoidance of doubt, only an ISS which Impax provides support to in the form of financial or technical support, supplies of Licensed Products obtained
directly from Impax or its Affiliates, or other support or enablement, shall be considered an Impax Study. For the avoidance of doubt, any Impax Study shall be subject to termination in accordance with Section 4.1.4(iii). 

4.1.3. AstraZeneca [***]. 
 (i) If Impax wishes to conduct any Impax Study, or to provide support of any kind to any Third Party to conduct an Impax Study (including an ISS), Impax shall [***] the proposed protocol for such Impax
Study. Impax also shall provide to AstraZeneca any other clinical, safety, toxicology and other data and information controlled by Impax or its Affiliates that AstraZeneca reasonably requests and that is reasonably necessary to determine [***].

 (ii) If Impax (or the applicable Third Party) wishes to amend a protocol for an Impax Study [***] in accordance with
Section 4.1.3(i), Impax shall [***]. Impax also shall provide to AstraZeneca any other clinical, safety, toxicology and other data and information controlled by Impax or its Affiliates that AstraZeneca reasonably requests and that is reasonably
necessary to determine [***]. 
 (iii) [***] the (a) proposed protocol for any Impax Study or (b) any proposed
amendment to a protocol for an Impax Study [***]. In no event shall [***]. 

  
 45 

 (iv) Any protocol for an Impax Study, including any amendment thereto, in each case that
[***] is herein referred to as [***]. 
 4.1.4. Impax Study Conduct; Reporting; Cessation. 

(i) Impax shall, and shall cause its Affiliates and shall require each applicable Third Party (including any investigator for an ISS)
to, conduct each Impax Study strictly in accordance with the [***] therefor and Applicable Law, except for those deviations from [***] necessitated by the care and treatment of a subject following an adverse reaction. 

(ii) Impax shall keep AstraZeneca reasonably informed on at least a semi-annual basis, and more frequently if reasonably requested by
AstraZeneca, concerning the progress and results of any Impax Study. At AstraZeneca’s request, Impax promptly shall provide to AstraZeneca all Impax Study Data then available in such form as AstraZeneca may reasonably request, including WORD or
..pdf format. 
 (iii) AstraZeneca shall have the right to require Impax to terminate, or to cause its Affiliate or the
applicable Third Party to terminate, any Impax Study by giving written notice that AstraZeneca in good faith believes that the continued conduct of such Impax Study would present a substantial safety risk, and any such termination shall be at
Impax’ cost except that, in the event Impax gives written notice to AstraZeneca that Impax in good faith believes that such a safety risk is not presented that would warrant termination of an Impax Study, termination of the Impax Study shall be
at AstraZeneca’s reasonable cost. 
 4.1.5. Ownership and Limitations on Use of Impax Study Data. With
respect to any Study Data resulting from any Impax Study (the “Impax Study Data”), (i) Impax shall own all rights with respect to such Impax Study Data, subject to the license grants set forth in Sections 6.2 and 14.7.7, and
(ii) Impax covenants to AstraZeneca that none of Impax or any of its Affiliates or Sublicensees shall use (a) any Impax Study Data (including any such study conducted at any sites outside the United States), or (b) any other data
generated during the Term in connection with any Development activities, in any filing or submission to a Regulatory Authority outside the United States [***]. 
 4.2. Development Costs. Impax shall be responsible for all costs and expenses in connection with all Impax Studies. For the avoidance of doubt, AstraZeneca shall bear, and shall not be
entitled to reimbursement for, any costs and expenses incurred in connection with the performance of the Selected Mandated Studies. 
 4.3. Records. Impax shall maintain, or cause to be maintained, records of its Impax Study activities in sufficient detail and in good scientific and regulatory manner, and in compliance with
Applicable Law, which shall be materially complete and accurate and shall properly reflect all work done and results achieved in the performance of the Impax Studies. Such records shall be retained by Impax for at least [***] after the termination
of this Agreement, or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy any such records. 

  
 46 

 4.4. Disclosure of AstraZeneca Regulatory Documentation. No later than [***]
following the end of each Calendar Year during the first [***] Calendar Years of the Term, AstraZeneca shall provide to Impax a high level overview of Development activities planned by AstraZeneca or any of its Affiliates for the applicable Calendar
Year in support of obtaining or maintaining Regulatory Approvals in any Major Market. Upon the reasonable request of Impax, solely for use in connection with the exercise of its rights under this Agreement, (i) AstraZeneca shall make available
to Impax (a) the Existing Regulatory Documentation, and (b) any Material AstraZeneca Regulatory Documentation relating to the Selected Mandated Studies, and (ii) AstraZeneca shall consider in good faith making available to Impax
additional Material AstraZeneca Regulatory Documentation, in each case related to the Exploitation of Licensed Products in the Field in the Territory, including in the case of clause (ii) any such Material AstraZeneca Regulatory Documentation
with regard to any AstraZeneca Improvements, in each case ((i) and (ii)) in such form as such Regulatory Documentation is maintained by AstraZeneca; provided that AstraZeneca shall not be required to provide any such Regulatory Documentation to
Impax to the extent such Regulatory Documentation cannot be located, collected, organized or provided by AstraZeneca without undue burden, as determined by AstraZeneca in its reasonable discretion. In the event Impax requests AstraZeneca provide
Regulatory Documentation as described in the preceding sentence, AstraZeneca and Impax shall discuss Impax’ desired need for and use of such information and AstraZeneca shall consider each such request in good faith, taking into account
Impax’ need for such information, the utility of such information for Impax’ intended activities and AstraZeneca’s internal ability and resources to locate, collect, organize and provide such information to Impax. In the event that
AstraZeneca undertakes to provide any such Regulatory Documentation to Impax at Impax’ request, AstraZeneca shall provide Impax with a cost and expense estimate for AstraZeneca’s activities and Impax promptly shall reimburse AstraZeneca
for its reasonable costs and expenses (both internal and out-of-pocket) incurred as a result of providing such Regulatory Documentation; provided that AstraZeneca, at Impax’ request, shall provide Impax with an estimate of such costs and
expenses prior to the time when they are incurred and with sufficient notice so that Impax can withdraw its request for such Regulatory Documentation. Notwithstanding anything contained in this Section 4.4, AstraZeneca shall be under no
obligation to disclose or make available pursuant to this Section 4.4 (1) [***], (2) [***], (3) [***], or (4) any Information or materials not permitted to be disclosed pursuant to Applicable Law and consistent with
AstraZeneca’s and its Affiliates’ obligations to Third Parties. 
 4.5. New AstraZeneca Studies. 

4.5.1. AstraZeneca shall use Commercially Reasonable Efforts to provide Impax with reasonable advance notice of any Study it or
its Affiliates plans to conduct in the Territory or a Major Market with respect to the Licensed Compound and products containing the Licensed Compound that are commenced on or after the Effective Date (each, an “AstraZeneca Study”).
AstraZeneca shall use Commercially Reasonable Efforts to provide Impax with a copy of the protocol pursuant to which it will conduct any AstraZeneca Study. AstraZeneca shall consider in good faith any comments Impax provides on any AstraZeneca Study
protocol but shall not be obligated to accept or implement any such comments. Notwithstanding the foregoing, this Section 4.5.1 shall not apply with respect to (and, for purposes of this Section 4.5, an AstraZeneca Study shall not include)
any ISS or any protocol outside the Territory. 

  
 47 

 4.5.2. Through the JOC, AstraZeneca shall keep Impax reasonably informed on at least
a quarterly basis with regard to the progress and status of the Selected Mandated Studies and any AstraZeneca Study. 

Article 5 

REGULATORY MATTERS 
 5.1. Ownership of Regulatory Documentation 
 5.1.1. All
Regulatory Documentation (including NDAs and Product Labeling and Inserts) relating to the Existing Products and Impax Generic Versions (whether for the Approved Indications or any New Indication) other than INDs filed by Impax or its Affiliates for
Impax Studies relating to Existing Products, shall be retained and owned by, and shall be the sole property and held in the name of, AstraZeneca or its designated Affiliate (the “AstraZeneca Regulatory Documentation”). 

5.1.2. All Regulatory Documentation (including NDAs and Product Labeling and Inserts) relating to Additional Products, and all
INDs filed by Impax or its Affiliates for Impax Studies relating to Existing Products, shall be retained and owned by, and shall be the sole property and held in the name of, Impax or its designated Affiliate (or the applicable Third Party in the
case of an ISS) (the “Impax Regulatory Documentation”). For clarity, notwithstanding the ownership thereof by Impax or its designated Affiliate (or the applicable Third Party, the case of an ISS), the content of all Material Impax
Regulatory Documentation shall be subject to approval by AstraZeneca pursuant to Section 5.2.2. 
 5.2. Regulatory
Responsibilities. 
 5.2.1. AstraZeneca Regulatory Responsibilities. 

(i) Except as otherwise agreed by the Parties, AstraZeneca or its designated Affiliate shall have the sole right and responsibility
(subject to Impax’ rights under Section 5.2.1(iii)) for (a) preparing, submitting and maintaining all Regulatory Documentation and Regulatory Approvals in accordance with Applicable Law and (b) conducting all written and oral
communication and discussions with, and preparing and responding to all correspondence with, Regulatory Authorities in the Territory in accordance with Applicable Law, in each case ((a) and (b)), with respect to (1) (A) the Existing
Products in the dosage strengths approved by the FDA in the Territory as of the Effective Date and (B) [***] , in each case ((A) and (B)) in the Approved Indications (except as set forth in Section 5.2.2(ii) with respect to changes in
Product Labeling and Inserts proposed by Impax), (2) the Selected Mandated Studies, (3) any AstraZeneca Studies, and (4) the Manufacture of the Supplied Products (collectively, the “AstraZeneca Regulatory
Responsibilities”). 
 (ii) AstraZeneca shall perform the AstraZeneca Regulatory Responsibilities at its sole cost;
provided, however, that AstraZeneca shall not be obligated to reimburse Impax for any costs Impax incurs in providing materials for, attending, and assisting with any AstraZeneca Regulatory Responsibilities. 

  
 48 

 (iii) AstraZeneca shall provide to Impax, reasonably in advance of the submission date
therefor, each item of Material AstraZeneca Regulatory Documentation for the Territory proposed by AstraZeneca (other than Material AstraZeneca Regulatory Documentation prepared by Impax pursuant to Section 5.2.2(ii)), and AstraZeneca shall
consider in good faith any comments thereon made by Impax in a timely manner. 
 (iv) Impax, at its sole cost, shall provide
AstraZeneca with such information as AstraZeneca reasonably requests (in writing, and no less than [***] in advance, unless a shorter time period is required to satisfy the requirements or requests of the Regulatory Authorities) to enable
AstraZeneca to maintain the AstraZeneca Regulatory Documentation and related Regulatory Approvals for the Existing Products and the Impax Generic Versions in the Territory or as may be requested or required by Regulatory Authorities from time to
time and which is in the possession of Impax, including details of the Existing Products and the Impax Generic Versions sold by Impax by NDC number. In addition, Impax at its sole cost shall make its employees, consultants and other staff available
upon reasonable notice during normal business hours to attend AstraZeneca’s meetings with Regulatory Authorities in the Territory concerning the Existing Products, including Impax Generic Versions. 

5.2.2. Impax Regulatory Responsibilities. 
 (i) Subject to Section 5.1.1, except as otherwise agreed by the Parties, Impax shall have the sole right and responsibility [***] for (a) preparing, submitting and maintaining all Regulatory
Documentation and Regulatory Approvals in accordance with Applicable Law and (b) and conducting all written and oral communication and discussions with, and preparing and responding to all correspondence with, Regulatory Authorities in the
Field in the Territory in accordance with Applicable Law, in each case ((a) and (b)) with respect to (1) any Additional Products, (2) any Impax Studies (including the INDs filed by Impax or its Affiliates therefor), and (3) the
Manufacture of Licensed Products other than Supplied Products (collectively, the “Impax Primary Regulatory Responsibilities”). 
 (ii) Except as otherwise agreed by the Parties, Impax shall have primary operational responsibility for preparing (a) all Regulatory Documentation and Regulatory Approvals and (b) all
correspondence with, Regulatory Authorities in the Field in the Territory, in each case ((a) and (b)) with respect to (1) the Existing Products in any dosage strength other than (A) the dosage strengths approved by the FDA in the Territory
as of the Effective Date and (B) [***], (2) the Existing Products in any New Indication, and (3) any changes to the Product Labels and Inserts proposed by Impax for Existing Products in the Approved Indications (collectively, the
“Impax Supporting Regulatory Responsibilities”). All Regulatory Documentation and correspondence prepared by Impax pursuant to this Section 5.2.2(ii) shall be submitted to the FDA by and in the name of, and [***]. Any such
[***], and AstraZeneca shall [***] such Regulatory Documentation within [***]. 
 (iii) Impax shall perform the Impax Primary
Regulatory Responsibilities and the Impax Supporting Regulatory Responsibilities at its sole cost; provided, however, that Impax shall not be obligated to reimburse AstraZeneca for any costs AstraZeneca incurs in providing materials for, attending,
and assisting with any Impax Primary Regulatory Responsibilities or Impax Supporting Regulatory Responsibilities. 

  
 49 

 (iv) Prior to submission to any Regulatory Authority, Impax shall submit to AstraZeneca
[***] the form and content of, and strategy for, each item of Material Impax Regulatory Documentation proposed by Impax. AstraZeneca’s [***] pursuant to this Section 5.2.2(iv) shall [***]. AstraZeneca shall use Commercially Reasonable
Efforts to [***] within (i) [***] of receipt by AstraZeneca of such proposed Material Impax Regulatory Documentation that relates to the Additional Products and (ii) [***] of receipt by AstraZeneca of such proposed Material Impax
Regulatory Documentation that relates to the Existing Products, in each case, except as otherwise set forth in Section 4.1.3(i) with respect to proposed protocols and amendments thereto for Impax Studies. 

(v) Except as provided in Section 5.2.2(i), 3.14.4 or 3.15.5, or as required by Applicable Law, Impax shall not communicate
directly with any Regulatory Authorities regarding the Licensed Compound or the Licensed Products or otherwise take any action concerning any Regulatory Approval, and in no event shall Impax communicate with any Regulatory Authority, regarding the
AstraZeneca Regulatory Documentation or any Existing Product without [***]. 
 (vi) From time to time Impax may propose changes
to the Product Labels and Inserts for Existing Products in the Approved Indications; provided that [***]. 
 5.2.3. General
Regulatory Responsibilities. 
 (i) Each Party shall promptly provide the other Party with copies of all Material
Regulatory Documentation received by such Party from the Regulatory Authorities in the Territory with respect to the Licensed Products. The Parties shall use good faith efforts to agree in advance on the scheduling of all meetings, conferences, and
discussions scheduled with the FDA with respect to any Licensed Products in the Territory (including FDA advisory committee meetings and any other meeting of experts convened by the FDA concerning any topic relevant to Licensed Products, as well as
labeling discussions) and on the objectives to be accomplished at, and the agendas for, such meetings, conferences, and discussions; provided that in the event that the Parties cannot agree [***]. To the extent permitted by the FDA, each Party shall
use good faith efforts to ensure that the other Party shall be entitled to have a representative present at, and to participate in, all such meetings, conferences or discussions. Each Party shall use good faith efforts to provide the other Party
with an opportunity to be present at and participate in, to the extent practical, any unscheduled or ad-hoc meetings, conferences and discussions with the FDA concerning the Licensed Products. For clarity, in no event shall the failure of
AstraZeneca to attend any meeting, conference or discussion (whether scheduled, unscheduled or ad-hoc) [***] with respect to any Material Regulatory Documentation. 
 (ii) The Product Labels and Inserts for the Licensed Products, excluding any Impax Generic Versions, for use in the Field in the Territory shall identify in equal prominence the Corporate Names of both
AstraZeneca (or the applicable manufacturer) and Impax (except as required by Applicable Law). 

  
 50 

 5.3. Violation of Law. In the event that Impax receives notice of or otherwise
becomes aware of the same, it shall promptly report to AstraZeneca all notices (or threatened notices) of violation of Applicable Law related to Impax’ Exploitation of the Licensed Products in the Territory received from Regulatory Authorities
or any competitor company or other Person and shall provide to AstraZeneca copies of all such notices and related communications. In the event that AstraZeneca receives notice of or otherwise becomes aware of the same, it shall immediately report to
Impax all notices (or threatened notices) of violation of Applicable Law related to Impax’ Exploitation of the Licensed Products in the Territory received from Regulatory Authorities or any competitor company or other Person and shall provide
to Impax copies of all such notices and related communications. 
 5.4. Pharmacovigilance. Each Party shall duly
and punctually perform all of its obligations under and pursuant to the Safety Agreement. 
 5.5. Medical Affairs
Activities. AstraZeneca shall use Commercially Reasonable Efforts to provide without charge to Impax during the Term medical affairs professional information request (PIR) support for the Existing Products on a support level consistent with the
Tier 2 PIR Support Level. If at any time beginning on the first anniversary of the Effective Date Impax wishes to assume responsibility for medical affairs PIR support for the Existing Products (other than with respect to ISS) on a support level
consistent with the Tier 2 PIR Support Level, Impax shall so notify AstraZeneca and, if Impax can demonstrate to AstraZeneca’s reasonable satisfaction that Impax is reasonably capable of providing such support at such support level, thereafter
shall be responsible for doing so, following a reasonable transition period. 
 Article 6 

GRANT OF RIGHTS 

6.1. Grants to Impax. Subject to Sections 6.6 and 6.7 and the other terms and conditions of this Agreement, AstraZeneca, on behalf
of itself and its Affiliates, hereby grants to Impax: 
 6.1.1. an exclusive (even as to AstraZeneca and its Affiliates)
royalty-bearing right and license, with the right to sublicense solely as provided in Section 6.3, under the AstraZeneca Patents to Commercialize Existing Products in the Field in the Territory, including, subject to Sections 4.1.2 and 4.1.3,
New Indications for Existing Products in the Field in the Territory and subject to Section 6.5, Generic Versions of Existing Products in the Field in the Territory. 
 6.1.2. a non-exclusive royalty-bearing right and license, with the right to sublicense solely as provided in Section 6.3, under the AstraZeneca Patents (i) subject to Sections 4.1.2 and
4.1.3, to Develop anywhere in the world New Indications for Existing Products for Commercialization in the Field in the Territory, and (ii) following the termination by AstraZeneca of the Supply Term with respect to each Existing Product, to
Manufacture such Existing Product anywhere in the world solely for use in the exercise of the license rights granted in Section 6.1.1 and clause (i) of this Section 6.1.2. 

  
 51 

 6.1.3. subject to Sections 4.1.2 and 4.1.3, an exclusive (even as to AstraZeneca and
its Affiliates) royalty-bearing right and license, with the right to sublicense solely as provided in Section 6.3, under the AstraZeneca Patents to Commercialize Additional Products in the Field in the Territory. 

6.1.4. subject to Sections 4.1.2 and 4.1.3, a non-exclusive royalty-bearing right and license, with the right to sublicense
solely as provided in Section 6.3, under the AstraZeneca Patents (i) to Develop anywhere in the world one or more Additional Products for Commercialization in the Field in the Territory, and (ii) to Manufacture Additional Products
anywhere in the world solely for use in the exercise of the license rights granted in Section 6.1.3 and clause (i) of this Section 6.1.4. 
 6.1.5. a royalty-bearing exclusive (even as to AstraZeneca and its Affiliates) sublicense, without the right to further sublicense, under the license granted to AstraZeneca by [***] pursuant to
Section 2.1 of the [***] License Agreement solely for Impax to Commercialize in the Field in the Territory Zomig-ZMT [***]. The sublicense granted by AstraZeneca to Impax pursuant to this Section 6.1.5 shall be subject and subordinate to
the terms and conditions of the [***] License Agreement, including the confidentiality obligations set forth therein, and shall be effective solely to the extent permitted under the terms of such agreement. Except as provided in this
Section 6.1.5, AstraZeneca grants no sublicense rights under any license agreement entered into by AstraZeneca and any Third Party(ies). Without limitation of the foregoing, in the event and to the extent that the [***] License Agreement
(i) contains terms and conditions that provide AstraZeneca a license or the right to grant (sub)licenses for a field of use, territory, compound or product that is narrower or more limited than the corresponding provisions of this Agreement,
the sublicenses granted by AstraZeneca to Impax under such license shall be deemed to permit Impax to exercise such sublicense only with respect to such more limited field, territory, compound or product, as applicable, each as defined in the [***]
License Agreement (and, for clarity, in no event shall the scope of any definition or terms under the [***] License Agreement expand the sublicense granted herein), or (ii) requires that particular terms or conditions of such agreement be
contained or incorporated in any agreement granting a sublicense thereunder, such terms and conditions are hereby deemed to be incorporated herein by reference and made applicable to the sublicense granted herein under the [***] License Agreement.
Except for any sublicense granted pursuant to a settlement agreement under Section 10.3.2, AstraZeneca covenants to Impax that AstraZeneca shall not, and shall cause its Affiliates not to, grant to any Third Party any sublicense under the
license granted to AstraZeneca by [***] pursuant to Section 2.1 of the [***] License Agreement to Commercialize Zomig-ZMT in the Field in the Territory during the Term. 
 6.1.6. a royalty-bearing, non-exclusive right of cross-reference or right of reference under the Regulatory Approvals (including the NDAs with respect to the Existing Products listed in Schedule
12.2.1(ii)) and the INDs that AstraZeneca or its Affiliates Control with respect to the Existing Products, and a non-exclusive license under any AstraZeneca Regulatory Documentation that is provided by AstraZeneca to Impax pursuant to
Section 4.4, as necessary for use by Impax in the activities contemplated by Sections 6.1.1 through 6.1.5 and subject to the requirements set forth in Sections 4.1.2, 4.1.3 and 6.5. Such license, other than with respect to Impax Generic
Versions, shall be sublicensable to Third Parties to which Impax grants a sublicense under the license granted to it in Section 6.1.1 or 6.1.3. In connection with 

  
 52 

 
the foregoing, in the event the FFDCA or its applicable implementing regulations, or equivalent Applicable Laws in foreign jurisdictions, require AstraZeneca to provide Impax or its Sublicensees
with a signed statement to effectuate the intent of this Section 6.1.6, AstraZeneca shall provide any such signed statement if requested by Impax in accordance with the FFDCA or other Applicable Law, or will otherwise communicate as necessary
with the FDA or other Regulatory Authority to ensure that Impax and its Sublicensees may conduct the activities contemplated by Sections 6.1.1 and 6.1.3, which in the case of Commercialization of Licensed Products shall be conducted solely in the
Territory. For clarity, reference in the foregoing sentence to foreign jurisdictions and Regulatory Authorities other than the FDA are not intended and shall not be construed to require AstraZeneca to grant any right of cross reference or right of
reference outside the Territory to enable, or in support of, Impax’ Commercialization of any Licensed Product outside the Territory, and any right or cross reference or right of reference outside the Territory shall be granted solely in
connection with Impax’ conduct of any Impax Study outside the Territory for the purpose of Commercializing Licensed Products in the Territory, subject to the requirements set forth in Section 4.1.2 and 4.1.3 and the other terms and
conditions of this Agreement. 
 6.1.7. a non-exclusive right and license, with the right to sublicense solely as
provided in Section 6.3, under the AstraZeneca Improvement Patents for Impax to engage in the activities provided in clauses 6.1.1 through 6.1.5; provided, however, that for the avoidance of doubt, AstraZeneca shall have no obligation to
disclose any AstraZeneca Improvements or AstraZeneca Improvement Patents to Impax or transfer any of the foregoing in connection with this Section 6.1.7 or the other terms or conditions of this Agreement, except to the extent that disclosure is
required in connection with activities conducted pursuant to Section 8.19. 
 6.1.8. subject to
Section 10.1.4, a non-exclusive license to use AstraZeneca’s Corporate Names solely for the Commercialization of the Licensed Products in the Field in the Territory in accordance with the terms and conditions of this Agreement, including
Sections 3.15.7 and 5.2.3(ii), and for no other purpose. Such license shall be sublicensable to Third Parties to which Impax grants a sublicense under the licenses granted to it in Section 6.1.1 or 6.1.3. 

6.1.9. an exclusive (even as to AstraZeneca and its Affiliates) royalty-bearing right and license, to use the Product Trademarks
solely for Commercialization of the Licensed Products in the Field in the Territory in accordance with the terms and conditions of this Agreement. Such license shall be sublicensable to Third Parties to which Impax grants a sublicense under the
license granted to it in Section 6.1.1 and 6.1.3; provided, however, that Impax obtains AstraZeneca’s prior written consent to any such sublicense, not to be unreasonably withheld, conditioned or delayed, and AstraZeneca shall respond to a
request for consent pursuant to this Section 6.1.9 within [***]. This license shall not permit Impax to use the Product Trademarks on or in connection with any Impax Generic Version or any product other than the Licensed Products. 

For clarification, all royalty-bearing licenses shall bear royalties solely in accordance with Article 7. 

  
 53 

 6.2. Grants to AstraZeneca. Subject to 6.6.1 and the other terms and
conditions of this Agreement, Impax hereby grants to AstraZeneca: 
 6.2.1. a non-exclusive, royalty-free right and
license, without the right to grant sublicenses, under the Impax Patents, Impax Improvement Patents and Impax Know-How, solely for the purposes of performing its obligations under this Agreement. 

6.2.2. an irrevocable, royalty-free, perpetual, non-exclusive license and right of cross-reference or right of reference under
the Impax Study Data, Impax Regulatory Documentation and Regulatory Approvals that Impax or its Affiliates Control with respect to the Licensed Compound or Licensed Products solely as reasonably necessary for (i) AstraZeneca and its Affiliates
or (sub)licensees (a) to comply with any requirement to report worldwide clinical studies or safety information with respect to a product containing the Licensed Compound to Regulatory Authorities or (b) to make filings seeking or
maintaining Regulatory Approval of such product containing the Licensed Compound and (ii) AstraZeneca and its Affiliates to perform AstraZeneca’s obligations under this Agreement. In connection with the foregoing, in the event the FFDCA or
its applicable implementing regulations, or equivalent Applicable Laws in foreign jurisdictions, require Impax to provide AstraZeneca or any of its Affiliates or (sub)licensees with a signed statement to effectuate the intent of this
Section 6.2.2, Impax shall provide any such signed statement if requested by AstraZeneca in accordance with the FFDCA or other Applicable Law, or will otherwise communicate as necessary with the FDA or other Regulatory Authority to ensure that
AstraZeneca or any of its Affiliates or sublicensees may conduct the activities contemplated by this Section 6.2.2. 

6.2.3. an irrevocable, royalty-free, perpetual, non-exclusive right and license, with the right to sublicense through multiple
tiers, under the Impax Improvement Patents to (i) Exploit the Licensed Compound and products containing the Licensed Compound outside the Territory or in the Territory in support of Exploitation outside the Territory (including to conduct
Development activities in the Field in the Territory in furtherance of the right to Exploit the Licensed Compound or products containing the Licensed Compound outside the Territory), and (ii) to Manufacture or have Manufactured anywhere in the
world the Licensed Compound or products containing the Licensed Compound for use in the activities provided in clause (i); provided, however, that for the avoidance of doubt, Impax shall have no obligation to disclose any Impax Improvements or Impax
Improvement Patents to AstraZeneca in connection with this Section 6.2.3 or the other terms or conditions of this Agreement, except to the extent that disclosure is required in connection with activities conducted pursuant to Article 4 or
Article 5. 
 6.2.4. a royalty-free, non-exclusive license to use Impax’ Corporate Names solely as required to
Manufacture the Supplied Products in accordance with this Agreement and as required for any actions in connection with any submissions to Regulatory Authorities as contemplated hereunder or as required by Applicable Law. 

  
 54 

 6.3. Impax Sublicenses. 

6.3.1. Obligations with respect to Sublicensees. Any sublicenses that Impax is permitted to grant pursuant to
Section 6.1 or Section 10.3.2 shall be subject to (i) the prior written consent of [***] if required under the [***] License Agreement, and (ii) AstraZeneca’s prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed; [***] and provided further that in the case of any sublicense under clause (ii) of Section 6.1.2, such consent shall be subject to the applicable Third Party qualifying as a Third Party contract
manufacturer as contemplated in Section 8.19.2, and in each case AstraZeneca shall respond to a request for consent pursuant to this clause (ii) within [***]. Impax shall include in each sublicense agreement (except for those sublicenses
granted pursuant to a settlement agreement under Section 10.3.2) terms and conditions that require the Sublicensee to comply with the applicable terms and conditions of this Agreement and, as applicable, the [***] License Agreement, and shall
use Commercially Reasonable Efforts to cause each Sublicensee to comply with the applicable terms and conditions of this Agreement and, as applicable, the [***] License Agreement, provided, however, that if any Sublicensee fails to comply with the
terms and conditions of this Agreement (including Section 3.9, 3.16.2 or this Section 6.3.1) or the sublicense agreement, Impax shall promptly notify AstraZeneca in writing upon becoming aware of any such non-compliance and, whether or not
Impax has fulfilled its notice obligations, in the event of any such non-compliance by any of its Sublicensees, AstraZeneca shall have the right to terminate such Sublicensee’s sublicense or right of reference, as applicable, and [***],
effective automatically upon AstraZeneca’s providing notice thereof to Impax. [***] Any such permitted sublicenses shall be consistent with and expressly made subject to the terms and conditions of this Agreement and, as applicable, the [***]
License Agreement. A copy of any sublicense agreement executed by Impax shall be provided to AstraZeneca within [***] after its execution; provided that the financial terms and other terms of any such sublicense agreement may be redacted to the
extent not pertinent to an understanding of a Party’s obligations or benefits under this Agreement. 
 6.3.2.
Termination of Sublicenses. In the event of termination of this Agreement, any sublicense granted by Impax shall automatically be deemed to terminate to the same extent as the license or other rights granted by AstraZeneca to Impax in
Section 6.1, and the other terms and conditions of this Agreement, terminate. 
 6.4. [***] Compliance. 

6.4.1. AstraZeneca shall, and cause its Affiliates to, [***] of the [***] License Agreement and [***] Supply Agreement, including
by making all payments required thereunder to [***] (provided that nothing contained in this Section 6.4.1 shall apply with respect to terms that depend for compliance on the acts or omissions of Impax or any of its Affiliates or Sublicensees
or any Third Party to which a sublicense is granted pursuant to a settlement agreement under Section 10.3.2). For clarity, (i) any costs, payments and fees due from or payable by AstraZeneca or its Affiliates under the terms of the [***]
License Agreement or [***] Supply Agreement shall be paid by [***], and (ii) the [***] from [***] for supply to Impax as Supplied Products. 
 6.4.2. AstraZeneca shall not, and shall cause its Affiliates not to, exercise any right of AstraZeneca or its Affiliates to [***]; provided, however, that AstraZeneca shall be permitted to [***].

  
 55 

 6.4.3. AstraZeneca shall provide to Impax reasonable notice of
(i) AstraZeneca’s or its Affiliate’s receipt of [***] and (ii) AstraZeneca’s or its Affiliate’s receipt of [***]. AstraZeneca shall provide to Impax prompt written notice [***]. 

6.4.4. In the event of termination of the [***] License Agreement, in whole or in part with respect to the Territory, any
sublicense granted by Impax under such [***] License Agreement shall automatically terminate to the same extent as the license or other rights granted to AstraZeneca in such [***] License Agreement. 

6.5. Authorized Generics. 
 6.5.1. The license granted by AstraZeneca to Impax pursuant to Section 6.1.1 shall include the exclusive (even as to AstraZeneca and its Affiliates) right to Commercialize in the Field in the
Territory an Impax Generic Version of each Existing Product mode of administration and dosage strength in reliance on AstraZeneca’s NDA with respect to such Existing Product, subject to the terms and conditions of this Section 6.5 and the
other terms and conditions of this Agreement. Any such Impax Generic Version shall be identical to the corresponding branded Existing Product, except that the Impax Generic Version shall not be sold under the Product Trademarks (and Product Labels
and Inserts with respect to any Impax Generic Versions shall be modified accordingly). 
 6.5.2. Impax covenants to
AstraZeneca that [***]: 
 (i) in the case of all Impax Generic Versions, Impax may, [***] (a) notify potential customers
that it will have the right to sell such Impax Generic Version as of the applicable Generic Launch Date, (b) engage in discussions with or enter into arrangements with customers relating to such Impax Generic Version [***] in accordance with
Applicable Law and in accordance with other procedures approved in advance by AstraZeneca, such approval with respect to procedures not to be unreasonably conditioned, withheld or delayed; 

(ii) in the case of all Impax Generic Versions, Impax may, [***], [***] Product of such Impax Generic Version [***] owned by Impax or
any of its Affiliates or by one or more [***] pursuant to the terms of a [***] Agreement to be entered into between AstraZeneca and Impax, and a further Third Party [***] Agreement to be entered into between Impax and one or more [***] for such
Impax Generic Version, in each case in the form of agreement to be agreed upon by the Parties in good faith pursuant to Section 6.5.3; 
 (iii) in the case of any Impax Generic Version with respect to a Licensed Product consisting of any [***], in addition to the Impax rights pursuant to clauses (i) and (ii), Impax shall have the
right, [***] (a) to [***] pursuant to the terms of a [***] Agreement to be entered into between AstraZeneca and Impax, and a further Third Party [***] Agreement to be entered into between Impax and [***] for such Impax Generic Version, in each
case in the form of agreement to be agreed upon by the Parties in good faith pursuant to Section 6.5.3; and (b) to take such other reasonable [***] as are consistent with the terms of this Agreement and Applicable Law, including [***].
Further, in the event a [***], then Impax and AstraZeneca shall in good faith discuss whether [***] activities for the corresponding Impax Generic Version of such Existing Product as provided under this Section 6.5.2(iii) for Impax Generic
Versions of [***].  

  
 56 

 (iv) Except as expressly permitted pursuant to the preceding clauses (i) through
(iii), Impax shall not advertise, market, sell, accept orders for sale, ship, or Commercialize any Impax Generic Version to Third Parties prior to [***]. 
 6.5.3. With respect to each Existing Product, upon (i) [***] of an Existing Product in the Territory or (ii) reasonably in advance of the Anticipated Generic Date, at the request of
either Party, (a) the Parties shall coordinate in good faith with respect to the [***] activities with respect to the Impax Generic Version as set forth in Section 6.5.2; and (b) the Parties shall negotiate in good faith to agree upon
the form of [***] Agreement that will apply with respect to the applicable Impax Generic Version, and the form of any Third Party [***] Agreement that must be used by Impax in entering into any such [***] agreement with Third Parties, including, as
applicable[***] as permitted pursuant to this Section 6.5. Any such [***] Agreement or Third Party [***] Agreement shall provide, among other terms, that (x) [***], and (y) notwithstanding clause (x), subject to Section 8.17.3
and 8.17.4, [***]. 
 6.5.4. In the event that, following the launch by Impax of such Impax Generic Version, there
[***], Impax shall immediately [***] in the Field in the Territory (and [***]). 
 6.5.5. Impax shall [***] by this
Agreement. 
 6.5.6. Except as provided in this Section 6.5, no Party shall have the right to, and each Party
covenants to the other Party that it shall not, and shall cause its Affiliates and Sublicensees not to, directly or indirectly, [***] in the Field in the Territory during the Term, or, [***]. Except with respect to the Exploitation of an Impax
Generic Version in accordance with this Section 6.5, Impax covenants to AstraZeneca that neither Impax nor any of its Affiliates or Sublicensees will [***]. 
 6.6. Reservation of Rights. 
 6.6.1. Any rights of a Party not
expressly granted to the other Party under the provisions of this Agreement shall be retained by such Party. In addition, AstraZeneca and its Affiliates expressly retain the rights under the AstraZeneca Patents, AstraZeneca Improvement Patents,
AstraZeneca Corporate Names, Product Trademarks, the AstraZeneca Regulatory Documentation Regulatory Approvals or Controlled by AstraZeneca, the Manufacturing Know-How, and any other Patent or intellectual property rights, to perform all its
obligations pursuant to this Agreement. 
 6.6.2. Except as expressly provided herein, AstraZeneca grants no other right
or license, including any rights or licenses to the AstraZeneca Patents, AstraZeneca Improvement Patents, AstraZeneca Corporate Names, Product Trademarks, the Regulatory Approvals or Regulatory Documentation Controlled by AstraZeneca, the
Manufacturing Know-How, or any other Patent or intellectual property rights not otherwise expressly granted herein. Except as expressly provided herein, Impax grants no other right or license, including any rights or licenses to the Impax Patents,
Impax Improvement Patents, Impax Corporate Names, the Regulatory Approvals or Regulatory Documentation Controlled by Impax (including Impax Regulatory Documentation), or any other Patent or intellectual property rights not otherwise expressly
granted herein. 

  
 57 

 6.7. Non-Compete Covenants. Subject to Section 6.8, neither Party shall
(and each Party shall cause its Affiliates and, with respect to Section 6.7.2 only, Impax shall cause its Sublicensees, not to) directly or indirectly: 
 6.7.1. market, distribute or sell or otherwise Commercialize any Competing Product for use in the Field in the Territory during the Term; 

6.7.2. market, distribute or sell or otherwise Commercialize any Restricted Product inside or outside of the Territory during the
Term; provided, however, that the covenant set forth in this Section 6.7.2 shall automatically be null and void beginning on the first date on which [***]. 
 6.7.3. develop or seek regulatory approval for any Competing Product in the Field for Commercialization in the Territory [***]; or 

6.7.4. [***] (in the case of Section 6.7.2, for so long as such Section remains in effect). 

The Parties acknowledge that all restrictions contained in this Section 6.7 and in Section 6.9 are reasonable, valid and necessary for each
party to get the full benefits contemplated by this Agreement and that the Parties would not have entered into this Agreement without the protection afforded to them by this Section 6.7 and Section 6.9. 

6.8. [***]. Notwithstanding Section 6.7, if a [***] of any Party or any of its Affiliates (collectively, the
“Subject Party”) occurs or the Subject Party [***] and the Third Party to such transaction was engaged in an activity that would have otherwise constituted a breach of Section 6.7, then [***]. Within [***] of the consummation
of such a [***], the Subject Party (or its successor) shall provide the other Party with written notice thereof. 
 6.9.
[***]. 
 6.10. [***] Products. 
 6.10.1. Except as provided herein in connection with AstraZeneca’s performance of its obligations under this Agreement, including under the Transition Plan, AstraZeneca covenants to Impax that
it shall not, and shall cause its Affiliates not to, directly or indirectly, launch or Commercialize any product that [***], or, except for any license granted in a settlement agreement under Section 10.3.2, license or assist any Third Party to
[***]. 
 6.10.2. Impax covenants to AstraZeneca that it shall not, and shall cause its Affiliates and Sublicensees not
to, directly or indirectly, [***] except under this Agreement, or, except for any (sub)license granted in a settlement agreement under Section 10.3.2, license or assist any Third Party to [***]. 

  
 58 

 6.11. Certain Licenses to Impax Study Data and Impax Regulatory Documentation.

 6.11.1. Notwithstanding Section 6.2.2, in the event AstraZeneca desires to obtain a license to utilize or
otherwise file with a Regulatory Authority the Impax Study Data or Impax Regulatory Documentation, in each case to obtain or maintain Regulatory Approval outside the Territory for a product containing the Licensed Compound other than an Existing
Product or for an indication other than an Approved Indication, AstraZeneca and Impax shall negotiate in good faith a separate license agreement pursuant to which Impax would license such Impax Study Data or Impax Regulatory Documentation to
AstraZeneca for purposes of obtaining or maintaining such Regulatory Approval outside the Territory on commercially reasonable terms. For clarity, nothing contained in this Section 6.11.1 is intended or shall be construed to be in derogation of
AstraZeneca’s rights and licenses under clause (i)(a) of Section 6.2.2 or to obligate any Party to enter into a license under this Section 6.11.1. 
 6.11.2. In the event AstraZeneca desires to obtain an exclusive license under any Impax Improvement Patent to Commercialize the Licensed Compound and products containing the Licensed Compound
outside the Territory, AstraZeneca and Impax shall negotiate in good faith a separate license agreement pursuant to which Impax would license such Impax Improvement Patent on commercially reasonable terms. Nothing contained in this
Section 6.11.2 is intended or shall be construed to be in derogation of the non-exclusive license provided to AstraZeneca in Section 6.2.3 or to obligate any Party to enter into a license under this Section 6.11.2. 

Article 7 

PAYMENTS AND RECORDS 

7.1. Lump Sum Payments. Subject to the other provisions of this Section 7.1, Impax shall pay AstraZeneca an amount
equal to (i) [***]; (ii) [***]; (iii) [***]; and (iv) [***] (each such payment is referred to herein as a “Fixed Payment” and collectively as the “Fixed Payments”). Each Fixed Payment shall be
nonrefundable and non-creditable against any other payments due hereunder. In the event that any [***] occurs during the period between any two (2) successive Fixed Payments or, in the case of the first Fixed Payment, the period between the
Effective Date and the first Fixed Payment (each such period, a “Payment Period”), then Impax can elect (in its sole discretion by written notice to AstraZeneca) at any time during such Payment Period to reduce the amount of the
Fixed Payment to be made at the end of such Payment Period by an amount equal to [***] (each such affirmative election to reduce, a “Proration Election”), and upon such Proration Election, such Fixed Payment will be reduced accordingly. In
the event that Impax makes a Proration Election, then [***]. For clarity, (x) Impax’ right to make a Proration Election is available for [***] solely to the extent occurring [***] except as described in this Section 7.1, and
(y) Impax shall [***]. 
 7.2. Royalties. 
 7.2.1. Royalty Payments for Licensed Products other than Impax Generic Versions. 

  
 59 

 (i) As further consideration for the rights granted to Impax hereunder, Impax shall pay to
AstraZeneca a royalty on Net Sales of each Existing Product (for clarity excluding any Impax Generic Version) in the Territory during each applicable period at the following rates: 

 

				September 30,	
	Net Sales in the Territory of the applicable Existing Products (for clarity excluding any Impax Generic Version)	    	Royalty Rate	 
	 For aggregate Net Sales of all Existing Products (for clarity excluding any Impax Generic Version) in the Territory during
[***]
	    	 	[	***] 
	 For aggregate Net Sales of all Existing Products (for clarity excluding any Impax Generic Version), [***] in the Territory during
[***]
	    	 	[	***] 
	 For aggregate Net Sales of [***] (for clarity excluding any Impax Generic Version) in the Territory during [***]
	    	 	[	***] 

 (ii) As further consideration for the rights granted to Impax hereunder, Impax shall pay to AstraZeneca
a royalty on Net Sales of each Additional Product in the Territory during each Calendar Year (or portion thereof) during the Royalty Term at a rate of [***] of the aggregate Net Sales of all Additional Products in the Territory during such Calendar
Year (or portion thereof) during the Royalty Term. 
 (iii) In the event that, at any time during the Royalty Term on or after
[***], with respect to any Existing Product mode of administration and dosage strength, a Third Party Generic Version is sold commercially in the Field in the Territory, beginning with the first day of the Calendar Quarter following the Calendar
Quarter in which the first commercial sale of such Third Party Generic Version occurs (or if the first commercial sale occurs prior to [***], beginning on [***]), the royalty on aggregate Net Sales set forth in this Section 7.2 for the Existing
Product (for clarity excluding any Impax Generic Version) with the same mode of administration and dosage strength shall be reduced to [***]. For clarity, in the event that the first commercial sale of any such Third Party Generic Version occurs
prior to [***], and all such Third Party Generic Versions cease to be sold prior to [***], the full royalty rate shall remain unchanged until such time that a [***]. 
 7.2.2. Royalty Payments for Impax Generic Versions. As further consideration for the rights granted to Impax hereunder[***], Impax shall pay AstraZeneca royalties on Gross Profit from Impax
Generic Versions in the Territory during each Calendar Year (or portion thereof) during the Royalty Term at a rate of [***] of the aggregate Gross Profit of such Impax Generic Versions during such Calendar Year (or portion thereof) during the
Royalty Term (such payments, “Impax Generic Version Payments”). 

  
 60 

 7.2.3. Royalty Reduction for Licensed Products. Subject to Section 7.2.4 and
7.2.5: 
 (i) If, during the Term, Impax enters into a license with a Third Party pursuant to Section 10.6 with
respect to Patents necessary to Commercialize Existing Products in the Territory for Approved Indications, then, as of the effective date of any such license and thereafter during the remainder of the period during which Impax owes royalties to
AstraZeneca hereunder on Net Sales of any Licensed Product in the Territory, the amounts payable under Sections 7.2.1 and 7.2.2 in a Calendar Quarter on sales of such Existing Products in the Territory shall be reduced by an amount equal to the sum
of [***] of all license fees (including royalties, milestones and upfront payments, but solely to the extent reasonably allocable to the Commercialization of Existing Products for Approved Indications in the Territory) paid under such license by or
on behalf of Impax to such Third Party in such Calendar Quarter on sales of such Existing Product in the Territory. 
 (ii) If
during the Term, in accordance with Section 10.4, Impax pays to a Third Party(ies) [***] with respect to an Existing Product for an Approved Indication, or pays to a Third Party(ies) [***] with the prior written approval of AstraZeneca, not to
be unreasonably withheld, conditioned or delayed, then to the extent such amounts are not subject to an indemnification obligation of AstraZeneca pursuant to Section 13.2, the amounts payable under Sections 7.2.1 and 7.2.2 in a Calendar Quarter
on sales of such Existing Products in the Territory shall be reduced by an amount equal to the sum of [***] of all such amounts [***] in the applicable Calendar Quarter. In the event that Impax [***] with respect to this Section 7.2.3(ii), and
either Party is [***]. 
 7.2.4. Maximum Amount of Royalty Reduction. Notwithstanding any term or condition of
this Agreement to the contrary, in no event shall the royalties payable to AstraZeneca pursuant to Sections 7.2.1 and 7.2.2 be reduced by more than [***] in any Calendar Quarter as a result of any reductions, offsets or setoffs permitted pursuant to
this Agreement, whether taken in a Calendar Quarter alone or in the aggregate with other permitted reductions or offsets, including pursuant to Section 7.2.3 and Section 8.15. Reductions not applied or exhausted in any Calendar Quarter as
a result of this Section 7.2.4 may be carried into future Calendar Quarters until fully applied or exhausted, subject to the foregoing sentence, and [***] and with respect to which a reduction in royalties is available pursuant to
Section 7.2.3, may be carried into [***] or subsequent Calendar Quarters, as the case may be, until fully used in accordance with this Section 7.2.4. 
 7.2.5. Other Limitation on Royalty Reductions. Notwithstanding any right of offset or reduction of royalties provided in this Agreement, in no event shall any offset or reduction in
royalties payable by Impax, including pursuant to Sections 7.2.3, 8.15, 10.4.2, and 10.6 whether such reduction is calculated alone or as aggregated with other permitted reductions or offsets, cause the royalty amount payable by Impax to AstraZeneca
in any Calendar Quarter to fall below [***] with respect to such Calendar Quarter [***] in the Territory. The Parties will coordinate to ensure that Impax has information sufficient to [***], taking account of this Section 7.2.5, in sufficient
time for Impax to make timely payments to AstraZeneca under this Agreement. Reductions not applied or exhausted in any Calendar Quarter as a result of this Section 7.2.5 may be carried into future Calendar Quarters until fully applied or
exhausted, subject to the foregoing sentence. For clarity, nothing in this Section 7.2.5 shall apply with respect to [***]. 

  
 61 

 7.2.6. Reasonableness of Royalty Payments and Impax Generic Version Payments.
The Parties acknowledge and agree that the Royalty Payments and Impax Generic Version Payments are fair and reasonable in that they represent blended rates and a blended percentage, respectively, as consideration for the various rights and licenses
granted by AstraZeneca to Impax hereunder, including AstraZeneca’s grants to Impax of the licenses and rights of reference provided in Section 6.1 with respect to AstraZeneca Patents, AstraZeneca Improvement Patents, Product Trademarks,
Regulatory Approvals and Regulatory Documentation, as well as consideration to AstraZeneca for various activities to be performed by AstraZeneca hereunder and under the Safety Agreement, including in regard to regulatory activities, medical affairs,
pharmacovigilance and maintenance of the global safety database. 
 7.2.7. Royalty Term. With respect to each
Licensed Product or Impax Generic Version, Impax’ obligation to make Royalty Payments and Impax Generic Version Payments shall commence on the date of the First Commercial Sale of such Licensed Product or Impax Generic Version, as applicable,
and shall continue for as long as such product is sold in the Territory by or on behalf of Impax (such period, the “Royalty Term”). 
 7.3. Payments and Reports. Impax shall calculate all amounts payable to AstraZeneca pursuant to Sections 7.2.1 and 7.2.2 at the end of each Calendar Quarter. Impax shall pay to AstraZeneca
the Royalty Payments and Impax Generic Version Payments due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment due to AstraZeneca shall be accompanied by a statement of the amount of gross
sales, Net Sales and Gross Profit, as applicable, of each Licensed Product in the Territory during the applicable Calendar Quarter and a calculation of the amount due on such Net Sales and Gross Profit for such Calendar Quarter. Without limiting the
generality of the foregoing, Impax shall require its Affiliates and Sublicensees to account for its Net Sales and Gross Profit to provide such reports with respect thereto as if such sales were made by Impax. 

7.4. Mode of Payment. All payments to either Party under this Agreement shall be made by electronic transfer of Dollars in
the requisite amount to such bank account as the receiving Party may from time to time designate by notice to the paying Party. 

7.5. Taxes. 
 7.5.1. The amounts payable by one Party to the other Party pursuant to this Agreement (each, a “Payment”) shall be paid free and clear of any and all taxes, except for any
withholding taxes required by Applicable Law. Except as provided in this Section 7.5, the Party receiving any Payment hereunder shall be solely responsible for paying any income and other taxes arising with respect to such Payment. If any
Payment is subject to withholding tax, the Parties shall use Commercially Reasonable Efforts to perform all acts (including by executing all appropriate documents) so as to enable the Party receiving such Payment to take advantage of any applicable
double taxation agreement or treaty. In the event there is no applicable double taxation agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the Party making
such Payment to the other Party shall pay the applicable withholding or similar tax to the appropriate government authority, shall deduct the amount paid from the amount due to the other Party, and shall provide to the other Party evidence of such
payment within [***] following such payment. 

  
 62 

 7.5.2. All Payments pursuant to this Agreement are exclusive of Indirect Taxes. If
any Indirect Taxes are chargeable in respect of any Payments, the payer shall pay such Indirect Taxes at the applicable rate in respect of any such Payments following the receipt, where applicable, of an Indirect Taxes invoice in the appropriate
form issued by the recipient in respect of those Payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement
purposes. 
 7.6. Interest on Late Payments. If any Payment due to either Party under this Agreement is not paid
when due, then such paying Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of [***], such interest to run from the date on which payment of such sum became due until
payment thereof in full together with such interest. 
 7.7. Financial Records. 

7.7.1. Impax shall, and shall cause its Affiliates to, keep complete and accurate books and records pertaining to Net Sales and
Gross Profits, in sufficient detail to calculate all amounts payable hereunder and to verify compliance with its obligations under this Agreement, including the Transition Plan. Such books and records shall be retained by Impax and its Affiliates
until the later of (i) [***] after the end of the period to which such books and records pertain, and (ii) the expiration of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be
required by Applicable Law. 
 7.7.2. AstraZeneca shall, and shall cause its Affiliates to, keep complete and accurate
books and records pertaining to each Supply Price and, in connection with its obligations pursuant to the Transition Plan, AstraZeneca Net Sales of Transition Product, in sufficient detail to calculate all amounts payable hereunder and to verify
compliance with its obligations under this Agreement. Such books and records shall be retained by AstraZeneca and its Affiliates until the later of (i) [***] after the end of the period to which such books and records pertain, and (ii) the
expiration of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be required by Applicable Law. 
 7.8. Payment Audit. 
 7.8.1. At the request of either Party, the
other Party being audited shall, and shall cause its Affiliates to, permit an independent auditor designated by the auditing Party and reasonably acceptable to the audited Party (the “Independent Auditor”), at reasonable times and
upon reasonable notice, to audit the books and records maintained pursuant to Section 7.7 to ensure the accuracy of all reports and payments made hereunder. The Party being audited shall cooperate with the Independent Auditor’s
investigation, and the results of any audit under this Section 7.8.1 shall (i) disclose only whether any report or payment made under this Agreement is correct or incorrect and the amount of any discrepancy and (ii) be made available

  
 63 

 
to both Parties. Except as provided below, the cost of this audit shall be borne by the auditing Party, unless the audit reveals a variance of more than [***] from the reported amounts and such
variance benefitted the audited Party, in which case the audited Party shall bear the cost of the audit. Unless disputed pursuant to Section 7.8.2, if such audit concludes that (a) additional amounts were owed by the audited Party, the
audited Party shall pay the additional amounts, or (b) excess payments were made by the audited Party, the auditing Party shall reimburse such excess payments, in either case ((a) or (b)), with interest from the date originally due as provided
in Section 7.6 and within [***] after the date on which such audit is completed by the auditing Party. 
 7.8.2. In
the event of a dispute with respect to any audit under Section 7.8.1, AstraZeneca and Impax shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within
[***], the dispute shall be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the
“Arbitrator”). The decision of the Arbitrator shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Arbitrator shall determine. Not later than
[***] after such decision and in accordance with such decision, the audited Party shall pay the additional amounts that were not paid, with interest from the date originally due as provided in Section 7.6, or the auditing Party shall reimburse
the excess payments that were paid, as applicable. 
 7.8.3. Each Party shall treat all information subject to review
under this Section 7.8 in accordance with the confidentiality provisions of Article 11 and the Parties shall cause the Arbitrator to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such firm to
retain all such financial information in confidence pursuant to such confidentiality agreement. 
 7.9. No Setoff;
Offset. Except as expressly provided in this Agreement, neither Party shall have a right of offset or setoff of any amounts due and payable to the other Party pursuant to this Agreement, or any Losses arising under this Agreement against any
amounts due and payable from the other Party, or any other Losses arising under this Agreement. The payment obligations and Losses arising under this Agreement shall remain independent obligations of each Party, irrespective of any amounts owed or
Losses attributable to the other Party under this Agreement. 
 Article 8 

SUPPLY 
 8.1. Supply Obligations. Subject to the terms and conditions of this Agreement, during the applicable Supply Term, AstraZeneca agrees to use [***] to supply to Impax, and Impax agrees to
purchase from AstraZeneca, all of Impax’ clinical and commercial requirements of the Supplied Products. Subject to Section 8.23, AstraZeneca, in its sole discretion, shall determine from time-to-time whether to Manufacture the Supplied
Products or to have an Affiliate of AstraZeneca or Third Party Manufacturer Manufacture the Supplied Products and there shall be no limitation on AstraZeneca’s use of an Affiliate or Third Party Manufacturer to Manufacture the Supplied
Products. 

  
 64 

 8.2. Supply Term. 

8.2.1. The applicable supply and purchase obligations on AstraZeneca and Impax set forth pursuant to this Article 8 with respect
to each Supplied Product shall begin on the Effective Date (or such later time as specified in the Transition Plan) and shall continue until the earlier of (i) the date on which this Agreement is terminated in accordance with the terms hereof
and (ii), the date on which AstraZeneca terminates its obligation to supply with respect to the applicable Supplied Product in accordance with this Section 8.2.1 (each such period with respect to each Supplied Product, the “Supply
Term”). AstraZeneca shall have the right to terminate the Supply Term on a Supplied Product-by-Supplied Product basis on at least [***] prior written notice (provided that, in the case of [***] and the corresponding Impax Generic Version,
AstraZeneca shall [***]), provided that the Supply Term with respect to: (a) Zomig Tablets and the corresponding Impax Generic Version shall end no earlier than [***], (b) Zomig-ZMT and the corresponding Impax Generic Version shall end no
earlier than the earlier of [***] or, subject to Section 8.2.2, such earlier date as results from the [***] and (c) the Zomig Nasal Spray and the corresponding Impax Generic Version shall end no earlier than [***], provided, further, that
in the case of Zomig Nasal Spray and the corresponding Impax Generic Version, AstraZeneca shall have the right to terminate the Supply Term prior to [***], on at least [***] prior written notice in the event that (1) [***], (2) [***] or
(3) [***]. 
 8.2.2. In the event that [***], AstraZeneca shall continue to provide Zomig-ZMT as a Supplied Product
to Impax during the Supply Term with respect to Zomig-ZMT. AstraZeneca shall not, and shall cause its Affiliates not to, exercise any right of AstraZeneca or its Affiliates to [***]. For clarity, there shall be no restriction on AstraZeneca’s
right to [***]. 
 8.2.3. Notwithstanding Section 8.2.1, in the event that during the Supply Term for Zomig Nasal
Spray and the corresponding Impax Generic Version, the demand for Zomig Nasal Spray or the corresponding Impax Generic Version declines to a level such that either Party determines it is no longer commercially reasonable for such Party to continue
supplying or purchasing, as applicable, Zomig Nasal Spray or the corresponding Impax Generic Version during the Supply Term, the Parties shall discuss in good faith alternative supply arrangements. 

8.3. Supplied Products Packaging. 
 8.3.1. As soon as practicable and in any event within [***] following the Effective Date, the Parties shall meet to discuss in good faith the appropriate arrangements and timing for the supply of
Supplied Products by AstraZeneca to Impax in the packaging and trade dress of Impax, to be agreed upon by the Parties in writing. Each Party shall use Commercially Reasonable Efforts to effect the transition to the Impax packaging and trade dress.
Subject to Section 8.5, AstraZeneca shall supply Supplied Products to Impax in the packaging and trade dress agreed to pursuant to this Section 8.3.1, as the same may be changed in accordance with the terms of this Agreement. 

  
 65 

 8.3.2. AstraZeneca shall bear the cost of initial conversion of the Product Labels
and Inserts for the Existing Products in order to reflect that Impax will be the distributing Party in the Territory. In the event that, thereafter during the Supply Term for a Supplied Product, Impax requests modifications to the Product Labels and
Inserts for any such Supplied Product (including changes to the packaging presentation), Impax shall bear the costs of such modifications, including the amount of any write-off associated with materials bearing Impax’ previous trade dress or
conforming to the previous packaging and labeling. AstraZeneca shall use Commercially Reasonable Efforts to coordinate with Impax to minimize such write-offs. 
 8.4. Additional Product Supply. For the avoidance of doubt, AstraZeneca shall have no supply or Manufacturing obligations pursuant to this Article 8 with respect to (i) any Additional
Products or (ii) the Existing Products in any dosage strength other than (A) the dosage strengths approved by the FDA in the Territory as of the Effective Date and (B) the [***], in either case ((i) and (ii)), unless AstraZeneca
otherwise agrees in its sole discretion. 
 8.5. Impax Generic Version. Subject to Sections 6.5, 8.6, and 8.7 and
the terms and conditions of any [***], in the event that Impax Commercializes an Impax Generic Version in accordance with this Agreement with a dosage strength and mode of administration corresponding to an Existing Product that is a Supplied
Product that is then being supplied pursuant to Section 8.1 and Section 8.2, AstraZeneca shall use [***] to supply Impax’ requirements of such Impax Generic Version prior to the Anticipated Generic Date and during the applicable
Supply Term in packaging and trade dress of Impax to be reasonably agreed by the Parties. 
 8.6. Forecasts and Orders.

 8.6.1. Initial Purchase Orders. Except with respect to samples of each Existing Product, the initial draft
Purchase Orders for the Supplied Products (broken out by packaging configuration for each dosage strength of each Supplied Product and by NDC) for the month in which the Impax Commercialization Date occurs with respect to the applicable Supplied
Product and each of the first [***] following the Impax Commercialization Date for each such Supplied Product are attached hereto as Schedule 8.6.1 Part A and the delivery schedule for the Supplied Products ordered pursuant to such Purchase Orders
is attached hereto as Schedule 8.6.1 Part B; such drafts to be updated or confirmed as final by Impax within [***] following the Effective Date. The initial Purchase Orders for the Supplied Products consisting of samples (broken out by packaging
configuration for each dosage strength of each Supplied Product and by NDC) for each month beginning with the month in which the Promotion Commencement Date will occur and with respect to each of the [***] following such month are attached hereto as
Schedule 8.6.1 Part C and the delivery schedule for the Supplied Products ordered pursuant to such Purchase Orders is attached hereto as Schedule 8.6.1 Part D. For clarity, AstraZeneca shall have the right to fulfill any or all such Purchase Orders
for the Supplied Products consisting of samples in whole or in part with Supplied Product bearing the AstraZeneca Corporate Names and NDC. 
 8.6.2. Subsequent Forecasts and Purchase Orders. On or before the first day of each month after the Impax Commercialization Date for any Supplied Product other than samples, and on or before
the first day of each month after the Promotion Commencement Date for any Supplied Products consisting of samples, Impax shall provide to AstraZeneca a good faith forecast for such Supplied Products by unit (broken out by packaging configuration

  
 66 

 
for each dosage strength of each such Supplied Product and by NDC) by month for the following [***] (each, a “Planning Forecast”). Except as set forth in Section 8.8, each
Planning Forecast shall be non-binding and shall be used for planning purposes only. On or before the first day of each full Calendar Quarter (the “Current Quarter”) after the Impax Commercialization Date for any Supplied Product,
and after the Promotion Commencement Date for any Supplied Products consisting of samples, Impax shall provide to AstraZeneca (except to the extent already covered by the Purchase Orders described in this Section 8.6) a separate Purchase Order
for each month for such Supplied Products (broken out by packaging configuration for each dosage strength of each such Supplied Product and by NDC) required by Impax in each month for the Calendar Quarter following the Current Quarter. 

8.6.3. Good Faith Forecast by Impax. In addition to the forecasts described above in this Section 8.6, Impax shall
also provide to AstraZeneca, within [***] following the Effective Date, a non-binding, [***], good faith forecast for its requirements of the Supplied Products by unit on a Calendar Quarter basis (broken out by packaging configuration for each
dosage strength of each such Supplied Product and by NDC). Subsequently throughout the Term, Impax shall supply AstraZeneca by [***], a non-binding, [***], good faith forecast for its requirements for the Supplied Products by unit on a Calendar
Quarter basis (broken out by packaging configuration for each dosage strength of each such Supplied Product and by NDC). 

8.6.4. Safety Stock. Except during any period in which AstraZeneca is in breach of its supply obligations hereunder in
circumstances that adversely impact Impax’ ability to comply with this Section 8.6.4, Impax shall use [***] to at all times maintain a level of stock of each Supplied Product NDC approximating at least [***] of anticipated demand from
wholesalers, retailers and other customers for such Supplied Product, provided that this obligation shall not commence until (i) immediately prior to the Impax Commercialization Date with respect to each Existing Product NDC, and
(ii) immediately prior to First Commercial Sale of any Impax Generic Version or other Supplied Product (if any) hereunder. Impax shall submit forecasts and Purchase Orders in accordance with this Article 8 that enable Impax to satisfy its
obligations under this Section 8.6.4. 
 8.6.5. Monthly Supply Chain Meetings. During the Supply Term with
respect to any Supplied Product, AstraZeneca and Impax shall conduct telephonic monthly supply chain meetings in order for the Parties to coordinate on supply chain matters, and shall discuss at such meetings, for each such Supplied Product, on an
NDC-by-NDC basis, the following: (i) the quantity of such Supplied Product that each Party is holding, (ii) anticipated market changes reasonably expected to impact the demand for such Supplied Product in the Territory,
(iii) anticipated supply and demand of such Supplied Product in the Territory, (iv) Purchase Orders that Impax anticipates submitting, and (v) anticipated delivery schedules. 

8.7. Purchase Orders. All Purchase Orders for the purchase of Supplied Products shall be made in accordance with the
then-current minimum order quantities and order multiples with respect to each Supplied Product. The minimum order quantities and order multiples in effect as of the Effective Date are set forth on Schedule 8.7. Impax acknowledges and agrees that
the minimum order quantities and order multiples for each Supplied Product may be changed by AstraZeneca from time to time, provided that AstraZeneca provides to Impax reasonable prior notice of any such change. Delivery by AstraZeneca of a quantity
at least equal to 

  
 67 

 
[***], and not greater than [***], of the actual quantity ordered by Impax in a Purchase Order shall constitute fulfillment of such Purchase Order and Impax shall pay for the amount so delivered
in accordance with the terms hereof. All Purchase Orders shall constitute a binding obligation on Impax to purchase the indicated quantities of Supplied Products, subject to Article 14. In the event that the terms of any Purchase Order are
not consistent with or are in addition to the terms of this Agreement, the terms of this Agreement shall prevail. Impax acknowledges and agrees that AstraZeneca shall be obligated to supply Supplied Products only in the packaging configurations set
forth on Schedule 8.7. Notwithstanding the foregoing or any term or condition of this Agreement to the contrary, the Parties acknowledge and agree [***], and AstraZeneca shall not have any obligation to accept (and may reject) any Purchase Order
with respect to [***] for initial Purchase Orders with respect thereto. 
 8.8. Conformity to Planning Forecasts.
Each Purchase Order for Supplied Products submitted by Impax to AstraZeneca for a month shall not be more than [***] above the amount forecasted by Impax in the Planning Forecast for such month most recently provided prior to the submission of such
Purchase Order, as the case may be. In addition, each Purchase Order submitted by Impax to AstraZeneca for a month shall not be more than [***] below the amount forecasted by Impax in the Planning Forecast for such month most recently provided prior
to submission of such Purchase Order. 
 8.9. Limit on Obligation to Supply. AstraZeneca shall consider in good
faith but be under no obligation to supply additional quantities of the Supplied Products in the event that a Purchase Order submitted to AstraZeneca by Impax is more than [***] above the amount of Supplied Products specified in the applicable
Planning Forecast, as the case may be, for the applicable period, provided that AstraZeneca shall use [***] (subject to constraints imposed by Third Party Manufacturers to AstraZeneca and the terms and conditions of applicable agreements with any
such Third Party Manufacturers, including the [***] Supply Agreement) to supply reasonable additional quantities of the Supplied Products as specified in the applicable Purchase Order in the event of a product recall in order to replace the Supplied
Products so recalled, subject to Section 8.17.2. Any Purchase Order submitted to AstraZeneca by Impax that is more than [***] above the amount of Supplied Products specified in the Planning Forecast with respect to such Supplied Products, as
the case may be, for the applicable period shall be reasonably necessary to satisfy increased customer demand for Supplied Products projected in good faith to arise during the relevant forecast period for such Purchase Order or to replace recalled
Supplied Product and shall not be for the purpose of stockpiling Supplied Products beyond any Safety Stock deemed necessary by Impax. 
 8.10. Shortfall. In the event that a Purchase Order for Supplied Products submitted to AstraZeneca by Impax is less than [***] of the amount of Supplied Products specified in the applicable
Planning Forecast, AstraZeneca shall have no obligation to accept such Purchase Order. If it does accept such Purchase Order, AstraZeneca shall have the right, in its sole discretion, to invoice Impax within [***] for the direct cost of all Supplied
Product components, raw materials, work in process, finished Supplied Products on hand that was obtained or Manufactured by AstraZeneca to meet the unit quantities set forth in Impax’ applicable Planning Forecast for Supplied Products, as the
case may be, along with any related destruction costs associated therewith, for the relevant period, and for which, despite AstraZeneca’s Commercially Reasonable Efforts, AstraZeneca is not able to incorporate, integrate or otherwise use in any
other products, including Supplied Products. Impax shall pay any such invoice within [***] of such invoice date. 

  
 68 

 8.11. Monthly Deliveries by AstraZeneca. Except as otherwise agreed in writing
by the Parties, AstraZeneca shall use [***] to supply the Supplied Products ordered under a Purchase Order by way of monthly delivery, pursuant to Section 8.13 or, in the case of the Supplied Products ordered pursuant to the Purchase Orders
attached hereto as Schedule 8.6.1 Part A, based on the delivery schedules set forth in Schedule 8.6.1 Part B. AstraZeneca shall [***] deliver all quantities of the Supplied Products ordered by Impax for a month by the last day of such month.
Notwithstanding the foregoing, AstraZeneca may, in its sole discretion, satisfy its delivery obligations by making multiple deliveries during a month that, in total, supply all quantities of the Supplied Products ordered by Impax for such month.

 8.12. Expiration Dating. Unless otherwise agreed by the Parties, all supplies of Supplied Products supplied to
Impax hereunder shall have upon delivery to Impax at least [***] remaining expiration dating, except [***] therefor specified in the applicable NDA as approved by the FDA. 
 8.13. Delivery Terms; Title Passage. 
 8.13.1. Except with respect
to [***] Product, with respect to which the [***], AstraZeneca shall deliver all Supplied Products to Impax, FCA (Incoterms 2010) AstraZeneca’s or its designee’s shipping point in the Territory. For clarity, Impax shall be responsible for
the freight and insurance costs of delivery of supplies of the Supplied Products to Impax’ warehouse. 
 8.13.2.
Except with respect to [***] Product, with respect to which [***], title and risk of loss for the supplies of Supplied Products shall pass to Impax on delivery to Impax in accordance with Section 8.13.1. 

8.14. Suspension of Shipment; Payments in Event of Default. In addition to AstraZeneca’s rights under
Section 2-702 of the Uniform Commercial Code, AstraZeneca shall have the right to suspend shipments of Supplied Products during any period in which Impax is in payment default under this Agreement (including pursuant to Article 7), whether or
not such payment default is subject to cure. 
 8.15. Supply Price. 

8.15.1. AstraZeneca shall charge Impax on a per unit basis a supply price for each Supplied Product mode of administration and
dosage strength (the “Supply Price”), which Supply Price initially shall be the applicable amount set forth in Schedule 8.15.1. [***]. During the Supply Term, AstraZeneca shall use reasonable efforts, consistent with the timing of
its internal budget cycle, (i) to notify Impax on or before [***] of each Calendar Year for budget planning purposes of a preliminary Supply Price (including the Selected Manufacturing Costs contained in such Supply Price) for each Supplied
Product mode of administration and dosage strength for the following Calendar Year, and (ii) to promptly notify Impax (in no event later than [***] of each Calendar Year) of the Supply Price (including the Selected Manufacturing Costs contained
in such Supply Price) for each Supplied Product mode of administration and dosage strength for the following Calendar Year. Concurrently with the notice of each Supply Price increase or decrease (whether preliminary or final), AstraZeneca shall
provide reasonable evidence to Impax of [***]in the Selected Manufacturing Costs for each Supplied Product mode of administration and dosage strength. 

  
 69 

 (i) If the Selected Manufacturing Costs for any dosage strength of Zomig Tablets increase
on a per unit basis by more than [***] in any Calendar Year compared to the immediately preceding Calendar Year (the amount of such excess Selected Manufacturing Cost increase above [***], the “Royalty Tablet Offset Amount”),
then beginning on the date of such increase, the royalties payable by Impax pursuant to Section 7.2 on Zomig Tablets for each Calendar Quarter in the applicable Calendar Year shall be reduced by the Royalty Tablet Offset Amount attributable to
those units of Zomig Tablets purchased by Impax at the applicable Supply Price during such Calendar Quarter; provided that the Royalty Tablet Offset Amount shall not exceed [***] on a per unit basis of the immediately preceding Calendar Year’s
Selected Manufacturing Costs for such Zomig Tablets. If the Selected Manufacturing Costs for any formulation or dosage of Zomig Tablets increases by more than [***] on a per unit basis in any Calendar Year compared to the immediately preceding
Calendar Year, then Impax shall have the right to terminate this Agreement as provided in Section 14.3.3. 
 (ii) If the
Selected Manufacturing Costs for any dosage strength of Zomig-ZMT increase on a per unit basis by more than [***] in any Calendar Year compared to the immediately preceding Calendar Year (the amount of such excess Selected Manufacturing Cost
increase above [***], the “Royalty ZMT Offset Amount”), then beginning on the date of such increase, the royalties payable by Impax pursuant to Section 7.2 on Zomig-ZMT for each Calendar Quarter in the applicable Calendar Year
shall be reduced by the Royalty ZMT Offset Amount attributable to those units of Zomig-ZMT purchased by Impax at the applicable Supply Price during such Calendar Quarter; provided that the Royalty ZMT Offset Amount shall not exceed more than [***]
on a per unit basis of the immediately preceding Calendar Year’s Selected Manufacturing Costs for such Zomig-ZMT. If the Selected Manufacturing Costs for any formulation or dosage of Zomig-ZMT increases by more than [***] on a per unit basis in
any Calendar Year compared to the immediately preceding Calendar Year, then Impax shall have the right to terminate this Agreement as provided in Section 14.3.3. 
 (iii) If the Selected Manufacturing Costs for any dosage strength of Zomig Nasal Spray increase on a per unit basis by more than [***] in any Calendar Year compared to the immediately preceding Calendar
Year (the amount of such excess Selected Manufacturing Cost increase above [***], the “Royalty Nasal Offset Amount”), then beginning on the date of such increase, the royalties payable by Impax pursuant to Section 7.2 on
Zomig Nasal Spray for each Calendar Quarter in the applicable Calendar Year shall be reduced by the Royalty Nasal Offset Amount attributable to those units of Zomig Nasal Spray purchased by Impax at the applicable Supply Price during such Calendar
Quarter; provided that the Royalty Nasal Offset Amount shall not exceed more than [***] on a per unit basis of the immediately preceding Calendar Year’s Selected Manufacturing Costs for such Zomig Nasal Spray. If the Selected Manufacturing
Costs for any formulation or dosage of Zomig Nasal Spray increases by more than [***] on a per unit basis in any Calendar Year compared to the immediately preceding Calendar Year, then Impax shall have the right to terminate this Agreement as
provided in Section 14.3.3. 

  
 70 

 (iv) For clarity, (a) clauses (i) through (iii) also apply with respect to Impax Generic
Versions of the applicable Existing Products, and (b) the calculation of any Royalty Tablet Offset Amount, Royalty ZMT Offset Amount and Royalty Nasal Offset Amount shall apply on a Calendar Year-by-Calendar Year basis with the amount of any
increase (or decrease) calculated solely on the basis of the immediately preceding Calendar Year. 
 (v) This Section 8.15
shall be subject to Section 7.2.4 and 7.2.5. 
 (vi) An example calculation with respect to clauses (i), (ii) and
(iii) is set forth in Schedule 8.15.1(vi), which example is provided solely by way of example and without limitation. In the event of any conflict between the terms of Schedule 8.15.1(vi) and this Agreement, this Agreement shall control.

 8.15.2. AstraZeneca shall invoice Impax for the applicable Supply Price together with, or promptly after, each
delivery to Impax of conforming supplies of the Supplied Products ordered by Impax. Impax shall pay in full each such invoice in accordance with Section 7.4 within [***] of the invoice date. 

8.15.3. AstraZeneca has provided Impax with AstraZeneca’s Supply Prices for each Supplied Product for [***] for each
Supplied Product for [***] and those Supply Prices shall remain in effect until [***]. AstraZeneca shall provide to Impax AstraZeneca’s Supply Prices for the following Calendar Years based upon [***] as provided in Section 8.15.1.
Impax [***] may retain an Independent Auditor that is approved by AstraZeneca to conduct an audit of the basis for any Supply Price increase or decrease for a given Calendar Year, which audit shall occur no more than [***] with respect to each
Calendar Year and shall be conducted prior to [***] of the Calendar Year in which such increase or decrease will be in effect. Any such approval with respect to the selection of an independent auditor shall not be unreasonably withheld, conditioned
or delayed, and AstraZeneca shall respond to such request for approval pursuant to this Section 8.15.3 within [***]. AstraZeneca shall cooperate with such Independent Auditor’s investigation, and the results of any audit under this
Section 8.15.3 shall (i) disclose only whether any increase or decrease in [***] under this Agreement is correct or incorrect and the amount of any discrepancy and (ii) be made available to both Parties. Prior to and as a condition to
the Independent Auditor conducting any audit, Impax shall ensure that the Independent Auditor has entered into a confidentiality agreement with obligations no less restrictive than those obligations set forth in Article 11. In no event may the
Independent Auditor disclose to Impax any documentation, calculations or information provided to the Independent Auditor by AstraZeneca that has not been approved by AstraZeneca, such approval not to be unreasonably withheld, conditioned or delayed,
and AstraZeneca shall respond to such request for approval pursuant to this Section 8.15.3 within [***]. Except as provided below, the cost of this audit shall be borne by Impax, unless the audit reveals a variance in the aggregate (taking
account of all Supplied Products) of more than [***] from the reported Supply Price increase(s) or decrease(s) and the variance benefitted AstraZeneca, in which case AstraZeneca shall bear the cost of the audit. Unless disputed pursuant to
Section 8.15.4, if such audit concludes for the period of time following the enactment of the applicable Supply Price increase or decrease that excess payments were made by Impax, AstraZeneca shall reimburse such excess payments with interest
from the date originally due as provided in Section 7.6 within [***] after the date on which such audit is completed by Impax. 

  
 71 

 8.15.4. In the event of a dispute with respect to any audit under
Section 8.15.3, AstraZeneca and Impax shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***], the dispute shall be submitted for resolution to
an Arbitrator. The decision of the Arbitrator shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Arbitrator shall determine. Not later than [***] after such decision
and in accordance with such decision, the audited Party shall pay the additional amounts that were not paid, with interest from the date originally due as provided in Section 7.6, or the auditing Party shall reimburse the excess payments that
were paid, as applicable. 
 8.16. Change to Specifications. In its sole discretion, AstraZeneca shall have the
right, at its cost and expense, to make modifications to the specifications or Manufacturing processes employed with regard to the Manufacture of the Supplied Products from time to time, subject to such modifications being approved by the FDA to the
extent required by Applicable Law. For clarity, Impax shall have no right to change specifications or Manufacturing process for any Supplied Product that is supplied by AstraZeneca, its Affiliates or a Third Party Manufacturer. 

8.17. Failure or Inability to Supply. 
 8.17.1. Notification of Inability to Supply. In the event that AstraZeneca, at any time during the Supply Term, shall have determined that it shall be unable to supply Impax with the full
quantity of Supplied Product forecasted to be ordered or actually ordered by Impax in a timely manner and in conformity with the warranty set forth in Section 8.24, AstraZeneca shall promptly notify Impax thereof. Promptly thereafter, the
Parties shall meet to discuss how Impax shall obtain such full quantity of conforming Supplied Product. 
 8.17.2.
Allocation in Event of Supply Shortfall. In the event that at any time during the Supply Term sufficient quantities of a Supplied Product are not available to satisfy Impax’ Purchase Orders, unless otherwise agreed by the Parties,
the available quantities of Supplied Product shall be allocated between Impax for the Territory and AstraZeneca and its Affiliates and licensees outside of the Territory [***] during the [***] months immediately preceding such shortfall. 

8.17.3. Failure to Supply Conforming Supplied Product. Impax shall perform a reasonable and customary inspection of the
Supplied Products upon delivery of each shipment of Supplied Products hereunder. In the event that Impax determines, within [***] after delivery thereof by AstraZeneca (or within [***] after discovery of any nonconformity that could not reasonably
have been detected by Impax’ reasonable and customary acceptance inspection procedures), that any Supplied Products supplied hereunder does not conform to the warranty set forth in Section 8.24, Impax shall give AstraZeneca notice thereof
within the applicable [***] period (including a sample of each such Supplied Product, if applicable). AstraZeneca shall undertake appropriate evaluation of such sample and shall notify Impax whether it has confirmed such nonconformity within [***]
after receipt of such notice 

  
 72 

 from Impax. If AstraZeneca notifies Impax that it has not confirmed such nonconformity, the Parties shall
submit the dispute to an independent testing laboratory or other appropriate expert mutually acceptable to the Parties (the “Testing Laboratory”) for evaluation. Both Parties shall cooperate with the Testing Laboratory’s
reasonable requests for assistance in connection with its evaluation hereunder. The findings of the Testing Laboratory shall be binding on the Parties, absent manifest error. The expenses of the Testing Laboratory shall be borne by AstraZeneca if
the testing confirms the nonconformity and otherwise by Impax. 
 8.17.4. Credit Note; Replacement Supplied Products;
Defective Supplied Products. If AstraZeneca or the Testing Laboratory confirms that a batch of Supplied Products does not conform to the warranty set forth in Section 8.24, AstraZeneca shall, at Impax’ option, (i) as expeditiously
as commercially practicable, supply Impax with a conforming quantity of Supplied Products at AstraZeneca’s expense or (ii) promptly issue Impax a Credit Note in an amount equal to the Supply Price paid by Impax with respect to such
nonconforming Supplied Products if already paid. Any Supplied Product that is agreed or determined to be defective shall be destroyed by Impax at AstraZeneca’s expense and Impax shall, at AstraZeneca’s option, either (a) allow an
AstraZeneca representative to be present during such destruction or (b) provide a certificate of such destruction. Except for AstraZeneca’s obligations under Section 9.1 and Section 13.2, AstraZeneca shall [***]. 

8.17.5. No Liability After Delivery. Notwithstanding anything herein to the contrary, AstraZeneca shall have no liability
for damage or other defects to Supplied Products to the extent such damage or other defects occur after delivery pursuant to this Agreement. 
 8.18. Right of Impax to Visit Premises. Subject to the terms and conditions of this Section 8.18, AstraZeneca shall permit Impax or its authorized representatives to visit (upon
reasonable prior notice) the sites operated by AstraZeneca or any of its Affiliates listed in Schedule 1.188 [***] during any [***] period to review the conduct of Selected Manufacturing Activities at the sites; provided, however, that Impax shall
be entitled to conduct additional visits as reasonably agreed upon by the Parties during such period in the event AstraZeneca receives any notice of violation of Applicable Law from any Regulatory Authority with respect to the Supplied Products.
During any such visit, Impax shall be permitted to review only that Manufacturing-related documentation listed in Schedule 8.18 to the extent relevant to the Selected Manufacturing Activities being conducted at the applicable site and any other
documents with respect to which the Parties mutually agree. AstraZeneca shall have the right to redact such documentation and otherwise require that the inspection be conducted in a manner that permits AstraZeneca to avoid disclosure of
(i) [***], and (ii) other information with respect to products other than Supplied Products (including products that contain the Licensed Compound that are Manufactured for use outside the Territory). Following any such visit and review of
documentation, AstraZeneca shall [***]. Such visits shall be conducted during normal business hours. In the event that, consistent with Section 8.23, AstraZeneca engages any Third Party Manufacturing to perform any Selected Manufacturing
Activities with respect to any Supplied Product, AstraZeneca shall use Commercially Reasonable Efforts to secure the Third Party Manufacturer’s consent to allow Impax to visit the applicable facility and review documentation in a manner
consistent with the rights provided to Impax under this Section 8.18 with respect to the designated AstraZeneca facilities. 

  
 73 

 8.19. Manufacturing Technology Transfer and Manufacturing License. 

8.19.1. In the event that AstraZeneca notifies Impax that AstraZeneca is terminating the Supply Term with respect to any Supplied
Product (other than in connection with Zomig-ZMT or in circumstances involving a termination of this Agreement), at Impax’ request, AstraZeneca and Impax shall enter into a Manufacturing technology transfer agreement pursuant to the terms of
this Section 8.19 to be negotiated in good faith between the Parties. If the Parties are unable to agree upon the terms of the Manufacturing technology transfer agreement, then the terms of that agreement will be on terms determined by a
neutral third party arbitrator to be reasonably necessary to effectuate such Manufacturing technology transfer in accordance with this Section 8.19.1. To carry out such Manufacturing technology transfer, AstraZeneca shall, and shall cause its
Affiliates to, transfer to Impax Manufacturing-related documentation with respect to Zomig Tablets or Zomig Nasal Spray (but not, for clarity, Zomig-ZMT) which information is reasonably necessary for Manufacturing Zomig Tablets or Zomig Nasal Spray
(and excludes facility-related documentation), solely to the extent such documentation is Controlled by AstraZeneca or its Affiliates and is being utilized at such time by or on behalf of AstraZeneca or its Affiliates for the Manufacture of Zomig
Tablets or Zomig Nasal Spray, as applicable (the Manufacturing Know-How embodied in such documentation, “Manufacturing Know-How”) in order to assist Impax in establishing the capability to supply, or to engage a Third Party to
supply, Zomig Tablets or Zomig Nasal Spray, as applicable, solely for Development or Commercialization by Impax in the Field in the Territory in accordance with the terms and conditions of this Agreement. In addition, AstraZeneca shall grant to
Impax a non-exclusive license, without the right to sublicense without AstraZeneca’s consent, to use such transferred Manufacturing Know-How to Manufacture or have Manufactured Zomig Tablets or Zomig Nasal Spray, as applicable, solely for
Development or Commercialization in the Field in the Territory during the Term in accordance with the terms and conditions of this Agreement. 
 8.19.2. Notwithstanding anything contained in Section 8.19.1, prior to AstraZeneca providing the transfer of Manufacturing-related documentation (or Manufacturing Know-How) or granting to
Impax the license contemplated in Section 8.19.1, [***]. In addition, [***]. Following such [***], Impax shall, and shall cause any approved Third Party contract manufacturer to, enter into such agreements as are reasonably required to
establish the manufacturing arrangements, including with respect to quality, safety and other Third Party manufacturing terms. 

8.19.3. Each Party shall bear its own costs, internal and external, with respect to carrying out, (i) in the case of
AstraZeneca, its obligations pursuant to this Section 8.19, provided that AstraZeneca shall not be required to dedicate more than [***] hours to the performance of its obligations pursuant to Section 8.19.1 unless Impax agrees to reimburse
AstraZeneca for its internal costs with respect thereto on an hourly basis in an amount to be agreed in advance by the Parties, and (ii) in the case of Impax, establishing, whether directly or through a Third Party, the capability and capacity
to Manufacture or have Manufactured the applicable Supplied Product(s). 
 8.19.4. Solely in the event AstraZeneca
notifies Impax that AstraZeneca is terminating the Supply Term with respect to Zomig-ZMT in accordance with Section 8.2, then [***] for sale in the Field in the Territory during the Term or pursuant to which [***]. If Impax

  
 74 

 
desires to Manufacture or to [***]Third Party contract manufacturer to Manufacture Zomig-ZMT (i) Impax shall [***], and (ii) [***]. Following such qualification, Impax shall, and shall
cause [***] or such Third Party to, enter into such agreements as are reasonably required to establish the manufacturing arrangements, including with respect to quality, safety and other Third Party manufacturing terms. 

8.20. Supplied Product Storage and Distribution. 
 8.20.1. Generally. AstraZeneca shall supply the Supplied Products to Impax in finished and packaged form in accordance with the terms of this Agreement. Impax shall not repackage or in any way
alter the Product Labels and Inserts of the Supplied Products without the prior written consent of AstraZeneca. Impax shall store, handle, transport and dispose of the Supplied Products in compliance with the requirements set out in the Quality
Assurance Agreement, the Regulatory Approvals and Applicable Law and under conditions that maintain the quality, stability and integrity of the Supplied Products. 
 8.20.2. Notice of Inspections by Regulatory Authorities. Except as otherwise provided in the Quality Assurance Agreement, in the event of any inspections or audits by any Regulatory
Authority of Impax’ premises or, if applicable, any of its Affiliates’ premises (to the extent related to the Supplied Products), Impax promptly shall notify AstraZeneca and shall ensure that AstraZeneca receives any reports by such
Regulatory Authorities to the extent applicable to the Supplied Product as promptly as practicable following receipt thereof by Impax. Impax shall provide AstraZeneca with a reasonable opportunity to review and comment on any and all submissions to
any Regulatory Authority to the extent related to the Supplied Products prior to the submission thereof; provided that AstraZeneca shall provide its comments, if any, on any draft submission within [***] after receipt thereof or within such shorter
period as may be required under the circumstances. 
 8.20.3. Right of AstraZeneca to Inspect Premises. Impax
shall permit AstraZeneca or its authorized representatives to inspect, verify and audit (upon reasonable prior notice) Impax’ compliance with Applicable Law applicable to this Agreement, including Impax’ premises used for the storage of
the Supplied Products and to audit Impax’ working methods and procedures with respect to the Supplied Products [***] during any [***] period; provided, however, that AstraZeneca shall be entitled to conduct additional inspections and audits in
the event (i) Impax receives any notice of inspection or violation of Applicable Law from any Regulatory Authority to the extent related to the Supplied Products or (ii) if any audit under this Section 8.20.3 reveals that Impax is or
was not in material compliance with this Agreement or with Applicable Law to the extent related to the Supplied Products, in either case ((i) or (ii)), as may be reasonably required by AstraZeneca to determine whether Impax has appropriately
remedied any such violation or non-compliance. Such inspections and audits shall be conducted during normal business hours. In the event such inspections identify premises, working methods or procedures are not in material conformity with such
Applicable Law or the provisions of this Agreement, AstraZeneca shall give written notice of such non-conformity to Impax and, if such non-conformity rises to the level of a material default hereunder, the provisions of Section 14.2.1 shall
apply; provided, however, that if Impax provides written notice to AstraZeneca that it disputes the results of such inspection, and such dispute cannot be resolved within [***] after such notice by Impax, then the matter shall be referred to an
Independent Expert for a non-

  
 75 

 
binding recommendation. If the Parties are not able to resolve such dispute after receiving the non-binding recommendation of the Independent Expert (which shall be delivered as soon as
reasonably practicable, but no later than [***] after the matter is referred to the Independent Expert), each Party may pursue all legal and contractual remedies available to it. If the result of the audit is not disputed, AstraZeneca shall discuss
its observations and conclusions with Impax and Impax shall implement such corrective actions as may be reasonably determined by AstraZeneca within [***] after notification thereof by AstraZeneca. 

8.21. Quality Assurance Agreement. Each Party shall duly and punctually perform all of its obligations under and pursuant
to the Quality Assurance Agreement. 
 8.22. Number of Facilities and Suppliers. Impax acknowledges and agrees
that AstraZeneca shall have no obligation pursuant to this Agreement to qualify or maintain more than one facility or supplier for the Manufacture or supply of the Licensed Compound or any Supplied Product pursuant to this Agreement. 

8.23. Third Party Contract Manufacturers. 
 8.23.1. The Parties acknowledge and agree that, as of the Effective Date, AstraZeneca has entered into arrangements with various Third Party contract manufacturers with respect to the Manufacture
of Existing Product for use or Commercialization in the Territory. Except as otherwise provided in this Section 8.23 or in Sections 6.4, 8.2, or 12.2.3 during the Term, AstraZeneca shall have the right, in its sole discretion to modify or
terminate any such arrangement, or to enter into one or more additional arrangements with Third Party contract manufacturers, in order to perform AstraZeneca’s obligations hereunder with respect to Supplied Products for use or Commercialization
by Impax or its Affiliates and Sublicensees in the Territory or to carry out activities with respect to products containing the Licensed Compound consistent with AstraZeneca’s retained rights with respect to such products, provided that
AstraZeneca shall provide Impax with [***] advance notice of any such new subcontracting agreement with a Third Party Manufacturer with respect to Supplied Product for use or Commercialization by Impax or its Affiliates and Sublicensees in the
Territory if such arrangement involves Selected Manufacturing Activities. A copy of any such subcontract executed by AstraZeneca that provides for the performance by the Third Party Manufacturer of Selected Manufacturing Activities shall be provided
to Impax within [***] after its execution, provided that AstraZeneca shall have the right to redact financial provisions and other commercially sensitive terms. 
 8.23.2. Notwithstanding the foregoing, and except as otherwise provided in this Section 8.23.2, after the Effective Date and during the Supply Term with respect to any Supplied Product,
AstraZeneca shall obtain Impax’ written consent, not to be unreasonably withheld, conditioned or delayed, prior to entering into an agreement that would result in a Manufacturing Split with respect to the applicable Supplied Product. For
purposes of this Agreement, and subject to this Section 8.23.2, a “Manufacturing Split” shall occur with respect to any Supplied Product delivered to Impax pursuant to this Agreement in the event that: 

  
 76 

 (i) AstraZeneca or any of its Affiliates (a) enters into a subcontract agreement with
a Third Party Manufacturer pursuant to which the Third Party Manufacturer is engaged to perform Selected Manufacturing Activities with respect to such Supplied Product for use or Commercialization by Impax or its Affiliates and Sublicensees in the
Territory, or (b) enters into any other contractual agreement with a Third Party Manufacturer pursuant to which the Third Party Manufacturer is engaged by AstraZeneca to perform Selected Manufacturing Activities with respect to any product
containing the Licensed Compound which is being sold by AstraZeneca or any of its Affiliates or sublicenses under the Product Trademarks outside of the Territory and which product constitutes the equivalent of such Supplied Product in the
jurisdiction(s) in which such product is sold (each an “Equivalent Product”), and 
 (ii) entering into an
agreement described in clause (i)(a) or (i)(b) would result in the Selected Manufacturing Activities for the applicable Supplied Product delivered to Impax pursuant to this Agreement to be conducted at a different location or by a different Person
than for the applicable Equivalent Product(s); 
 provided, however, that notwithstanding anything contained in this Section 8.23 or
any other term or condition of this Agreement to the contrary, it shall be deemed to not constitute a “Manufacturing Split” if AstraZeneca or any of its Affiliates enters into a subcontract agreement as described in clause (i)(a) or an
agreement with a Third Party Manufacturer as described in clause (i)(b) in any of the following circumstances: (1) in order to ensure AstraZeneca’s or any of its Affiliate’s compliance with Applicable Law; (2) (A) for
AstraZeneca or any of its Affiliates to avail itself of benefits, efficiencies or incentives (whether legal, business, financial or otherwise) that are offered by local or regional officials or agencies or to conduct its business as AstraZeneca or
such Affiliate deems necessary and appropriate anywhere in the world or (B) in connection with or as a result of a divestiture (including by sale or lease) by AstraZeneca or any of its Affiliates of any facility or site where Selected
Manufacturing Activities or any other manufacturing activities are conducted; (3) for the production of any generic product (including a Generic Version) or any product in the OTC Field, in each case contained in this clause (3) for use
outside of the Territory; (4) in connection with or that results from a divestiture by AstraZeneca or any of its Affiliates with respect to rights with respect to one or more products containing the Licensed Compound in any jurisdiction outside
the Territory or the grant by AstraZeneca or any of its Affiliates to one or more Third Parties of a license or other similar rights to commercialize such product(s) outside the Territory; or (5) in connection with or that results from
AstraZeneca’s or any of its Affiliate’s good faith business or manufacturing needs, initiatives, processes or decisions, whether local, regional or global in nature. With respect to the occurrence of any of the circumstances contemplated
in clause (1), (2), (3), (4) or (5), AstraZeneca shall not have an obligation to obtain Impax’ consent, but shall be required to provide Impax notice of the applicable event within [***] after AstraZeneca or its Affiliate closes the
transaction contemplated by such applicable agreement or, if later, within [***] of AstraZeneca determining to have Selected Manufacturing Activities for the Supplied Product be conducted at a different location or by a different Person than the
location or Person used for the conduct of such activities for the Equivalent Product as a result of having entered into such applicable agreement. 
 8.24. Product Representations and Warranties. AstraZeneca represents and warrants to Impax that at the time of shipment of each Supplied Product to Impax, such Supplied Product shall
(i) have been Manufactured in accordance with applicable GMP, (ii) have been Manufactured in accordance with the specifications set forth in the applicable NDA, (iii) not be 

  
 77 

 
adulterated or misbranded under the FFDCA or any other Applicable Law, (iv) may be introduced into interstate commerce under the FFDCA, and (v) have an expiration date in accordance
with Section 8.12. Upon transfer by AstraZeneca of title and risk of loss of each Supplied Product, as provided in Section 8.13.2 or pursuant to the [***], good and valid title to such Supplied Product sold hereunder will be conveyed by
AstraZeneca to Impax free and clear of any encumbrances. 
 Article 9 

RECALLS 
 9.1. Notification and Recall. In the event that any Regulatory Authority issues or requests a recall or takes similar action in connection with a Licensed Product in the Field in the
Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal of the Licensed Product in the Field, the Party notified of or desiring such recall
or market withdrawal shall, within [***], advise the other Party thereof by telephone or facsimile. Following such notice, either Party may decide whether a recall or withdrawal shall be conducted in a Class I Situation with respect to any Licensed
Product (except in the case of a government-mandated recall), and in the event of a disagreement between the Parties with respect to whether a recall or withdrawal shall be conducted, either Party may require such recall or withdrawal. The Party
that holds the NDA shall decide the manner in which any such recall or withdrawal shall be conducted. Following such notice, the Party that holds the NDA with respect to the applicable Licensed Product may decide whether to conduct a recall or
withdrawal in any situation which is not a Class I Situation (except in the case of a government-mandated recall) and the manner in which any such recall or withdrawal shall be conducted. For clarity, nothing contained in this Section 9.1 is
intended or shall be construed to permit the Party other than the Party that holds the NDA to determine whether to cause a permanent recall or withdrawal of a Product from the market. 

9.2. Recall Expenses. AstraZeneca shall bear the expenses of any recall or market withdrawal of any Supplied Product in the
Territory; provided, however, that Impax shall bear the reasonable, out-of-pocket expenses of a recall or market withdrawal incurred by AstraZeneca to the extent that such recall resulted from Impax’ material breach of this Agreement or
Impax’ or any of its Affiliate’s gross negligence or willful or intentional misconduct (which expenses, for clarity, shall be borne by Impax). Impax shall bear the expenses of any recall or market withdrawal of any Licensed Product that is
not a Supplied Product in the Territory; provided, however, that AstraZeneca shall bear the reasonable, out-of-pocket expenses of a recall or market withdrawal incurred by Impax to the extent any such recall resulted from AstraZeneca’s material
breach of this Agreement or AstraZeneca’s or any of its Affiliate’s gross negligence or willful or intentional misconduct (which expenses, for clarity, shall be borne by AstraZeneca). 

9.3. Commercialization Records. Impax shall keep complete and accurate records of the distribution of the Licensed Products
in the Territory in accordance with Applicable Law to enable appropriate procedures to be implemented in the event that a voluntary or mandatory recall or market withdrawal of the Licensed Products is required. AstraZeneca shall be entitled to
inspect and audit (upon reasonable notice, during normal business hours and subject to Article 11) Impax’ recall or withdrawal procedures and such records to ensure that Impax is complying with all Applicable Law and this Agreement. 

  
 78 

 Article 10 
 INTELLECTUAL PROPERTY 
 10.1.
Ownership of Intellectual Property.  
 10.1.1. Ownership of Technology. Subject to Sections 5.1 and 5.2,
as between the Parties, each Party shall own and retain all right, title, and interest in and to any and all: (i) Information and inventions that are conceived, discovered, developed, or otherwise made by or on behalf of such Party (or its
Affiliates or sublicensees) under or in connection with this Agreement, whether or not patented or patentable, and any and all Patents and other intellectual property rights with respect thereto, and (ii) other Information, inventions, Patents,
and other intellectual property rights that are owned or otherwise Controlled (other than pursuant to the license grants set forth in Sections 6.1 and 6.2) by such Party, its Affiliates or (sub)licensees. 

10.1.2. United States Law. The determination of whether Information and inventions are conceived, discovered, developed,
or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United
States as such law exists as of the Effective Date irrespective of where such conception, discovery, development or making occurs. 
 10.1.3. Assignment Obligation. Each Party shall cause all Persons who perform activities for such Party under this Agreement to be under an obligation to assign (or, if such Party is unable
to cause such Person to agree to such assignment obligation despite such Party’s using Commercially Reasonable Efforts to negotiate such assignment obligation, provide a license under) their rights in any Information and inventions resulting
therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public institutions which have standard policies against such an assignment (in which case a suitable license, or
right to obtain such a license, shall be obtained). 
 10.1.4. Ownership of Corporate Names. As between the
Parties, each Party shall retain all right, title and interest in and to its respective Corporate Names. 
 10.2. Maintenance
and Prosecution of Patents. 
 10.2.1. Patent Prosecution and Maintenance of AstraZeneca Patents and [***]
Patents. Subject to Section 10.2.2, AstraZeneca, through patent attorneys or agents of its choice and at its sole cost and expense, shall have the first right, but not the obligation, to maintain in the Territory the AstraZeneca Patents.
AstraZeneca shall not abandon any application for any AstraZeneca U.S. Patents or permit any Patent issuing therefrom to lapse without first notifying Impax and permitting Impax to continue the prosecution of such applications or pay any required
fees in the name of AstraZeneca, at Impax’ sole cost and expense and through patent attorneys or agents reasonably acceptable to AstraZeneca. Impax shall not become an assignee of any application for any AstraZeneca U.S. Patents as a result of
its continuing the prosecution of an application for such Patent or paying any fees according to 

  
 79 

 
this Section 10.2.1. If AstraZeneca receives notice [***], and AstraZeneca has the right to [***] and AstraZeneca [***], then AstraZeneca will so notify Impax and, upon Impax’ request
and at Impax’ expense, AstraZeneca will [***] in a manner consistent with, and subject to, the terms and conditions of, the [***]. 
 10.2.2. Cooperation. The Parties agree to reasonably cooperate in the preparation, filing, prosecution, and maintenance of the AstraZeneca U.S. Patents in the Territory under this Agreement.
The Party controlling Patent prosecution shall provide the other Party with copies of all office actions and other material documents received or submitted to a patent office and shall confer with the other Party on all material issues and keep the
other Party reasonably informed of any and all material developments and consider reasonable opinions, input, and advice from the other Party during the course of the prosecution. 

10.2.3. Patent Term Extension. AstraZeneca shall have the right to make decisions regarding patent term extensions,
including any extensions that are now or become available in the future, wherever applicable, for the AstraZeneca U.S. Patents in the Territory. AstraZeneca shall have the primary responsibility of applying for any extension with respect to such
AstraZeneca U.S. Patents in the Territory. In the event AstraZeneca elects not to extend any applicable patent term in circumstances where an extension becomes available it shall so notify Impax and permit Impax to file for such patent term
extension and pay any required fees in the name of AstraZeneca, at Impax’ sole cost and expense. 
 10.2.4.
Patent Listings. AstraZeneca shall have the sole right and obligation to make all filings with Regulatory Authorities in the Territory with respect to AstraZeneca U.S. Patents, including as required or allowed in the United States, in the
FDA’s Orange Book with respect to Existing Products; provided that AstraZeneca shall consult with Impax to determine the course of action with respect to such filings in the United States. Impax shall have the right and obligation to make all
filings with Regulatory Authorities in the Territory with respect to AstraZeneca Patents, including as required or allowed in the United States, in the FDA’s Orange Book with respect to Additional Products in the Field; provided that Impax
shall consult with AstraZeneca to determine the course of action with respect to such filings in the United States. 
 10.3.
Enforcement of Patents. 
 10.3.1. Enforcement of AstraZeneca Patents. Each Party shall promptly notify the
other Party in writing of any alleged or threatened infringement of the AstraZeneca U.S. Patents or any [***] Patents by a Third Party in the Territory of which such Party becomes aware (including alleged or threatened infringement based on the
development, commercialization, or an application to market a product containing the Licensed Compound or any Licensed Product in the Field in the Territory (the “Product Infringement”)). As between the Parties, AstraZeneca shall
have the first right, but not the obligation, to respond to any such Product Infringement in the Territory, including by filing an infringement suit, asserting a counterclaim or entering into a contractual arrangement or settlement with respect to
such infringement (the “AstraZeneca Controlled Infringement”) at its sole expense. If AstraZeneca (i) notifies Impax that it does not intend to respond to any AstraZeneca Controlled Infringement or (ii) does not take
commercially reasonable steps to eliminate any AstraZeneca Controlled 

  
 80 

 
Infringement with respect to any AstraZeneca U.S. Patent (a) within [***] following the first notice provided above with respect to the AstraZeneca Controlled Infringement, or (b) [***]
before [***], then Impax may then prosecute the Product Infringement in the Field solely with respect to any AstraZeneca U.S. Patent at its own cost and expense; provided, however, (except in the case of [***]) that if AstraZeneca has commenced
negotiations with an alleged infringer for discontinuance of such Product Infringement within such [***] period set forth in clause (a) of this sentence, AstraZeneca shall have an additional [***] to conclude its negotiations before Impax may
bring suit for such Product Infringement with respect to any AstraZeneca U.S. Patent. For clarity, no rights are granted to Impax hereunder with respect to the prosecution of Product Infringement in the Field with respect to any [***] Patents.

 10.3.2. Cooperation. The Parties agree to cooperate fully in any infringement action pursuant to this
Section 10.3. Where a Party brings such an action, the other Party shall, where necessary or desirable for the prosecution of such action, at its option (except when required) either furnish a power of attorney solely for such purpose or shall
join in, or be named as a party to, such action. Each Party shall assist and cooperate with the other Party as such other Party may reasonably request from time to time in connection with its activities set forth in this Section 10.3, including
by providing reasonable access to relevant documents and other evidence, and making its employees available at reasonable business hours. Unless otherwise set forth herein, the Party entitled to bring any patent infringement litigation in accordance
with this Section 10.3 [***]. Subject to the restrictions of Applicable Law and any orders or rules of any tribunal, the Party commencing the litigation shall provide the other Party with copies of all pleadings and other documents filed with
the court and shall confer with the other Party on all material issues and keep the other Party reasonably informed of any and all material developments and consider reasonable opinions, input, and advice from the other Party during the course of
the proceedings. 
 10.3.3. Costs and Recovery. Except as otherwise agreed by the Parties in connection with a
cost sharing arrangement, any recovery realized as a result of such litigation described in Section 10.3.1 or 10.3.2 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in
making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be [***]; provided, however, that [***] with respect to the applicable
Licensed Product(s), taking into account the applicable adjustments set forth in Article 7. 
 10.4. Infringement Claims by
Third Parties. 
 10.4.1. Subject to each Party’s indemnification obligations set forth in Sections 13.1 and
13.2, if the manufacture, sale, offer for sale, importation or use of a Licensed Product in the Field in the Territory pursuant to this Agreement results in, or may result in, any claim, suit, or proceeding by a Third Party alleging patent
infringement by either Party (or its Affiliates or, in the case of Impax, Sublicensees), such Party shall promptly notify the other Party thereof in writing. Each Party who is sued may conduct and control the defense of any such claim, suit, or
proceeding brought against such Party (or its Affiliates or, in the case of Impax, Sublicensees). Each Party shall keep the other Party reasonably informed of all material developments in connection with any such claim, suit, or proceeding.
Following execution of a 

  
 81 

 
mutually agreeable common interest agreement, and subject to any restrictions imposed by Applicable Law or the orders or rules of any tribunal, each Party agrees to provide the other Party with
copies of all pleadings filed in such action. Each Party shall assist and cooperate with the other Party as such other Party may reasonably request from time to time in connection with its activities set forth in this Section 10.4, including by
providing reasonable access to relevant documents and other evidence, and making its employees available at reasonable business hours. 
 10.4.2. Subject to each Party’s indemnification rights and obligations, each Party shall conduct and control the defense of any claim, suit, or proceeding brought against such Party (or its
Affiliates or, in the case of Impax, Sublicensees) at such Party’s own expense, provided that in the case of Impax, Impax shall have the rights set forth in Section 7.2.3 with respect to certain royalty deductions. Any recoveries by either
Party of any sanctions or other recoveries awarded to such Party and against a party asserting a claim being defended under this Section 10.4 shall be applied first to reimburse the defending Party for its reasonable out-of-pocket costs of
defending such claim, suit, or proceedings. The balance of any such recoveries shall be allocated between the Parties as provided in manner consistent with Section 10.3.3. For clarity, nothing contained in this Section 10.4 is intended or
shall be construed to confer on a Party a right to assert claims or counterclaims in connection with any action brought against such Party (or its Affiliates or, in the case of Impax, Sublicensees) and covered by this Section 10.4 in a manner
inconsistent with Section 10.3 (which allocates to AstraZeneca the first right to enforce the AstraZeneca U.S. Patents in the Territory). 
 10.5. Invalidity or Unenforceability Defenses or Actions. 
 10.5.1.
Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any of the AstraZeneca U.S. Patents or [***] Patents by a Third Party, in each case in the
Territory and of which such Party becomes aware, except that any invalidity or unenforceability defense or action that arises in connection with enforcement proceedings shall be governed by the provisions of Section 10.3 instead of this
Section 10.5. 
 10.5.2. AstraZeneca U.S. Patents. Subject to Section 10.3, [***] shall have the first
right, but not the obligation, to defend and control the defense of the validity and enforceability of the AstraZeneca U.S. Patents at its own expense in the Territory. If [***] (i) notifies [***] that it does not intend to respond to any claim
against the validity and enforceability of the AstraZeneca U.S. Patents or (ii) does not take commercially reasonable steps to eliminate any claim against the validity and enforceability of the AstraZeneca U.S. Patents, then [***] may conduct
and control the defense of any such claim, suit, or proceeding at its own expense; provided, however, that if [***] has commenced negotiations with the parties contesting the validity or enforceability of the AstraZeneca U.S. Patents, then [***] may
not conduct or control the defense of any such defense claim, suit or proceeding until [***] has notified [***] that is has discontinued such negotiations. For clarity, no rights are granted to Impax hereunder with respect to the defense of any
[***] Patents. 
 10.5.3. Cooperation. Each Party shall assist and cooperate with the other Party as such other
Party may reasonably request from time to time in connection with its activities set forth in this Section 10.5, including by being joined as a party plaintiff in such 

  
 82 

 
action or proceeding, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours. In connection with any such defense or claim or
counterclaim, the controlling Party shall consider in good faith any opinions, comments, advice, and input from the other Party and shall keep the other Party reasonably informed of any steps taken, and shall, subject to the restrictions of
Applicable Law or any order or rules of any tribunal, provide copies of all documents filed, in connection with such defense, claim, or counterclaim. In connection with the activities set forth in this Section 10.5, each Party shall consult
with and reasonably consider all advice, input, and opinions of the other as to the strategy for the defense of the AstraZeneca U.S. Patents. 
 10.6. Third Party Licenses. If in the reasonable opinion of Impax or AstraZeneca, the Development, Manufacture, or Commercialization of any Existing Product by Impax, any of its Affiliates, or any
of its or their Sublicensees infringes or misappropriates any Patent, trade secret, or other intellectual property right of a Third Party in the Territory, such that Impax, any of its Affiliates or any of its or their Sublicensees cannot Develop,
Manufacture, or Commercialize any Existing Product in the Field in the Territory without infringing or misappropriating such Patent, trade secret, or other intellectual property right of such Third Party, then [***] shall have the first right, but
not the obligation, to negotiate and obtain a license from such Third Party as necessary for [***], and its and their [***] to Develop, Manufacture, and Commercialize Existing Products in the Field in the Territory (a “Third Party
License”), provided that, in the event [***] does not obtain a Third Party License within [***] with respect to a given infringement or misappropriation, [***] shall have the second right, but not the obligation, to commence negotiations and to
enter into such a Third Party License with respect to the Territory. In the event that AstraZeneca obtains a Third Party License, AstraZeneca shall grant to Impax a sublicense with respect to Existing Products under any such Patent, trade secret, or
other intellectual property right Controlled by AstraZeneca pursuant to such license, which sublicense shall be granted with a scope and on terms consistent with the grants provided to Impax in Section 6.1 and subject to the applicable terms
and conditions of the Third Party License. Impax shall be responsible for all payments to the applicable Third Party to the extent reasonably allocable to Impax’ exercise of its rights with respect to the Existing Products in the Field in the
Territory (and to the extent allocable to Impax’ exercise of any other rights as may be granted to Impax pursuant to such sublicense with respect to Additional Products), provided that, for purposes of Section 7.2.3, such payments shall be
deemed to have been made by Impax directly to such Third Party and shall be subject to Section 7.2.3 to the extent applicable. Subject to Section 7.2.3, Impax shall be responsible for all payments made by Impax or any of its Affiliates to
any Third Parties for any license or other rights granted to Impax with respect to Licensed Products, including any Third Party License entered into by Impax consistent with this Section 10.6. Except as provided in this Section 10.6, Impax
shall not be restricted from entering into any license agreement with any Third Party pursuant to which Impax obtains any license or similar rights to permit the full and unhindered exercise of its rights under this Agreement with respect to
Licensed Products. 

  
 83 

 10.7. Product Trademarks. 

10.7.1. Ownership and Prosecution of Product Trademarks. AstraZeneca shall own all right, title, and interest to the
Product Trademarks in the Territory, and shall be responsible for the registration, prosecution, and maintenance thereof during the Term. All costs and expenses of registering, prosecuting, maintaining and renewing the Product Trademarks shall be
borne solely by AstraZeneca. Impax shall provide all assistance and documents reasonably requested by AstraZeneca in support of its prosecution, registration, and maintenance of the Product Trademarks. AstraZeneca shall not abandon or elect not to
renew any Product Trademark in the Territory without first notifying Impax and permitting Impax to continue the prosecution, maintenance or renewal of such Product Trademark in the Territory and pay any required fees in the name of AstraZeneca, at
Impax’ sole cost and expense and through attorneys or agents reasonably acceptable to AstraZeneca. Impax shall not become an assignee of any Product Trademark as a result of its continuing the prosecution, maintenance or renewal for such
Product Trademark or paying any fees according to this Section 10.7.1. 
 10.7.2. Enforcement of Product
Trademarks. AstraZeneca shall have the first right (but not the obligation) for taking such action as AstraZeneca deems necessary against a Third Party based on any alleged, threatened, or actual infringement, dilution, misappropriation, or
other violation of, or unfair trade practices or any other like offense relating to, the Product Trademarks by a Third Party in the Territory. AstraZeneca shall bear the costs and expenses relating to any enforcement action commenced pursuant to
this Section 10.7.2 and any settlements and judgments with respect thereto, and shall retain any damages or other amounts collected in connection therewith. In the event that AstraZeneca elects not to assume responsibility for such enforcement,
Impax shall have the right, but not the obligation, for such action using counsel reasonably acceptable to AstraZeneca, in which case Impax shall bear all costs and expenses and shall retain any damages or other amounts collected in connection
therewith; provided, however, that Impax shall reasonably consult with AstraZeneca regarding strategy and settlement of any such action. 
 10.7.3. Third Party Claims. AstraZeneca shall have the first right, but not the obligation, for defending against any alleged, threatened, or actual claim by a Third Party against
AstraZeneca or Impax that the use or registration of the Product Trademarks in the Territory infringes, dilutes, misappropriates, or otherwise violates any Trademark or other right of that Third Party or constitutes unfair trade practices or any
other like offense, or any other claims as may be brought by a Third Party against a Party in connection with the use of the Product Trademarks with respect to a Licensed Products in the Territory (including the right to settle such claims in its
sole discretion). AstraZeneca shall bear the costs and expenses relating to any defense commenced pursuant to this Section 10.7.3 and any settlements and judgments with respect thereto, and shall retain any damages or other amounts collected in
connection therewith. In the event that AstraZeneca elects not to assume responsibility for such defense, Impax shall have the right, but not the obligation, for such action using counsel reasonably acceptable to AstraZeneca, in which case Impax
shall bear all costs and expenses and shall retain any damages or other amounts collected in connection therewith; provided, however, that Impax shall reasonably consult with AstraZeneca regarding strategy and settlement of any such action.

 10.7.4. Third Party Licenses. Nothing in this Section 10.7 shall prevent either Party, at its own
expense, from obtaining any trademark license or other rights from Third Parties it deems appropriate in order to permit the full and unhindered exercise of its rights under this Agreement. 

 

  
 84 

 10.7.5. Notice and Cooperation. Each Party shall provide to the other Party
prompt written notice of any actual or threatened infringement of the Product Trademarks in the Territory and of any actual or threatened claim that the use of the Product Trademarks in the Territory violates the rights of any Third Party. Each
Party agrees to cooperate fully with the other Party with respect to any enforcement action or defense commenced pursuant to this Section 10.7. 
 Article 11 
 CONFIDENTIALITY,
NON-DISCLOSURE, SECURITIES MATTERS 
 11.1.
Confidentiality Obligations. At all times during the Term and (i) for a period of [***] years following termination of this Agreement in its entirety or (ii) such longer period as required by the [***] License Agreement or [***]
Supply Agreement, each Party shall, and shall cause its officers, directors, employees, agents and sublicensees to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any
Confidential Information of the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential Information” means any technical, business, or other information provided
by or on behalf of one Party to the other Party in connection with this Agreement, whether prior to, on, or after the Effective Date, including any such information relating to the terms of this Agreement, the Quality Assurance Agreement, the
Licensed Compound or any product that contains the Licensed Compound (including the Regulatory Documentation), any Development or Commercialization of the Licensed Compound or any product that contains the Licensed Compound, any know-how with
respect thereto developed by or on behalf of the disclosing Party or its Affiliates (including Impax Know-How, as applicable), or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing,
(a) all Regulatory Documentation owned by AstraZeneca pursuant to Section 5.1.1 shall be deemed to be the Confidential Information of AstraZeneca, and AstraZeneca shall be deemed to be the disclosing Party and Impax shall be deemed to be
the receiving Party with respect thereto, and (b) all Regulatory Documentation owned by Impax pursuant to Section 5.1.2 shall be deemed to be the Confidential Information of Impax, and Impax shall be deemed to be the disclosing Party and
AstraZeneca shall be deemed to be the receiving Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 11.1 with respect to any Confidential Information shall not include any
information that: 
 11.1.1. is or hereafter becomes part of the public domain by public use, publication, general
knowledge or the like through no wrongful act, fault or negligence on the part of the receiving Party; 
 11.1.2. can be
demonstrated by documentation or other competent proof to have been in the receiving Party’s or its Affiliates’ possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such
information; provided that the foregoing exception shall not apply with respect to Regulatory Documentation; 
 11.1.3.
is subsequently received by the receiving Party or its Affiliates from a Third Party or a sublicensee who is not bound by any obligation of confidentiality with respect to such information; 

  
 85 

 11.1.4. has been published by a Third Party or otherwise enters the public domain
through no fault of the receiving Party in breach of this Agreement; or 
 11.1.5. can be demonstrated by documentation
or other competent evidence to have been independently developed by or for the receiving Party or its Affiliates without reference to the disclosing Party’s Confidential Information; provided that the foregoing exception shall not apply with
respect to Regulatory Documentation. 
 Specific aspects or details of Confidential Information shall not be deemed to be within the public
domain or in the possession of the receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential
Information shall not be considered in the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the
combination and its principles are in the public domain or in the possession of the receiving Party. 
 11.2.
Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is: 

11.2.1. made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national,
regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the receiving Party’s legal counsel, such disclosure is otherwise required by law, including by reason of filing
with securities regulators; provided, however, that the receiving Party shall first have given notice to the disclosing Party and given the disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential
treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided further
that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order; 

11.2.2. made by or on behalf of the receiving Party to the Regulatory Authorities as required in connection with any filing,
application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law; 

11.2.3. made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary or useful for purposes
of obtaining or enforcing a Patent; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

11.2.4. made by the receiving Party or its Affiliates to an acquirer or potential acquirer of all or substantially all of the
assets of such receiving Party or its Affiliates to which this Agreement relates; provided, however, that such persons (other than the disclosing Party’s attorneys) shall be subject to obligations of confidentiality and non-use with respect to
such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this Article 11; or 

  
 86 

 11.2.5. made by the receiving Party or its Affiliates or sublicensees to its or
their attorneys, auditors, advisors, consultants, contractors, existing or prospective collaboration partners, or (sub)licensees as may be necessary or useful in connection with the Exploitation or Manufacture of the Licensed Compound, the Licensed
Products, or, in the case of AstraZeneca as the receiving Party, other products that contain the Licensed Compound, or otherwise in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement;
provided, however, that such persons (other than the disclosing Party’s attorneys) shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of
confidentiality and non-use of the receiving Party pursuant to this Article 11 (with a duration of confidentiality and non-use obligations as appropriate that is no less than [***] from the date of disclosure). 

11.3. Third Party Confidentiality Obligations. Notwithstanding the foregoing in this Article 11, in the event that any
agreement between AstraZeneca and a Third Party that contains terms and conditions with respect to the use or disclosure of any Confidential Information provided by AstraZeneca to Impax, including the [***] Supply Agreement or the [***] License
Agreement, if such agreement contains one or more confidentiality or non-disclosure provisions applicable to the information provided to Impax that are more restrictive than those contained herein, then the confidentiality or non-disclosure
obligations of such agreement shall prevail and Impax shall be obligated to comply with such obligations with respect to the applicable information, provided, however, that such requirement shall only apply to Impax to the extent AstraZeneca has
disclosed to Impax in writing such obligations. 
 11.4. Use of Name. Except as expressly provided herein, neither
Party shall mention or otherwise use the name, logo, or Trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of
publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 11.4 shall not prohibit either Party from making any disclosure identifying the other Party that is required by
Applicable Law or the requirements of a national securities exchange or another similar regulatory body, provided that any such disclosure shall be governed by this Article 11. Further, the restrictions imposed on each Party under this
Section 11.4 are not intended, and shall not be construed, to prohibit a Party from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this
Article 11. 
 11.5. Public Announcements. The Parties have agreed upon the content of a press release which shall
be issued by Impax substantially in the form attached hereto as Schedule 11.5, the release of which the Parties shall coordinate in order to accomplish such release promptly upon execution of this Agreement. Neither Party shall issue any other
public announcement, press release, or other public disclosure regarding this Agreement or the Exploitation of any Licensed Product in the Field in the Territory without the other Party’s prior written consent, except for any such disclosure
that is a republication (while still current and accurate) of a prior disclosure or in the opinion of the disclosing Party’s counsel, required by 

  
 87 

 
Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is, in
the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party shall submit the
proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon. 

11.6. Publications. Each Party recognizes that the publication of papers regarding results of, and other information
regarding, activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is the
intent of the Parties to maintain the confidentiality of any Confidential Information included in any invention disclosures or draft Patent application until such Patent application has been filed. Accordingly, each Party shall have the right to
review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains clinical data from, or pertains to results of, any Impax Study or AstraZeneca Study in the Field, or that includes
Confidential Information of the other Party. Any such approval shall not be unreasonably withheld, conditioned or delayed. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall
deliver a then-current copy of the paper or materials for oral presentation to the other Party at least [***] prior to submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments
to the publishing Party within [***] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and
shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [***] from the date of delivery to the other Party. Failure to respond within such [***] shall be
deemed approval to publish or present. If approval is not given or deemed given, either Party may refer the matter to the Senior Officers for resolution together with the reasons for withholding approval. Notwithstanding the foregoing, the
publishing or presenting Party shall comply with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and shall withhold publication of any such paper or any presentation of same
for an additional [***] in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning
scientific credit, either through authorship or acknowledgement, as may be appropriate. Each Party shall use Commercially Reasonable Efforts to cause investigators and institutions with which it contracts for the conduct of clinical studies covered
by this Section 11.6, to agree to terms substantially similar to those set forth in this Section 11.6, which efforts shall satisfy such Party’s obligations under this Section 11.6 with respect to such investigators and
institutions. Notwithstanding the foregoing, in the case of AstraZeneca with respect to AstraZeneca Studies outside the Territory, AstraZeneca shall be deemed to satisfy its obligations under this Section 11.6 if it uses Commercially Reasonable
Efforts to comply with this Section 11.6. 

  
 88 

 11.7. Return of Confidential Information. Upon the effective date of the
termination of this Agreement for any reason, either Party may request in writing, and the other Party shall either, with respect to Confidential Information to which such first Party does not retain rights under the surviving provisions of this
Agreement: (i) promptly destroy all copies of such Confidential Information in the possession of the other Party and confirm such destruction in writing to the requesting Party except to the extent retention is required by Applicable Law; or
(ii) promptly deliver to the requesting Party, at the other Party’s expense, all copies of such Confidential Information in the possession of the other Party; provided, however, the other Party shall be permitted to retain one
(1) copy of such Confidential Information for the sole purpose of performing any continuing obligations hereunder or for archival purposes. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies
of or any computer records or files containing such Confidential Information that have been created solely by such Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other
Party’s standard archiving and back-up procedures, but not for any other use or purpose. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 11.1. 

11.8. Disclosure Required by Applicable Law. Notwithstanding this Article 11, each Party may disclose the terms of this
Agreement, including the identity of the Parties and the payment terms, to any governmental authority if the Party wishing to make such disclosure determines, upon advice of counsel, that such disclosure is reasonably necessary. The Party wishing to
make such disclosure shall consult with the other Party prior thereto, unless the Party wishing to make such disclosure determines in its reasonable judgment that such consultation would be inappropriate in the circumstances. 

11.9. Securities Laws. Each Party acknowledges that the securities of Affiliates of the other Party are publicly traded and
that as a result of the information shared under this Agreement, such first Party may be in possession of material non-public information about the other Party, and that as a result of the receipt of such information, the first Party may be
precluded under applicable securities laws from trading in the securities of the other Party. Upon reasonable request of either Party made within [***] of the Effective Date, the other Party shall, and shall use reasonable efforts to cause its
Affiliates and representatives to, provide any information reasonably required by the requesting Party to comply with its obligations under Regulation S-X and Form 8-K of the U.S. Securities Exchange Act of 1934, including information reasonably
necessary to prepare any applicable pro forma financial information required to be filed by the requesting Party with the Securities and Exchange Commission. The requesting Party shall promptly reimburse the other Party for all costs and
expenses (internal and external) reasonably incurred by the other Party, its Affiliates or its representatives in connection with the prior sentence.

  
 89 

 Article 12 
 REPRESENTATIONS AND WARRANTIES 

12.1. Mutual Representations and Warranties. AstraZeneca and Impax each represents and warrants to the other, as of the
Effective Date, and, to the extent applicable, covenants, as follows: 
 12.1.1. Organization. It is a
corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.

 12.1.2. Authorization. The execution and delivery of this Agreement and the performance by it of the
transactions contemplated hereby have been duly authorized by all necessary corporate action, and do not violate (i) such Party’s charter documents, bylaws, or other organizational documents, (ii) in any material respect, any
agreement, instrument, or contractual obligation to which such Party is bound, (iii) any requirement of any Applicable Law, or (iv) any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency
presently in effect applicable to such Party. 
 12.1.3. Binding Agreement. This Agreement is a legal, valid, and
binding obligation of such Party enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial
principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity). 
 12.1.4. No Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of
this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 
 12.2.
Additional Representations and Warranties of AstraZeneca. AstraZeneca further represents and warrants to Impax and, to the extent applicable, covenants, as follows: 

12.2.1. Regulatory Matters. 
 (i) As of the Effective Date, AstraZeneca and its Affiliates have complied in all material respects with all Applicable Law and applicable Regulatory Approvals with respect to the Exploitation of the
Existing Products in the Territory. 
 (ii) AstraZeneca or one more of its Affiliates or any successor or permitted assignee is
the sole and exclusive owner of all Regulatory Approvals relied upon by AstraZeneca and its Affiliates or such successor or permitted assignee to commercially distribute, sell or market the Existing Products for use for the Approved Indications in
the Territory. As of the Effective Date, such Regulatory Approvals are in full force and effect and have been duly and validly issued. The NDAs with respect to the Existing Products in the Territory are listed on Schedule 12.2.1(ii). 

(iii) Except as disclosed on Schedule 12.2.1(iii), no Existing Product has been recalled, suspended, or withdrawn from the market in the
[***] year period prior to the Effective Date, and as of the Effective Date, no Existing Product is currently involved in any ongoing, or to the Knowledge of AstraZeneca, threatened or potential recall, withdrawal, or suspension from the market.

  
 90 

 (iv) AstraZeneca or one of more of its Affiliates have all material approvals, licenses,
and registrations required from any Regulatory Authority as of the Effective Date for AstraZeneca to Commercialize and Manufacture the Existing Products for Approved Indications in the Territory and to fulfill its obligations under this Agreement.

 12.2.2. Intellectual Property. 
 (i) To AstraZeneca’s Knowledge, other than the AstraZeneca U.S. Patents and the [***] Patents, there are no Patents Controlled by AstraZeneca or its Affiliates as of the Effective Date that would,
but for the rights granted to Impax pursuant to this Agreement, be infringed by the Exploitation by Impax of Existing Products in the Territory under this Agreement. 
 (ii) As of the Effective Date, AstraZeneca or one or more of its Affiliates is the sole and exclusive owner of the entire right, title and interest in the AstraZeneca U.S. Patents and is entitled to grant
the licenses specified herein. As of the Effective Date, such rights are not subject to any encumbrance, lien or, to AstraZeneca’s Knowledge, claim of ownership by any Third Party. 

(iii) To AstraZeneca’s Knowledge, as of the Effective Date, there is no actual infringement or threatened infringement of the
AstraZeneca U.S. Patents or Product Trademarks utilized by AstraZeneca as of the Effective Date by any Third Party in the Field in the Territory. As of the Effective Date, neither AstraZeneca nor its Affiliates has received notice of a certification
filed under the U.S. “Drug Price Competition and Patent Term Restoration Act” of 1984 (21 United States Code §335(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV)) (a “Paragraph IV Notice”) with respect to an Existing Product
claiming that any AstraZeneca U.S. Patent is invalid or unenforceable or claiming that any AstraZeneca U.S. Patent will not be infringed by the Manufacture, use, marketing or sale of a product for which an application under such act is filed.

 (iv) As of the Effective Date, to AstraZeneca’s Knowledge, (a) Impax’ Commercialization of the Existing
Products for the Approved Indications in the Territory will not infringe any Patent of any Third Party, and (b) Impax’ use of the Product Trademarks utilized by AstraZeneca as of the Effective Date in connection with such Commercialization
will not infringe any Trademark of any Third Party in the Territory. 
 (v) As of the Effective Date, to AstraZeneca’s
Knowledge, no claim or litigation has been brought or threatened by any Third Party alleging that (a) any AstraZeneca U.S. Patent is invalid or unenforceable, (b) the Commercialization of the Existing Products for the Approved Indications
in the Territory infringes any Patent of any Third Party or (c) such Third Party owns any interest in AstraZeneca U.S. Patents. 
 (vi) Neither AstraZeneca nor any of its Affiliates (a) has previously entered into any agreement, whether written or oral, with respect to, or otherwise assigned, transferred, licensed, conveyed or
otherwise encumbered its right, title or interest in or to, the AstraZeneca U.S. Patents, the Product Trademarks utilized by AstraZeneca as of the Effective Date or any Regulatory Documentation Controlled by AstraZeneca in the Territory in the Field
as of the Effective Date, and (b) shall enter into any such agreements or grant any such right, title or interest to any Person, in each case ((a) and (b)) that is inconsistent with the rights and licenses granted to Impax under this Agreement.

  
 91 

 12.2.3. [***] Agreements. AstraZeneca and its Affiliates are the licensees of
certain rights, title and interest in and to the [***] Patents pursuant to the terms of that certain [***] License Agreement. A true, complete and correct copy of the [***] License Agreement and the [***] Supply Agreement, each as amended as of the
Effective Date, have been provided to Impax prior to the date first above written. To AstraZeneca’s Knowledge, as of the Effective Date, (i) [***], (ii) AstraZeneca, its Affiliates and [***] are [***], (iii) neither AstraZeneca
nor any of its Affiliates have [***]. AstraZeneca shall not take or omit to take any actions that would [***]. AstraZeneca has received [***]. 
 12.2.4. Litigation. Except as set forth on Schedule 12.2.4, to AstraZeneca’s Knowledge there are no other lawsuits, government investigations, judicial or arbitral actions, or legal
proceedings (public or private) in the Territory against AstraZeneca or any of its Affiliates involving the Licensed Compound (i) threatened or pending as of the Effective Date, or (ii) that have been pending at any time in the [***] years
prior to the Effective Date. 
 12.2.5. No Debarment. As of the Effective Date, neither AstraZeneca nor any of
its Affiliates has been debarred or is subject to debarment and neither AstraZeneca nor any of its Affiliates shall use in any capacity, in connection with the activities to be performed under this Agreement, any Person (including any Third Party
Manufacturer) who has been debarred pursuant to Section 306 of the FFDCA, or who is the subject of a conviction described in such section. AstraZeneca agrees to inform Impax in writing promptly if it or any such Person who is performing
activities hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of AstraZeneca’s or its
Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of AstraZeneca or any such Person performing activities hereunder. 
 12.2.6. Third Party Rights. AstraZeneca shall obtain from each of its Affiliates, employees and agents, and from the employees and agents of its Affiliates and agents, who are performing
activities under this Agreement, rights to any and all Regulatory Documentation that relates to the Licensed Compound or any Licensed Products for use for the Approved Indications in the Territory and all AstraZeneca Improvements, such that Impax
shall, by virtue of this Agreement, receive from AstraZeneca, without payments beyond those required by Article 7, the licenses and other rights with respect thereto granted to Impax hereunder. 

12.2.7. No Channel Stuffing. Since [***] and until the Effective Date, to the Knowledge of AstraZeneca, AstraZeneca and
its Affiliates (i) have sold Existing Products in the Territory to wholesalers or distributors only in the ordinary course of business and in amounts that are generally consistent with past sales by AstraZeneca and its Affiliates to their
wholesale and distributor customers during comparable periods (which, for the avoidance of doubt, shall take into account seasonality, cyclicality and other market conditions), and (ii) have donated Existing Product to non-profit or charitable
organizations in the Territory only in amounts (if any) that are generally consistent with past Existing Product donations by 

  
 92 

 
AstraZeneca and its Affiliates to non-profit or charitable organizations in the Territory during comparable periods, or otherwise to avoid obsolescence of inventory of Existing Product, and
(iii) have not engaged in any practice in the Territory with the intent of increasing the levels of inventory of the Existing Products in the distributor or wholesaler channels outside of the ordinary course of business and in anticipation of
entering into this Agreement or any similar transactions with respect to Existing Products. 
 12.2.8. CIA. As of
the Effective Date, other than the CIA, AstraZeneca and its Affiliates are not a party to or bound by any other agreements or contracts with any Regulatory Authority, or bound by any orders, consent decrees, or other similar directives of any
Regulatory Authority, that would be reasonably likely to have a material adverse effect on Impax’ ability to Commercialize the Existing Products in the Territory in accordance with Applicable Law; provided that nothing contained herein is
intended or shall be construed to include any representation or warranty with respect to any requirement arising under Regulatory Approval or Applicable Law. 
 12.3. Additional Representations and Warranties of Impax. Impax further represents and warrants to AstraZeneca and, to the extent applicable, covenants, as follows: 

12.3.1. As of the Effective Date, except as set forth on Schedule 12.3.1, Impax is not an Affiliate of any other pharmaceutical
manufacturer, or distributor, or any Competitor. 
 12.3.2. As of the Effective Date, neither Impax nor any of its
Affiliates manufacture or commercialize any Competing Product or Restricted Product. 
 12.3.3. From the time of receipt
of each Supplied Product from AstraZeneca, such Supplied Product (i) shall be stored and shipped in material accordance with GMP, (ii) shall be stored and shipped in compliance with the specifications provided by AstraZeneca and the
applicable NDA, and (iii) shall not be adulterated or misbranded in each case by Impax or its Affiliates under the FFDCA or under any other Applicable Law. 
 12.3.4. Except as set forth on Schedule 12.3.4, Impax, with respect to the conduct of its business as of the Effective Date, has been and is in compliance in all material respects with Applicable
Laws and is not in receipt of notice of, and is not subject to, any adverse inspection, finding of deficiency, finding of non-compliance, compelled or voluntary recall, investigation, penalty for corrective or remedial action or other compliance or
enforcement action, in each such case which could reasonably be expected to have a material adverse effect on the Commercialization of the Licensed Products in the Territory, AstraZeneca’s exercise of its rights hereunder or Impax’ ability
to perform its obligations under this Agreement. 
 12.3.5. Except with respect to the NDAs for the Existing Products,
Impax or one of more of its Affiliates have or will have prior to the applicable Impax Commercialization Date all material approvals, licenses, and registrations required from any Regulatory Authority as of the Effective Date for Impax to
Commercialize the Existing Products for Approved Indications in the Territory and to fulfill its obligations under this Agreement with respect to which performance is required to commence as of the Effective Date or as of the Impax Commercialization
Date with respect to each Existing Product. 

  
 93 

 12.3.6. As of the Effective Date, neither Impax nor any of its Affiliates has been
debarred or is subject to debarment and neither Impax nor any of its Affiliates shall use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the
FFDCA, or who is the subject of a conviction described in such section. Impax agrees to inform AstraZeneca in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in
Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of Impax’ or its Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of Impax or any
such Person performing services hereunder. 
 12.3.7. Impax shall obtain from each of its Affiliates, Sublicensees,
employees and agents, and from the employees and agents of its Affiliates, Sublicensees and agents, who are performing activities under this Agreement rights to any and all Impax Study Data, Regulatory Documentation that relates to the Licensed
Compound or any Licensed Products and all Impax Improvements and Impax Improvement Patents, such that AstraZeneca shall, by virtue of this Agreement, receive from Impax, without any related payment obligation, the licenses and other rights with
respect thereto granted to AstraZeneca hereunder. 
 12.3.8. Unless contained in reports filed by Impax with the U.S.
Securities and Exchange Commission under the Exchange Act, Impax shall deliver to AstraZeneca, within [***] after the end of each Calendar Quarter during the Term, consolidated balance sheets of Impax as of the end of such period, and consolidated
statements of income and cash flow for such period and for the current fiscal year to date, prepared in accordance with GAAP (other than for accompanying notes). 
 12.3.9. As of the Effective Date and the date of each Fixed Payment pursuant to Section 7.1, immediately after giving effect to all of the transactions contemplated by this Agreement,
including the Fixed Payments due pursuant to Section 7.1, and payment of all related fees and expenses, Impax shall be Solvent. For purposes of this Section 12.3.9, the term “Solvent” with respect to Impax means that,
as of any date of determination, the amount of the fair value of the assets of Impax and its subsidiaries, taken as a whole, exceeds, as of such date, the fair value of all liabilities of Impax and its subsidiaries, taken as a whole, as of such
date, as such terms are generally determined in accordance with the Applicable Law of Delaware governing determinations of the solvency of debtors. 
 12.4. DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE 12 AND IN SECTIONS 3.7.3 AND 8.24, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 94 

 Article 13 
 INDEMNITY 
 13.1. Indemnification of AstraZeneca.
Subject to Section 13.5.5, Impax shall indemnify AstraZeneca, its Affiliates and its and their respective directors, officers, employees, and agents (collectively, the “AstraZeneca Indemnified Parties”), and defend and save
each of them harmless, from and against any and all losses, damages, liabilities, costs, and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) arising from or occurring as a result of any and
all suits, investigations, litigation, arbitrations, claims, or demands of Third Parties (including governmental entities) (collectively, “Third Party Claims”) arising from or occurring as a result of: 

13.1.1. the breach by Impax (including through any of its other Party Members) of any representation, warranty, covenant or other
term or condition of this Agreement (including any representation, warranty or undertaking set forth in Sections 3.7.2, 3.7.3 or 12.3.3) or any Ancillary Agreements; 
 13.1.2. the gross negligence or willful or intentional misconduct on the part of Impax or any of its Affiliates, Subcontractors or Sublicensees or its or their respective directors, officers,
employees, and agents in performing its or their obligations under this Agreement or any Ancillary Agreement; 
 13.1.3.
any actual or alleged violations of Applicable Law by Impax or any of its Affiliates, Subcontractors or Sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees, and agents in connection
with the performance of any activity contemplated by this Agreement or the Ancillary Agreements; 
 13.1.4. the
(i) [***] by Impax or any of its Affiliates, Sublicensees or Subcontractors, or (ii) [***] by Impax or any of its Affiliates, Sublicensees or Subcontractors, including any Losses arising from or occurring as a result of the [***] in
violation of Applicable Law, except in each case ((i) and (ii)) to the extent that any such Losses arise from or occur as a result of (a) the [***], during any period in which such [***]; or (y) such [***]; or (b) AstraZeneca’s
use outside the Territory of any [***]. 
 13.1.5. the Exploitation on or after the Effective Date of the Licensed
Compound or any products containing the Licensed Compound (including any and all Existing Products, Additional Products and Impax Generic Versions) by Impax or any of its Affiliates, Sublicensees or Subcontractors or its or their distributors or
contractors or its or their respective directors, officers, employees or agents, but excluding in each case Losses to the extent arising from or occurring as a result of (i) the [***], during any period in which [***]; or (b) any [***]; or
(ii) AstraZeneca’s use outside the Territory of any [***]; 
 13.1.6. Impax’ [***] with respect to
Licensed Products sold under Managed Market Contracts or contracts required to effect any Government Health Care Program; 

  
 95 

 13.1.7. the content of any Product Labels and Inserts for a Licensed Product to the
extent the content thereof is adopted by AstraZeneca at Impax’ request or reflects a change to any Product Label and Insert for a Licensed Product that is implemented by AstraZeneca at Impax’ request; 

13.1.8. the conduct of any Impax Study; 
 13.1.9. the enforcement by AstraZeneca of its rights under this Article 13; 
 except in
each case (Sections 13.1.1 through 13.1.9) for those Losses for which AstraZeneca has an obligation to indemnify the Impax Indemnified Parties pursuant to Section 13.2, as to which Losses each Party shall indemnify the other Party to the extent
of its respective liability for such Losses. 
 13.2. Indemnification of Impax. Subject to Section 13.5.5,
AstraZeneca shall indemnify Impax, its Affiliates and its and their respective directors, officers, employees, and agents (collectively, the “Impax Indemnified Parties”), and defend and save each of them harmless, from and against
any and all Losses arising from or occurring as a result of any and all Third Party Claims arising from or occurring as a result of: 
 13.2.1. the breach by AstraZeneca (including through any of its other Party Members) of any representation, warranty, covenant or other term or condition of this Agreement (including any
representation, warranty or undertaking set forth in Sections 3.7.2, 3.7.3 or 8.24) or any Ancillary Agreements; 
 13.2.2.
the gross negligence or willful or intentional misconduct on the part of AstraZeneca or any of its Affiliates or Subcontractors or its or their respective directors, officers, employees, and agents in performing its or their obligations under
this Agreement or any Ancillary Agreement; 
 13.2.3. any actual or alleged violations of Applicable Law by AstraZeneca
or any of its Affiliates or Subcontractors or its or their respective directors, officers, employees, and agents in connection with the performance of any activity contemplated by this Agreement or any Ancillary Agreement; 

13.2.4. the Exploitation of the Existing Products or the Licensed Compound or any products containing the Licensed Compound by
AstraZeneca or any of its Affiliates or its or their distributors or contractors or its or their respective directors, officers, employees, or agents to the extent arising from or occurring as a result of Existing Products or any products containing
the Licensed Compound sold or distributed prior to January 1, 2012; 
 13.2.5. the Exploitation of the Existing
Products or the Licensed Compound or any products containing the Licensed Compound by AstraZeneca or any of its Affiliates or its or their distributors or contractors or its or their respective directors, officers, employees, or agents to the extent
arising from or occurring specifically as a result of activities conducted after January 1, 2012 in relation to or in furtherance of any interests in such Existing Products, Licensed Compound or products containing the Licensed Compound outside
the Territory (which activities are not also being conducted by AstraZeneca or any of its Affiliates in satisfaction of obligations under this Agreement or in support of the Exploitation of products containing the Licensed Compound in the Territory)
or outside the Field in the Territory; 

  
 96 

 13.2.6. any personal injury or death suffered by a Person as a result of the use of
an Existing Product (for clarity, excluding Additional Products) to the extent such personal injury or death was caused by (i) [***] sold or distributed during the Term by Impax or any of its Affiliates in the Field in the Territory or by or on
behalf of AstraZeneca or any of its Affiliates after January 1, 2012 pursuant to the Transition Plan; or (ii) AstraZeneca’s decision not to implement a change to Product Labels and Inserts for an Existing Product, or a recall of an
Existing Product, in each case as proposed by Impax; provided that this Section 13.2.6 is not intended and shall not be construed to require AstraZeneca to indemnify for personal injury or death caused by any Existing Product for a New
Indication developed or an approved New Indication commercialized by Impax or any of its Affiliates or Sublicensees. 

13.2.7. the conduct of the Selected Mandated Studies or any AstraZeneca Studies; 

13.2.8. the enforcement by Impax of its rights under this Article 13. 
 except in each case (Sections 13.2.1 through 13.2.8) for those Losses for which Impax has an obligation to indemnify any AstraZeneca Indemnified Party pursuant to Section 13.1, as to which Losses
each Party shall indemnify the other Party to the extent of its respective liability for such Losses. 
 13.3. Notice
of Claim. An Indemnified Party shall give the Indemnifying Party prompt written notice of any Loss or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 13.1 or 13.2 (an
“Indemnification Claim Notice”). In no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing the Indemnification Claim Notice. Each Indemnification Claim Notice shall contain a
description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and
official documents received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or its or their respective directors, officers, employees and agents shall be made solely by such
Party to this Agreement. 
 13.4. Control of Defense. 

13.4.1. In General. At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving
written notice to the Indemnified Party within [***] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be construed as an
acknowledgment that the Indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified
Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying

  
 97 

 
Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents
(including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 13.4.2, the Indemnifying Party shall not
be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in writing by the Indemnifying
Party. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the
Indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of the Third Party Claim that they would not otherwise have incurred if no
Indemnity Claim Notice was presented. 
 13.4.2. Right to Participate in Defense. Without limiting
Section 13.4.1, any Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the
Indemnified Party’s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (ii) the Indemnifying Party has failed to assume the defense and employ counsel in accordance
with Section 13.4.1 (in which case the Indemnified Party shall control the defense), or (iii) the interests of the indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the
representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles. 
 13.4.3.
Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that shall not result in the Indemnified Party’s becoming subject to injunctive or other relief, and as
to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or
otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of
the Third Party Claim in accordance with Section 13.4.1, the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided it obtains the prior written
consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed). If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against such
Third Party Claim, provided that with respect to any Losses for which the Indemnified Party intends to seek indemnification hereunder, the Indemnified Party shall not consent to the entry of any judgment, enter into any settlement or otherwise
dispose of such Loss without providing to the Indemnifying Party reasonable prior notice and an opportunity to discuss the proposed action. 
 13.4.4. Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each indemnitee to,
reasonably cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably
requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant
to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall
reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 

  
 98 

 13.4.5. Expenses. Except as expressly provided above, the reasonable and
verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim shall be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

13.5. LIMITATIONS OF LIABILITY. 
 13.5.1. SPECIAL, INDIRECT AND CERTAIN OTHER DAMAGES. Notwithstanding any term or condition of this Agreement or any Ancillary Agreement to the contrary, neither Party nor any of its Affiliates
shall be liable for special, indirect, incidental or consequential damages, or for lost profits, whether in contract, warranty, negligence, tort, strict liability or otherwise (i) arising out of the development, manufacture, or
commercialization of the Licensed Compound or any product containing the Licensed Compound, or (ii) otherwise arising out of this Agreement or any Ancillary Agreement or the activities that a Party or any of its Affiliates conducts or fails to
conduct hereunder, except in each case ((i) and (ii)) to the extent any such damages (a) result from a Party’s breach of its obligations under [***], (b) result from a [***] or a [***] and Impax is expressly permitted to recover such
damages pursuant to Section 13.5.2 (and subject to the limitations on AstraZeneca’s liability set forth in Section 13.5.2) or to make a Proration Election pursuant to Section 7.1, or (c) are required to be paid to a Third
Party as part of a claim for which a Party provides indemnification under Section 13.1 or Section 13.2. 
 13.5.2.
DAMAGES LIMITATION FOR CERTAIN CLAIMS. Subject to a Proration Election permitted pursuant to Section 7.1 and subject to Section 13.5.3 and except to the extent of any Losses that are required to be paid to a Third Party as part of a
claim for indemnification under Section 13.1 or Section 13.2, notwithstanding any other term or condition of this Agreement or any Ancillary Agreement to the contrary, the total aggregate liability of AstraZeneca (and its Affiliates) for
claims asserted by Impax based in whole or in part on damages (including direct damages, special, indirect, incidental or consequential damages, or for lost profits) resulting from any [***] or [***] (whether such claims are based on contract,
warranty, negligence, tort, strict liability or otherwise, and whether such claims are alleged to arise or arise as a result of breach or failure to perform any of the provisions of this Agreement or any Ancillary Agreement by AstraZeneca or any of
its Affiliates or whether such claims are based on any intentional or willful misconduct of AstraZeneca or any of its Affiliates) shall be limited (i) for any and all [***] occurring on or before [***], to [***], and (ii) for any and all
[***] occurring after [***], to the amount, if positive, equal to [***] (such limitation as it may apply prior to, on and after December 31, 2015, the “Liability Cap”). 

  
 99 

 13.5.3. PRORATION ELECTION. Notwithstanding any term or condition of this Agreement
(including Section 13.5.2) or any Ancillary Agreement to the contrary, in the event that Impax makes a Proration Election pursuant to Section 7.1 with respect to [***] occurring during the related Payment Period, such Proration Election
shall be Impax’ sole and exclusive remedy with respect to such [***] breach of this Agreement or any Ancillary Agreement or intentional or willful misconduct by AstraZeneca or any of its Affiliates, and Impax shall not be entitled to any other
amounts, damages or remedies from AstraZeneca in connection therewith. 
 13.5.4. OTHER SUPPLY FAILURES. Notwithstanding
any term or condition of this Agreement (including Section 13.5.2) or any Ancillary Agreement to the contrary, except to the extent of any damages that are required to be paid to a Third Party as part of a claim for which a Party provides
indemnification under Section 13.1 or Section 13.2, and except to the extent resulting from one or more [***]), in no event shall AstraZeneca be liable to Impax for any monetary damages or other monetary amounts in connection with any
Supply Failure. In the event of any Supply Failure, other than a [***], Impax’ sole and exclusive monetary remedies shall be as set forth in Sections 8.17, as applicable. After the Liability Cap is exhausted, Impax’ sole and exclusive
monetary remedies for any [***] shall be as set forth in Sections 8.17, as applicable. For clarity, this Section 13.5.4 is not intended and shall not be construed to limit Impax’ right to make a Proration Election pursuant to
Section 7.1 or to recover monetary damages for a [***] in accordance with Section 13.5.2. 
 13.5.5. PRODUCTS
LIABILITY. 
 (i) Notwithstanding any term or condition of this Agreement or any Ancillary Agreement to the contrary,
neither Impax nor any of its Affiliates shall be liable to any AstraZeneca Indemnified Party for any Losses, whether in contract, warranty, negligence, tort, strict liability or otherwise, to the extent arising out of or occurring as a result of any
personal injury or death suffered by a Person as a result of the use of any Licensed Product or any product containing the Licensed Compound, except to the extent that Impax has an indemnity obligation under this Article 13 toward an AstraZeneca
Indemnified Party for any Losses arising from or occurring as a result of a Third Party Claim during or after the Term as a result of (a) a breach of the obligations under Section 12.3.3 by Impax any of its Affiliates or Sublicensees,
(b) an Existing Product sold or distributed by Impax or any of its Affiliates or Sublicensees that is used for (x) development of a New Indication by Impax or any of its Affiliates or Sublicensees or (y) an approved New Indication
commercialized by Impax or any of its Affiliates or Sublicensees, (c) an Additional Product developed, manufactured or commercialized by Impax or any of its Affiliates or Sublicensees or (d) any product containing the Licensed Compound
developed, manufactured or commercialized by Impax or any of its Affiliates or (sub)licensees after the Term, except that, without limitation to clauses (a), (b) and (c), this clause (d) shall be deemed not to cover any Licensed Product
sold or distributed by Impax after the last day of the Term pursuant to the sell off right provided in Section 14.7.4. 

  
 100

 (ii) Notwithstanding any term or condition of this Agreement or any Ancillary Agreement to
the contrary, neither AstraZeneca nor any of its Affiliates shall be liable to any Impax Indemnified Party for any Losses, whether in contract, warranty, negligence, tort, strict liability or otherwise, to the extent arising out of or occurring as a
result of any personal injury or death suffered by a Person as a result of the use of any Impax Generic Version, except to the extent that AstraZeneca has an indemnity obligation under this Article 13 toward an Impax Indemnified Party for any Losses
arising from or occurring as a result of a Third Party Claim as a result of a breach of the obligations under Section 8.24 by AstraZeneca or any of its Affiliates. 
 (iii) Notwithstanding any term or condition of this Agreement or any Ancillary Agreement to the contrary, neither AstraZeneca nor any of its Affiliates shall be liable to any Impax Indemnified Party for
any Losses, whether in contract, warranty, negligence, tort, strict liability or otherwise, to the extent` arising out of or occurring as a result of any personal injury or death suffered by a Person as a result of the use of any Additional Product
developed, manufactured or commercialized by Impax or any of its Affiliates or Sublicensees during or after the Term, other than any Additional Product developed or commercialized by AstraZeneca or any of its Affiliates or sublicensees outside the
Territory or outside the Field inside the Territory. 
 13.6. Insurance. 

13.6.1. Each Party shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply, use and
sale of the Licensed Compound and the Licensed Products as is normal and customary in the pharmaceutical industry generally for persons similarly situated, and shall upon request provide the other Party with a copy of its policies of insurance in
that regard, along with any amendments and revisions thereto. 
 13.6.2. Notwithstanding the foregoing, at a minimum,
each Party shall maintain during the Term, (i) commercial general liability insurance, including contractual liability insurance, with a combined single limit for bodily injury and property damage of not less than [***], (ii) products
liability/completed operations coverage with a minimum indemnity limit of [***] per occurrence, and (iii) an all-risks insurance policy covering its facilities with a minimum indemnity limit of [***] per occurrence. The General Liability
requirement can be satisfied by the combination of primary and umbrella/excess liability policies. Such policies in the case of policies maintained by Impax shall (a) be provided by reputable insurance carrier(s), and (b) show the other
Party as additional insured and loss payee, as its interests may appear. Such policies shall remain in effect throughout the Term and shall not be canceled or subject to a reduction of coverage without the prior written authorization of the other
Party. Should a Party who should have been insured at any time or for any reason fail to obtain the insurance required herein, or should such insurance be canceled or the above limits reduced, the other Party shall have the right to procure the same
and the cost and expense thereof shall be deducted from any compensation then due or thereafter to become due under this Agreement to the Party which should have been insured. Notwithstanding the foregoing, AstraZeneca shall have the right to
satisfy the requirements of this Section 13.6 through a program of self-insurance. 

  
 101

 Article 14 
 TERM, TERMINATION AND OTHER REMEDIES 
 14.1. Term. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect until terminated in accordance with
the termination provisions set forth in this Article 14 (such period, the “Term”). 
 14.2. Mutual
Termination Rights. 
 14.2.1. Material Breach. If either Party (the “Non-Breaching Party”) believes that
the other Party (the “Breaching Party”) has materially breached one or more of its material obligations under this Agreement, then the Non-Breaching Party may deliver notice of such material breach to the Breaching Party (a “Default
Notice”). If the Breaching Party disputes that it has committed a material breach of one or more of its material obligations under this Agreement, then it may refer the matter to the JOC for dispute resolution in accordance with
Section 2.2.3 and, if the JOC is unable to resolve the dispute as contemplated in Section 2.2.3, then to the JSC for dispute resolution in accordance with Sections 2.1.1 and 2.1.3 (except that the provisions of the third sentence of
Section 2.1.3(i) (regarding the power to make final resolutions held by the Senior Officer of Impax) shall not apply for purposes of this Section 14.2.1). If the JOC and the JSC are unable to resolve the dispute, and the Breaching Party
fails to cure such alleged breach, within [***] after receipt of the Default Notice, or in the case of a Payment default, within [***] after receipt of the Default Notice, the Non-Breaching Party may terminate this Agreement upon written notice to
the Breaching Party. Notwithstanding the foregoing, in the event a breach (other than a payment breach or a breach by Impax under Section 3.5) cannot be cured within such [***] period, the period for cure may be extended an additional [***]
provided that the Breaching Party has promptly commenced efforts to cure such breach after the Default Notice and thereafter diligently continues such efforts. 
 14.2.2. Permanent Recall or Withdrawal. Either Party may terminate this Agreement with respect to a Licensed Product in the event that Regulatory Authorities cause the recall or withdrawal
(or if the applicable NDA holder (i.e., AstraZeneca in the case of any Existing Product and Impax in the case of any Additional Product) initiates such a recall or withdrawal) of such Licensed Product in the Territory where such recall or withdrawal
is (i) reasonably expected to be permanent and (ii) is not limited to particular Licensed Product batches or lots as a result of a correctable Manufacturing process defect. 

14.3. Additional Termination by Impax. 
 14.3.1. Impax may terminate this Agreement any time after December 31, 2015, by giving AstraZeneca [***] prior written notice thereof. 

14.3.2. Impax may terminate this Agreement any time after the first date on which a Third Party Commercializes a Third Party
Generic Version of the Zomig Nasal Spray by giving AstraZeneca [***] prior written notice thereof. 
 14.3.3. Impax may
terminate this Agreement in accordance with Section 8.15.1. 

  
 102

 14.4. Additional Termination by AstraZeneca. In the event that Impax or any of
its Affiliates or Sublicensees, anywhere in the Territory, [***], or (ii) [***], in each case, AstraZeneca shall have the right to immediately terminate this Agreement, including the rights of any Sublicensees, upon written notice to Impax;
provided that Section 14.4 as it applies to any [***] shall only apply during the term of [***]. 
 14.5.
Termination for Insolvency. In the event that either Party (i) files for protection under bankruptcy or insolvency laws, (ii) makes an assignment for the benefit of creditors, (iii) appoints or suffers appointment of a
receiver or trustee over substantially all of its property that is not discharged within [***] after such filing, (iv) proposes a written agreement of composition or extension of its debts, (v) proposes or is a party to any dissolution or
liquidation, (vi) files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within [***] of the filing thereof, or (vii) admits in writing its inability generally to meet its
obligations as they fall due in the general course, then the other Party may terminate this Agreement effective immediately upon written notice to such Party. 
 14.6. Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Impax or AstraZeneca are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree
that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties
further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such
proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall
be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations
under this Agreement, or (ii) if not delivered under clause (i) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. The Parties
acknowledge and agree that payments made under Section 7.1 and 7.2 shall constitute royalties within the meaning of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. 

14.7. Effect of Termination. In the event of any termination of this Agreement, the provisions of this Section 14.7
shall apply; provided that a Recall Termination shall not have any effect on any Licensed Product which is not terminated in such Recall Termination. 
 14.7.1. Impax Rights Terminate. Except as otherwise provided in Section 14.7.5, all licenses, including rights of reference, granted by AstraZeneca hereunder shall immediately terminate
and [***]. 

  
 103

 14.7.2. Certain Licenses Granted to AstraZeneca Continue. Notwithstanding
anything to the contrary contained in this Agreement, (a) the licenses and rights of reference or cross-reference granted by Impax to AstraZeneca pursuant to [***] shall survive any termination of this Agreement with respect to any intellectual
property or documentation that Impax Controls at the time of such termination, solely for the purposes set forth in clause (i) of [***]; and (b) the license set forth in [***] shall survive any termination of this Agreement, provided that
in the case of the license set forth in [***], such license after the effective date of termination of this Agreement in its entirety shall become subject to a royalty in the case of any Selected Additional Products to the extent provided in
Section 14.7.6(iv). For clarity, a Recall Termination shall not have any effect on [***], which shall continue in full force and effect in the case of a Recall Termination. 

14.7.3. Pending Orders. If immediately prior to termination, AstraZeneca or its Affiliate was Manufacturing any Terminated
Product which was a Supplied Product pursuant to Section 8.1, then the provisions of this Section 14.7.3 shall apply. 
 (i) Non-Recall or Non-Impax Related Termination. The provisions of this Section 14.7.3(i) shall apply, except in the case of a Recall Termination or an Impax Related Termination. 

(a) Finished Inventory. Any finished inventory Manufactured by or on behalf of AstraZeneca for supply to Impax for which title
has not passed to Impax and which bears any NDC or Corporate Name of Impax or its Affiliates shall be, at Impax’ option, (y) delivered, transferred and sold by AstraZeneca to Impax in accordance with Article 8, or (z) destroyed by
AstraZeneca at Impax’ cost and Impax shall reimburse AstraZeneca for the Supply Price of such destroyed inventory. 
 (b)
Work in Process. Any work-in-process inventory Manufactured by or on behalf of AstraZeneca for supply to Impax for which title has not passed to Impax and which bears any NDC or Corporate Name of Impax or its Affiliates shall be, at
Impax’ option, (y) completed, delivered, transferred and sold by AstraZeneca to Impax in accordance with Article 8, or (z) destroyed by AstraZeneca at Impax’ cost and Impax shall reimburse AstraZeneca for the reasonable cost of
such destroyed work-in-process inventory. 
 (c) Outstanding POs. Any outstanding Purchase Orders shall be canceled
(other than with respect to the inventory referenced in Section 14.7.3(i)(a) and (b) above). 
 (d) Certain
Components, Raw Materials, Work-in-Process and Finished Inventory. Solely in the case of a termination of this Agreement pursuant to Section 14.3, and except with respect to any finished inventory or work-in-process inventory covered by
Section 14.7.3(i)(a) or (i)(b), AstraZeneca shall have the right to invoice Impax for all components, raw materials, work-in-process and finished inventory on hand that were obtained or Manufactured by AstraZeneca in order to supply Supplied
Product to Impax in quantities reasonably consistent with Impax’ forecasts and Purchase Orders and that, in the case of any components, raw materials and work-in-process, remain unused by AstraZeneca or any of its Affiliates [***] after the
effective date of termination and which are not reasonably expected 

  
 104

 
in AstraZeneca’s determination to be used by AstraZeneca or any of its Affiliates thereafter, in each case together with any related destruction costs associated therewith. The reimbursement
amount to be paid by Impax for any finished inventory on hand shall be the Supply Price therefor and the reimbursement amount to be paid by Impax for any such components, raw materials or work-in-process inventory on hand shall be AstraZeneca’s
reasonable costs therefor, as reasonably documented by AstraZeneca. For clarity, in no event shall this Section 14.7.3(i)(d) provide AstraZeneca the right to sell to any Third Party any finished inventory that bears any NDC or Corporate Name of
Impax or any of its Affiliates. 
 (ii) Recall or Impax Related Termination. The provisions of this
Section 14.7.3(ii) shall apply only in the case of a Recall Termination or any Impax Related Termination: 
 (a)
Outstanding POs. Any outstanding Purchase Orders for the applicable Terminated Products shall be canceled. 
 (b)
Finished Inventory and Work in Process. Any inventory or work-in-process inventory of the applicable Terminated Products Manufactured by AstraZeneca for supply to Impax for which title has not passed to Impax and which does not bear any NDC
or Corporate Name of Impax or its Affiliates may be retained by AstraZeneca, subject to clause (c) below. 
 (c)
Certain Components, Raw Materials, Work-in-Process and Finished Inventory. In the case of an Impax Related Termination (but not a Recall Termination), AstraZeneca shall have the right to invoice Impax for all components, raw materials,
work-in-process and finished inventory on hand that were obtained or Manufactured by AstraZeneca in order to supply Supplied Product to Impax in quantities reasonably consistent with Impax’ forecasts and Purchase Orders and that, in the case of
any components, raw materials and work-in-process, remain unused by AstraZeneca or any of its Affiliates [***] after the effective date of termination and which are not reasonably expected in AstraZeneca’s determination to be used by
AstraZeneca or any of its Affiliates thereafter, in each case together with any related destruction costs associated therewith. The reimbursement amount to be paid by Impax for any finished inventory on hand shall be the Supply Price therefor and
the reimbursement amount to be paid by Impax for any such components, raw materials or work in process inventory on hand shall be AstraZeneca’s reasonable costs therefor, as reasonably documented by AstraZeneca. For clarity, in no event shall
this Section 14.7.3(ii)(c) provide AstraZeneca the right to sell to any Third Party any finished inventory that bears any NDC or Corporate Name of Impax or any of its Affiliates. 

14.7.4. Sell Down Right. With respect to any Licensed Product which is not the subject of a Recall Termination and is not
the subject of any Impax Related Termination, Impax shall have the non-exclusive right and license for a period of [***] after the effective date of termination of this Agreement to sell down its remaining inventory of the Terminated Products
bearing any Corporate Name or NDC of Impax or its Affiliates, and such sales will be subject to the royalties contained in Article 7. 

  
 105

 14.7.5. Clinical Studies. Unless expressly prohibited by any Regulatory
Authority, at AstraZeneca’s written request, Impax shall and shall cause its Affiliates to transfer control to AstraZeneca of any or all clinical studies for any Terminated Products being conducted by Impax as of the effective date of
termination of this Agreement and continue to conduct such clinical studies for up to [***] at AstraZeneca’s cost to enable such transfer to be completed without interruption of any such clinical study; provided, however, that (a) neither
Party shall have any obligation to continue any such clinical study unless required by Applicable Law or by the applicable institutional review board or other similar monitoring body responsible for the conduct of such clinical study (the
“IRB”), and (b) with respect to each such clinical study for which such transfer is prohibited by the applicable Regulatory Authority or IRB, or any study for which AstraZeneca does not request and receive a transfer of
control, Impax shall continue to conduct such clinical study to completion, or at its election if consistent with Applicable Law and the requirements of the IRB, to wind down such clinical study. In the case of any clinical studies for any
Terminated Products being conducted by Impax as of the effective date of termination of this Agreement, continuation of such study(ies) or wind down of such study in accordance with this Section 14.7.4 shall be at Impax’ cost, except to
the extent of any study for which transfer of control has been requested by AstraZeneca, for which the costs of continuation or wind down after the effective date of termination, as the case may be, shall be at AstraZeneca’s cost with respect
to the [***] period referred to above, as applicable, and the period following any such transfer of control. At AstraZeneca’s request, Impax shall and shall cause its Affiliates to assign to AstraZeneca any or all agreements with any Third
Party to the extent related to the conduct of such clinical studies for the Terminated Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, such agreement
expressly prohibits such assignment, in which case Impax shall reasonably cooperate with AstraZeneca at AstraZeneca’s cost to secure the consent of the applicable Third Party to such assignment. 

14.7.6. Non-Recall or Non-AZ Related Terminations. In the event of a termination of this Agreement other than a Recall
Termination and other than an AstraZeneca Related Termination, the provisions of this Section 14.7.6 shall apply: 
 (i)
License For Existing Products. Impax, on behalf of itself and its Affiliates, shall, and hereby does effective as of the effective date of termination of this Agreement, grant AstraZeneca (a) a [***], non-exclusive license, with the
right to grant sublicenses through multiple tiers, under the Impax Patents and Impax Know-How to Exploit the Existing Products and (b) without limitation to Sections 6.2.3 and 14.7.2, a [***], non-exclusive license, with the right to grant
sublicenses through multiple tiers, under the Impax Improvement Patents to Exploit the Existing Products in the Territory; provided, however, that for the avoidance of doubt, Impax shall have no obligation to disclose any Impax Improvements or Impax
Improvement Patents to AstraZeneca in connection with this Section 14.7.6 or the other terms or conditions of this Agreement, except to the extent that disclosure is required in connection with activities conducted pursuant to Article 4 or
Article 5. 
 (ii) License For Selected Additional Products. Impax, on behalf of itself and its Affiliates, shall, and
hereby does effective as of the effective date of termination of this Agreement, grant AstraZeneca (a) a worldwide, non-exclusive, [***], license, with the right to grant sublicenses through multiple tiers, under the Impax Patents and

  
 106

 
Impax Know-How to Exploit the Selected Additional Products, and (b) without limitation to Sections 6.2.3 and 14.7.2, a non-exclusive, [***] license, with the right to grant sublicenses
through multiple tiers, under the Impax Improvement Patents to Exploit the Selected Additional Products in the Territory, which license shall be subject to a royalty to the extent provided pursuant to Section 14.7.6(iv); provided, however, that
for the avoidance of doubt, Impax shall have no obligation to disclose any Impax Improvements or Impax Improvement Patents to AstraZeneca in connection with this Section 14.7.6 or the other terms or conditions of this Agreement, except to the
extent that disclosure is required in connection with activities conducted pursuant to Article 4 or Article 5. 
 (iii)
License for Regulatory Materials. Without limitation to Sections 6.2.2 or 14.7.2, Impax, on behalf of itself and its Affiliates, shall, and hereby does effective as of the effective date of termination, grant to AstraZeneca, and shall cause
its Sublicensees to grant to AstraZeneca effective as of the effective date of termination, a worldwide, [***], non-exclusive license and right of reference, with the right to grant sublicenses and further rights of reference through multiple tiers,
in and to all Regulatory Approvals, Impax Regulatory Documentation and Impax Study Data owned or Controlled by Impax or its Affiliates or Sublicensees to Exploit the Existing Products and Selected Additional Products, which license and right of
reference shall be subject to a royalty with respect to the Selected Additional Products to the extent provided pursuant to Section 14.7.6(iv). 
 (iv) Royalty. With respect to each Selected Additional Product (but not any Existing Product) that is Commercialized by AstraZeneca, its Affiliates or sublicensees after the effective date of
termination of the Agreement in reliance on, or through use of, the license granted to AstraZeneca with respect to any Impax Patent, Impax Improvement Patent, Impax Know-How, Regulatory Approval, Impax Regulatory Documentation or Impax Study Data
pursuant to Section 6.2.3 (which survives termination as provided in Section 14.7.2) or Section 14.7.6, AstraZeneca shall pay to Impax a royalty of [***], on net sales of such Selected Additional Product by AstraZeneca, its Affiliates
or sublicensees on a quarterly basis for a period of [***] following the effective date of termination of this Agreement. For purposes of this Section 14.7.6(iv), “net sales” shall be calculated in a manner consistent with the
definition of Net Sales set forth in Section 1.143, substituting references to Impax with AstraZeneca, as appropriate. Notwithstanding the foregoing or any other term or condition of this Agreement to the contrary, no royalty
shall be payable by AstraZeneca to Impax pursuant to this Agreement (a) with respect to any such product Commercialized by AstraZeneca or any of its Affiliates or sublicensees for which the reliance on, or use of, the license granted to
AstraZeneca consists solely of the reliance on or use of any such Regulatory Approval, Impax Regulatory Documentation or Impax Study Data to comply with any requirement to report worldwide clinical studies or safety information with respect to a
product containing the Licensed Compound to Regulatory Authorities, or (b) based on the Exploitation by AstraZeneca or any of its Affiliates or sublicensees of any product that contains the Licensed Compound in the OTC Field outside the
Territory. Except as expressly set forth in Sections 6.2.2, 6.2.3 (which survives termination as provided in Section 14.7.2), and 14.7.6 (x) no license is granted by Impax or its Affiliates to AstraZeneca for the Exploitation, after the
termination of this Agreement, by AstraZeneca or its Affiliates or any sublicensees of any product that contains the Licensed Compound and (y) no other royalty shall be payable by AstraZeneca to Impax based on the Exploitation by AstraZeneca or
its Affiliates or any sublicensees of any product that contains the Licensed Compound, including any Existing Product.  

  
 107

 (v) Marketing Material Copyrights. Impax, on behalf of itself and its Affiliates,
shall grant to AstraZeneca a non-exclusive license to use all Marketing Material Copyrights, excluding any Corporate Names belonging to Impax, applicable to the Existing Products and Selected Additional Products, which Marketing Material Copyrights
are then owned or Controlled by Impax or any of its Affiliates. 
 (vi) [***]. Without limitation to any other surviving
obligation of Impax pursuant to this Agreement, for a period of [***] following the effective date of termination of this Agreement in its entirety, [***]. 
 (vii) Survival of Covenant. Except in the case of an AstraZeneca Related Termination, the covenant granted by Impax in Section 4.1.5 shall survive for a period of [***] following the effective
date of termination of this Agreement. 
 (viii) Impax Manufacturing and Technology Transfer. At the time of termination
of this Agreement in its entirety, if Impax is Manufacturing or having Manufactured by a Third Party any Existing Product(s) (including any Impax Generic Version thereof) or Selected Additional Product(s), at AstraZeneca’s written request,
Impax shall use good faith efforts to supply to AstraZeneca such reasonable quantities of such Licensed Products as AstraZeneca indicates in written forecasts and orders therefor from time to time until the earlier of (a) the [***] of the
effective date of termination of this Agreement, and (b) such time as AstraZeneca has established an alternate, validated source of supply for such Licensed Products and AstraZeneca is receiving supply from such alternative source sufficient to
meet market demand in the Territory. The cost to AstraZeneca for such supply shall be at Impax’ [***] to Manufacture such Licensed Products. For purposes of this Section 14.7.6(viii), “manufacturing costs” shall be calculated in
a manner consistent with the definition of Manufacturing Costs set forth in Section 1.128 to the extent applicable, substituting references to AstraZeneca with Impax, as appropriate. In addition, at AstraZeneca’s sole cost and expense,
Impax shall provide a technology transfer to AstraZeneca or its designee with respect to Manufacturing technology Controlled by Impax that is being utilized by or on behalf of Impax or any of its Affiliates or Sublicensees to Manufacture such
Licensed Products as of the effective date of termination of this Agreement, to the extent such technology is within the scope of the licenses, assignments and other rights granted to AstraZeneca in Section 6.2.2, 6.2.3 (which survives
termination as provided in Section 14.7.2) or 14.7.6 and is not then in the possession of AstraZeneca. The technology transfer pursuant to this Section 14.7.6(viii) shall approximate the technology transfer that AstraZeneca may be required
to carry out pursuant to Section 8.19 (including resolution of terms by a Third Party arbitrator as provided in Section 8.19.1). In addition, Impax shall grant to AstraZeneca a non-exclusive license, with the right to sublicense through
multiple tiers, to use transferred Manufacturing documentation and know-how to Manufacture or have Manufactured anywhere in the world such Licensed Products, which license shall be subject to a royalty with respect to the Selected Additional
Products to the extent provided pursuant to Section 14.7.6(iv). Any other supply terms which are not specified in this Section 14.7.6(viii) shall be based upon the terms contained in Section 8.1, 8.3, 8.6.1 through 8.6.3, 8.7 through
8.18 (provided that in the case of Section 8.18 as applied to Existing Products, the site visit permitted thereunder shall be expanded as necessary to permit AstraZeneca to conduct inspections that satisfy its obligations as the NDA holder for
such products), 8.20.1, 8.20.2, 8.20.3 (solely in the case of Section 8.20.3 with respect to any Selected Additional Product), 8.22 and 8.24 of this Agreement, which shall apply mutatis mutandis to the supply obligations and technology
transfer contained in this Section 14.7.6(viii). 

  
 108

 14.7.7. Cooperation and Further Assurances. Notwithstanding anything to the
contrary contained in this Section 14.7.7, nothing in this Section 14.7.7 shall apply in the event of a Recall Termination. Impax shall and shall cause its Affiliates to reasonably cooperate with AstraZeneca to facilitate and carry out an
orderly transition back to AstraZeneca of the Existing Products (and the Selected Additional Products solely to the extent a license is granted to AstraZeneca for such Selected Additional Products under Sections 6.2.2, 6.2.3 (which survives
termination as provided in Section 14.7.2) or 14.7.6). Impax shall and shall cause its Affiliates to notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect such transition. At AstraZeneca’s
written request, Impax and AstraZeneca shall enter into an agreement setting forth the terms and conditions pursuant to which AstraZeneca and Impax will effectuate and coordinate the provisions of this Section 14.7 as reasonably necessary for
AstraZeneca to Exploit the Existing Products (and the Selected Additional Products solely to the extent a license is granted to AstraZeneca for such Selected Additional Products in Section 6.2.2, 6.2.3 (which survives termination as provided in
Section 14.7.2) or 14.7.6) in the Territory upon and after termination of this Agreement in its entirety (the “Reversion Agreement”). The terms of the Reversion Agreement shall be negotiated by the Parties promptly and in good
faith, and the Parties shall endeavor to agree upon such terms and have them become effective prior to the effective date of termination of this Agreement in its entirety, unless the Parties mutually agree to a later date in writing. In the case of
(a) any Impax Related Termination, Impax shall bear its own expenses with respect to this Section 14.7.7, and (b) any other termination, AstraZeneca shall reimburse Impax for its reasonable costs and expenses (internal and external) with
respect thereto. 
 14.8. Remedies. Except as otherwise expressly provided herein, termination of this Agreement
in accordance with the provisions hereof, and the other terms and conditions of this Article 14, shall not limit remedies that may otherwise be available in law or equity. 
 14.9. Accrued Rights; Surviving Obligations. Termination of this Agreement shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such
termination. Such termination shall not relieve a Party from obligations that are expressly indicated to survive the termination of this Agreement. Without limiting the foregoing, upon the termination of this Agreement, (i) Article 1 shall
survive as necessary for reference by any other surviving provisions in the Agreement, (ii) Article 9 shall survive with respect to any Licensed Product sold by Impax or any of its Affiliates or Sublicensees pursuant to this Agreement,
(iii) Article 11 shall survive in accordance with its terms, except that Section 11.6 shall survive for [***], provided that AstraZeneca shall not have obligations under Section 11.6 with respect to publications that do not contain
data or results from an Impax Study and do not contain any Confidential Information of Impax and (iv) Article 15 and the following Sections shall survive in accordance with their terms, or if no term is specified, indefinitely: 3.8, 3.11 (with
respect to Licensed Products sold under Impax NDCs prior to the effective date of termination or as permitted after such date pursuant to Section 14.7.4), 4.1.4 (with respect to any Impax Study initiated prior to the effective date of
termination or conducted after such date in accordance with Section 14.7.5), 4.1.5 (to the extent 

  
 109

 provided in Section 14.7.6(vii)), 4.2, 4.3, 5.1.1, 5.1.2, 5.3, 5.4, 6.2.2, 6.2.3, 7.2 (with respect to
sales of Licensed Product prior to the effective date of termination or as permitted after such date pursuant to Section 14.7.4), 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.20 (solely with respect to Supplied Product supplied prior to the effective
date of termination or supplied pursuant to Section 14.7.3), 8.21, 8.24, 10.1, 10.4, 10.7.1 (solely with respect to the first two sentences thereof), 10.7.3, 13.1 through 13.5, 14.6, 14.7, 14.8 and 14.9. 

Article 15 

MISCELLANEOUS 
 15.1. Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling
or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes,
hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of
the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any
term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated
duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use Commercially Reasonable Efforts to
remedy its inability to perform. Without limitation to the foregoing, in the event that either Party is the non-performing Party and the suspension of performance continues for [***] after the date of the occurrence, the other Party shall have the
right to terminate this Agreement pursuant to Section 14.2.1 as if the non-performing Party had committed a material breach, except that in such event no cure period shall apply and the other Party shall have the right to effect such
termination upon written notice to the non-performing party, in its sole discretion. 
 15.2. Export Control. This
Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it shall not export,
directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other
governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law. 
 15.3. Assignment. 
 15.3.1. Without the prior written consent of
the other Party, such consent not to be unreasonably withheld, conditioned, or delayed beyond [***], neither Party shall sell, transfer, assign, delegate, pledge, or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or
otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that either Party may make such an assignment without the other Party’s consent to a 

  
 110

 
successor, whether in a merger, sale of stock, sale of assets or any other transaction, of the business to which this Agreement relates. Notwithstanding the foregoing, either Party shall have the
right, without the other Party’s consent, to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates. Each Party shall remain responsible for the performance of its rights
and obligations that are performed or exercised by any of its Affiliates hereunder. Any attempted assignment or delegation in violation of this Section 15.3 shall be void and of no effect. All validly assigned and delegated rights and
obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted assigns of AstraZeneca or Impax, as the case may be. In the event either Party seeks and obtains
the other Party’s consent to assign or delegate its rights or obligations to another Party, the assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. 

15.3.2. The rights to Information, materials and intellectual property: (i) controlled by a Third Party permitted assignee
of a Party, which Information, materials and intellectual property were controlled by such assignee immediately prior to such assignment; or (ii) controlled by an Affiliate of a Party who becomes an Affiliate through any Change in Control of or
Acquisition by such Party, which Information, materials and intellectual property were controlled by such Affiliate immediately prior to such Change in Control or Acquisition, in each case ((i) and (ii)), shall be automatically excluded from the
rights licensed or granted to the other Party under this Agreement. 
 15.4. Severability. If any provision of
this Agreement is held to be illegal, invalid, or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (i) such provision
shall be fully severable, (ii) this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full
force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom, and (iv) in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of
this Agreement a legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each
Party hereby waives any provision of law that would render any provision hereof illegal, invalid, or unenforceable in any respect. 
 15.5. Governing Law, Jurisdiction and Service. 
 15.5.1.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of
this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods. 

15.5.2. Jurisdiction. Subject to any dispute resolution provisions set forth herein, the Parties hereby irrevocably and
unconditionally consent to the exclusive jurisdiction of the courts of the State of Delaware for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit
or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and unconditionally waive their right to a jury trial. 

  
 111

 15.5.3. Venue. The Parties further hereby irrevocably and unconditionally
waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of Delaware, and hereby further irrevocably and unconditionally waive
and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 
 15.5.4. Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.6.2 shall be effective
service of process for any action, suit, or proceeding brought against it under this Agreement in any such court. 
 15.6.
Notices. 
 15.6.1. Notice Requirements. Any notice, request, demand, waiver, consent, approval, or other
communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by
internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 15.6.2 or to such other address as the Party to whom notice is to be given may
have provided to the other Party in accordance with this Section 15.6.1. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at
the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 15.6.1 is not
intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 
 15.6.2. Address for Notice. 
 If to Impax, to: 

Impax Pharmaceuticals 
 31047 Genstar Road 
 Hayward, CA 94544 

Attention: [***], Impax 
 Pharmaceuticals 
 Facsimile: [***] 

  
 112

 with a copy (which shall not constitute notice) to: 

Impax Laboratories, Inc. 
 31047 Genstar Road 
 Hayward, CA 94544 

Attention: [***] 
 Facsimile: [***] 
 If to AstraZeneca, to: 

AstraZeneca UK Limited 
 Mereside 
 Alderley Park, Macclesfield, Cheshire 

SK10 4TF 

England 

Attention: Deputy General Counsel, Corporate 
 Facsimile: [***] 
 with a copy (which shall not constitute notice) to:

 AstraZeneca Pharmaceuticals LP 
 1800 Concord Pike 
 Wilmington, DE 19803-2902 

U.S.A. 

Attention: General Counsel 
 Fax: [***] 
 15.7. Entire Agreement. This Agreement, together with
the Schedules attached hereto, constitutes the entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of
the Agreement. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability
for fraud. All Schedules referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. 
 15.8. English Language. This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and in the
event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 

15.9. Expenses. Except as otherwise expressly provided in this Agreement, each Party shall bear the fees and expenses of
its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

  
 113

 15.10. Equitable Relief. Each Party acknowledges and agrees that the
restrictions set forth in Section 3.9 and Section 6.7 as well as Article 10 and Article 11 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this
Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of such Sections or Articles shall result in irreparable injury to such other Party for which there shall be no adequate remedy at law. In the
event of a breach or threatened breach of any provision of such Sections or Articles, the non-breaching Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent,
specific performance, and an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be
entitled in law or equity. Both Parties agree to waive any requirement that the other (i) post a bond or other security as a condition for obtaining any such relief, and (ii) show irreparable harm, balancing of harms, consideration of the
public interest, or inadequacy of monetary damages as a remedy. Nothing in this Section 15.10 is intended, or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of
this Agreement. 
 15.11. Waiver and Non-Exclusion of Remedies. A Party’s failure to enforce, at any time or
for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising
any rights or remedies. To be effective any waiver must be in writing. The rights and remedies provided herein are cumulative and, except as expressly provided in Article 14 and elsewhere in this Agreement, do not exclude any other right or remedy
provided by law or otherwise available, except as expressly set forth herein. 
 15.12. No Benefit to Third Parties.
The covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons. 

15.13. Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such
further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

15.14. Amendments. Any amendment, discharge, waiver or modification of this Agreement must be in writing and signed by
authorized representatives of both Parties. 
 15.15. Relationship of the Parties. The status of a Party under
this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between the Parties or, except as otherwise expressly provided in this
Agreement, as granting either Party the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties or commitments on behalf of the other Party. All persons
employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

  
 114

 15.16. Counterparts; Facsimile Execution. This Agreement may be executed in
two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures and such
signatures shall be deemed to bind each Party hereto as if they were original signatures. 
 15.17. References.
Unless otherwise specified, (i) references in this Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (ii) references in any Section to any clause are references
to such clause of such Section, and (iii) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or
supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto. 
 15.18. Schedules. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. 

15.19. Construction. Except where the context requires otherwise, whenever used the singular includes the plural, the
plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or.” Whenever this Agreement refers to a number of days, unless otherwise
specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or limit the scope or intent of this Agreement or the scope or intent of any provision contained
in this Agreement. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. Whenever this Agreement refers to termination of this
Agreement “in its entirety,” it shall be understood to mean a termination of this Agreement as a whole (rather than on a Licensed Product-by-Licensed Product basis as occurs pursuant to Section 14.2.2), provided that a reference to
“in its entirety” is not intended and shall not be construed to be in derogation of the survival provisions of Section 14.9. Whenever this Agreement refers to a licensee or sublicensee (or (sub)licensee)) of AstraZeneca or any of its
Affiliates, the reference to such licensee or sublicensee (or (sub)licensee)) shall be deemed to exclude Impax and its Affiliates and Sublicensees. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no
rule of strict construction shall be applied against any Party. 
 [SIGNATURE PAGE FOLLOWS.] 

  
 115

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written
above. 
  

									
	AstraZeneca UK LIMITED	 		 	IMPAX LABORATORIES, INC.
					
	 By:
	 	 /s/ William (Liam) McIlveen
	 		 	By:	 	 /s/ Larry Hsu

	 Name: William (Liam) McIlveen
	 		 	Name: Larry Hsu
	 Title: Authorized Signatory
	 		 	Title: President and Chief Executive Officer

 [SIGNATURE PAGE TO DISTRIBUTION,
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT]8.50% Senior Secured Second Lien Note Indenture

 Exhibit 4.1 
 HUTCHINSON TECHNOLOGY INCORPORATED 
 8.50% SENIOR SECURED SECOND LIEN
NOTES DUE 2017 
  
  

INDENTURE 

DATED AS OF MARCH 30, 2012 
  

 
 WELLS FARGO
BANK, NATIONAL ASSOCIATION, 
 AS TRUSTEE AND COLLATERAL AGENT 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	 ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE
	  	 	1	  
			
	 Section 1.01
	 	 Definitions.
	  	 	1	  
	 Section 1.02
	 	 Other Definitions.
	  	 	26	  
	 Section 1.03
	 	 Trust Indenture Act Provisions.
	  	 	27	  
	 Section 1.04
	 	 Rules of Construction.
	  	 	27	  
	 Section 1.05
	 	 Acts of Holders.
	  	 	28	  
		
	 ARTICLE II THE NOTES
	  	 	28	  
			
	 Section 2.01
	 	 Form and Dating.
	  	 	28	  
	 Section 2.02
	 	 Execution and Authentication.
	  	 	30	  
	 Section 2.03
	 	 Registrar and Paying Agent.
	  	 	31	  
	 Section 2.04
	 	 Paying Agent to Hold Money in Trust.
	  	 	31	  
	 Section 2.05
	 	 Lists of Holders of Notes.
	  	 	31	  
	 Section 2.06
	 	 Transfer and Exchange.
	  	 	32	  
	 Section 2.07
	 	 Replacement Notes.
	  	 	32	  
	 Section 2.08
	 	 Outstanding Notes.
	  	 	33	  
	 Section 2.09
	 	 Treasury Notes.
	  	 	33	  
	 Section 2.10
	 	 Temporary Notes.
	  	 	34	  
	 Section 2.11
	 	 Cancellation.
	  	 	34	  
	 Section 2.12
	 	 Additional Transfer and Exchange Requirements.
	  	 	34	  
	 Section 2.13
	 	 CUSIP Numbers.
	  	 	38	  
		
	 ARTICLE III REDEMPTION AND PURCHASE
	  	 	38	  
			
	 Section 3.01
	 	 Optional Redemption.
	  	 	38	  
	 Section 3.02
	 	 Selection of Notes to be Redeemed.
	  	 	39	  
	 Section 3.03
	 	 Notice of Redemption.
	  	 	39	  
	 Section 3.04
	 	 Effect of Notice of Redemption.
	  	 	40	  
	 Section 3.05
	 	 Deposit of Redemption Price.
	  	 	40	  
	 Section 3.06
	 	 Notes Redeemed in Part.
	  	 	41	  
	 Section 3.07
	 	 Purchase of Notes in Open Market.
	  	 	41	  
	 Section 3.08
	 	 Offer to Purchase by Application of Excess Proceeds.
	  	 	41	  
		
	 ARTICLE IV COVENANTS
	  	 	43	  
			
	 Section 4.01
	 	 Payment of Notes.
	  	 	43	  
	 Section 4.02
	 	 Maintenance of Office or Agency.
	  	 	44	  
	 Section 4.03
	 	 SEC and Other Reports.
	  	 	44	  
	 Section 4.04
	 	 Compliance Certificates.
	  	 	45	  
	 Section 4.05
	 	 Taxes.
	  	 	46	  
	 Section 4.06
	 	 Stay, Extension and Usury Laws.
	  	 	46	  
	 Section 4.07
	 	 Restricted Payments.
	  	 	46	  
			
	 Section 4.08
	 	 Dividend and Other Payment Restrictions Affecting Subsidiaries.
	  	 	51	  

  
 -i-

 TABLE OF CONTENTS 

(Continued) 
  

							
	 	 	 	  	Page	 
			
	 Section 4.09
	 	 Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock.
	  	 	53	  
	 Section 4.10
	 	 Asset Sales.
	  	 	56	  
	 Section 4.11
	 	 Transactions with Affiliates.
	  	 	58	  
	 Section 4.12
	 	 Liens.
	  	 	60	  
	 Section 4.13
	 	 Business Activities.
	  	 	60	  
	 Section 4.14
	 	 Maintenance of Corporate Existence.
	  	 	60	  
	 Section 4.15
	 	 Offer to Repurchase Upon Change of Control.
	  	 	61	  
	 Section 4.16
	 	 Note Guaranties.
	  	 	62	  
	 Section 4.17
	 	 Designation of Restricted and Unrestricted Subsidiaries.
	  	 	63	  
	 Section 4.18
	 	 Additional Collateral.
	  	 	64	  
	 Section 4.19
	 	 Operating Leases.
	  	 	65	  
	 Section 4.20
	 	 Consolidated Total Assets.
	  	 	65	  
	 Section 4.21
	 	 Free Cash Flow.
	  	 	65	  
		
	 ARTICLE V CONSOLIDATION; MERGER; CONVEYANCE; TRANSFER OR LEASE
	  	 	66	  
			
	 Section 5.01
	 	 Company May Consolidate, Etc., Only on Certain Terms.
	  	 	66	  
	 Section 5.02
	 	 Successor Substituted.
	  	 	66	  
		
	 ARTICLE VI DEFAULT AND REMEDIES
	  	 	67	  
			
	 Section 6.01
	 	 Events of Default.
	  	 	67	  
	 Section 6.02
	 	 Acceleration.
	  	 	70	  
	 Section 6.03
	 	 Other Remedies.
	  	 	70	  
	 Section 6.04
	 	 Waiver of Defaults and Events of Default.
	  	 	70	  
	 Section 6.05
	 	 Control by Majority.
	  	 	70	  
	 Section 6.06
	 	 Limitations on Suits.
	  	 	71	  
	 Section 6.07
	 	 Rights of Holders to Receive Payment.
	  	 	71	  
	 Section 6.08
	 	 Collection Suit by Trustee.
	  	 	71	  
	 Section 6.09
	 	 Trustee May File Proofs of Claim.
	  	 	72	  
	 Section 6.10
	 	 Priorities.
	  	 	72	  
	 Section 6.11
	 	 Undertaking for Costs.
	  	 	72	  
	 Section 6.12
	 	 Restoration of Rights and Remedies.
	  	 	73	  
	 Section 6.13
	 	 Rights and Remedies Cumulative.
	  	 	73	  
	 Section 6.14
	 	 Delay or Omission Not Waiver.
	  	 	73	  
		
	 ARTICLE VII TRUSTEE
	  	 	73	  
			
	 Section 7.01
	 	 Obligations of Trustee.
	  	 	73	  
	 Section 7.02
	 	 Rights of Trustee.
	  	 	74	  
	 Section 7.03
	 	 Individual Rights of Trustee.
	  	 	76	  
	 Section 7.04
	 	 Trustee’s Disclaimer.
	  	 	76	  
	 Section 7.05
	 	 Notice of Default or Events of Default.
	  	 	76	  
	 Section 7.06
	 	 Reports by Trustee to Holders.
	  	 	76	  
	 Section 7.07
	 	 Compensation and Indemnity.
	  	 	76	  
	 Section 7.08
	 	 Replacement of Trustee.
	  	 	77	  

  
 -ii-

 TABLE OF CONTENTS 

(Continued) 
  

							
	 	 	 	  	Page	 
			
	 Section 7.09
	 	 Successor Trustee by Merger, Etc.
	  	 	78	  
	 Section 7.10
	 	 Eligibility; Disqualification.
	  	 	78	  
	 Section 7.11
	 	 Preferential Collection of Claims Against Company.
	  	 	79	  
		
	 ARTICLE VIII LEGAL DEFEASANCE AND COVENANT DEFEASANCE
	  	 	79	  
			
	 Section 8.01
	 	 Option to Effect Legal Defeasance or Covenant Defeasance.
	  	 	79	  
	 Section 8.02
	 	 Legal Defeasance and Discharge.
	  	 	79	  
	 Section 8.03
	 	 Covenant Defeasance.
	  	 	79	  
	 Section 8.04
	 	 Conditions to Legal or Covenant Defeasance.
	  	 	80	  
	 Section 8.05
	 	 Repayment to Company.
	  	 	81	  
	 Section 8.06
	 	 Reinstatement.
	  	 	82	  
		
	 ARTICLE IX AMENDMENTS; SUPPLEMENTS AND WAIVERS
	  	 	82	  
			
	 Section 9.01
	 	 Without Consent of Holders.
	  	 	82	  
	 Section 9.02
	 	 With Consent of Holders.
	  	 	83	  
	 Section 9.03
	 	 Compliance with Trust Indenture Act.
	  	 	84	  
	 Section 9.04
	 	 Revocation and Effect of Consents.
	  	 	84	  
	 Section 9.05
	 	 Notation On or Exchange of Notes.
	  	 	84	  
	 Section 9.06
	 	 Trustee to Sign Amendments, Etc.
	  	 	84	  
	 Section 9.07
	 	 Effect of Supplemental Indentures.
	  	 	85	  
	 Section 9.08
	 	 Payment for Consent.
	  	 	85	  
		
	 ARTICLE X COLLATERAL AND SECURITY
	  	 	85	  
			
	 Section 10.01
	 	 Security Interest.
	  	 	85	  
	 Section 10.02
	 	 Intercreditor Agreement.
	  	 	86	  
	 Section 10.03
	 	 Release of Liens in Respect of Notes.
	  	 	86	  
	 Section 10.04
	 	 Collateral Agent.
	  	 	88	  
	 Section 10.05
	 	 Further Assurances.
	  	 	89	  
	 Section 10.06
	 	 Insurance.
	  	 	90	  
	 Section 10.07
	 	 Impairment of Security Interest.
	  	 	90	  
		
	 ARTICLE XI NOTE GUARANTIES
	  	 	90	  
			
	 Section 11.01
	 	 Guaranty.
	  	 	90	  
	 Section 11.02
	 	 Limitation on Guarantor Liability.
	  	 	92	  
	 Section 11.03
	 	 Execution and Delivery of Note Guaranty.
	  	 	92	  
	 Section 11.04
	 	 Guarantors May Consolidate, etc., on Certain Terms.
	  	 	93	  
	 Section 11.05
	 	 Releases.
	  	 	93	  
		
	 ARTICLE XII SATISFACTION AND DISCHARGE OF INDENTURE
	  	 	94	  
			
	 Section 12.01
	 	 Satisfaction and Discharge of Indenture.
	  	 	94	  
	 Section 12.02
	 	 Application of Trust Money.
	  	 	95	  
	 Section 12.03
	 	 Repayment to Company.
	  	 	95	  
	 Section 12.04
	 	 Reinstatement.
	  	 	95	  
		
	 ARTICLE XIII MISCELLANEOUS
	  	 	96	  
			
	 Section 13.01
	 	 Trust Indenture Act Controls.
	  	 	96	  

  
 -iii-

 TABLE OF CONTENTS 

(Continued) 
  

							
	 	 	 	  	Page	 
			
	 Section 13.02
	 	 Notices.
	  	 	96	  
	 Section 13.03
	 	 Communications by Holders with Other Holders.
	  	 	97	  
	 Section 13.04
	 	 Certificate and Opinion as to Conditions Precedent.
	  	 	97	  
	 Section 13.05
	 	 Record Date for Vote or Consent of Holders of Notes.
	  	 	98	  
	 Section 13.06
	 	 Rules by Trustee, Paying Agent and Registrar.
	  	 	98	  
	 Section 13.07
	 	 Legal Holidays.
	  	 	98	  
	 Section 13.08
	 	 Governing Law.
	  	 	98	  
	 Section 13.09
	 	 No Adverse Interpretation of Other Agreements.
	  	 	98	  
	 Section 13.10
	 	 No Recourse Against Others.
	  	 	98	  
	 Section 13.11
	 	 Successors.
	  	 	98	  
	 Section 13.12
	 	 Multiple Counterparts.
	  	 	98	  
	 Section 13.13
	 	 Separability.
	  	 	99	  
	 Section 13.14
	 	 Table of Contents, Headings, Etc.
	  	 	99	  
	 Section 13.15
	 	 Jurisdiction.
	  	 	99	  

  

			
	 EXHIBIT A
	 	Form of Note
		
	 EXHIBIT B
	 	Form of Note Guaranty
		
	 EXHIBIT C
	 	Form of Supplemental Indenture
		
	 EXHIBIT D
	 	Form of Private Placement Legend

  
 -iv-

 CROSS REFERENCE TABLE* 

 

					
	 TIA SECTION
	  	 INDENTURE

SECTION

	 Section
	  	310	  	13.01
		  	310(a)(1)	  	7.10
		  	(a)(2)	  	7.10
		  	(a)(3)	  	N.A.**
		  	(a)(4)	  	N.A.
		  	(a)(5)	  	7.10
		  	(b)	  	7.10
	 Section
	  	311	  	13.01
		  	311(a)	  	7.11
		  	(b)	  	7.11
	 Section
	  	312	  	13.01
		  	312(a)	  	2.05
		  	(b)	  	13.03
		  	(c)	  	13.03
	 Section
	  	313	  	13.01
		  	313(a)	  	7.06
		  	(b)(1)	  	7.06
		  	(b)(2)	  	7.06
		  	(c)	  	7.06; 10.06; 13.02
		  	(d)	  	7.06
	 Section
	  	314	  	13.01
		  	314(a)	  	4.03; 4.04; 10.01; 13.02; 13.04
		  	(b)	  	10.01
		  	(c)(1)	  	10.01; 13.04
		  	(c)(2)	  	10.01; 13.04
		  	(c)(3)	  	N.A.
		  	(d)	  	10.01; 10.03
		  	(e)	  	10.01; 13.04
		  	(f)	  	N.A.
	 Section
	  	315	  	13.01
		  	315(a)	  	7.01
		  	(b)	  	7.05; 13.02
		  	(c)	  	7.01
		  	(d)	  	7.01
		  	(d)(2)	  	7.01
		  	(d)(3)	  	7.01
		  	(e)	  	6.11
	 Section
	  	316	  	13.01
		  	316(a) (last sentence)	  	2.09
		  	(a)(1)(A)	  	6.05
		  	(a)(1)(B)	  	6.04
		  	(a)(2)	  	N.A.
		  	(b)	  	6.07
		  	(c)	  	13.05
	 Section
	  	317(a)(1)	  	6.08
		  	(a)(2)	  	6.09
		  	(b)	  	2.09
	 Section
	  	318(a)	  	13.01
		  	(b)	  	N.A.
		  	(c)	  	13.01

  

	*	This Cross-Reference Table shall not, for any purpose, be deemed a part of this Indenture. 

	**	N.A. means Not Applicable. 

 THIS INDENTURE dated as of March 30, 2012 is among Hutchinson Technology Incorporated, a
corporation duly organized under the laws of the State of Minnesota (the “Company”), the Guarantors (as defined herein) from time to time party hereto and Wells Fargo Bank, National Association, a national banking association organized and
existing under the laws of the United States, as Trustee and Collateral Agent. 
 In consideration of the purchase of the Notes
(as defined herein) by the Holders (as defined herein) thereof, the parties hereto agree as follows for the benefit of each other and for the equal and ratable benefit of the Holders of the Company’s 8.50% Senior Secured Second Lien Notes due
2017. 
 ARTICLE I 
 DEFINITIONS AND INCORPORATION BY REFERENCE 
 Section 1.01 Definitions.

 “Acquired Debt” means, with respect to any specified Person: 

(1) Indebtedness of any other Person existing at the time such other Person is merged with or into or became a Subsidiary of such
specified Person, whether or not such Indebtedness is incurred in connection with, or in contemplation of, such other Person merging with or into, or becoming a Restricted Subsidiary of, such specified Person; and 

(2) Indebtedness secured by a Lien encumbering any asset acquired by such specified Person. 

“Additional Intercreditor Agreement” means any intercreditor agreement, other than the PNC Intercreditor Agreement, with terms
no less favorable to the Holders than the PNC Intercreditor Agreement entered into by the agent or other representative of holders of Priority Lien Obligations designated pursuant to the terms of the relevant Priority Lien Documents, as senior
agent, and the Trustee and Collateral Agent, as junior agent, as amended, restated, adjusted, waived, renewed, extended, supplemented or otherwise modified from time to time. 
 “Affiliate” means, with respect to any specified Person, any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified
Person. For the purposes of this definition, “control,” when used with respect to any Person, means possession, directly or indirectly, of the power to direct the management or policies of such Person, whether through the ownership of
voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 
 “Agent” means any Registrar, co-registrar, Paying Agent, additional paying agent, Collateral Agent or co-collateral agent. 

“Applicable Premium” means, with respect to any Note on any Redemption Date, the excess of: (a) the present value at such
Redemption Date of (i) the principal amount of the Note 

 
redeemed plus (ii) all required interest payments due on such principal amount from such Redemption Date through the Final Maturity Date (excluding accrued but unpaid interest to the
Redemption Date), computed using a discount rate equal to the Treasury Rate as of such Redemption Date plus 50 basis points; over (b) the principal amount of the Note redeemed. 

Calculation of the Applicable Premium will be made by the Company or on behalf of the Company by such Person as the Company shall
designate, and in any event, such calculation shall not be a duty or obligation of the Trustee. The Company will deliver an Officers’ Certificate to the Trustee at least two Business Days prior to the applicable Redemption Date advising the
Trustee of the Applicable Premium, together with the basis for such calculation in reasonable detail. 
 “Applicable
Procedures” means, with respect to any transfer or exchange of beneficial ownership interests in a Global Note, or from a Certificated Note into a Global Note, the rules and procedures of the Depositary, to the extent applicable to such
transfer or exchange. 
 “Asset Sale” means: 
 (1) the sale, conveyance, lease or other disposition of any assets or rights by the Company or any of the Company’s Restricted Subsidiaries (other than Equity Interests in any Unrestricted
Subsidiary), provided that (i) the sale, conveyance, lease or other disposition of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, will be governed by Section 4.15 and/or
Section 5.01 hereof and not by Section 4.10 hereof, and (ii) any TSA+ Disposition will be governed by Section 4.15 and not by Section 4.10 hereof; and 
 (2) the issuance of Equity Interests by any of the Company’s Restricted Subsidiaries. 
 Notwithstanding the preceding, none of the following items will be deemed to be an Asset Sale: 
 (1) any single transaction or series of related transactions that involves assets having a Fair Market Value (as determined in good faith by the Board of Directors or the Chief Financial Officer of the
Company) of less than $2.0 million; 
 (2) a transfer of assets (i) by the Company or any of its Restricted
Subsidiaries to the Company or any Guarantor, or (ii) by a Restricted Subsidiary of the Company that is not a Guarantor to another Restricted Subsidiary of the Company that is not a Guarantor; 

(3) an issuance of Equity Interests by a Restricted Subsidiary of the Company to the Company or to a Restricted Subsidiary of the
Company; 
 (4) the sale, other disposition or discount of products, services, accounts receivable, equipment or other goods in
the ordinary course of business (other than sales, dispositions or discounts of products, services, accounts receivable, equipment or goods by the Company or a Guarantor to any Subsidiary of the Company that is not a Guarantor or a Pledged
Restricted Subsidiary, the Fair Market Value (as determined in good faith by the Board of Directors or Chief Financial Officer of the Company) of which exceed $2.0 million in any single transaction or series of related transactions or in any
fiscal year of the Company); 

  
 -2-

 (5) any sale, lease or other disposition of surplus, damaged, unserviceable, worn-out or
obsolete assets in the ordinary course of business and the assignment, license, cancellation, abandonment or other disposition of intellectual property that is no longer useful in any material respect in the conduct of the business of the Company
and its Restricted Subsidiaries taken as a whole; 
 (6) licenses and sublicenses by the Company or any of its Restricted
Subsidiaries of intellectual property in the ordinary course of business or in settlement of any litigation or claims in respect of intellectual property, and leases or subleases of real property and equipment in the ordinary course of business;

 (7) any surrender or waiver of contract rights or settlement, release, recovery on or surrender of contract, tort or other
claims in the ordinary course of business and the liquidation of any assets received in settlement of claims owed to the Company or any of its Restricted Subsidiaries; 
 (8) the granting of Liens not prohibited by Section 4.12 hereof; 
 (9) the
sale or other disposition of cash or Cash Equivalents or other Investments permitted by clause (2) of the definition of Permitted Investments; 
 (10) a Restricted Payment (or any transaction that would be a Restricted Payment but for an exclusion from the definition thereof) that does not violate Section 4.07 hereof or a Permitted Investment;
and 
 (11) any issuance or sale of Equity Securities in the Company. 

“Attributable Debt” in respect of a sale and leaseback transaction means, at the time of determination, the present value of
the obligation of the lessee for net rental payments during the remaining term of the lease included in such sale and leaseback transaction including any period for which such lease has been extended or may, at the option of the lessor, be extended.
Such present value shall be calculated using a discount rate equal to the rate of interest implicit in such transaction, determined in accordance with GAAP; provided, however, that if such sale and leaseback transaction results in a
Capital Lease Obligation, the amount of Indebtedness represented thereby will be determined in accordance with the definition of “Capital Lease Obligation.” 
 “Banking Services” means each and any of the following bank services provided to the Company or any Subsidiary of the Company by any lender under the Credit Agreement or another Credit Facility
or any Affiliate thereof: (a) commercial credit cards, (b) stored value cards and (c) treasury management services (including controlled disbursement, automated clearinghouse transactions, return items, overdrafts and interstate
depository network services). 
 “Banking Services Obligations” means any and all obligations of the Company or any
Subsidiary of the Company, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor) in connection with Banking
Services. 

  
 -3-

 “Beneficial Ownership” means the definition such term is given in accordance with
Rule 13d-3 promulgated by the SEC under the Exchange Act. 
 “Board of Directors” means either the board of
directors of the Company or any committee of the Board of Directors authorized to act for it with respect to this Indenture. 

“Business Day” means any weekday that is not a day on which banking institutions in New York, New York, Chicago, Illinois or
Minneapolis, Minnesota are authorized or obligated to close. 
 “Capital Lease Obligation” means, at the time any
determination is to be made, the amount of the liability in respect of a capital lease that would at that time be required to be capitalized on a balance sheet prepared in accordance with GAAP, and the Stated Maturity thereof shall be the date of
the last payment of rent or any other amount due under such lease prior to the first date upon which such lease may be prepaid by the lessee without payment of a penalty. 
 “Capital Stock” of any Person means any and all shares, interests, participations or other equivalents of or interests in (however designated) equity of such Person. 

“Cash Equivalents” means: 
 (1) United States dollars; 
 (2) securities issued or directly and fully
guaranteed or insured by the United States government or any agency or instrumentality of the United States government (provided that the full faith and credit of the United States is pledged in support of those securities) having maturities
of not more than one year from the date of acquisition; 
 (3) certificates of deposit and eurodollar time deposits with
maturities of one year or less from the date of acquisition, bankers’ acceptances with maturities not exceeding one year, overnight bank deposits, and demand and time deposits, in each case, with any lender party to the Credit Agreement or
another Credit Facility or with any domestic commercial bank having capital and surplus of at least $500.0 million and a Thomson Bank Watch Rating of “B” or better; 

(4) repurchase obligations with a term of not more than seven days for underlying securities of the types described in clauses (2)
and (3) above entered into with any financial institution meeting the qualifications specified in clause (3) above; 

(5) commercial paper having one of the two highest ratings obtainable from Moody’s or S&P and, in each case, maturing within one
year after the date of acquisition; and 
 (6) money market funds at least 95% of the assets of which constitute Cash
Equivalents of the kinds described in clauses (1) through (5) of this definition. 

  
 -4-

 “Certificated Note” means a Note in definitive form that is in substantially the
form attached as Exhibit A but that does not include the text appearing therein that is marked as only relating to Notes issued in global form. 
 “Change of Control” means the occurrence of any of the following after the date hereof: (i) the acquisition by any Person of Beneficial Ownership, directly or indirectly, of shares of the
Company’s Capital Stock entitling that Person to exercise 50% or more of the total voting power of all shares of the Company’s Capital Stock entitled to vote generally in elections of directors, including without limitation by merger or
consolidation; or (ii) the direct or indirect consolidation or merger of the Company with or into any other Person, or any direct or indirect merger of another Person into the Company, provided that this clause (ii) shall not apply
to (A) any transaction (y) that does not result in any reclassification, conversion, exchange or cancellation of outstanding shares of the Company’s Capital Stock and (z) pursuant to which holders of the Company’s Capital
Stock immediately prior to the transaction have the entitlement to exercise, directly or indirectly, 50% or more of the total voting power of all shares of the Capital Stock entitled to vote generally in elections of directors of the continuing or
surviving Person immediately after the transaction; or (B) any merger solely for the purpose of changing the Company’s jurisdiction of incorporation and resulting in a reclassification, conversion or exchange of outstanding shares of
common stock solely into shares of common stock of the surviving entity; or (iii) any direct or indirect conveyance, transfer, sale, lease or other disposition of all or substantially all of the properties and assets of the Company and its
Subsidiaries, taken as a whole, to another Person; or (iv) the first day on which a majority of the members of the Board of Directors of the Company are not Continuing Directors; or (v) the adoption of a plan relating to the liquidation or
dissolution of the Company; or (vi) a TSA+ Disposition. 
 “Collateral” means any property or assets of the
Company, any Guarantor or any other Restricted Subsidiary of the Company, whether now owned or hereafter acquired, subject or purported to be subject to a Lien granted to secure the Note Obligations pursuant to any Security Document. 

“Collateral Agent” means Wells Fargo Bank, N.A., in its capacity as collateral agent under this Indenture, together with its
successors in such capacity. 
 “Company” means the party named as such in the first paragraph of this Indenture until
a successor replaces it pursuant to the applicable provisions of this Indenture, and thereafter “Company” shall mean such successor Company. 
 “Consolidated EBITDA” means, with respect to any specified Person for any period, the Consolidated Net Income of such Person for such period 

(1) plus, without duplication: 
 (i) provision for taxes based on income or profits of such Person and its Restricted Subsidiaries for such period, to the extent that such provision for taxes was deducted in computing such Consolidated
Net Income; plus 

  
 -5-

 (ii) the Fixed Charges of such Person and its Restricted Subsidiaries for
such period, to the extent that such Fixed Charges were deducted in computing such Consolidated Net Income; plus 

(iii) depreciation, amortization (including amortization of intangibles but excluding amortization of prepaid cash
expenses that were paid in a prior period) and other non-cash charges and expenses (excluding any such non-cash charge or expense to the extent that it represents an accrual of or reserve for cash charges or expenses in any future period or
amortization of a prepaid cash charge or expense that was paid in a prior period) of such Person and its Restricted Subsidiaries for such period to the extent that such depreciation, amortization and other non-cash charges or expenses were deducted
in computing such Consolidated Net Income; 
 (2) minus non-cash items increasing such Consolidated Net Income for such
period, other than the accrual of revenue in the ordinary course of business, 
 in each case, on a consolidated basis and determined in
accordance with GAAP. 
 “Consolidated Net Income” means, with respect to any specified Person for any period, the
aggregate of the net income (or loss) of such Person and its Restricted Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP, provided that: 

(1) all extraordinary or non-recurring gains (but not losses) and all gains (but not losses) realized in connection with any Asset Sale
(without giving effect to any threshold set forth in the definition thereof) or the disposition of securities, together with any related provision for taxes on any such gain, will be excluded; 

(2) the net income (and loss) of any Person that is not the specified Person or a Restricted Subsidiary of the specified Person
(including without limitation, in the case of the Company, any Unrestricted Subsidiary) will be excluded, provided that Consolidated Net Income of the specified Person for any period will be increased by the amount of any dividends or similar
distributions paid in cash by such Person to the specified Person or a Restricted Subsidiary of the specified Person in respect of such period; 
 (3) the cumulative effect of a change in accounting principles will be excluded; 

(4) non-cash gains (and losses) attributable to movement in the mark-to-market valuation of Hedging Obligations pursuant to Financial
Accounting Standards Board Statement No. 133 will be excluded; 
 (5) any non-cash compensation charge arising from any
grant of stock, stock options or other equity based awards will be excluded, provided that the proceeds resulting from any such grant will be excluded from clause (y)(B) of Section 4.07(a) hereof; 

(6) any gains (and losses) due solely to fluctuations in currency values will be excluded; 

(7) any gains (but not losses) from discontinued operations will be excluded; and 

  
 -6-

 (8) the after-tax effect of any income (and loss) from the early extinguishment of
Indebtedness will be excluded. 
 “Continuing Directors” means as of any date of determination, any member of the
Board of Directors of the Company who: 
 (1) was a member of such Board of Directors on the date of this Indenture; or

 (2) was nominated for election or elected to such Board of Directors with the approval of a majority of the Continuing
Directors who were members of such Board of Directors at the time of such nomination or election. 
 “Corporate Trust
Office” means the office of the Trustee at which at any particular time the trust created by this Indenture shall be administered, which initially will be the office of Wells Fargo Bank, National Association, located at 625 Marquette
Avenue, MAC N9311-110, Minneapolis, Minnesota 55479, Attention: Hutchinson Administrator. 
 “Credit Agreement”
means that certain Revolving Credit and Security Agreement dated as of September 16, 2011 by and among PNC Bank, National Association (as lender and as agent), the Company and the other borrowers signatory thereto, providing for revolving
credit borrowings and issuances of letters of credit, including any related notes, guarantees, collateral documents, instruments and agreements executed in connection therewith, and, in each case, as amended, restated, modified, renewed, refunded,
replaced in any manner (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time (provided, that the rate of or method of
calculating interest on the Indebtedness incurred under such Revolving Credit and Security Agreement as so amended, restated, modified, renewed, refunded, replaced or refinanced is not materially less favorable to the Company and the Guarantors, as
determined in good faith by the Board of Directors, than that provided in such Revolving Credit and Security Agreement as in effect on the date of this Indenture, except to the extent such rate or method is permitted to be modified without the
consent of the Trustee or the Holders of the Notes pursuant to the terms of the Intercreditor Agreement). 
 “Credit
Facilities” means, one or more debt facilities (including, without limitation, the Credit Agreement) or commercial paper facilities, in each case, with banks or other institutional lenders or investors providing for revolving credit loans, term
loans, receivables financing (including through the sale of receivables to such lenders or investors or to special purpose entities formed to borrow from such lenders or investors against such receivables) or letters of credit, in each case, as
amended, restated, modified, renewed, refunded, replaced in any manner (whether upon or after termination or otherwise) or refinanced (including by means of sales of debt securities to institutional investors) in whole or in part from time to time.
Notwithstanding the foregoing, no debt or commercial paper facilities shall constitute Credit Facilities if the rate of or method of calculating interest on the Indebtedness incurred thereunder is materially less favorable to the Company and the
Guarantors, as determined in good faith by the Board of Directors, than that provided in the Credit Agreement as in effect on the date of this Indenture, except to the extent such rate or method is permitted to be modified without the consent of the
Trustee or the Holders of the Notes pursuant to the terms of the Intercreditor Agreement. 

  
 -7-

 “Default” means, when used with respect to the Notes, any event that, after notice
or passage of time, or both, would be an Event of Default. 
 “Development Center” means that certain real property in
Hutchinson, Minnesota, known as McLeod County Property Tax Identification Number R23.246.0015. The Development Center parcel consists of a two-story commercial building with approximately 234,882 square feet of interior space, situated on a parcel
of approximately 59.56 acres. 
 “Disqualified Stock” means any Capital Stock that, by its terms (or by the terms of
any security into which it is convertible, or for which it is exchangeable, in each case, at the option of the holder of the Capital Stock), or upon the happening of any event, matures or is mandatorily redeemable, pursuant to a sinking fund
obligation or otherwise, or redeemable at the option of the holder of the Capital Stock, in whole or in part, on or prior to the date that is 180 days after the Final Maturity Date. Notwithstanding the preceding sentence, any Capital Stock that
would constitute Disqualified Stock solely because the holders of the Capital Stock have the right to require the Company to repurchase such Capital Stock upon the occurrence of a change of control or an asset sale will not constitute Disqualified
Stock if the terms of such Capital Stock provide that the Company may not repurchase or redeem any such Capital Stock pursuant to such provisions unless such repurchase or redemption complies with Section 4.07 hereof. The amount of Disqualified
Stock deemed to be outstanding at any time for purposes of this Indenture will be the maximum amount that the Company and its Restricted Subsidiaries may become obligated to pay upon the maturity of, or pursuant to any mandatory redemption
provisions of, such Disqualified Stock, exclusive of accrued dividends. 
 “Domestic Joint Venture” means a Joint
Venture that was formed under the laws of the United States or any state of the United States or the District of Columbia. 

“Domestic Subsidiary” means any Restricted Subsidiary of the Company that was formed under the laws of the United States or any
state of the United States or the District of Columbia. 
 “Equity Interest” means Capital Stock and all warrants,
options or other rights to acquire Capital Stock (but excluding any debt security that is convertible into, or exchangeable for, Capital Stock). 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, as in effect from time to time, or any successor statute or statutes
thereto. 
 “Excluded Assets” means the following property or assets of the Company or any Guarantor, except to the
extent that the Company or any Guarantor is required to and has granted a Lien on such property or assets to secure the Note Obligations pursuant to Section 4.18(b), (c) or (d) hereof: 

(1) any item of general intangibles of the Company or any Guarantor, but only to the extent that such item of general intangibles (or any
agreement evidencing such item of general intangibles) contains a term or is subject to any law that restricts, prohibits or requires a consent (that has not been obtained) of another Person to the creation, attachment or perfection of a Lien
thereon, which restriction, prohibition and/or requirement of consent is not rendered ineffective by applicable law; 

  
 -8-

 (2) (a) the Equity Interests in any Foreign Subsidiary other than (x) HTI
Thailand or (y) any other Foreign Subsidiary that, after the date of this Indenture, becomes a Pledged Restricted Subsidiary either at the option of the Company or as required by the terms of this Indenture (together with HTI Thailand, the
“Pledged Foreign Subsidiaries”), or (b) that portion of the Equity Interests in any Pledged Foreign Subsidiary that exceeds 66% of the Equity Interests of such Pledged Foreign Subsidiary (the Equity Interests in any Pledged Foreign
Subsidiary excluded from the Collateral by operation of this clause (2)(b) being referred to in this Indenture as “Foreign Subsidiary Excluded Equity Interests”); 

(3) the Equity Interests of any Subsidiary to the extent that, in the reasonable judgment of the Company, if such Equity Interests were
not excluded from the Collateral then Rule 3-16 or Rule 3-10 of Regulation S-X under the Securities Act would require the filing of separate financial statements of such Subsidiary with the SEC or any other governmental agency due to
the fact that such Subsidiary’s Equity Interests secure the Note Obligations but solely to the extent necessary so as not to subject such Subsidiary to such separate financial statements requirement; provided that, in the event
Rule 3-16 or Rule 3-10 of Regulation S-X under the Securities Act is (x) amended, modified or interpreted by the SEC to permit (or is replaced with another rule or regulation, or any other law, rule or regulation is adopted,
which would permit) such Equity Interests to be included in the Collateral without subjecting such Subsidiary to such separate financial statements requirement or (y) no longer applicable to the Company, such Equity Interests of such Subsidiary
which were previously excluded by operation of this provision shall automatically be deemed to be part of the Collateral but only to the extent so as not to subject such Subsidiary to such separate financial statements requirement (the Equity
Interests excluded from the Collateral by operation of this clause (3) being referred to in this Indenture as the “Rule 3-16 Excluded Assets”); 
 (4) any property of the Company or a Guarantor that is subject to a Lien of the type referred to in clause (6) or (17) of the definition of Permitted Liens, but only if any agreement granting or
relating to such Lien prohibits the granting of a Lien in favor of the Collateral Agent on such property; 
 (5) intent to use
trademarks until such time as the Company or the applicable Guarantor begins to use such trademark in the applicable jurisdiction; 
 (6) any item of intellectual property that arises under, or is governed by, the laws of a country or political subdivision thereof other than the United States or a political subdivision thereof, if the
creation, attachment or perfection of a Lien under the security documents thereon would violate any applicable law or require the consent of any governmental authority of such country or political subdivision or impair in any material respect the
value of such item of intellectual property; 
 (7) any real property or interest therein; and 

  
 -9-

 (8) other property or assets of the Company or any Guarantor to the extent and only for so
long as such property or assets are not subject to Liens securing the Priority Lien Obligations (except for property and assets released from such Liens in connection with the payment in full of the Priority Lien Debt and the termination or
expiration of all commitments, if any, to extend credit that would constitute Priority Lien Debt), 
 provided that the term
“Excluded Assets” shall in no event include any property or assets of the Company or any Guarantor, other than Rule 3-16 Excluded Assets, if such property or assets are then subject to Liens securing any Priority Lien Debt.

 “Existing Indebtedness” means all Indebtedness of the Company and its Subsidiaries (other than Indebtedness under
the Credit Agreement) in existence on the date of this Indenture (including without limitation any Outstanding 3.25% Notes and Outstanding 8.50% Notes that remain outstanding after consummation of the Tender/Exchange Offers), until such amounts are
repaid. 
 “Fair Market Value” means the value that would be paid by a willing buyer to an unaffiliated willing seller
in a transaction not involving distress or necessity of either party, determined in good faith by the Board of Directors or, if expressly permitted by this Indenture, the Chief Financial Officer of the Company. 

“Final Maturity Date” means January 15, 2017. 
 “Fixed Charges” means, with respect to any specified Person for any period, the sum, without duplication, of: 
 (1) the consolidated interest expense of such Person and its Restricted Subsidiaries for such period, whether paid or accrued, including, without limitation, amortization of debt issuance costs and
original issue discount, non-cash interest payments, the interest component of any deferred payment obligations, the interest component of all payments associated with Capital Lease Obligations, imputed interest with respect to Attributable Debt,
and commissions, discounts and other fees and charges incurred in respect of letter of credit or bankers’ acceptance financings, and net of the effect of all payments made or received pursuant to Hedging Obligations in respect of interest
rates; plus 
 (2) the consolidated interest expense of such Person and its Restricted Subsidiaries that was capitalized during
such period; plus 
 (3) any interest on Indebtedness of another Person that is guaranteed by such Person or one of its
Restricted Subsidiaries or secured by a Lien on assets of such Person or one of its Restricted Subsidiaries, whether or not such guarantee or Lien is called upon; plus 
 (4) all dividends, whether paid or accrued and whether or not cash, paid on any Disqualified Stock or any series of preferred stock of such Person or any of its Restricted Subsidiaries, provided
that such dividends will be multiplied by a fraction the numerator of which is one and the denominator of which is one minus the effective combined tax rate of the issuer of such securities (expressed as a decimal) for such period (as estimated by
the Chief Financial Officer of such Person in good faith); plus 

  
 -10-

 (5) interest expense incurred in connection with Investments in discontinued operations;
plus 
 (6) cash contributions by such Person or any of its Restricted Subsidiaries to any employee stock ownership plan or
similar trust to the extent such contributions are used by such plan or trust to pay interest or fees to any Person (other than such specified Person) in connection with Indebtedness incurred by such plan or trust. 

“Foreign Subsidiary” means any Restricted Subsidiary of the Company that is not a Domestic Subsidiary. 

“Foreign Subsidiary Excluded Equity Interests” has the meaning ascribed thereto in the definition of Excluded Assets.

 “GAAP” means generally accepted accounting principles in the United States of America as in effect from time to
time, including those set forth in (1) the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants, (2) the statements and pronouncements of the Financial Accounting
Standards Board, and (3) the rules and regulations of the SEC governing the inclusion of financial statements (including pro forma financial statements) in registration statements filed under the Securities Act and periodic reports required to
be filed pursuant to Section 13 of the Exchange Act, including opinions and pronouncements in staff accounting bulletins and similar written statements from the accounting staff of the SEC. 

“Global Note” means a Note in global form that is in substantially the form attached as Exhibit A, including the text
appearing therein that is marked as only relating to Notes issued in global form, and that is deposited with the Depositary or its custodian and registered in the name of the Depositary or its nominee. Only Unrestricted Notes may be in the form of a
Global Note. 
 “Government Securities” means direct obligations of, or obligations guaranteed by, the United States
of America, and the payment for which the United States pledges its full faith and credit. 
 “guarantee” means a
guarantee other than by endorsement of negotiable instruments for collection in the ordinary course of business, direct or indirect, in any manner including, without limitation, by way of a pledge of assets or through letters of credit or
reimbursement agreements in respect thereof, of all or any part of any Indebtedness (whether arising by virtue of partnership arrangements, or by agreements to keep-well, to purchase assets, goods, securities or services, to take or pay or to
maintain financial statement conditions or otherwise). 
 “Guarantor” means any Restricted Subsidiary of the Company
that may hereafter guarantee payment and performance of the Company’s obligations under this Indenture and the Notes pursuant to a Note Guaranty (provided that any such Restricted Subsidiary shall cease to constitute a Guarantor when its
Note Guaranty is released in accordance with this Indenture); and “Guarantors” means collectively all such Restricted Subsidiaries. 
 “Guarantor Subordinated Obligation” means, with respect to a Guarantor, any Indebtedness of such Guarantor which is expressly subordinate in right of payment to the

  
 -11-

 
obligations of such Guarantor under its Note Guaranty pursuant to a written agreement (it being understood that no Indebtedness shall be considered to be a Guarantor Subordinated Obligation
solely by virtue of being unsecured or by virtue of being secured on a junior priority basis). 
 “Hedge Agreement”
means any exchange, collar, cap, swap, adjustable strike cap, adjustable strike corridor, forward purchase or similar agreement dealing with interest rates, currency exchange rates or commodity prices, either generally or under specific
contingencies. 
 “Hedging Obligations” means, with respect to any specified Person, the obligations of such Person
under any Hedge Agreement. 
 “Holder” or “Holder of a Note” means the Person in whose name a Note is
registered on the Registrar’s books. 
 “HTI Thailand” means Hutchinson Technology Operations (Thailand) Co.,
Ltd., a company organized under the laws of Thailand. 
 “Indebtedness” means, with respect to any specified Person,
any indebtedness of such Person (excluding accrued expenses and trade payables), whether or not contingent: 
 (1) in respect of
borrowed money; 
 (2) evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement
agreements in respect thereof); 
 (3) in respect of banker’s acceptances; 

(4) representing Capital Lease Obligations or Attributable Debt in respect of sale and leaseback transactions; 

(5) representing the balance deferred and unpaid of the purchase price of any property or services due more than six months after such
property is acquired or such services are completed (other than obligations in respect of earnouts); or 
 (6) representing the
net amount due under any Hedging Obligations, 
 if and to the extent any of the preceding items (other than letters of credit,
Attributable Debt and Hedging Obligations) would appear as a liability upon a balance sheet of the specified Person prepared in accordance with GAAP. In addition, the term “Indebtedness” includes all Indebtedness of others secured by a
Lien on any asset of the specified Person (whether or not such Indebtedness is assumed by the specified Person) and, to the extent not otherwise included, the guarantee by the specified Person of any Indebtedness of any other Person. Indebtedness
shall be calculated without giving effect to the effects of Statement of Financial Accounting Standards No. 133 and related interpretations to the extent such effects would otherwise increase or decrease an amount of Indebtedness for any
purpose under this Indenture as a result of accounting for any embedded derivatives created by the terms of such Indebtedness. 

  
 -12-

 “Indenture” means this Indenture as amended or supplemented from time to time
pursuant to the terms of this Indenture, including the provisions of the TIA that are automatically deemed to be a part of this Indenture by operation of the TIA. 
 “Insolvency or Liquidation Proceeding” means: 
 (1) any case commenced
by or against the Company or any Guarantor under Bankruptcy Law, any other proceeding for the reorganization, recapitalization or adjustment or marshalling of the assets or liabilities of the Company or any Guarantor, any receivership or assignment
for the benefit of creditors relating to the Company or any Guarantor or any similar case or proceeding relative to the Company or any Guarantor or its creditors, as such, in each case whether or not voluntary; 

(2) any liquidation, dissolution, marshalling of assets or liabilities or other winding up of or relating to the Company or any
Guarantor, in each case whether or not voluntary and whether or not involving bankruptcy or insolvency; or 
 (3) any other
proceeding of any type or nature in which substantially all claims of creditors of the Company or any Guarantor are determined and any payment or distribution is or may be made on account of such claims. 

“Intercreditor Agreement” means, collectively, the PNC Intercreditor Agreement and any Additional Intercreditor
Agreement. 
 “Interest Payment Date” means January 15 and July 15 of each year, commencing July 15,
2012. 
 “Investments” means, with respect to any Person, all direct or indirect investments by such Person in other
Persons (including Affiliates) in the forms of loans (including guarantees or other obligations), advances or capital contributions (excluding commission, travel and similar advances to directors, officers and employees made in the ordinary course
of business), and purchases or other acquisitions for consideration of Indebtedness, Equity Interests or other securities, together with all items that are or would be classified as investments on a balance sheet prepared in accordance with GAAP. If
the Company or any Restricted Subsidiary of the Company sells or otherwise disposes of any Equity Interests of any direct or indirect Restricted Subsidiary of the Company such that, after giving effect to any such sale or disposition, such Person is
no longer a Restricted Subsidiary of the Company, the Company will be deemed to have made an Investment on the date of any such sale or disposition equal to the Fair Market Value of the Company’s Investments in such Subsidiary that were not
sold or disposed of in an amount determined as provided in Section 4.07 hereof. The acquisition by the Company or any Restricted Subsidiary of the Company of a Person that holds an Investment in a third Person will be deemed to be an Investment
by the Company or such Restricted Subsidiary in such third Person in an amount equal to the Fair Market Value of the Investments held by the acquired Person in such third Person in an amount determined as provided in Section 4.07 hereof. Except
as otherwise provided in this Indenture, the amount of an Investment will be determined at the time the Investment is made and without giving effect to subsequent changes in value. 

  
 -13-

 “Issue Date” of any Note means the date on which the Note was originally issued or
deemed issued as set forth on the face of the Note. 
 “Joint Venture” means any corporation, partnership or other
entity (other than a Subsidiary of the Company) in which the Company or any of its Restricted Subsidiaries holds any Equity Interests. 
 “Learning Center” means that certain real property in Hutchinson, Minnesota, known as McLeod County Property Tax Identification Number R23.246.0013. The Learning Center parcel consists of a
one-story commercial building with a building footprint of approximately 20,276 square feet, situated on a parcel of approximately 8.65 acres. 
 “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise
perfected under applicable law, including any conditional sale or other title retention agreement, any capital lease, or any option or other agreement to sell or give a security interest. 

“Moody’s” means Moody’s Investors Service, Inc. 

“Net Proceeds” means the aggregate cash proceeds and Cash Equivalents received by the Company or any of its Restricted
Subsidiaries in respect of any Asset Sale (including, without limitation, any cash or Cash Equivalents received upon the sale or other disposition of any non-cash consideration received in any Asset Sale), net of the direct costs relating to such
Asset Sale, including, without limitation, legal, accounting and investment banking fees, and sales commissions, and any relocation expenses incurred as a result of the Asset Sale, taxes paid or payable as a result of the Asset Sale, in each case,
after taking into account any available tax credits or deductions and any tax sharing arrangements, amounts required to be applied to the repayment of Indebtedness secured by a Lien on the asset or assets that were the subject of such Asset Sale,
and any reserve for adjustment or indemnification obligations in respect of the sale price of such asset or assets established in accordance with GAAP. 
 “Non-Recourse Debt” means Indebtedness: 
 (1) as to which neither the
Company nor any of its Restricted Subsidiaries (a) provides credit support of any kind (including any undertaking, agreement or instrument that would constitute Indebtedness) or (b) is directly or indirectly liable as a guarantor or
otherwise; and 
 (2) as to which the lenders or investors have been notified in writing that they will not have any recourse to
the stock or assets of the Company or any of its Restricted Subsidiaries (other than the Equity Interests of an Unrestricted Subsidiary). 
 “Note Documents” means the Indenture, the Notes and the Security Documents. 
 “Note Guaranty” means the guarantee by each Guarantor of the Company’s obligations under this Indenture and the Note pursuant to the provisions of this Indenture. 

  
 -14-

 “Notes” means the Unrestricted Notes and the Restricted Notes, or any of them
(each a “Note”). The Unrestricted Notes and the Restricted Notes shall be treated as a single series for all purposes of this Indenture. 
 “Notes Custodian” means the Trustee, as custodian with respect to the Global Notes, or any successor thereto. 
 “Obligations” means any principal (including reimbursement obligations with respect to letters of credit whether or not drawn), interest (including, to the extent legally permitted, all interest
accrued thereon after the commencement of any Insolvency or Liquidation Proceeding at the rate, including any applicable post-default rate, specified in the relevant documentation, even if such interest is not enforceable, allowable or allowed as a
claim in such proceeding), premium (if any), fees, indemnifications, reimbursements, expenses and other liabilities payable under the documentation governing any Indebtedness. 
 “Officer” means the Chairman or any Co-Chairman of the Board of Directors, any Vice Chairman of the Board of Directors, or the Chief Executive Officer, the President, any Vice President, the
Chief Financial Officer, the Treasurer, the Controller, the Secretary, any Assistant Controller or any Assistant Secretary of the Company. 
 “Officers’ Certificate” means a certificate signed on behalf of the Company by two Officers; provided, however, that for purposes of Section 4.04, “Officers’
Certificate” means a certificate signed by (a) the principal executive officer, principal financial officer or principal accounting officer of the Company and (b) one other Officer of the Company. 

“Opinion of Counsel” means a written opinion from legal counsel reasonably acceptable to the Trustee. The counsel may be an
employee of or counsel to the Company or the Trustee. 
 “Outstanding 3.25% Notes” means the Company’s
outstanding 3.25% Convertible Subordinated Notes due 2026. 
 “Outstanding 8.50% Notes” means the Company’s
outstanding 8.50% Convertible Senior Notes due 2026. 
 “Permitted Businesses” means any of the businesses in which
the Company and its Restricted Subsidiaries are engaged on the date of this Indenture (the “existing business”) and any business reasonably related, incidental, complementary or ancillary thereto (including without limitation the
manufacture and sale of other products with the same type of machinery and equipment as is used in the existing business and the sale of products manufactured by the Company or any of its Restricted Subsidiaries as part of the existing business to,
or the performance of services offered by the Company or any of its Restricted Subsidiaries as part of the existing business for, customers in markets other than markets sold to or served by the existing business). 

  
 -15-

 “Permitted Investments” means: 

(1) any Investment (i) by the Company or any Restricted Subsidiary of the Company in the Company or in a Guarantor, or (ii) by
any Restricted Subsidiary of the Company that is not a Guarantor in any other Restricted Subsidiary of the Company that is not a Guarantor; 
 (2) any Investment in Cash Equivalents or other Investments permitted by the Company’s investment policy as in effect on the date of this Indenture; 

(3) any Investment by the Company or any Restricted Subsidiary of the Company in a Person whose primary business is a Permitted Business,
if as a result of such investment: (a) such Person becomes a Restricted Subsidiary, or (b) such Person is merged, consolidated or amalgamated with or into, or transfers or conveys substantially all of its assets to, or is liquidated into,
the Company or a Restricted Subsidiary of the Company; 
 (4) any Investment made as a result of the receipt of non-cash
consideration from an Asset Sale that was made pursuant to and in compliance with Section 4.10 hereof; 
 (5) any
acquisition of assets or Capital Stock solely in exchange for the issuance of Equity Interests (other than Disqualified Stock) of the Company; 
 (6) any Investments received in compromise or resolution of (a) obligations of trade creditors or customers that were incurred in the ordinary course of business of the Company or any of its
Restricted Subsidiaries, including pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor or customer; or (b) litigation, arbitration or other disputes; 

(7) Investments represented by Hedging Obligations; 
 (8) loans or advances to directors, officers and employees made in the ordinary course of business; 
 (9) repurchases of the Notes or other Indebtedness of the Company or any Restricted Subsidiary of the Company; 
 (10) any guarantee of Indebtedness permitted to be incurred by Section 4.09 hereof; 
 (11) any Investment existing on, or made pursuant to binding commitments existing on, the date of this Indenture and any Investment consisting of an extension, modification or renewal of any Investment
existing on, or made pursuant to a binding commitment existing on, the date of this Indenture, provided that the amount of any such Investment may be increased (a) as required by the terms of such Investment as in existence on the date
of this Indenture or (b) as otherwise permitted under this Indenture; 
 (12) Investments acquired after the date of this
Indenture as a result of the acquisition by the Company or any Restricted Subsidiary of the Company of another Person (including by way of a merger, amalgamation or consolidation with or into the Company or any of its Restricted Subsidiaries) in a
transaction that is not prohibited by this Indenture, to the extent that 

  
 -16-

 
such Investments were not made in contemplation of such acquisition, merger, amalgamation or consolidation and were in existence on the date of such acquisition, merger, amalgamation or
consolidation; 
 (13) any Investment in a Restricted Subsidiary of the Company that is not a Guarantor, the proceeds of which
are used by such Restricted Subsidiary to purchase equipment, products or other goods or services from the Company or any Guarantor, provided that such Restricted Subsidiary is a Pledged Restricted Subsidiary; 

(14) any Investment consisting of a contribution of property or assets of the BioMeasurement Division of the Company to the capital of
any Domestic Subsidiary or any Domestic Joint Venture, provided that, in the case of a Domestic Subsidiary, such Domestic Subsidiary is a Pledged Restricted Subsidiary and, in the case of a Domestic Joint Venture, the Equity Interests in such
Domestic Joint Venture owned by the Company or any Restricted Subsidiary of the Company are included in Collateral; 
 (15) any
Investment in a Restricted Subsidiary of the Company that is not a Guarantor having an aggregate Fair Market Value (measured on the date each such Investment is made and without giving effect to subsequent changes in value), as determined in good
faith by the Board of Directors or the Chief Financial Officer of the Company, when taken together with all other Investments made pursuant to this clause (15) that are at the time outstanding, not to exceed $20.0 million, provided
that such Restricted Subsidiary is a Pledged Restricted Subsidiary; and 
 (16) other Investments in any Person having an
aggregate Fair Market Value (measured on the date each such Investment is made and without giving effect to subsequent changes in value), as determined in good faith by the Board of Directors or the Chief Financial Officer of the Company, when taken
together with all other Investments made pursuant to this clause (16) that are at the time outstanding, not to exceed $5.0 million. 
 “Permitted Liens” means: 
 (1) Liens securing (a) Priority Lien
Debt in an aggregate outstanding principal amount not exceeding the Priority Lien Cap and (b) all other Priority Lien Obligations; 
 (2) Liens securing the Notes, the Note Guaranties and any other Note Obligations; 

(3) Liens in favor of the Company or the Guarantors; 
 (4) Liens on property (including Capital Stock) existing at the time of acquisition of the property by the Company or any Subsidiary of the Company or Liens on property or Equity Interests of another
Person at the time such other Person becomes a Subsidiary of the Company or a Restricted Subsidiary of the Company, provided that such Liens were in existence prior to such acquisition and not incurred in contemplation of, such acquisition;

 (5) Liens to secure the performance of bids, tenders, contracts (other than contracts for the payment of Indebtedness),
leases, statutory obligations, insurance, surety or appeal bonds, workers compensation obligations, performance bonds or other obligations of a like nature incurred in the ordinary course of business (including Liens to secure letters of credit
issued to assure payment of such obligations); 

  
 -17-

 (6) Liens to secure Indebtedness (including Capital Lease Obligations) permitted by
clause (4) of Section 4.09(b) hereof covering only the assets acquired with or financed by such Indebtedness and any improvements or accessions thereto and the proceeds thereof; 

(7) Liens for taxes, assessments or governmental charges or claims that are not yet delinquent or that are being contested in good faith
by appropriate proceedings promptly instituted and diligently concluded, provided that any reserve or other appropriate provision as is required in conformity with GAAP has been made therefor; 

(8) Liens imposed by law, such as carriers’, warehousemen’s, landlord’s and mechanics’ Liens, in each case, incurred
in the ordinary course of business; 
 (9) survey exceptions, easements or reservations of, or rights of others for, licenses,
rights-of-way, sewers, electric lines, telegraph and telephone lines and other similar purposes, or zoning or other restrictions as to the use of real property that were not incurred in connection with Indebtedness and that do not in the aggregate
materially adversely affect the value of said properties or materially impair their use in the operation of the business of such Person; 
 (10) Liens to secure any Permitted Refinancing Indebtedness permitted to be incurred under this Indenture; provided, however, that: 

(a) the new Lien is limited to all or part of the same property and assets that secured or, under the written agreements
pursuant to which the original Lien arose, could secure the Indebtedness renewed, refinanced, replaced, defeased or discharged with such Permitted Refinancing Indebtedness (plus improvements and accessions to such property and proceeds or
distributions thereof); 
 (b) the Indebtedness secured by the new Lien is not increased to any amount greater
than the sum of (i) the outstanding principal amount, or, if greater, committed amount, of the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged with such Permitted Refinancing Indebtedness and (ii) an amount
necessary to pay any fees and expenses, including premiums, related to such renewal, refunding, refinancing, replacement, defeasance or discharge; and 
 (c) if the Lien on any Collateral securing the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged with such Permitted Refinancing Indebtedness is junior in priority to the Lien
in such Collateral securing the Note Obligations, then the Lien on such Collateral securing such Permitted Refinancing Indebtedness shall be junior in priority to the Lien on such Collateral securing the Note Obligations; 

(11) Liens on insurance policies and proceeds thereof, or other deposits, to secure insurance premium financings; 

  
 -18-

 (12) Liens on the Collateral (or any portion thereof) securing Indebtedness permitted to be
incurred under clause (1) of Section 4.09(a) hereof, so long as such Liens are junior in priority to the Liens securing the Note Obligations; 
 (13) bankers’ Liens, rights of setoff, Liens arising out of judgments or awards not constituting an Event of Default and notices of lis pendens and associated rights related to litigation being
contested in good faith by appropriate proceedings and for which adequate reserves have been made; 
 (14) Liens on cash, Cash
Equivalents or other property arising in connection with the defeasance, discharge or redemption of Indebtedness; 
 (15) Liens
on specific items of inventory or other goods (and the proceeds thereof) of any Person securing such Person’s obligations in respect of bankers’ acceptances issued or created in the ordinary course of business for the account of such
Person to facilitate the purchase, shipment or storage of such inventory or other goods; 
 (16) licenses or sublicenses of
intellectual property in the ordinary course of business or in settlement of any litigation or claims in respect of intellectual property and leases or subleases of real property or equipment in the ordinary course of business; 

(17) Liens existing on the date of this Indenture (other than Liens securing Priority Lien Obligations); 

(18) Liens in favor of custom and revenue authorities arising as a matter of law to secure payment of customs duties in connection with
the importation of goods; and 
 (19) Liens arising out of conditional sale, title retention, consignment or similar
arrangements for the sale of goods entered into in the ordinary course of business. 
 “Permitted Prior Liens” means
(i) those Liens which, under each of the Priority Lien Documents, are permitted to be incurred on a priority basis to the Priority Liens and (ii) at any time when no Priority Lien Documents remain in effect, Permitted Liens which are prior
to the Liens securing the Note Obligations as a matter of law or pursuant to any agreement consented to by the Holders of the Notes in accordance with Article IX hereof. 
 “Permitted Refinancing Indebtedness” means any Indebtedness of the Company or any of its Restricted Subsidiaries issued in exchange for, or the net proceeds of which are used to renew, refund,
refinance, replace, defease or discharge, other Indebtedness of the Company or any of its Restricted Subsidiaries (other than intercompany Indebtedness); provided that: 
 (1) the principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness renewed,
refunded, refinanced, replaced, defeased or discharged (plus all accrued interest on the Indebtedness and the amount of all fees and expenses, including premiums, incurred in connection therewith); 

  
 -19-

 (2) such Permitted Refinancing Indebtedness has (a) a final maturity date not earlier
than the earlier of (i) the final maturity date of the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged and (ii) the date 180 days after the Final Maturity Date of the Notes, and (b) has a Weighted
Average Life to Maturity that is equal to or greater than the Weighted Average Life to Maturity of the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged; 

(3) if the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged is subordinated in right of payment to the
Notes, such Permitted Refinancing Indebtedness is subordinated in right of payment to the Notes on terms at least as favorable to the Holders of Notes as those contained in the documentation governing the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged; and 
 (4) such Indebtedness is incurred either by the Company or by the
Restricted Subsidiary of the Company that was the obligor on the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged. 
 “Person” or “person” means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust, unincorporated organization,
government or any agency or political subdivision thereof or any syndicate or group that would be deemed to be a “person” under Section 13(d)(3) of the Exchange Act or any other entity. 

“Pledged Restricted Subsidiary” means any Restricted Subsidiary of the Company, provided that all of the Equity
Interests in such Restricted Subsidiary owned by the Company or any other Restricted Subsidiary of the Company, other than Foreign Subsidiary Excluded Equity Interests and Rule 3-16 Excluded Assets, are included in the Collateral. 

“PNC Intercreditor Agreement” means the Intercreditor Agreement dated as of the date of this Indenture between Wells Fargo
Bank, National Association, as junior agent, and PNC Bank, National Association, as senior agent, as amended, restated, adjusted, waived, renewed, extended, supplemented or otherwise modified from time to time. 

“Principal” or “principal” of a debt security, including the Notes, means the principal of the security plus, when
appropriate, the premium, if any, on the security. 
 “Priority Lien” means a Lien granted by a Priority Lien Document
on any property of the Company, any Guarantor or any other Restricted Subsidiary of the Company to secure Priority Lien Obligations. 
 “Priority Lien Cap” means, as of any date, the aggregate principal amount of Indebtedness under the Credit Agreement and/or any other Credit Facility that may be incurred under clause (1)
of Section 4.09(b) hereof as of such date. 
 “Priority Lien Debt” means: 

(1) Indebtedness of the Company or any Guarantor under the Credit Agreement; and 

  
 -20-

 (2) Indebtedness of the Company or any Guarantor under any other Credit Facility that is
secured by a Lien on the Collateral, provided, in the case of any Indebtedness referred to in this clause (2), that 
 (a) on or before the date on which such Indebtedness is incurred by the Company or such Guarantor, such Indebtedness is designated by the Company in an Officers’ Certificate delivered to the Trustee
and Collateral Agent as “Priority Lien Debt” for purposes of this Indenture; and 
 (b) the agent or
other representative with respect to such Indebtedness has duly executed and delivered an Intercreditor Agreement (or a joinder to an Intercreditor Agreement). 
 “Priority Lien Documents” means the Credit Agreement and documents governing any other Credit Facility pursuant to which any Priority Lien Debt is incurred and the security documents that secure
the Priority Lien Debt. 
 “Priority Lien Obligations” means the Priority Lien Debt and all other Obligations of the
Company, any Guarantor or any other Restricted Subsidiary of the Company in respect of Priority Lien Debt or under any Priority Lien Documents, together with Hedging Obligations and Banking Services Obligations that are secured under Priority Lien
Documents. 
 “Private Placement Legend” means the legend initially set forth on the Restricted Notes in the form set
forth on Exhibit D. 
 “Purchase Agreement” means the that certain Securities Purchase Agreement dated as of
March 28, 2012 by and among the Company and the original holders of the Restricted Notes. 
 “Redemption Date” when
used with respect to any Note to be redeemed, means the date fixed by the Company for such redemption pursuant to Article III. 
 “Registration Statement” means the registration statement on Form S-1 (No. 333-179384) filed by the Company with the SEC on February 6, 2012, as amended. 

“Regular Record Date” means, with respect to each Interest Payment Date, the January 1 or July 1, as the case may be,
next preceding such Interest Payment Date. 
 “Restricted Investment” means an investment other than a Permitted
Investment. 
 “Restricted Notes” means the 8.50% Senior Secured Second Lien Notes due 2017, or any of them (each a
“Restricted Note”), as amended or supplemented from time to time, that are issued under this Indenture and sold to Persons in the United States pursuant to the Purchase Agreement in reliance upon an exemption from registration under the
Securities Act and that constitute “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act. 
 “Restricted Subsidiary” of a Person means any Subsidiary of the referent Person that is not an Unrestricted Subsidiary. 

  
 -21-

 “Rule 3-16 Excluded Assets” has the meaning ascribed thereto in the
definition of Excluded Assets. 
 “S&P” means Standard & Poor’s Ratings Group. 

“SEC” means the Securities and Exchange Commission. 
 “Second Lien Security Agreement” means the Second Lien Security Agreement dated as of the date of this Indenture among the Company, the Guarantors from time to time party thereto, and the
Collateral Agent, as amended, restated, adjusted, waived, renewed, extended, supplemented or otherwise modified from time to time. 
 “Second Lien Security Agreement Joinder” has the meaning set forth in the Second Lien Security Agreement. 
 “Secured Debt” means (i) the Notes, (ii) Priority Lien Debt, and (iii) other Indebtedness of the Company or any Guarantor that is secured by all or any part of the Collateral
(which other Indebtedness, if incurred pursuant to Section 4.09(a) hereof, shall have the Lien priority specified in clause (12) of the definition of Permitted Liens). 

“Secured Leverage Ratio” means the ratio of the Secured Debt as of the last day of any period of four full fiscal quarters to
the Company’s Consolidated EBITDA for such period. In the event that the Company or any Guarantor incurs, assumes, guarantees, repays, repurchases, redeems, defeases or otherwise discharges any Secured Debt (other than borrowings pursuant to
any working capital or other revolving facility) subsequent to the commencement of the period for which the Secured Leverage Ratio is being calculated and on or prior to the date on which the event for which the calculation of the Secured Leverage
Ratio is made (the “Calculation Date”), then the Secured Leverage Ratio will be calculated giving pro forma effect (in accordance with Regulation S-X under the Securities Act) to such incurrence, assumption, guarantee, repayment,
repurchase, redemption, defeasance or other discharge of Indebtedness and the use of the proceeds therefrom, as if the same had occurred at the beginning of the applicable four-quarter reference period. 

In addition, for purposes of calculating the Secured Leverage Ratio: 

(1) acquisitions that have been made by the Company or any Guarantor, including through mergers or consolidations, and including all
related financing transactions and including increases in ownership of Restricted Subsidiaries, during the four-quarter reference period or subsequent to such reference period and on or prior to the Calculation Date, or that are to be made on the
Calculation Date, will be given pro forma effect (in accordance with Regulation S-X under the Securities Act) as if they had occurred on the first day of the four-quarter reference period; 

(2) the Consolidated EBITDA attributable to discontinued operations, as determined in accordance with GAAP, and operations or businesses
(and ownership interests therein) disposed of on or prior to the Calculation Date, will be excluded; 

  
 -22-

 (3) any Person that is a Restricted Subsidiary on the Calculation Date will be deemed to
have been a Restricted Subsidiary at all times during such four-quarter period; and 
 (4) any Person that is not a Restricted
Subsidiary on the Calculation Date will be deemed not to have been a Restricted Subsidiary at any time during such four-quarter period. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as in effect from time to time, or any successor statute or statutes thereto.

 “Security Documents” means the Second Lien Security Agreement, each Second Lien Security Agreement Joinder and all
other security agreements, pledge agreements, collateral assignments, mortgages, deeds of trust, collateral agency agreements, control agreements or other grants or transfers for security executed and delivered by the Company, any Guarantor or any
other Restricted Subsidiary of the Company creating (or purporting to create) a Lien upon Collateral in favor of the Collateral Agent (or a co-collateral agent), in each case, as amended, modified, renewed, restated or replaced, in whole or in part,
from time to time. 
 “Significant Subsidiary” means any Subsidiary of the Company that would be a “significant
subsidiary” as defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act, as in effect on the date of this Indenture. 
 “Stated Maturity” mean, with respect to any installment of interest or principal on any Indebtedness, the date on which the payment of interest or principal was scheduled to be paid in the
documentation governing such Indebtedness as of the date of this Indenture, and will not include any contingent obligations to repay, redeem or repurchase any such interest or principal prior to the date originally scheduled for payment thereof.

 “Subordinated Obligation” means any Indebtedness of the Company which is expressly subordinate in right of payment
to the Notes pursuant to a written agreement (it being understood that no Indebtedness shall be considered to be a Subordinated Obligation solely by virtue of being unsecured or by virtue of being secured on a junior priority basis). 

“Subsidiary” means, in respect of any Person, any corporation, association, partnership or other business entity of which more
than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general partners or trustees thereof is at the time owned or controlled,
directly or indirectly, by (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person. 
 “Tender/Exchange Offers” means the concurrent offer to exchange Outstanding 3.25% Notes for Unrestricted Notes, offer to purchase Outstanding 3.25% Notes and offer to purchase Outstanding 8.50%
Notes made by the Company pursuant to the Registration Statement. 
 “TIA” means the Trust Indenture Act of 1939, as
amended, and the rules and regulations thereunder as in effect on the date of this Indenture, except to the extent that the Trust Indenture Act or any amendment thereto expressly provides for application of the Trust Indenture Act as in effect on
another date. 

  
 -23-

 “Treasury Rate” means, as of any Redemption Date, the yield to maturity as of such
Redemption Date of United States Treasury securities with a constant maturity (as compiled and published in the most recent Federal Reserve Statistical Release H.15 (519) that has become publicly available at least three Business Days
prior to the Redemption Date (or, if such Statistical Release is no longer published, any publicly available source of similar market data)) most nearly equal to the period from the Redemption Date to the Final Maturity Date; provided,
however, that if the period from the Redemption Date to the Final Maturity Date is less than one year, the weekly average yield on actually traded United States Treasury securities adjusted to a constant maturity of one year will be used.

 “Trust Officer” means, with respect to the Trustee, any officer assigned to the Corporate Trust Office having
direct responsibility for the administration of this Indenture, and also, with respect to a particular matter, any other officer to whom such matter is referred because of such officer’s knowledge of and familiarity with the particular subject.

 “Trustee” means the party named as such in the first paragraph of this Indenture until a successor replaces it in
accordance with the provisions of this Indenture, and thereafter means such successor. 
 “TSA+ Disposition” means:

 (1) the sale, conveyance, transfer, leasing (including subleasing), licensing (including sublicensing) or other disposition
by the Company or any of its Subsidiaries to any Person of the trade secret and know-how and process technology necessary for making suspension assembly flexures produced using additive manufacturing processes, known as the Company’s TSA+
flexure (the “TSA+ Assets”) and any patents that cover TSA+ Assets (the “TSA+ Patents”), provided that the Company and its Subsidiaries may, in the good faith determination of the Board of Directors and on commercially
reasonable terms (including reasonable precautions to be taken to protect the proprietary nature of the TSA+ Assets), lease, sublease, license or sublicense, on a non-exclusive basis, the TSA+ Patents (and, in the case of clause (c) below, TSA+
Assets) to the following Persons (none of which shall constitute a TSA+ Disposition): 
 (a) any Person that owns
intellectual property for the same or similar systems, methods, products and services as the TSA+ Assets to the extent the Company receives a lease, sublease, license or sublicense of such intellectual property from such Person of similar scope
consistent with past practices of the Company; 
 (b) any Person that is a customer of the Company purchasing
TSA+ flexures solely to the extent necessary for such customer to use, sell or otherwise dispose of the TSA+ flexures; 
 (c) any Person not primarily engaged in the disk drive industry for use outside the disk drive industry; and 
 (d) renewals or extensions of existing leases, subleases, licenses or sublicenses existing on the date hereof; or 

  
 -24-

 (2) the sale, conveyance, transfer or other disposition of all or a material portion of the
physical assets relating to the TSA+ Assets or the TSA+ Patents (other than due to replacement of damaged, unserviceable, worn-out or obsolete assets or for improved process capability, provided reasonable precautions are taken to protect the
proprietary nature of the TSA+ Assets) used by the Company or its Subsidiaries for the manufacturing of TSA+ flexures. 

“Unrestricted Notes” means the 8.50% Senior Secured Second Lien Notes due 2017, or any of them (each an “Unrestricted
Note”), as amended or supplemented from time to time, that are issued under this Indenture and offered and sold to Persons pursuant to the Registration Statement or that were initially offered and sold as Restricted Notes but that no longer
constitute “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act. 

“Unrestricted Subsidiary” means any Subsidiary of the Company that is designated by the Board of Directors as an Unrestricted
Subsidiary pursuant to a resolution of the Board of Directors, but only to the extent that such Subsidiary: 
 (1) has no
Indebtedness other than Non-Recourse Debt; 
 (2) except as permitted by Section 4.11 hereof, is not party to any
agreement, contract, arrangement or understanding with the Company or any Restricted Subsidiary of the Company unless the terms of any such agreement, contract, arrangement or understanding are no less favorable to the Company or such Restricted
Subsidiary than those that might be obtained by the Company or such Restricted Subsidiary in a comparable transaction on an arms’-length basis at the time from Persons who are not Affiliates of the Company; 

(3) is a Person with respect to which neither the Company nor any of its Restricted Subsidiaries has any direct or indirect obligation
(a) to subscribe for additional Equity Interests or (b) to maintain or preserve such Person’s financial condition or to cause such Person to achieve any specified levels of operating results; and 

(4) has not guaranteed or otherwise directly or indirectly provided credit support (including by granting Liens on its assets) for any
Indebtedness of the Company or any of its Restricted Subsidiaries. 
 “Vice President” when used with respect to the
Company or the Trustee, means any vice president, whether or not designated by a number or a word or words added before or after the title “vice president.” 
 “Warrants” means detachable warrants to purchase shares of common stock of the Company issued by the Company pursuant to the Purchase Agreement. 

“Weighted Average Life to Maturity” means, when applied to any Indebtedness at any date, the number of years obtained by
dividing: 
 (1) the sum of products obtained by multiplying (a) the amount of each then remaining installment, sinking
fund, serial maturity or other required payment of principal, including payment at final maturity, in respect of Indebtedness, by (b) the number of years (calculated to the nearest one-twelfth) that will elapse between such date and the making
of such payment, by 

  
 -25-

 (2) the then outstanding principal amount of such Indebtedness. 

“Wholly Owned Restricted Subsidiary” means a Restricted Subsidiary of the Company all of the Equity Interests in which (other
than directors’ qualifying shares or Investments by foreign nationals mandated by applicable law) are owned by (i) the Company; (ii) the Company and one or more Wholly Owned Restricted Subsidiaries; or (iii) one or more Wholly
Owned Restricted Subsidiaries. 
 Section 1.02 Other Definitions. 

 

						
	 Term
	  	Defined in Section
	 “Affiliate Transaction”
	  	 	 	4.11	 
	 “Agent Members”
	  	 	 	2.01	 
	 “Asset Sale Offer”
	  	 	 	3.08	 
	 “Bankruptcy Law”
	  	 	 	6.01	 
	 “Change of Control Offer”
	  	 	 	4.15	 
	 “Change of Control Payment”
	  	 	 	4.15	 
	 “Change of Control Payment Date”
	  	 	 	4.15	 
	 “Company Order”
	  	 	 	2.02	 
	 “Covenant Defeasance”
	  	 	 	8.03	 
	 “DTC”
	  	 	 	2.01	 
	 “Depositary”
	  	 	 	2.01	 
	 “Event of Default”
	  	 	 	6.01	 
	 “Excess Proceeds”
	  	 	 	4.10	 
	 “incur”
	  	 	 	4.09	 
	 “Legal Defeasance”
	  	 	 	8.02	 
	 “Legal Holiday”
	  	 	 	13.07	 
	 “Note Obligations”
	  	 	 	10.01	 
	 “Notice of Default”
	  	 	 	6.01	 
	 “Offer Amount”
	  	 	 	4.10	 
	 “Offer Period”
	  	 	 	3.08	 
	 “Paying Agent”
	  	 	 	2.03	 
	 “Permitted Debt”
	  	 	 	4.09	 
	 “Purchase Date”
	  	 	 	3.08	 
	 “Primary Registrar”
	  	 	 	2.03	 
	 “Receiver”
	  	 	 	6.01	 
	 “Redemption Price”
	  	 	 	3.01	 
	 “Registrar”
	  	 	 	2.03	 
	 “Restricted Certificated Note”
	  	 	 	2.01	 
	 “Restricted Payments”
	  	 	 	4.07	 

  
 -26-

 Section 1.03 Trust Indenture Act Provisions. 

Whenever this Indenture refers to a provision of the TIA, that provision is incorporated by reference in and made a part of this
Indenture. This Indenture shall also include those provisions of the TIA required to be included herein by the provisions of the Trust Indenture Reform Act of 1990. The following TIA terms used in this Indenture have the following meanings:

 “indenture securities” means the Notes; 
 “indenture security holder” means a Holder of a Note; 
 “indenture
to be qualified” means this Indenture; 
 “indenture trustee” or “institutional trustee” means the
Trustee; and 
 “obligor” on Notes and the Note Guaranties means the Company and the Guarantors, respectively, and any
successor obligor upon the Notes and the Note Guaranties, respectively. 
 All other terms used in this Indenture that are
defined in the TIA, defined by reference in the TIA to another statute or defined by any SEC rule and not otherwise defined herein have the meanings assigned to them in the TIA, such other statute or such SEC Rule (as the case may be). 

Section 1.04 Rules of Construction. 
  

	 	(a)	Unless the context otherwise requires: 

 (1) a term has the meaning assigned to it; 
 (2) an accounting term
not otherwise defined has the meaning assigned to it in accordance with GAAP; 
 (3) words in the singular
include the plural, and words in the plural include the singular; 
 (4) provisions apply to successive events
and transactions; 
 (5) the term “merger” includes a statutory share exchange and the term
“merged” has a correlative meaning; 
 (6) the masculine gender includes the feminine and the neuter;

 (7) references to agreements and other instruments include subsequent amendments thereto; and 

(8) all “Article”, “Exhibit” and “Section” references are to Articles, Exhibits and
Sections, respectively, of or to this Indenture unless otherwise specified herein, and the terms “herein,” “hereof” and other words of similar import refer to this Indenture as a whole and not to any particular Article,
Section or other subdivision. 

  
 -27-

 Section 1.05 Acts of Holders. A Holder entitled to take any action hereunder
with regard to any particular Note may do so with regard to all or any portion (in an authorized denomination) of the principal amount of such Note or by one or more duly appointed agents, each of which may do so pursuant to such appointment with
regard to all or any portion (in an authorized denomination) of such principal amount. Any notice given or action taken by a Holder or its agents with regard to different portions of such principal amount pursuant to this Section shall have the same
effect as if given or taken by separate Holders of each such different portion. 
 ARTICLE II 

THE NOTES 

Section 2.01 Form and Dating. 
 (a) The Notes and the Trustee’s certificate of authentication shall be substantially in the respective forms set forth in Exhibit A, which Exhibit is incorporated in and made part of this
Indenture. The Notes may have notations, legends or endorsements required by law, stock exchange or automated quotation system rule or regulation or usage. The Company shall provide any such notations, legends or endorsements to the Trustee in
writing. Each Note shall be dated the date of its authentication. 
 (b) (1) All of the Unrestricted Notes shall be issued
initially in the form of a Global Note, which shall be deposited with the Trustee, at its Corporate Trust Office, as custodian for the depositary, The Depository Trust Company (“DTC”, and such depositary, or any successor thereto, being
hereinafter referred to as the “Depositary”), and registered in the name of its nominee, Cede & Co. (or any successor thereto), for the accounts of participants in the Depositary, duly executed by the Company and authenticated by
the Trustee as hereinafter provided. The aggregate principal amount of a Global Note may from time to time be increased or decreased by adjustments made on the records of the Trustee and the Notes Custodian as hereinafter provided, subject in each
case to compliance with the Applicable Procedures. 
 (2) All of the Restricted Notes shall be issued initially
in the form of Certificated Notes (the “Restricted Certificated Notes”), duly executed by the Company and authenticated by the Trustee as hereinafter provided, and shall bear the Private Placement Legend set forth in Exhibit D. 

(c) Each Global Note shall represent such of the outstanding Unrestricted Notes as shall be specified therein and each shall provide that
it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes represented thereby may from time to time be reduced or increased, as appropriate,
to reflect issuances, replacements, exchanges, purchases, redemptions, 

  
 -28-

 
or transfers of such Notes, including exchanges of Restricted Certificated Notes for beneficial interests in a Global Note. Any adjustment of the aggregate principal amount of a Global Note to
reflect the amount of any increase or decrease in the aggregated principal amount of outstanding Notes represented thereby shall be made by the Trustee in accordance with instructions given by the Holder thereof as required by Section 2.12 and
shall be made on the records of the Trustee, the Notes Custodian and the Depositary. 
 (d) Members of, or participants in, the
Depositary (“Agent Members”) shall have no rights under this Indenture with respect to any Global Note held on their behalf by the Depositary or under any Global Note, and the Depositary (including, for this purpose, its nominee) may be
treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and Holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall (1) prevent the Company, the
Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (2) impair, as between the Depositary and its Agent Members, the operation of
customary practices governing the exercise of the rights of a Holder of any Note. 
 (e) The Company shall execute and the
Trustee shall, in accordance with this Section 2.01(e), authenticate and deliver initially one or more Global Notes representing Unrestricted Notes that (1) shall be registered in the name of the Depositary or its nominee, (2) shall
be delivered by the Trustee to the Depositary or pursuant to the Depositary’s instructions and (3) shall bear a legend substantially to the following effect: 
 “UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY
CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY
AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN. THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN
THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR A NOTE IN CERTIFICATED FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE
DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE 

  
 -29-

 
DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.” 

(f) The Company shall execute and the Trustee shall, in accordance with this Section 2.01(f), authenticate and deliver initially
Certificated Notes representing Restricted Notes that (1) shall each be registered in the name of a Holder thereof in accordance with the Purchase Agreement, (2) shall be delivered by the Trustee to the respective Holder and (3) shall
bear the Private Placement Legend. 
 Section 2.02 Execution and Authentication. 

(a) The aggregate principal amount of Notes which may be authenticated and delivered under this Indenture is $78,931,000. 

(b) An Officer shall sign the Notes for the Company by manual or facsimile signature. Typographic and other minor errors or defects in
any such facsimile signature shall not affect the validity or enforceability of any Note that has been authenticated and delivered by the Trustee. 
 (c) If an Officer whose signature is on a Note no longer holds that office at the time the Trustee authenticates the Note, the Note shall be valid nevertheless. 

(d) A Note shall not be valid until an authorized signatory of the Trustee by manual signature signs the certificate of authentication on
the Note. The signature shall be conclusive evidence that the Note has been authenticated under this Indenture. 
 (e) The
Trustee shall authenticate and make available for delivery Notes for original issue upon receipt of a written order or orders of the Company signed by an Officer of the Company (a “Company Order”). The Company Order shall specify the total
amount of Notes to be authenticated, the amount of such Notes which are Unrestricted Notes and the amount of such Notes which are Restricted Notes, whether such Notes will be represented by a Global Note or Certificated Notes and the date on which
each original issue of Notes is to be authenticated. 
 (f) The Trustee shall act as the initial authenticating agent.
Thereafter, the Trustee may appoint an authenticating agent reasonably acceptable to the Company to authenticate Notes. An authenticating agent may authenticate Notes whenever the Trustee may do so. Each reference in this Indenture to authentication
by the Trustee includes authentication by such agent. An authenticating agent shall have the same rights as an Agent to deal with the Company or an Affiliate of the Company. 
 (g) The Notes shall be issuable only in registered form without coupons and only in denominations of $2,000 principal amount and any integral multiple of $1,000 in excess thereof. 

  
 -30-

 Section 2.03 Registrar and Paying Agent. 

(a) The Company shall maintain one or more offices or agencies where Notes may be presented for registration of transfer or for exchange
(each, a “Registrar”) and one or more offices or agencies where Notes may be presented for payment (each, a “Paying Agent”). One of the Registrars (the “Primary Registrar”) shall keep a register of the Notes and of
their transfer and exchange. The Company may change any Paying Agent or Registrar without prior notice to any Holder of Notes, provided that the Company will deliver written notice of any such change in Paying Agent or Registrar to each
Holder of a Note within two Business Days after such change. 
 (b) The Company shall enter into an appropriate agency agreement
with any Agent not a party to this Indenture, provided that the Agent may be an Affiliate of the Trustee. The agreement shall implement the provisions of this Indenture that relate to such Agent. The Company shall notify the Trustee in
writing of the name and address of any Agent not a party to this Indenture. If the Company fails to maintain a Registrar or Paying Agent, or fails to give the foregoing notice, the Trustee shall act as such. The Company or any Affiliate of the
Company may act as Paying Agent (except for the purposes of Section 4.01 and Article XII). 
 (c) The Company hereby
initially designates the Trustee as Paying Agent, Registrar and Notes Custodian. 
 Section 2.04 Paying Agent to Hold
Money in Trust. Prior to 12:00 p.m. (noon), New York City time, on each due date of the payment of principal of, or interest on, any Notes, the Company shall deposit with the Paying Agent a sum sufficient to pay such principal or interest
so becoming due. Subject to Section 12.03, a Paying Agent shall hold in trust for the benefit of Holders of Notes or the Trustee all money held by the Paying Agent for the payment of principal of, or interest on, the Notes, and shall notify the
Trustee in writing of any failure by the Company (or any other obligor on the Notes) to make any such payment. If the Company or an Affiliate of the Company acts as Paying Agent, it shall, before 12:00 p.m. (noon), New York City time, on each
due date of the principal of, or interest on, any Notes, segregate the money held by it as Paying Agent and hold it as a separate trust fund for the benefit of Holders of Notes. The Company at any time may require a Paying Agent to pay all money
held by it to the Trustee, and the Trustee may at any time during the continuance of any Event of Default, upon written request to a Paying Agent, require such Paying Agent to pay forthwith to the Trustee all sums so held in trust by such Paying
Agent. Upon doing so, the Paying Agent (other than the Company) shall have no further liability for the money. Upon any bankruptcy or reorganization proceedings relating to the Company, the Trustee will serve as Paying Agent. 

Section 2.05 Lists of Holders of Notes. The Trustee shall preserve in as current a form as is reasonably practicable the most
recent list available to it of the names and addresses of Holders of Notes. If the Trustee is not the Primary Registrar, the Company shall furnish to the Trustee at least five (5) Business Days before each Interest Payment Date and at such
other times as the Trustee may request in writing, a list in such form and as of such date as the Trustee may reasonably require of the names and addresses of Holders of Notes. 

  
 -31-

 Section 2.06 Transfer and Exchange. 

(a) Subject to compliance with any applicable additional requirements contained in Section 2.12, when a Note is presented to a
Registrar with a request to register a transfer thereof or to exchange such Note for an equal principal amount of Notes of other authorized denominations, the Registrar shall register the transfer or make the exchange as requested; provided,
however, that every Note presented or surrendered for registration of transfer or exchange shall be duly endorsed or accompanied by an assignment form in the form included in Exhibit A, and completed in a manner satisfactory to the
Registrar and duly executed by the Holder thereof or its attorney duly authorized in writing. To permit registration of transfers and exchanges, upon surrender of any Note for registration of transfer or exchange at an office or agency maintained
pursuant to Section 2.03, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate Notes of a like aggregate principal amount at the Registrar’s request. Any exchange or transfer shall be without charges
or fees, except that the Company or the Registrar may require payment of a sum sufficient to cover any transfer tax or other similar governmental charge that may be imposed in relation thereto, provided that this sentence shall not apply to
any transfer or exchange pursuant to Section 2.10, 3.06, 3.08, 4.15 or 9.05. 
 (b) Neither the Company, any Registrar nor
the Trustee shall be required to exchange or register a transfer of (1) any Notes for a period of 15 days next preceding mailing of a notice of Notes to be redeemed, or (2) any Notes or portions thereof selected or called for redemption
(except, in the case of redemption of a Note in part, the portion thereof not to be redeemed). 
 (c) All Notes issued upon any
transfer or exchange of Notes shall be valid and legally binding obligations of the Company, evidencing the same debt and entitled to the same benefits under this Indenture, as the Notes surrendered upon such transfer or exchange. 

(d) Any Registrar appointed pursuant to Section 2.03 shall provide to the Trustee such information as the Trustee may reasonably
require in connection with the delivery by such Registrar of Notes upon transfer or exchange of Notes. 
 Section 2.07
Replacement Notes. 
 (a) If any mutilated Note is surrendered to the Company, a Registrar or the Trustee, or the Company,
a Registrar and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Note, and there is delivered to the Company, the applicable Registrar and the Trustee such security or indemnity as may be required by them
to save each of them harmless from any loss that any of them may suffer as a result of the replacement of such Note, then, in the absence of notice to the Company, such Registrar or the Trustee that such Note has been acquired by a bona fide
purchaser, the Company shall execute, and upon delivery of a Company Order the Trustee shall authenticate and deliver, in exchange for any such mutilated Note or in lieu of any such destroyed, lost or stolen Note, a new Note of like tenor and
principal amount, bearing a number not contemporaneously outstanding. 

  
 -32-

 (b) If any such mutilated, destroyed, lost or stolen Note has become or is about to become
due and payable, or is about to be purchased or redeemed by the Company pursuant to Article III or Section 4.10 or 4.15, the Company in its discretion may, instead of issuing a new Note, pay, redeem or purchase such Note, as the case may
be. 
 (c) Upon the issuance of any new Notes under this Section 2.07, the Company may require the payment of a sum
sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other reasonable expenses (including the reasonable fees and expenses of the Trustee or the Registrar) in connection therewith. 

(d) Every new Note issued pursuant to this Section 2.07 in lieu of any mutilated, destroyed, lost or stolen Note shall constitute an
original additional contractual obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Note shall be at any time enforceable by anyone, and shall be entitled to all benefits of this Indenture equally and proportionately
with any and all other Notes duly issued hereunder. 
 (e) The provisions of this Section 2.07 are (to the extent lawful)
exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Notes. 
 Section 2.08 Outstanding Notes. 
 (a) Notes outstanding at any time are
all Notes authenticated by the Trustee, except for those canceled by it, those redeemed or purchased pursuant to Article III or Section 4.10 or 4.15, those delivered to the Trustee for cancellation and those described in this
Section 2.08 as not outstanding. 
 (b) If a Note is replaced pursuant to Section 2.07, it ceases to be outstanding
unless the Company receives proof satisfactory to it that the replaced Note is held by a bona fide purchaser. 
 (c) If a Paying
Agent (other than the Company or an Affiliate of the Company) holds in respect of the outstanding Notes on a Redemption Date, Purchase Date, Change of Control Payment Date or the Final Maturity Date money sufficient to pay the principal of and
accrued interest on the Notes (or portions thereof) payable on that date, then on and after such Redemption Date, Purchase Date, Change of Control Payment Date or Final Maturity Date, as the case may be, such Notes (or portions thereof, as the case
may be) shall cease to be outstanding and interest on them shall cease to accrue, provided that if such Notes are to be redeemed, notice of such redemption has been duly given pursuant to this Indenture or provision thereof satisfactory to
the Trustee has been made. 
 (d) Subject to the restrictions contained in Section 2.09, a Note does not cease to be
outstanding because the Company or an Affiliate of the Company holds the Note. 
 Section 2.09 Treasury Notes. In
determining whether the Holders of the required principal amount of Notes have concurred in any notice, direction, waiver or consent, Notes owned by the Company or any other obligor on the Notes or by any Affiliate of the Company or of such other
obligor shall be disregarded, except that, for purposes of determining whether the 

  
 -33-

 
Trustee shall be protected in relying on any such notice, direction, waiver or consent, only Notes which a Trust Officer of the Trustee with responsibility for this Indenture actually knows are
so owned shall be so disregarded. Notes so owned which have been pledged in good faith shall not be disregarded if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to the Notes and that the
pledgee is not the Company or any other obligor on the Notes or any Affiliate of the Company or of such other obligor. 

Section 2.10 Temporary Notes. Until definitive Notes are ready for delivery, the Company may prepare and execute, and, upon
receipt of a Company Order, the Trustee shall authenticate and deliver, temporary Notes. Temporary Notes shall be substantially in the form of definitive Notes but may have variations that the Company considers appropriate for temporary Notes.
Without unreasonable delay, the Company shall prepare and the Trustee shall authenticate and deliver definitive Notes in exchange for temporary Notes. 
 Section 2.11 Cancellation. The Company at any time may deliver Notes to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee or its agent any Notes
surrendered to them for transfer, exchange, redemption, purchase or payment. The Trustee and no one else shall cancel, in accordance with its standard procedures, all Notes surrendered for transfer, exchange, redemption, purchase, payment or
cancellation and shall dispose of the cancelled Notes in accordance with its customary procedures or deliver the canceled Notes to the Company. All Notes which are redeemed, purchased or otherwise acquired by the Company or any of its Subsidiaries
prior to the Final Maturity Date pursuant to Article III or Section 4.10 or 4.15 shall be delivered to the Trustee for cancellation, and the Company may not hold or resell such Notes. 

Section 2.12 Additional Transfer and Exchange Requirements. 

(a) A Global Note may not be transferred, in whole or in part, to any Person other than the Depositary or a nominee or any successor
thereof, and no such transfer to any such other Person may be registered, provided that the foregoing shall not prohibit any transfer of a Note that is issued in exchange for a Global Note but is not itself a Global Note, subject as
applicable to the provisions of Section 2.12(d). No transfer of a Note to any Person shall be effective under this Indenture or the Notes unless and until such Note has been registered in the name of such Person. Notwithstanding any other
provisions of this Indenture or the Notes, transfers of a Global Note, in whole or in part, shall be made only in accordance with this Section 2.12. 
 (b) Whenever any Note other than a Global Note is presented or surrendered for registration of transfer or in exchange for a Note registered in a name other than that of the Holder, such Note must be
accompanied by an assignment form in substantially the form set forth in Exhibit A, dated the date of such surrender and signed by the Holder of such Note. The Registrar shall not be required to accept for such registration of transfer or
exchange any such Note not so accompanied by a properly completed assignment form. As used in this Section 2.12, the term “transfer” encompasses any sale, pledge, transfer, exchange, hypothecation or other disposition of any Note.

  
 -34-

 (c) The provisions below shall apply to Global Notes: 

(1) Each Global Note authenticated under this Indenture shall be registered in the name of the Depositary or a nominee
thereof and delivered to such Depositary or a nominee thereof or custodian therefor, and each such Global Note shall constitute a single Note for purposes of this Indenture. 

(2) Notwithstanding any other provisions of this Indenture or the Notes, a Global Note shall not be exchanged in whole or
in part for a Note registered, and no transfer of a Global Note in whole or in part shall be registered, in the name of any Person other than the Depositary or one or more nominees or any successor thereof, provided that a Global Note may be
exchanged for one or more Certificated Notes registered in the names of any person designated by the Depositary in the event that (A) the Depositary has notified the Company that it is unwilling or unable to continue as Depositary for such
Global Note or such Depositary has ceased to be a “clearing agency” registered under the Exchange Act, and a successor Depositary is not appointed by the Company within 90 days after receiving such notice or becoming aware that the
Depositary has ceased to be a “clearing agency,” or (B) an Event of Default has occurred and is continuing with respect to the Notes and the Depositary requests the issuance of Certificated Notes. Any Global Note exchanged pursuant to
subclause (A) above shall be so exchanged in whole and not in part, and any Global Note exchanged pursuant to subclause (B) above may be exchanged in whole or from time to time in part as directed by the Depositary. Except as specifically
provided in the preceding sentence, any Note issued in exchange for a Global Note or any portion thereof shall be a Global Note, provided that any such Note so issued that is registered in the name of a Person other than the Depositary or a
nominee thereof shall not be a Global Note. 
 (3) Notes issued in exchange for a Global Note or any portion
thereof shall be issued in definitive, fully registered form, without interest coupons, shall have an aggregate principal amount equal to that of such Global Note or portion thereof to be so exchanged, shall be registered in such names and be in
such authorized denominations as the Depositary shall designate. Any Global Note to be exchanged in whole shall be surrendered by the Depositary to the Trustee, as Registrar. With regard to any Global Note to be exchanged in part, either such Global
Note shall be so surrendered for exchange or, if the Trustee is acting as custodian for the Depositary or its nominee with respect to such Global Note, the principal amount thereof shall be reduced, by an amount equal to the portion thereof to be so
exchanged, by means of an appropriate adjustment made on the records of the Trustee. Upon any such surrender or adjustment, the Trustee shall authenticate and deliver the Note issuable on such exchange to or upon the order of the Depositary or an
authorized representative thereof. 
 (4) Subject to clause (6) of this Section 2.12(c), the registered
Holder may grant proxies and otherwise authorize any Person, including Agent Members and Persons that may hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the Notes. 

  
 -35-

 (5) In the event of the occurrence of any of the events specified in
clause (2) of this Section 2.12(c), the Company will promptly make available to the Trustee a reasonable supply of Certificated Notes in definitive, fully registered form, without interest coupons. 

(6) Neither Agent Members nor any other Persons on whose behalf Agent Members may act shall have any rights under this
Indenture with respect to any Global Note registered in the name of the Depositary or any nominee thereof, or under any such Global Note, and the Depositary or such nominee, as the case may be, may be treated by the Company, the Trustee and any
agent of the Company or the Trustee as the absolute owner and holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee
from giving effect to any written certification, proxy or other authorization furnished by the Depositary or such nominee, as the case may be, or impair, as between the Depositary, its Agent Members and any other Person on whose behalf an Agent
Member may act, the operation of customary practices of such Persons governing the exercise of the rights of a Holder of any Note. 
 (7) At such time as all interests in a Global Note have been redeemed, cancelled or exchanged for Notes in certificated form, such Global Note shall, upon receipt thereof, be cancelled by the Trustee in
accordance with standing procedures and instructions existing between the Depositary and the Notes Custodian, subject to Section 2.11 of this Indenture. At any time prior to such cancellation, if any interest in a Global Note is redeemed,
canceled or exchanged for Notes in certificated form, the principal amount of such Global Note shall, in accordance with the standing procedures and instructions existing between the Depositary and the Notes Custodian, be appropriately reduced, and
an endorsement shall be made on such Global Note, by the Trustee or the Notes Custodian, at the direction of the Trustee, to reflect such reduction. 
 (d) In addition to any other requirement of this Section 2.12, the following requirements shall apply with respect to the registration of any proposed transfer of a Restricted Note: 

(1) the transferor and transferee have delivered to the Trustee and the Company such certifications and legal opinions as
may be reasonably requested by the Trustee and the Company relating to compliance with applicable securities laws; and 
 (2) the Restricted Notes so transferred shall bear the Private Placement Legend, unless (i) there is delivered to the Trustee and the Company an Opinion of Counsel reasonably satisfactory to the
Company to the effect that neither such legend nor the related restrictions on transfer are required to maintain compliance 

  
 -36-

 
with the provisions of the Securities Act or (ii) such Restricted Note has been offered and sold pursuant to an effective registration statement under the Securities Act. 

(e) By its acceptance of any Restricted Note, each Holder of such a Restricted Note acknowledges the restrictions on transfer of such
Restricted Note set forth in this Indenture and in the Private Placement Legend and agrees that it will transfer such Restricted Note only as provided in this Indenture. 
 (f) Each Restricted Note may be exchanged or transferred for a beneficial interest in a Global Note after the requisite holding period permitting resale of the Note without limitation or restriction of
any kind under Rule 144 under the Securities Act in a transaction meeting the requirements of Rule 144 under the Securities Act. For any such exchange or transfer, the Holder of the Restricted Notes will provide the Trustee, the Company and the
Company’s counsel contemplated below with reasonable assurance that such Restricted Notes can be exchanged or transferred pursuant to Rule 144 under the Securities Act, including customary representations reasonably requested by the Trustee and
the Company with respect to such Holder’s holding period of its Restricted Notes and with respect to a determination whether such Holder is an Affiliate of the Company. The Holder of the Restricted Notes will also provide the Trustee and the
Company such information reasonably requested by the Trustee and the Company as being required by the Depositary to effect such exchange or transfer in accordance with the Applicable Procedures. 

If any Opinion of Counsel for such exchange or transfer is requested by the Trustee or the Company, the Company shall use its best
efforts to cause its counsel to deliver such Opinion of Counsel. 
 (g) In addition to any other requirement of this
Section 2.12, the following requirements shall apply with respect to the proposed exchange or transfer of any Restricted Note for a beneficial interest in a Global Note other than pursuant to Section 2.12(f) above: 

(1) there is delivered to the Trustee and the Company an Opinion of Counsel reasonably satisfactory to the Company to the
effect that neither the Private Placement Legend nor the related restrictions on transfer are required to maintain compliance with the provisions of the Securities Act; and 

(2) there is delivered to the Trustee and the Company such information reasonably requested by the Trustee and the Company
as being required by the Depositary to effect such exchange or transfer in accordance with the Applicable Procedures. 
 (h) To
facilitate an exchange or transfer of Restricted Notes for beneficial interests in a Global Note bearing the same CUSIP number as the Unrestricted Note, the Company and Trustee shall take all necessary actions reasonably requested by the Holder of
the Restricted Note, including cancelling the Certificated Note and increasing the aggregate principal amount of the Global Note through the Applicable Procedures, upon the Holder of the Restricted Note’s satisfaction of the provisions set
forth in either Section 2.12(f) or 2.12(g) above. 

  
 -37-

 (i) All Global Notes and Certificated Notes issued upon any exchange or registration of
transfer of Global Notes or Certificated Notes shall, upon execution by the Company and authentication by the Trustee, be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Indenture, as the
Global Notes or Certificated Notes surrendered upon such exchange or registration of transfer. 
 (j) The Registrar shall retain
copies of all letters, notices and other written communications received pursuant to Section 2.12 as long as there are any Notes outstanding. The Company shall have the right to inspect and make copies of all such letters, notices or other
written communications at any reasonable time upon the giving of reasonable written notice to the Registrar. 
 The Trustee
shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any
transfers between or among Depositary participants or beneficial owners of interests in any Global Note) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when
expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements hereof. 
 The Trustee shall have no responsibility for the actions or omissions of the Depositary, or the accuracy of the books and records of the Depositary. 

Section 2.13 CUSIP Numbers. The Company in issuing the Notes may use one or more “CUSIP” numbers (if then generally
in use), and, if so, the Trustee shall use the “CUSIP” number or numbers in notices of redemption or purchase as a convenience to Holders, provided that any such notice may state that no representation is made as to the correctness
of such number or numbers either as printed on the Notes or as contained in any notice of a redemption or purchase and that reliance may be placed only on the other identification numbers printed on the Notes, and any such redemption or purchase
shall not be affected by any defect in or omission of such number or numbers. The Company will promptly notify the Trustee in writing of any change in a “CUSIP” number. 

ARTICLE III 

REDEMPTION AND PURCHASE 
 Section 3.01 Optional Redemption. 
 (a) The Company may at any time on
any one or more occasions redeem all or a part of the Notes, upon not less than 30 nor more than 60 days’ notice, at a redemption price (the “Redemption Price”) equal to 100% of the principal amount of the Notes redeemed, plus the
Applicable Premium as of, and accrued and unpaid interest on the principal amount of the Notes redeemed to, the Redemption Date, subject to the rights of Holders of Notes on the relevant Regular Record Date to receive interest due on the relevant
Interest Payment Date as and to the extent provided in Section 3.05. 

  
 -38-

 (b) Except pursuant to Section 3.01(a), the Notes will not be redeemable at the
Company’s option prior to the Final Maturity Date. 
 (c) If the Company elects to redeem Notes pursuant to this
Section 3.01, it shall notify the Trustee in writing at least 15 days prior to the date it sends the redemption notice specified in Section 3.03 to the Holders (unless a shorter period shall be satisfactory to the Trustee), of the
Redemption Date and the principal amount of Notes to be redeemed. 
 Section 3.02 Selection of Notes to be Redeemed.

 (a) If less than all of the Notes are to be redeemed, unless the Applicable Procedures specify otherwise, the Trustee shall
select the Notes to be redeemed within five Business Days after it receives the notice described in Section 3.01(c). The Trustee shall make the selection from the Notes outstanding and not previously called for redemption by lot, or in its
discretion, on a pro rata basis or by another method that the Trustee considers fair and reasonable (so long as such method is not prohibited by the rules of any stock exchange or market on which the Notes are listed and the Trustee has knowledge of
such listing). Notes in denominations of $2,000 principal amount may only be redeemed in whole. The Trustee may select for redemption portions (equal to $2,000 principal amount or any integral multiple of $1,000 in excess thereof) of the principal
amount of Notes that have denominations larger than $2,000. Provisions of this Indenture that apply to Notes called for redemption also apply to portions of Notes called for redemption. The Trustee shall notify the Company promptly of the Notes or
portions of Notes to be redeemed. 
 (b) In the event of any redemption in part, the Company shall not be required to
(i) issue, register the transfer of or exchange any Note during a period beginning at the opening of business 15 days before any selection of Notes for redemption and ending at the close of business on the earliest date on which the relevant
notice of redemption is deemed to have been given to all Holders of Notes to be redeemed, or (ii) register the transfer or exchange of any Note so selected for redemption, in whole or in part, except the unredeemed portion of any security being
redeemed in part. 
 Section 3.03 Notice of Redemption. 

(a) At least 30 days but not more than 60 days before a Redemption Date, the Company shall mail or cause to be mailed a notice of
redemption to each Holder of Notes to be redeemed at such Holder’s address as it appears on the Registrar’s books. 

(b) The notice shall identify the Notes (including CUSIP number) to be redeemed and shall state: 

(1) the Redemption Date; 
 (2) the Redemption Price; 
 (3) the name and address of each Paying
Agent; 

  
 -39-

 (4) that Notes called for redemption must be presented and surrendered to a
Paying Agent to collect the Redemption Price; 
 (5) that, unless the Company has failed to make the payment of
such Redemption Price which is due and payable, interest will cease to accrue on and after the Redemption Date; 

(6) if any Note is being redeemed in part, the portion of the principal amount of such Note to be redeemed and that, after
the Redemption Date, upon presentation and surrender of such Note, a new Note or Notes in aggregate principal amount equal to the unredeemed portion thereof will be issued in the name of the Holder of such Note or, if requested by such Holder,
transferred by book-entry upon cancellation of the original Note; 
 (7) if Certificated Notes are outstanding
and fewer than all the outstanding Notes are to be redeemed, the certificate number and the principal amounts of the particular Notes to be redeemed; and 
 (8) if such notice is provided by the Trustee, that no representation is made as to the correctness or accuracy of the CUSIP number listed in such notice. 

(c) If any of the Notes to be redeemed are in the form of a Global Note, then the Company shall modify such notice to the extent
necessary to accord with the procedures of the Depositary applicable to redemptions. At the Company’s written request, which request shall (1) be irrevocable once given and (2) set forth all relevant information required by
clauses (1) through (7) of Section 3.03(b), the Trustee shall give the notice of redemption to each Holder in the Company’s name and at the Company’s expense; provided, however, that in all cases, the text of
such notice of redemption shall be prepared by the Company; and provided further that the Company submit to the Trustee such written request, along with an Officers’ Certificate, at least five Business Days prior to the date by which
such notice of redemption must be given to the Holders in accordance with this Section 3.03 (unless a shorter period should be satisfactory to the Trustee). 
 Section 3.04 Effect of Notice of Redemption. Once notice of redemption is mailed in accordance with Section 3.03, Notes called for redemption become irrevocably due and payable on the
Redemption Date and at the Redemption Price stated in the notice. On or after the Redemption Date and upon presentation and surrender to a Paying Agent, Notes called for redemption shall be paid at the Redemption Price. 

Section 3.05 Deposit of Redemption Price. 
 (a) Prior to 12:00 p.m. (noon), New York City time, on the Redemption Date, the Company shall deposit with a Paying Agent (or, if the Company acts as Paying Agent, shall segregate and hold in trust)
an amount of money (in immediately available funds if deposited on such Redemption Date) sufficient to pay the Redemption Price payable upon redemption on all Notes to be redeemed on that date, other than Notes or portions thereof called for
redemption on that date which have been delivered by the Company to the Trustee for cancellation. The Paying Agent shall as promptly as practicable return to the Company any money not required for that purpose because of the cancellation of Notes
or, if such money is then held by the Company in trust and is not required for such purpose, it shall be discharged from the trust. 

  
 -40-

 (b) If a Paying Agent holds, in accordance with the terms hereof, money sufficient to pay
the Redemption Price of any Note for which a notice of redemption has been tendered and not withdrawn in accordance with this Indenture then, on the Redemption Date, such Note will cease to be outstanding, whether or not the Note is delivered to the
Paying Agent, and the rights of the Holder in respect thereof shall terminate (other than the right to receive the Redemption Price as aforesaid). 
 (c) If a Note is redeemed on or after a Regular Record Date and on or before the related Interest Payment Date, any accrued and unpaid interest to the Redemption Date shall be paid on such Interest
Payment Date to the Person in whose name such Note was registered at the close of business on such Regular Record Date, and no additional interest will be payable to the Holder who tenders such Note for redemption. 

(d) If any Note called for redemption shall not be so paid upon surrender for redemption because of the failure of the Company to comply
with Section 3.05(a), interest at the rate provided in the Notes shall be paid on the unpaid principal called for redemption and, to the extent lawful, on any unpaid interest accrued to the Redemption Date on such unpaid principal, in each case
from the Redemption Date to the date such principal or interest (as the case may be) is paid. 
 Section 3.06 Notes
Redeemed in Part. Upon presentation and surrender of a Note that is redeemed in part, the Company shall execute and the Trustee shall authenticate and mail or deliver (or cause to be transferred by book entry) to the Holder, at the expense of
the Company, a new Note equal in principal amount to the unredeemed portion of the Note surrendered. 
 Section 3.07
Purchase of Notes in Open Market. The Company shall, in accordance with Section 2.11, surrender any Note purchased by the Company pursuant to this Article III to the Trustee for cancellation. Any Notes surrendered to the Trustee for
cancellation may not be reissued or resold by the Company and will be canceled promptly in accordance with Section 2.11. The Company may repurchase Notes in open market and negotiated transactions. 

Section 3.08 Offer to Purchase by Application of Excess Proceeds. 

In the event that, pursuant to Section 4.10 hereof, the Company is required to commence an offer to all Holders to purchase Notes (an
“Asset Sale Offer”), it will follow the procedures specified below. 
 The Asset Sale Offer shall be made to all
Holders of Notes and all holders of other Indebtedness that is pari passu with the Notes and contains provisions similar to those set forth in this Indenture with respect to offers to purchase, prepay or redeem with the proceeds of sales of assets.
The Asset Sale Offer will remain open for a period of at least 20 Business Days following its commencement or such longer period as may be required by applicable law (the “Offer Period”). No later than three Business Days after the
termination of the Offer Period (the “Purchase Date”), the Company will apply all of the Offer Amount to the purchase, prepayment or redemption of Notes and such other pari passu Indebtedness on a pro rata basis based on the

  
 -41-

 
principal amount of Notes and such other pari passu Indebtedness surrendered (with such adjustments as may be deemed appropriate by the Company so that only Notes in denominations of $2,000, or
an integral multiple of $1,000 in excess thereof, will be purchased) or, if the aggregate principal amount of the Notes and other pari passu Indebtedness that has been tendered or required to be prepaid or redeemed in response to the Asset Sale
Offer is less than the Offer Amount, all Notes and other pari passu Indebtedness tendered or required to be prepaid or redeemed. 
 If the Purchase Date is on or after a Regular Record Date and on or before the related Interest Payment Date, any accrued and unpaid interest to the Purchase Date will be paid on such Interest Payment
Date to the Person in whose name a Note is registered at the close of business on such Regular Record Date, and no additional interest will be payable to Holders who tender Notes pursuant to the Asset Sale Offer. 

Upon the commencement of an Asset Sale Offer, the Company will send, by first class mail, a notice to the Trustee and each of the
Holders, with a copy to the Trustee. The notice will contain all instructions and materials necessary to enable such Holders to tender Notes pursuant to the Asset Sale Offer. The Asset Sale Offer shall be made to all Holders and holders of other
pari passu Indebtedness. The notice, which will govern the terms of the Asset Sale Offer, will state: 
 (1) that the Asset Sale
Offer is being made pursuant to this Section 3.08 and Section 4.10 hereof and the length of time the Asset Sale Offer will remain open; 
 (2) the Offer Amount, the purchase price and the Purchase Date; 
 (3) that any
Note not tendered or accepted for payment will continue to accrue interest; 
 (4) that, unless the Company defaults in making
such payment, any Note accepted for payment pursuant to the Asset Sale Offer will cease to accrue interest after the Purchase Date; 
 (5) that Holders electing to have a Note purchased pursuant to an Asset Sale Offer may elect to have Notes purchased in denominations of $2,000 or an integral multiple of $1,000 in excess thereof;

 (6) that Holders electing to have Notes purchased pursuant to any Asset Sale Offer will be required to surrender the Note,
with the form entitled “Option of Holder to Elect Purchase” attached to the Notes completed, or transfer by book-entry transfer, to the Company, a Depositary, if appointed by the Company, or a Paying Agent at the address specified in the
notice at least three Business Days before the Purchase Date; 
 (7) that Holders will be entitled to withdraw their election if
the Company, the Depositary or the Paying Agent, as the case may be, receives, not later than the expiration of the Offer Period, a telegram, telex, facsimile transmission or letter setting forth the name of the Holder, the principal amount of the
Note the Holder delivered for purchase and a statement that such Holder is withdrawing his election to have such Note purchased; 

  
 -42-

 (8) that, if the aggregate principal amount of Notes and other pari passu Indebtedness
surrendered by holders thereof exceeds the Offer Amount, the Company will select the Notes and other pari passu Indebtedness to be purchased, prepaid or redeemed on a pro rata basis based on the principal amount of Notes and such other pari
passu Indebtedness surrendered (with such adjustments as may be deemed appropriate by the Company so that only Notes in denominations of $2,000, or an integral multiple of $1,000 in excess thereof, will be purchased); and 

(9) that Holders whose Notes were purchased only in part will be issued new Notes equal in principal amount to the unpurchased portion of
the Notes surrendered (or transferred by book-entry transfer). 
 On or before the Purchase Date, the Company will, to the
extent lawful, accept for payment, on a pro rata basis to the extent necessary, the Offer Amount of Notes and other pari passu Indebtedness or portions thereof tendered or required to be prepaid or redeemed pursuant to the Asset Sale Offer,
or if less than the Offer Amount has been tendered or required to be prepaid or redeemed, all Notes and other pari passu Indebtedness tendered or required to be prepaid or redeemed, and will deliver or cause to be delivered to the Trustee the Notes
properly accepted together with an Officers’ Certificate stating that such Notes or portions thereof were accepted for payment by the Company in accordance with the terms of this Section 3.08. The Company, the Depositary or the Paying
Agent, as the case may be, will promptly (but in any case not later than five days after the Purchase Date) mail or deliver to each tendering Holder an amount equal to the purchase price of the Notes tendered by such Holder and accepted by the
Company for purchase, and the Company will promptly issue a new Note, and the Trustee, upon written request from the Company, will authenticate and mail or deliver (or cause to be transferred by book entry) such new Note to such Holder, in a
principal amount equal to any unpurchased portion of the Note surrendered. Any Note not so accepted shall be promptly mailed or delivered by the Company to the Holder thereof. The Company will publicly announce the results of the Asset Sale Offer on
the Purchase Date. 
 ARTICLE IV 
 COVENANTS 
 Section 4.01 Payment of Notes. 

(a) The Company shall promptly make all payments in respect of the Notes on the dates and in the manner provided in the Notes and this
Indenture. A payment of principal or interest shall be considered paid on the date it is due if the Paying Agent (other than the Company or a Subsidiary thereof) holds by 12:00 p.m. (noon), New York City time, on that date money, deposited by
or on behalf of the Company in immediately available funds, designated for and sufficient to make such payment. Accrued and unpaid interest on any Note that is payable, and is punctually paid or duly provided for, on any Interest Payment Date shall
be paid to the Person in whose name that Note is registered at the close of business on the Regular Record Date for such interest at the office or agency of the Company maintained for such purpose. 

  
 -43-

 (b) Payment of the principal of and interest on the Notes shall be made at the office or
agency of the Company maintained for that purpose at the Corporate Trust Office of the Trustee in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts;
provided, however, that at the option of the Company payment of interest may be made through the Paying Agent by check mailed to the address of the Person entitled thereto as such address appears in the Registrar; provided
further that a Holder of Notes in an aggregate principal amount in excess of $2.0 million will be paid interest on such Notes by wire transfer in immediately available funds at the election of such Holder if such Holder has provided wire
transfer instructions to the Trustee at least 10 Business Days prior to the Interest Payment Date. Any wire transfer instructions received by the Trustee will remain in effect until revoked by the Holder. 

(c) The Company shall pay interest (including post-petition interest in any proceeding under any Bankruptcy Law) on overdue principal at
the rate equal to the then applicable interest rate on the Notes to the extent lawful, and shall pay interest (including post-petition interest in any proceeding under any Bankruptcy Law) on overdue installments of interest (without regard to any
applicable grace period) at the same rate to the extent lawful. 
 Section 4.02 Maintenance of Office or Agency. The
Company will maintain an office or agency of the Trustee, Registrar and Paying Agent where Notes may be presented or surrendered for payment, where Notes may be surrendered for registration of transfer or for exchange and where notices and demands
to or upon the Company in respect of the Notes and this Indenture may be served. The Corporate Trust Office shall initially be one such office or agency for all of the aforesaid purposes. The Company shall give prompt written notice to the Trustee
of the location, and of any change in the location, of any such office or agency (other than a change in the location of the office of the Trustee). If at any time the Company shall fail to maintain any such required office or agency or shall fail
to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the address of the Trustee set forth in Section 13.02. 

The Company may also from time to time designate one or more other offices or agencies where the Notes may be presented or surrendered
for any or all such purposes and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency.

 Section 4.03 SEC and Other Reports. 
 (a) Whether or not required by the rules and regulations of the SEC, so long as any Notes are outstanding, the Company will furnish to the Trustee and the Holders of Notes, within the time periods
specified in the SEC’s rules and regulations: 
 (1) all quarterly and annual reports that would be required
to be filed with the SEC on Forms 10-Q and 10-K if the Company were required to file such reports, including a “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and, with respect to the
annual information only, a report thereon by the Company’s certified independent accountants; and 

  
 -44-

 (2) all current reports that would be required to be filed with the SEC on
Form 8-K if the Company were required to file such reports. 
 (b) All such reports will be prepared in all material
respects in accordance with all of the rules and regulations applicable to such reports. In addition, for so long as the Company is subject to the periodic reporting requirements of the Exchange Act, the Company will file a copy of each of the
reports referred to in clauses (1) and (2) of Section 4.03(a) with the SEC for public availability within the time periods specified in the rules and regulations applicable to such reports. At such time as the Company is no longer
subject to the periodic reporting requirements of the Exchange Act for any reason, the Company shall make available the reports referred to in clauses (1) and (2) of Section 4.03(a) to any Holder or beneficial owner of Notes and any
record holder or beneficial owner of Warrants by posting such information on a reputable password protected online data system, such as Intralinks or DataSite, which shall require a confidentiality acknowledgement, and shall make such information
readily available to any prospective investor or any securities analyst who (a) agrees to treat such information as confidential or (b) accesses such information on such password protected online data system, which shall require a
confidentiality acknowledgment, provided that if such information is to be provided by means of a password protected online data system, then the Company shall post such information thereon and make readily available any password or other
login information to any such prospective investor or securities analyst. The Company will at all times comply with TIA §314(a). 
 (c) For so long as any Notes or Warrants remain outstanding, if at any time the Company is not required to file with the SEC the reports referred to in clauses (1) and (2) of
Section 4.03(a), the Company will furnish to the Holders and beneficial owners of Notes and the record holders and beneficial owners of Warrants and to securities analysts and prospective investors, upon their request, the information required
to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 
 (d) The Company will be deemed to have furnished
any reports referred to in clauses (1) and (2) of Section 4.03(a) to the Trustee and the Holders of Notes and Warrants if (i) the Company has filed such reports with the SEC using the Electronic Data Gathering Analysis and
Retrieval filing system and such reports are publicly available, or (ii) at such time as the Company is no longer subject to the periodic reporting requirements of the Exchange Act for any reason, the Company has made such reports available as
provided in the penultimate sentence of Section 4.03(b). 
 (e) Delivery of all reports, information and documents referred
to in clauses (1) and (2) of Section 4.03(a) to the Trustee is for informational purposes only, and the Trustee’s receipt of such reports, information or documents shall not constitute constructive notice of any information
contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants under this Indenture (as to which the Trustee is entitled to rely exclusively on Officers’ Certificates).

 Section 4.04 Compliance Certificates. The Company and each Guarantor (to the extent that such Guarantor is
required under the TIA) shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company (beginning with the fiscal year ending September 25, 2012), an Officers’ Certificate as to the signer’s knowledge
of the Company’s compliance with 

  
 -45-

 
all conditions and covenants on its part contained in this Indenture and stating whether or not the signer knows of any Default or Event of Default. If such signer knows of such a Default or
Event of Default, the Officers’ Certificate shall describe the Default or Event of Default and the efforts to remedy the same. For the purposes of this Section 4.04, compliance shall be determined without regard to any grace period or
requirement of notice provided pursuant to the terms of this Indenture. 
 Section 4.05 Taxes. The Company will pay,
and will cause each of its Subsidiaries to pay, prior to delinquency, all material taxes, assessments, and governmental levies except such as are contested in good faith and by appropriate proceedings or where the failure to effect such payment is
not adverse in any material respect to the Company and its Restricted Subsidiaries, taken as a whole, or the Holders of the Notes. 
 Section 4.06 Stay, Extension and Usury Laws. The Company and each of the Guarantors covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in
any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company or a Guarantor from paying all or any portion of the principal of or accrued but unpaid
interest, if any, on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture, and the Company and each of the Guarantors (to the extent it may
lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit
the execution of every such power as though no such law had been enacted. 
 Section 4.07 Restricted Payments. 

 (a) The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly: 

(1) declare or pay any dividend or make any other payment or distribution on account of the Company’s or any of its
Restricted Subsidiaries’ Equity Interests (including, without limitation, any payment in connection with any merger or consolidation involving the Company or any of its Restricted Subsidiaries) or to the direct or indirect holders of the
Company’s or any of its Restricted Subsidiaries’ Equity Interests in their capacity as such (other than dividends or distributions payable in Equity Interests (other than Disqualified Stock) of the Company and other than dividends or
distributions payable to the Company or a Restricted Subsidiary of the Company); 
 (2) purchase, redeem or
otherwise acquire or retire for value (including, without limitation, in connection with any merger or consolidation involving the Company) any Equity Interests of the Company or any direct or indirect parent of the Company; 

(3) make any payment on or with respect to, or purchase, redeem, defease or otherwise acquire or retire for value any
Subordinated Obligation or Guarantor Subordinated Obligation, except (x) a payment of interest or principal at the Stated 

  
 -46-

 
Maturity thereof, (y) intercompany Indebtedness between or among the Company and any Restricted Subsidiary or between or among Restricted Subsidiaries, or (z) the payment, purchase,
redemption, defeasance or other acquisition or retirement of any Subordinated Obligations or Guarantor Subordinated Obligations in anticipation of satisfying a sinking fund obligation, principal installment or payment at final maturity, in each case
due within one year of the date of such payment, purchase, repurchase, redemption, defeasance or other acquisition or retirement; 
 (4) make any payment on or with respect to, or purchase, redeem, defease or otherwise acquire or retire for value, any of the Outstanding 8.50% Notes, except (x) any payment of interest or principal
at the Stated Maturity thereof, or (y) the payment, purchase, redemption, defeasance or other acquisition or retirement of any Outstanding 8.50% Notes in anticipation of satisfying a payment at final maturity due within one year of the date of
such payment, purchase, redemption, defeasance or other acquisition or retirement; or 
 (5) make any Restricted
Investment, 
 (all such payments and other actions set forth in these clauses (1) through (5) above being collectively referred to as
“Restricted Payments”), unless, at the time of and after giving effect to such Restricted Payment: 

(x) no Default or Event of Default has occurred and is continuing or would occur as a consequence of such Restricted
Payment; and 
 (y) such Restricted Payment, together with the aggregate amount of all other Restricted Payments
made by the Company and its Restricted Subsidiaries since the date of this Indenture (excluding Restricted Payments permitted by clauses (2), (3), (4), (5), (6), (7), (8), (9), (10), (11) and (12) of paragraph (b) of this
Section 4.07), is less than the sum, without duplication, of: 
 (A) 50% of the Consolidated Net Income of
the Company for the period (taken as one accounting period) from the first full fiscal quarter following the date hereof to the end of the Company’s most recently ended fiscal quarter for which internal financial statements are available at the
time of such Restricted Payment (or, if such Consolidated Net Income for such period is a deficit, less 100% of such deficit); plus 
 (B) 100% of the aggregate net cash proceeds received by the Company since the date of this Indenture (i) as a contribution to its common equity capital or from the issue or sale of its Equity
Interests (other than Disqualified Stock and other than net cash proceeds received from an issuance or sale of such Equity Interests (x) to a Subsidiary of the Company or (y) to or under an employee stock ownership plan, option plan or
similar trust (to the extent such sale to an employee stock ownership plan, option plan or similar trust is financed by loans from or guaranteed by the Company or any Restricted Subsidiary except to the

  
 -47-

 
extent such loans have been repaid with cash on or prior to the date of determination)) or (ii) from the issue or sale of convertible or exchangeable Disqualified Stock of the Company or
convertible or exchangeable debt securities of the Company, in each case that have been converted into or exchanged for Equity Interests of the Company (other than convertible or exchangeable Disqualified Stock or debt securities sold to a
Subsidiary of the Company); plus  
 (C) to the extent not already included in Consolidated Net Income
for such period, (i) if any Restricted Investment that was made by the Company or any Restricted Subsidiary after the date of this Indenture is sold for cash (other than to any Subsidiary of the Company) or otherwise cancelled, liquidated or
repaid for cash, the cash return of capital with respect to such Restricted Investment resulting from such sale, liquidation or repayment (less any out-of-pocket costs incurred in connection with any such sale) and (ii) the amount returned in
cash to the Company or any of its Restricted Subsidiaries from such Restricted Investment resulting from payments of interest, dividends, principal repayments and other transfers, in an amount not to exceed the aggregate amount of such Restricted
Investment; plus  
 (D) in case any Unrestricted Subsidiary has been redesignated a Restricted
Subsidiary pursuant to the terms of this Indenture or has been merged or consolidated with or into, or transfers or otherwise disposes of all or substantially all of its properties or assets to or is liquidated into, the Company or a Restricted
Subsidiary, the lesser of, at the date of such redesignation, merger, consolidation, transfer, disposition or liquidation (i) the book value (determined in accordance with GAAP) of the aggregate Investments made by the Company and its
Restricted Subsidiaries in such Unrestricted Subsidiary (or of the properties or assets disposed of, as applicable) and (ii) the Fair Market Value of such Investment in such Unrestricted Subsidiary, in each case after deducting any Indebtedness
of such Unrestricted Subsidiary. 
 (b) The provisions of Section 4.07(a) hereof will not prohibit: 

(1) the making of any Restricted Payment (including a dividend) within 60 days after the date the Company or
Restricted Subsidiary became legally or contractually obligated to make such Restricted Payment (including the declaration of a dividend), if at the date of becoming so legally or contractually bound, such Restricted Payment would have complied with
the provisions of this Indenture (and such Restricted Payment shall be deemed to be made on the date of becoming so legally or contractually bound for purposes of any calculation required by this Section 4.07); 

(2) the making of any Restricted Payment in exchange for, or out of or with the net cash proceeds of the substantially
concurrent sale (other than to a Subsidiary of the Company) of, Equity Interests of the Company (other than Disqualified Stock and 

  
 -48-

 
other Equity Interests issued or sold to a Subsidiary of the Company or an employee stock ownership plan, option plan or similar trust to the extent such sale to an employee stock ownership plan,
option plan or similar trust is financed by loans from or guaranteed by the Company or any Restricted Subsidiary except to the extent such loans have been repaid with cash on or prior to the date of determination) or from the substantially
concurrent contribution of common equity capital to the Company, provided that the amount of any such net cash proceeds that are utilized for any such Restricted Payment will not be considered to be net proceeds of Equity Interests for
purposes of Section 4.07(a)(y)(B) hereof and may not be used for purposes of clause (6) below; 
 (3)
the payment of any dividend or distribution by a Restricted Subsidiary of the Company to the holders of its Equity Interests (other than Disqualified Stock) on a pro rata basis; 

(4) the repurchase, redemption, defeasance or other acquisition or retirement for value of Subordinated Obligations of the
Company or Guarantor Subordinated Obligations of any Guarantor with the net cash proceeds from a substantially concurrent incurrence of Permitted Refinancing Indebtedness; 

(5) the repurchase, redemption, defeasance or other acquisition for value of Outstanding 8.50% Notes with the net cash
proceeds from a substantially concurrent incurrence of Permitted Refinancing Indebtedness; 
 (6) so long as no
Default or Event of Default has occurred and is continuing, the repurchase, redemption or other acquisition or retirement for value of any Equity Interests of the Company or any Restricted Subsidiary of the Company held by any current or former
officer, director or employee of the Company or any of its Subsidiaries pursuant to any equity subscription agreement, stock option agreement, shareholders’ agreement or similar agreement, provided that the aggregate price paid for all
such repurchased, redeemed, acquired or retired Equity Interests may not exceed $1.0 million in any calendar year (with any unused amounts in any calendar year being carried over to succeeding calendar years), provided further
that such amount in any calendar year may be increased by an amount not to exceed: 
 (A) the cash proceeds
received by the Company from the sale of Equity Interests (other than Disqualified Stock) of the Company or any direct or indirect parent company of the Company to employees, members of management or directors of the Company or any direct or
indirect parent company of the Company or any Restricted Subsidiary of the Company that occurs after the date of this Indenture (to the extent the cash proceeds from the sale of such Equity Interests have not otherwise been applied to the payment of
Restricted Payments by virtue of Section 4.07(a)(y)(B) hereof or been used for purposes of clause (2) above); plus  
 (B) the cash proceeds of key man life insurance policies received by the Company or any Restricted Subsidiary of the Company after the date of this Indenture; less 

  
 -49-

 (C) the amount of any Restricted Payments made after the date of this
Indenture pursuant to clauses (A) and (B) of this Section 4.07(b)(6); 
 (7) purchases,
repurchases, redemptions or other acquisitions for value of Equity Interests deemed to occur upon the exercise of stock options, warrants or rights to acquire Equity Interests to the extent such Equity Interests represent a portion of the exercise
or exchange price thereof, and any purchases, repurchases, redemptions or other acquisitions for value of Equity Interests made in lieu of withholding taxes in connection with any exercise or exchange of warrants, options or rights to acquire Equity
Interests; 
 (8) payments of cash, dividends, distributions, advances or other Restricted Payments by the
Company or any of its Restricted Subsidiaries to allow the payment of cash in lieu of the issuance of fractional shares upon (i) the exercise of options or warrants, (ii) in connection with stock dividends, splits or combinations or
(iii) the conversion or exchange of Equity Interests or convertible indebtedness of any such Person; 
 (9)
the purchase, redemption or other acquisition of any Outstanding 3.25% Notes and any Outstanding 8.50% Notes pursuant to the Tender/Exchange Offers; 
 (10) the purchase, redemption or other acquisition of any Outstanding 3.25% Notes or any Outstanding 8.50% Notes pursuant to the indenture governing such notes upon the exercise by the holders of such
notes of any right of such holders under the indenture governing such notes to require the Company to purchase, redeem or otherwise acquire such notes; 
 (11) any purchase, redemption or other acquisition of any Outstanding 3.25% Notes after the consummation of the Tender/Exchange Offers at a price not to exceed 80% of the principal amount thereof (which
percentage shall be increased, for each day that has elapsed during the period from the consummation of the Tender/Exchange Offers to the first Put Right Purchase Date (as defined in the indenture governing the Outstanding 3.25% Notes), by a number
of basis points determined by dividing 2000 basis points by the total number of days in such period), plus accrued and unpaid interest thereon; and 
 (12) so long as no Default or Event of Default has occurred and is continuing at the time such Restricted Payment is made, other Restricted Payments in an aggregate amount not to exceed $5.0 million
since the date of this Indenture. 
 Except as otherwise provided in Section 4.16, in determining whether any Restricted
Payment is permitted by this Section 4.07, the Company may allocate or re-allocate all or any portion of such Restricted Payment among clauses (1) through (12) of Section 4.07(b), provided that at the time of such
allocation or re-allocation all such Restricted Payments or allocated portions thereof, and all prior Restricted Payments, would be permitted under the various provisions of this Section 4.07. The amount of all Restricted Payments (other than
cash) will be the Fair Market Value on the date of the Restricted Payment of the asset(s) or securities proposed to be transferred or issued by the Company or such Restricted Subsidiary, as the case may be, pursuant to the Restricted Payment.

  
 -50-

 Section 4.08 Dividend and Other Payment Restrictions Affecting Subsidiaries.

 (a) The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly, create or permit
to exist or become effective any consensual encumbrance or restriction on the ability of any Restricted Subsidiary to: 
 (1) pay dividends or make any other distributions on its Capital Stock to the Company or any of its Restricted Subsidiaries or pay any Indebtedness owed to the Company or any of its Restricted
Subsidiaries; 
 (2) make loans or advances to the Company or any of its Restricted Subsidiaries; or 

(3) sell, lease or transfer any of its properties or assets to the Company or any of its Restricted Subsidiaries.

 (b) The restrictions in Section 4.08(a) hereof will not apply to encumbrances or restrictions existing under or by
reason of: 
 (1) agreements governing Existing Indebtedness and Credit Facilities as in effect on the date of
this Indenture and any amendments, restatements, modifications, renewals, supplements, refundings, replacements or refinancings of those agreements, provided that (i) the amendments, restatements, modifications, renewals, supplements,
refundings, replacements or refinancings are not materially more restrictive, taken as a whole, with respect to such encumbrances and restrictions than those contained in those agreements on the date of this Indenture or (ii) the encumbrances
and restrictions in the amendments, restatements, modifications, renewals, supplements, refundings, replacements or refinancings will not materially adversely affect the Company’s ability to pay the principal of and interest on the Notes as and
when due; 
 (2) the Note Documents; 

(3) agreements governing other Indebtedness (other than intercompany Indebtedness between or among the Company and any of
its Restricted Subsidiaries) permitted to be incurred under Section 4.09 hereof and any amendments, restatements, modifications, renewals, supplements, refundings, replacements or refinancings of those agreements, provided that the
encumbrances and restrictions therein will not materially adversely affect the Company’s ability to pay the principal of and interest on the Notes as and when due; 

(4) applicable law, rule, regulation or order; 

(5) any instrument governing Indebtedness or Capital Stock of a Person acquired by the Company or any of its Restricted
Subsidiaries as in effect at the time of such acquisition (except to the extent such Indebtedness or Capital Stock was incurred in 

  
 -51-

 
connection with or in contemplation of such acquisition), which encumbrance or restriction is not applicable to any Person, or the properties or assets of any Person, other than the Person, or
the property or assets of the Person, so acquired, provided that, in the case of Indebtedness, such Indebtedness was permitted by the terms of this Indenture to be incurred; 

(6) customary non-assignment provisions in contracts; 

(7) in the case of clause (3) of Section 4.08(a) hereof, any encumbrance or restriction: 

(A) that restricts in a customary manner the subletting, assignment or transfer of any property or asset that is subject
to a lease, license or similar contract, or the assignment or transfer of any such lease, license or other contract; 
 (B) contained in any agreement creating Hedging Obligations permitted from time to time under this Indenture; or 
 (C) pursuant to customary provisions restricting dispositions of real property interests set forth in any reciprocal easement agreements of the Company or any Restricted Subsidiary; 

(8) any agreement for the sale or other disposition of a Restricted Subsidiary that imposes encumbrances or restrictions
of the nature described in clauses (1) through (3) of Section 4.08(a) hereof on that Restricted Subsidiary pending its sale or other disposition; 
 (9) Permitted Refinancing Indebtedness, provided that the encumbrances and restrictions contained in the agreements governing such Permitted Refinancing Indebtedness (i) are not materially
more restrictive, taken as a whole, than those contained in the agreements governing the Indebtedness being refinanced or (ii) will not materially adversely affect the Company’s ability to pay the principal of and interest in the Notes as
and when due; 
 (10) Liens permitted to be incurred under Section 4.12 hereof that limit the right of the
debtor to dispose of the assets subject to such Liens; 
 (11) provisions limiting the disposition or
distribution of assets or property in joint venture agreements, asset sale agreements, sale-leaseback agreements, stock sale agreements and other similar agreements (including agreements entered into in connection with a Restricted Investment)
entered into with the approval of the Board of Directors, which limitation is applicable only to the assets that are the subject of such agreements; and 
 (12) restrictions on cash or other deposits or net worth imposed by customers under contracts entered into in the ordinary course of business. 

  
 -52-

 Section 4.09 Incurrence of Indebtedness and Issuance of Disqualified Stock and
Preferred Stock. 
 (a) The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or
indirectly, create, incur, issue, assume, guarantee or otherwise become directly or indirectly liable, contingently or otherwise (collectively, “incur”), with respect to any Indebtedness (including Acquired Debt) or issue any Disqualified
Stock, and the Company will not permit any of its Restricted Subsidiaries to issue any shares of preferred stock; provided, however, that the Company and the Guarantors may incur (1) Secured Debt (including Acquired Debt) if the
Secured Leverage Ratio for the Company’s most recently ended four full fiscal quarters for which internal financial statements are available immediately preceding the date on which such additional Secured Debt is incurred would have been less
than 2.5 to 1.0, determined on a pro forma basis (including a pro forma application of the net proceeds therefrom), as if the additional Secured Debt had been incurred at the beginning of such four-quarter period and (2) unsecured Indebtedness,
provided that such unsecured Indebtedness has a final maturity date not earlier than 180 days after the Final Maturity Date and the terms, covenants and rates (including interest rates and fees) of such unsecured Indebtedness are commercially
reasonable at the time of incurrence thereof. 
 (b) The provisions of Section 4.09(a) hereof will not prohibit the
incurrence of any of the following items of Indebtedness (collectively, “Permitted Debt”): 
 (1)
Indebtedness of the Company or any Guarantor incurred pursuant to one or more Credit Facilities (including the Credit Agreement) in an aggregate principal amount outstanding at any given time not to exceed $35 million (less (x) the amount
of any permanent repayments of such Indebtedness pursuant to clause (1) of the second paragraph of Section 4.10 hereof, and (y) the aggregate amount outstanding at any given time of any Hedging Obligations and Banking Services
Obligations that constitute Priority Lien Obligations); 
 (2) the incurrence by the Company and its Restricted
Subsidiaries of the Existing Indebtedness; 
 (3) the incurrence by the Company and the Guarantors of
Indebtedness represented by the Notes and the Note Guaranties; 
 (4) the incurrence by the Company or any of its
Restricted Subsidiaries of Indebtedness represented by Capital Lease Obligations, mortgage financings or purchase money obligations, in each case, incurred for the purpose of financing all or any part of the purchase price, construction,
installation or improvement of property, plant or equipment used in the business of the Company or any of its Restricted Subsidiaries, in an aggregate principal amount, including all Permitted Refinancing Indebtedness incurred to renew, refund,
refinance, replace, defease or discharge any Indebtedness incurred pursuant to this clause (4), not to exceed at any time outstanding the maximum amount permitted by the Credit Agreement as in effect on January 12, 2012, provided
that the principal amount of any Indebtedness permitted under this clause (4) did not in each case at the time of incurrence exceed the Fair Market Value (as determined in good faith by 

  
 -53-

 
the Board of Directors or, if the principal amount of such Indebtedness is $5.0 million or less, the Chief Financial Officer of the Company) of the acquired, installed or constructed asset
or improvement so financed; 
 (5) the incurrence by the Company or any of its Restricted Subsidiaries of
Permitted Refinancing Indebtedness in exchange for, or the net proceeds of which are used to renew, refund, refinance, replace, defease or discharge any Indebtedness (other than intercompany Indebtedness) that was permitted by this Indenture to be
incurred under Section 4.09(a) hereof or clauses (2), (3), (4) or (5) of this Section 4.09(b); 
 (6) the incurrence by the Company or any of its Restricted Subsidiaries of intercompany Indebtedness between or among the Company and any of its Restricted Subsidiaries; provided, however,
that (i) if the Company or any Guarantor is the obligor on such Indebtedness and the payee is not the Company or a Guarantor, such Indebtedness must be unsecured and expressly subordinated to the prior payment in full in cash of all Obligations
then due with respect to the Notes, in the case of the Company, or the Note Guaranty, in the case of a Guarantor, and (ii) if the payee of such Indebtedness is the Company or any Guarantor, such Indebtedness shall become part of the Collateral;

 (7) the incurrence by the Company or any of its Restricted Subsidiaries of Hedging Obligations in the ordinary
course of business and not for speculative purposes; 
 (8) the guarantee by the Company or any of the Guarantors
of Indebtedness of the Company or a Restricted Subsidiary of the Company to the extent that the guaranteed Indebtedness was permitted to be incurred by another provision of this Section 4.09, provided that if the Indebtedness being
guaranteed is subordinated to the Notes or any Note Guaranty, then the guarantee must be subordinated to the same extent as the Indebtedness guaranteed; 
 (9) the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness in respect of (i) unsecured service fees payable to any Subsidiary of the Company in the ordinary course of
business, (ii) self-insurance obligations or bid, appeal, reimbursement, performance, surety and similar bonds and completion guarantees provided by the Company or a Restricted Subsidiary in the ordinary course of business and any Guaranties or
letters of credit functioning as or supporting any of the foregoing bonds or obligations and (iii) workers’ compensation claims in the ordinary course of business; 

(10) the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness arising from the honoring by a
bank or other financial institution of a check, draft or similar instrument inadvertently drawn against insufficient funds, so long as such Indebtedness is covered within five Business Days; 

(11) the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness arising from agreements of the
Company or any of its Restricted Subsidiaries providing for indemnification, or other purchase price adjustments or similar 

  
 -54-

 
obligations, in each case, incurred or assumed in connection with the disposition of any business or assets of the Company or any Restricted Subsidiary of the Company or of any Capital Stock of a
Subsidiary of the Company, provided that the maximum aggregate liability in respect of all such Indebtedness shall at no time exceed the gross proceeds actually received by the Company and its Restricted Subsidiaries in connection with such
disposition; 
 (12) Indebtedness of the Company or any Restricted Subsidiary with respect to the financing of
insurance premiums; and 
 (13) Indebtedness to the extent the net proceeds thereof are promptly deposited to
defease the Notes or to satisfy and discharge this Indenture. 
 The Company will not incur, and will not permit any Guarantor
to incur, any Indebtedness (including Permitted Debt) that is contractually subordinated in right of payment to any other Indebtedness of the Company or such Guarantor unless such Indebtedness is also contractually subordinated in right of payment
to the Notes or the applicable Note Guaranty, as the case may be, on substantially identical terms; provided, however, that no Indebtedness will be deemed to be contractually subordinated in right of payment to any other Indebtedness
of the Company or any Guarantor solely by virtue of being unsecured or by virtue of being secured on a junior priority basis. 

For purposes of determining compliance with this Section 4.09, in the event that an item of Indebtedness meets the criteria of more
than one of the categories of Permitted Debt described in clauses (2) through (13) above, or is entitled to be incurred pursuant to Section 4.09(a) hereof, the Company will be permitted to classify such item of Indebtedness on the
date of its incurrence, or later reclassify all or a portion of such item of Indebtedness, in any manner that complies with such clauses or paragraph of this Section 4.09. The accrual of interest or preferred stock dividends, the accretion or
amortization of original issue discount, and the payment of interest on any Indebtedness in the form of additional Indebtedness with the same terms, the reclassification of preferred stock as Indebtedness due to a change in accounting principles and
the payment of dividends on preferred stock or Disqualified Stock in the form of additional shares of the same class of preferred or Disqualified Stock will not be deemed to be an incurrence of Indebtedness or an issuance of preferred or
Disqualified Stock for purposes of this Section 4.09. For purposes of determining compliance with any U.S. dollar-denominated restriction on the incurrence of Indebtedness, the U.S. dollar-equivalent principal amount of Indebtedness denominated
in a foreign currency shall be utilized, calculated based on the relevant currency exchange rate in effect on the date such Indebtedness was incurred. Notwithstanding any other provision of this Section 4.09, the maximum amount of Indebtedness
that the Company or any Restricted Subsidiary may incur pursuant to this Section 4.09 shall not be deemed to be exceeded solely as a result of fluctuations in exchange rates or currency values. 

The amount of any Indebtedness outstanding as of any date will be: 

(1) the accreted value of the Indebtedness, in the case of any Indebtedness issued with original issue discount;

  
 -55-

 (2) in respect of Hedging Obligations, the net obligations of the specified
Person under the applicable Hedge Agreement that would be due and payable as of such date if such Hedge Agreement were terminated (as customarily determined); 
 (3) in respect of contingent obligations, the maximum liability upon the occurrence of the contingency giving rise to the obligations; 

(4) in respect of Indebtedness of another Person secured by a Lien on the assets of the specified Person, the lesser of:

 (A) the Fair Market Value of such assets at the date of determination; and 

(B) the principal amount of the Indebtedness of the other Person; and 

(5) the principal amount of the Indebtedness, in the case of any other Indebtedness. 

Section 4.10 Asset Sales. The Company will not, and will not permit any of its Restricted Subsidiaries to, consummate an
Asset Sale unless: 
 (1) the Company (or the Restricted Subsidiary, as the case may be) receives consideration
at the time of the Asset Sale at least equal to the Fair Market Value (measured as of the date of the definitive agreement with respect to such Asset Sale) of the assets or Equity Interests issued or sold or otherwise disposed of; and 

(2) at least 75% of the consideration received in the Asset Sale by the Company or such Restricted Subsidiary is in the
form of cash or Cash Equivalents. For purposes of this clause (2), each of the following will be deemed to be cash: 
 (A) any liabilities, as shown on the Company’s most recent consolidated balance sheet, of the Company or any Restricted Subsidiary (other than contingent liabilities and liabilities that are by their
terms subordinated to the Notes or any Note Guaranty) that are assumed by the transferee of any such assets pursuant to a customary novation or indemnity agreement that releases the Company or such Restricted Subsidiary from or indemnifies the
Company or such Restricted Subsidiary against further liability; and 
 (B) any securities, notes or other
obligations received by the Company or any such Restricted Subsidiary from such transferee that are contemporaneously, subject to ordinary settlement periods, converted by the Company or such Restricted Subsidiary into cash, to the extent of the
cash received in that conversion. 

  
 -56-

 Within 360 days after the receipt of any Net Proceeds from an Asset Sale, the Company
(or the applicable Restricted Subsidiary, as the case may be) may apply such Net Proceeds: 
 (1) to permanently
repay Priority Lien Debt and other outstanding Priority Lien Obligations, provided that, if such Priority Lien Debt is revolving credit Indebtedness, there is a corresponding permanent reduction in the commitments with respect thereto;

 (2) to purchase, redeem or otherwise acquire any Outstanding 3.25% Notes, provided that such purchase,
redemption or other acquisition is permitted under Section 4.07 hereof; 
 (3) to make capital expenditures
for the benefit of the business of the Company or any Restricted Subsidiary of the Company; or 
 (4) to acquire
other assets that are not classified as current assets under GAAP and that are used or useful in the business of the Company or any Restricted Subsidiary of the Company. 
 Notwithstanding the foregoing, the Net Proceeds of any Asset Sale by the Company or any Guarantor may be used to make capital expenditures or purchase assets for the benefit of a Restricted Subsidiary of
the Company that is not a Guarantor in satisfaction of the foregoing clause (3) or (4) only if the Investment of such Net Proceeds by the Company or such Guarantor in such Restricted Subsidiary would be permitted under clause (y) of
Section 4.07(a) hereof, clause (12) of Section 4.07(b) hereof, or clause (15) or (16) of the definition of Permitted Investments. 
 Pending the final application of any Net Proceeds, the Company (or the applicable Restricted Subsidiary) may temporarily reduce revolving credit borrowings or otherwise invest the Net Proceeds in any
manner that is not prohibited by this Indenture. 
 Any Net Proceeds from Asset Sales that are not applied or invested as
provided in the second paragraph of this Section 4.10 will constitute “Excess Proceeds.” When the aggregate amount of Excess Proceeds exceeds $10.0 million, within five days thereafter, the Company will make an Asset Sale Offer
to all Holders of Notes and all holders of other Indebtedness that is pari passu with the Notes and contains provisions similar to those set forth in this Indenture with respect to offers to purchase, prepay or redeem with the proceeds of sales of
assets, in accordance with Section 3.08 hereof, to purchase, prepay or redeem the maximum principal amount of Notes and such other pari passu Indebtedness that may be purchased, prepaid or redeemed out of the Excess Proceeds after deducting
from such Excess Proceeds all accrued and unpaid interest on the Notes and such other pari passu Indebtedness and the amount of all fees and expenses, including premiums, incurred in connection with such purchase, prepayment or redemption (the
“Offer Amount”). The offer price in any Asset Sale Offer will be equal to 100% of the aggregate principal amount purchased, prepaid or redeemed, plus accrued and unpaid interest on such principal amount to the Purchase Date, subject to the
rights of Holders of Notes on the relevant Regular Record Date to receive interest due on the relevant Interest Payment Date as and to the extent provided in Section 3.08 hereof, and will be payable in cash. If any

  
 -57-

 
Excess Proceeds remain after consummation of an Asset Sale Offer, the Company may use those Excess Proceeds for any purpose not otherwise prohibited by this Indenture. If the aggregate principal
amount of Notes and other pari passu Indebtedness tendered in or required to be prepaid or redeemed in connection with such Asset Sale Offer exceeds the Offer Amount, the Notes and other pari passu Indebtedness will be purchased, prepaid or redeemed
on a pro rata basis, based on the amounts tendered or required to be prepaid or redeemed (with such adjustments as may be deemed appropriate by the Company so that only Notes in denominations of $2,000, or an integral multiple of $1,000 in
excess thereof, will be purchased). Upon completion of each Asset Sale Offer, the amount of Excess Proceeds will be reset at zero. 
 The Company will comply with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in
connection with each repurchase of Notes pursuant to an Asset Sale Offer. To the extent that the provisions of any securities laws or regulations conflict with the provisions of Section 3.08 hereof or this Section 4.10, the Company will
comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under Section 3.08 hereof or this Section 4.10 by virtue of such compliance. 

Section 4.11 Transactions with Affiliates. 
 (a) The Company will not, and will not permit any of its Restricted Subsidiaries to, make any payment to or sell, lease, transfer or otherwise dispose of any of its properties or assets to, or purchase
any property or assets from, or enter into or make or amend any transaction, contract, agreement, understanding, loan, advance or guarantee with, or for the benefit of, any Affiliate of the Company (each, an “Affiliate Transaction”),
unless: 
 (1) the Affiliate Transaction is on terms that are no less favorable to the Company or the relevant
Restricted Subsidiary than those that would have been obtained by the Company or such Restricted Subsidiary in a comparable transaction on an arm’s-length basis with a Person that is not an Affiliate of the Company; and 

(2) the Company delivers to the Trustee: 

(A) with respect to any Affiliate Transaction or series of related Affiliate Transactions involving aggregate
consideration in excess of $5.0 million, a resolution of the Board of Directors of the Company set forth in an Officers’ Certificate certifying that such Affiliate Transaction complies with clause (1) of this Section 4.11(a) and
that such Affiliate Transaction has been approved by a majority of the disinterested members of the Board of Directors of the Company; and 
 (B) with respect to any Affiliate Transaction or series of related Affiliate Transactions involving aggregate consideration in excess of $20.0 million, an opinion as to the fairness to the Company or
such Restricted Subsidiary of such Affiliate Transaction from a financial point of view issued by an accounting, appraisal or investment banking firm of national standing. 

  
 -58-

 (b) The following items will not be deemed to be Affiliate Transactions and, therefore, will
not be subject to the provisions of Section 4.11(a) hereof: 
 (1) any employment agreement, change in
control or severance agreement, employee benefit plan, officer or director indemnification agreement or any similar arrangement entered into by the Company or any of its Restricted Subsidiaries in the ordinary course of business and payments
pursuant thereto; 
 (2) transactions between (a) the Company or any Restricted Subsidiary of the Company
that is a Guarantor or a Pledged Restricted Subsidiary and any other Restricted Subsidiary of the Company that is a Guarantor or a Pledged Restricted Subsidiary, or (b) any Restricted Subsidiary of the Company that is not a Guarantor or a
Pledged Restricted Subsidiary and any other Restricted Subsidiary of the Company that is not a Guarantor or a Pledged Restricted Subsidiary; 
 (3) the provision of customer support services by any Restricted Subsidiary of the Company that is not a Guarantor or a Pledged Restricted Subsidiary to the Company or any Restricted Subsidiary of the
Company that is a Guarantor or a Pledged Restricted Subsidiary, and the payment for such services (provided that all such payments by the Company or any Restricted Subsidiary of the Company that is a Guarantor or a Pledged Restricted
Subsidiary to any Restricted Subsidiary of the Company that is not a Guarantor or a Pledged Restricted Subsidiary may not exceed $4.0 million in the aggregate during any single fiscal year of the Company), in the ordinary course of business
consistent with past practice; 
 (4) transactions with a Person (other than an Unrestricted Subsidiary of the
Company) that is an Affiliate of the Company solely because such Person is a Joint Venture; 
 (5) payment of
reasonable and customary fees of directors of the Company or any of its Restricted Subsidiaries; 
 (6) any
issuance of Equity Interests (other than Disqualified Stock) of the Company to Affiliates of the Company; 
 (7)
Restricted Payments (or any transactions, other than Permitted Investments, that would be Restricted Payments but for an exclusion from the definition thereof) that do not violate Section 4.07 hereof; 

(8) loans or advances to directors, officers and employees in the ordinary course of business; 

(9) reimbursements of directors, officers and employees for moving, entertainment and travel expenses, drawing accounts
and other business expenditures, in each case in the ordinary course of business of the Company or any of its Restricted Subsidiaries; 

  
 -59-

 (10) indemnities of officers, directors and employees of the Company or any
Restricted Subsidiary of the Company consistent with applicable charter, by-law or statutory provisions; 
 (11)
transactions with customers, clients, suppliers, or purchasers or sellers of goods or services, in each case in the ordinary course of business and otherwise in compliance with the terms of this Indenture, provided that such transactions are
on terms not materially less favorable to the Company or the relevant Restricted Subsidiary than those that could reasonably be expected to be obtained in a comparable transaction at such time on an arm’s-length basis from a Person that is not
an Affiliate of the Company; and 
 (12) transactions between the Company or any Restricted Subsidiary of the
Company and any Person, a director of which is also a director of the Company or any direct or indirect parent company of the Company, and such director is the sole cause for such Person to be deemed an Affiliate of the Company or any Restricted
Subsidiary of the Company; provided, however, that such director shall abstain from voting as a director of the Company or such direct or indirect parent company, as the case may be, on any matter involving such other Person.

 Section 4.12 Liens. The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or
indirectly, create, incur, assume or suffer to exist any Lien of any kind upon any of its property or assets, including any income or profits therefrom, whether owned on the date of this Indenture or acquired after that date, securing any
Indebtedness, except Permitted Liens. 
 Section 4.13 Business Activities. The Company will not, and will not permit
any of its Restricted Subsidiaries to, engage in any business other than Permitted Businesses, except to such extent as would not be material to the Company and its Restricted Subsidiaries taken as a whole. 

Section 4.14 Maintenance of Corporate Existence. Subject to Article V, the Company will do or cause to be done all
things necessary to preserve and keep in full force and effect (i) its corporate existence, and the corporate, partnership or other existence of each of its Restricted Subsidiaries, in accordance with the respective organizational documents (as
the same may be amended from time to time) of the Company or such Restricted Subsidiary, and (ii) the material rights (charter and statutory), licenses and franchises of the Company and its Restricted Subsidiaries; provided,
however, that neither the Company nor any Restricted Subsidiary of the Company shall be required to maintain or preserve any such rights, licenses or franchises or, in the case of any such Restricted Subsidiary, its existence, if the Board of
Directors shall determine that the maintenance or preservation thereof is no longer desirable in the conduct of the business of the Company and its Restricted Subsidiaries, taken as a whole, and that the loss thereof would not be adverse in any
material respect to the Holders of the Notes. 

  
 -60-

 Section 4.15 Offer to Repurchase Upon Change of Control. 

(a) Upon the occurrence of a Change of Control, the Company will make an offer (a “Change of Control Offer”) to
each Holder to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s Notes at a purchase price in cash equal to 101% of the aggregate principal amount of Notes repurchased, plus
accrued and unpaid interest, if any, on such principal amount to the date of purchase, subject to the rights of Holders of Notes on the relevant Regular Record Date to receive interest due on the relevant Interest Payment Date as and to the extent
provided below (the “Change of Control Payment”). Within 30 days following any Change of Control, the Company will mail a notice to each Holder describing the transaction or transactions that constitute the Change of Control and
stating: 
 (1) that the Change of Control Offer is being made pursuant to this Section 4.15 and that all
Notes tendered will be accepted for payment; 
 (2) the purchase price and the purchase date, which shall be no
earlier than 30 days and no later than 60 days from the date such notice is mailed (the “Change of Control Payment Date”); 
 (3) that any Note not tendered will continue to accrue interest; 

(4) that, unless the Company defaults in the payment of the Change of Control Payment, all Notes accepted for payment
pursuant to the Change of Control Offer will cease to accrue interest after the Change of Control Payment Date; 

(5) that Holders electing to have any Notes purchased pursuant to a Change of Control Offer will be required to surrender
the Notes, with the form entitled “Option of Holder to Elect Purchase” attached to the Notes completed, or transfer by book-entry transfer, to the Paying Agent at the address specified in the notice prior to the close of business on the
third Business Day preceding the Change of Control Payment Date; 
 (6) that Holders will be entitled to withdraw
their election if the Paying Agent receives, not later than the close of business on the Business Day preceding the Change of Control Payment Date, a telegram, telex, facsimile transmission or letter setting forth the name of the Holder, the
principal amount of Notes delivered for purchase, and a statement that such Holder is withdrawing its election to have the Notes purchased; and 
 (7) that Holders whose Notes are being purchased only in part will be issued new Notes equal in principal amount to the unpurchased portion of the Notes surrendered, which unpurchased portion must be
equal to $2,000 in principal amount or an integral multiple of $1,000 in excess thereof. 
 If the Change of Control Payment
Date is on or after a Regular Record Date and on or before the related Interest Payment Date, any accrued and unpaid interest to the Change of Control Payment Date will be paid on such Interest Payment Date to the Person in whose name a Note is
registered at the close of business on such Regular Record Date, and no additional interest will be payable to Holders who tender Notes pursuant to the Change in Control. 

  
 -61-

 The Company will comply with the requirements of Rule 14e-1 under the Exchange Act and
any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result of a Change of Control. To the extent that the provisions of any securities laws
or regulations conflict with the provisions of this Section 4.15, the Company will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under this Section 4.15 by virtue of such
compliance. 
 (b) On or before the Change of Control Payment Date, the Company will, to the extent lawful: 

(1) accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer;

 (2) deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Notes or
portions of Notes properly tendered; and 
 (3) deliver or cause to be delivered to the Trustee the Notes
properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Notes or portions of Notes being purchased by the Company. 
 The Paying Agent will promptly mail (but in any case not later than three days after the Change of Control Payment Date) to each Holder of Notes properly tendered the Change of Control Payment for such
Notes, and the Trustee will promptly authenticate and mail or deliver (or cause to be transferred by book entry) to each Holder a new Note equal in principal amount to any unpurchased portion of the Notes surrendered, if any. The Company will
publicly announce the results of the Change of Control Offer on or as soon as practicable after the Change of Control Payment Date. 
 (c) Notwithstanding anything to the contrary in this Section 4.15, the Company will not be required to make a Change of Control Offer upon a Change of Control if (1) a third party makes the
Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in this Section 4.15 and purchases all Notes properly tendered and not withdrawn under the Change of Control Offer, or
(2) notice of redemption has been given pursuant to Section 3.01 hereof, unless and until there is a default in payment of the applicable Redemption Price. 
 (d) Notwithstanding anything to the contrary contained herein, a Change of Control Offer may be made in advance of a Change of Control, conditioned upon the consummation of such Change of Control, if a
definitive agreement is in place for the Change of Control at the time the Change of Control Offer is made. 
 Section 4.16
Note Guaranties. 
 (a) If, after the date of this Indenture, the Company or any Restricted Subsidiary of the Company
forms or acquires any Domestic Subsidiary that is a Wholly Owned Restricted Subsidiary, then the Company will promptly (and in any event within 10 Business Days) after the date of formation or acquisition cause such Domestic Subsidiary to provide a
Note Guaranty pursuant to a supplemental indenture in substantially the form of Exhibit C attached hereto. 

  
 -62-

 (b) If, after the date of this Indenture, any Restricted Subsidiary of the Company that is
not a Guarantor guarantees or provides credit support for (other than by granting Liens on its assets) any Priority Lien Obligations, then the Company will promptly (and in any event within 10 Business Days) thereafter cause such Restricted
Subsidiary to provide a Note Guaranty pursuant to a supplemental indenture in substantially the form of Exhibit C attached hereto. 
 (c) The Company will not, and will not permit any of its Restricted Subsidiaries to, make any Investment in any Person that is, or after the making of such Investment will be, a Restricted Subsidiary of
the Company that is not a Wholly Owned Restricted Subsidiary, unless (i) such Restricted Subsidiary is, or after the making of such Investment will be, a Guarantor, or (ii) such Investment is permitted under clause (y) of
Section 4.07(a) hereof, clause (12) of Section 4.07(b) hereof (without the ability of the Company to reallocate such Investment as permitted by the last paragraph of Section 4.07), or clause (14), (15) or
(16) of the definition of Permitted Investment. 
 Section 4.17 Designation of Restricted and Unrestricted
Subsidiaries. The Board of Directors of the Company may designate any Restricted Subsidiary to be an Unrestricted Subsidiary if that designation would not cause a Default or Event of Default. If a Restricted Subsidiary is designated as an
Unrestricted Subsidiary, the aggregate Fair Market Value of all outstanding Investments owned by the Company and its Restricted Subsidiaries in the Subsidiary designated as an Unrestricted Subsidiary will be deemed to be an Investment made as of the
time of the designation and will reduce the amount available for Restricted Payments under Section 4.07 hereof or under one or more clauses of the definition of Permitted Investments, as determined by the Company. That designation will only be
permitted if the Investment would be permitted at that time and if the Restricted Subsidiary otherwise meets the definition of an Unrestricted Subsidiary. 
 Any designation of a Subsidiary of the Company as an Unrestricted Subsidiary will be evidenced to the Trustee by filing with the Trustee a certified copy of a resolution of the Board of Directors giving
effect to such designation and an Officers’ Certificate certifying that such designation complied with the preceding conditions and was permitted by Section 4.07 hereof. If, at any time, any Unrestricted Subsidiary would fail to meet the
preceding requirements as an Unrestricted Subsidiary, it will thereafter cease to be an Unrestricted Subsidiary for purposes of this Indenture and any Indebtedness of such Subsidiary will be deemed to be incurred by a Restricted Subsidiary of the
Company as of such date and, if such Indebtedness is not permitted to be incurred as of such date under Section 4.09 hereof, the Company will be in default of such covenant. 

The Board of Directors of the Company may at any time designate any Unrestricted Subsidiary to be a Restricted Subsidiary of the Company,
provided that such designation will be deemed to be an incurrence of Indebtedness by a Restricted Subsidiary of the Company of any outstanding Indebtedness of such Unrestricted Subsidiary, and such designation will only be permitted if
(1) such Indebtedness is permitted under Section 4.09 hereof, calculated on a pro forma basis as if such designation had occurred at the beginning of the applicable reference period; and (2) no Default or Event of Default would be in
existence following such designation. 

  
 -63-

 Section 4.18 Additional Collateral. 

(a) If, after the date of this Indenture, the Company or any Restricted Subsidiary of the Company forms or acquires any Domestic
Subsidiary that is a Wholly Owned Restricted Subsidiary, then the Company will promptly (and in any event within 10 Business Days) after the date of formation or acquisition cause such Domestic Subsidiary to grant a Lien on substantially all of its
assets (other than Excluded Assets) to secure the Note Obligations, which Lien shall be subject to the Intercreditor Agreement, by executing and delivering to the Collateral Agent a Second Lien Security Agreement Joinder, and to otherwise comply
with the terms of the Second Lien Security Agreement regarding the perfection of such Liens. 
 (b) If, after the date of this
Indenture, the Priority Lien Debt is secured by Liens on any assets of the Company or its Restricted Subsidiaries not theretofore subject to a Priority Lien (other than Rule 3-16 Excluded Assets, but including any other Excluded Assets), the
Company shall promptly take or cause its Restricted Subsidiaries to take such action as may be reasonably required to grant to the Collateral Agent (or a co-collateral agent) a second priority Lien (subject to Priority Liens and Permitted Prior
Liens) on such assets to secure the Note Obligations. 
 (c) On or before the earlier of (i) August 31, 2012 or
(ii) the date that is five months after the closing of the Company’s issuance of the Notes, the Company shall, with respect to all real property that is owned by the Company on the date of this Indenture and located in the United States
(other than the Development Center and the Learning Center), deliver to the Collateral Agent the following documents and instruments: 
 (1) fully executed counterparts of a mortgage or deed of trust encumbering such real property in favor of the Collateral Agent (or a co-collateral agent), as agent for the benefit of the holders of the
Note Obligations (which mortgage or deed of trust may also secure the Priority Lien Obligations), duly executed and delivered by the Company, as mortgagor (which mortgage or deed of trust shall secure Indebtedness in a principal amount not to exceed
the Fair Market Value of the real property purported to be covered thereby), together with evidence of the completion, or reasonably satisfactory arrangements for the completion, of all recordings and filings of such mortgage or deed of trust (and
payment of any taxes or fees in connection therewith) as may be reasonably necessary to create a valid, perfected Lien against the real property purported to be covered thereby; 

(2) lender’s title insurance policies in favor of the Collateral Agent (or such co-collateral agent) with respect to
each such mortgage or deed of trust insuring that such mortgage or deed of trust constitutes a valid Lien on the real property described in such mortgage or deed of trust, subject only to Permitted Liens, together with evidence of the payment in
full of the premiums thereon; and 

  
 -64-

 (3) such affidavits that the title insurance company shall reasonably
request in connection with the issuance of the title policies referenced in clause (2) above. 
 (d) Upon the acquisition
by the Company or any Guarantor of any property that, upon such acquisition, will be subject to the Priority Liens, the Company or such Guarantor shall execute and deliver such Security Documents, if any, as shall be reasonably necessary to vest in
the Collateral Agent (or a co-collateral agent) a perfected second-priority security interest, subject to the Priority Liens and Permitted Prior Liens, in such property and to have such property added to the Collateral, and thereupon all provisions
of this Indenture relating to the Collateral shall be deemed to relate to such property to the same extent and with the same force and effect. 
 Section 4.19 Operating Leases. The Company will not, and will not permit any Guarantor to, enter into as lessee any lease of real or personal property (other than capital leases) if, after
giving effect thereto, rental payments of the Company and the Guarantors, on a consolidated basis, under all such leases would exceed the lesser of (i) $15.0 million per fiscal year in the aggregate, and (ii) the maximum amount
allowed under the Credit Agreement as in effect on January 12, 2012. 
 Section 4.20 Consolidated Total Assets.

 (a) The Company will not permit, as of the end of any fiscal quarter of the Company, the book value of the total assets of the
Company and the Guarantors on a consolidated basis to be less than 50% of the book value of the total assets of the Company and its Subsidiaries on a consolidated basis. 
 (b) The Company will not permit, as of the end of any fiscal quarter of the Company, the book value of the total assets of the Company, the Guarantors and the Pledged Restricted Subsidiaries on a
consolidated basis to be less than 90% of the book value of the total assets of the Company and its Subsidiaries on a consolidated basis. 
 (c) For purposes of the foregoing, the book value of any assets shall be the value at which those assets are carried on a balance sheet prepared in accordance with GAAP, and the phrase “on a
consolidated basis” means consolidation of the accounts of the Company and the Subsidiaries identified as consolidated with the Company for purposes of the foregoing without any elimination entries to remove the effects of intercompany
transactions between the Company or any such Subsidiary, on the one hand, and any Subsidiary of the Company that is not identified as consolidated with the Company for purposes of the foregoing, on the other hand. 

Section 4.21 Free Cash Flow. 
 (a) The Company will not permit the free cash flow of any Subsidiary of the Company that is not a Guarantor or a Pledged Restricted Subsidiary to be greater than $2.0 million per fiscal year of the
Company. 

  
 -65-

 (b) For purposes hereof, the “free cash flow” of any Subsidiary for any period
shall mean (i) the cash provided by such Subsidiary’s operating activities during such period, minus (ii) the capital expenditures of such Subsidiary for such period. 

ARTICLE V 

CONSOLIDATION; MERGER; CONVEYANCE; TRANSFER OR LEASE 
 Section 5.01 Company May Consolidate, Etc., Only on Certain Terms. The Company may not consolidate with or merge into any Person or directly or indirectly sell, assign, convey, lease, transfer
or otherwise dispose of all or substantially all of the property and assets of the Company and its Restricted Subsidiaries, taken as a whole, to another Person, unless: 
 (a) the Person (if other than the Company) formed by such consolidation, into which the Company is merged or which acquires by direct or indirect sale, assignment, conveyance, lease, transfer or other
disposition all or substantially all of the properties and assets of the Company and its Restricted Subsidiaries, taken as a whole, shall (i) be an entity organized and existing under the laws of the United States of America or any State
thereof or the District of Columbia (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation organized and existing under any such laws) and (ii) expressly assumes (A) by an indenture
supplemental hereto, executed and delivered to the Trustee, the obligations of the Company under the Notes and this Indenture and (B) by supplements thereto, executed and delivered to the Collateral Agent, the obligations of the Company under
the Security Documents; 
 (b) after giving effect to such transaction, no Default or Event of Default, shall have occurred and
be continuing; and 
 (c) the Company shall have, at or prior to the effective date of such consolidation, merger or transfer,
delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that such consolidation, merger or transfer complies with this Article V and, if a supplemental indenture and supplements to Security Documents are
required in connection with such transaction, such supplemental indenture and supplements comply with this Article V, and that all conditions precedent herein provided for relating to such transaction have been complied with. 

The foregoing clause (b) shall not apply to any sale, assignment, conveyance, lease, transfer or other disposition of properties or
assets between or among the Company and its Restricted Subsidiaries or any merger or consolidation of the Company with or into one of its Restricted Subsidiaries. 
 Section 5.02 Successor Substituted. Upon any consolidation of the Company with, or merger of the Company into, any other Person or any sale, assignment, conveyance, lease, transfer or other
disposition of all or substantially all of the properties and assets of the Company and its Restricted Subsidiaries, taken as a whole, in accordance with Section 5.01, the successor Person formed by such consolidation or into which the Company
is merged or to which such sale, assignment, conveyance, lease, transfer or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under the Note 

  
 -66-

 
Documents with the same effect as if such successor Person had been named as the Company herein and therein, and thereafter, except in the case of a lease and for obligations the predecessor
Person may have under a supplemental indenture or supplements to any Security Documents, the predecessor Person shall be relieved of all obligations and covenants under the Note Documents. 

ARTICLE VI 

DEFAULT AND REMEDIES 
 Section 6.01 Events of Default. 
 (a) An “Event of
Default” shall occur if: 
 (1) the Company shall fail to pay the Principal of any Note or any Redemption
Price when the same becomes due and payable, whether at the Final Maturity Date or upon redemption, repurchase or acceleration or otherwise; or 
 (2) the Company shall fail to pay an installment of interest on any of the Notes, which failure continues for 30 days after the date when due; or 

(3) the Company or any Restricted Subsidiary of the Company shall fail to comply with the provisions of Section 4.10,
4.15 or 5.01 hereof; or 
 (4) the Company or any Restricted Subsidiary of the Company shall fail to perform or
observe (or obtain a waiver with respect to) the provisions of Section 4.07, 4.08, 4.09, 4.11, 4.12, 4.13, 4.17, 4.19, 4.20 or 4.21 for a period of 45 days after receipt of a Notice of Default specifying such failure; or 

(5) the Company or any Restricted Subsidiary of the Company shall fail to perform or observe (or obtain a waiver with
respect to) any other term, covenant or agreement contained in the Note Documents for a period of 60 days after receipt of a Notice of Default specifying such failure; or 

(6) default in the payment of principal by the end of any applicable grace period or resulting in acceleration of other
indebtedness of the Company for borrowed money where the aggregate principal amount with respect to which the default or acceleration has occurred exceeds $5.0 million and such acceleration has not been rescinded or annulled or such
indebtedness repaid within a period of 30 days after receipt of a Notice of Default, provided that if any such default is cured, waived, rescinded or annulled, then the Event of Default by reason thereof would be deemed not to have occurred;
or 
 (7) a court or courts of competent jurisdiction shall render against the Company or any Significant
Subsidiary final judgments (not covered by insurance or a third party indemnity) for the payment of money in excess of $5.0 million in the aggregate, which final judgments are not paid, discharged or stayed for a period of 60 days; or

  
 -67-

 (8) the occurrence of any of the following: 

(A) except as permitted by the Intercreditor Agreement, this Indenture or such Security Document, any Security Document
ceases for any reason to be enforceable, provided that it will not be an Event of Default under this clause (8)(A) if the sole result of the failure of one or more Security Documents to be fully enforceable is that (i) any Lien
purported to be granted under such Security Documents on Collateral, individually or in the aggregate, having a Fair Market Value of not more than $1.0 million ceases to be an enforceable and perfected second priority Lien, subject only to
Priority Liens and Permitted Prior Liens, or (ii) any Lien purported to be granted under such Security Documents on Collateral, individually or in the aggregate, having a Fair Market Value in excess of $1.0 million ceases to be an
enforceable and perfected second priority Lien, subject only to Priority Liens and Permitted Prior Liens, and such defect is cured within 60 days after receipt of a Notice of Default; 

(B) except as permitted by the Intercreditor Agreement, this Indenture or such Security Document, any Lien purported to be
granted under any Security Document on Collateral, individually or in the aggregate, having a Fair Market Value in excess of $1.0 million ceases to be an enforceable and perfected second priority Lien, subject only to Priority Liens and
Permitted Prior Liens, and such defect is not cured within 60 days after receipt of a Notice of Default; or 

(C) the Company or any Guarantor, or any Person acting on behalf of any of them, denies or disaffirms, in writing, any
obligation of the Company or any Guarantor set forth in or arising under any Security Document; 
 (9) except as
permitted by this Indenture, any Note Guaranty is held in any judicial proceeding to be unenforceable or invalid or ceases for any reason to be in full force and effect, or any Guarantor, or any Person acting on behalf of any Guarantor, denies or
disaffirms its obligations under its Note Guaranty; 
 (10) the Company or any Significant Subsidiary pursuant to
or within the meaning of any Bankruptcy Law: 
 (A) commences as a debtor a voluntary case or proceeding;

 (B) consents to the entry of an order for relief against it in an involuntary case or proceeding or the
commencement of any case against it; 
 (C) consents to the appointment of a Receiver of it or for all or
substantially all of its property; 
 (D) makes a general assignment for the benefit of its creditors;

 (E) generally is not paying its debts as they become due; 

  
 -68-

 (F) files a petition in bankruptcy or answer or consent seeking
reorganization or relief; or 
 (G) consents to the filing of such a petition or the appointment of or taking
possession by a Receiver; or 
 (11) a court of competent jurisdiction enters an order or decree under any
Bankruptcy Law that: 
 (A) grants relief against the Company or any Significant Subsidiary in an involuntary
case or proceeding or adjudicates the Company or any Significant Subsidiary insolvent or bankrupt; 
 (B)
appoints a Receiver of the Company or any Significant Subsidiary or for all or substantially all of the property of the Company or any Significant Subsidiary; or 

(C) orders the winding up or liquidation of the Company or any Significant Subsidiary; 

and in each case the order or decree remains unstayed and in effect for 60 consecutive days. 

The term “Bankruptcy Law” means Title 11 of the United States Code (or any successor thereto) or any similar federal,
state or foreign law for the relief of debtors. The term “Receiver” means any receiver, trustee, assignee, liquidator, sequestrator or similar official under any Bankruptcy Law. 

(b) No Event of Default under clause (4), (5), (6), (8)(A) or 8(B) of Section 6.01(a) shall occur until the Trustee
notifies the Company in writing, or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding notify the Company and the Trustee in writing, of the Default (a “Notice of Default”), and the Company does not
cure the Default within the time specified in such clause after receipt of such notice. A notice given pursuant to this Section 6.01 shall be given by registered or certified mail, must specify the Default, demand that it be remedied and
state that the notice is a Notice of Default. When any Default under this Section 6.01 is cured, it ceases. 
 (c) The
Company will deliver to the Trustee promptly (and in any event within five Business Days) after any Officer becomes aware of the occurrence of a Default or Event of Default, written notice thereof. 

The Trustee shall not be charged with knowledge of any Event of Default unless written notice thereof shall have been given to a Trust
Officer with responsibility for this Indenture at the Corporate Trust Office of the Trustee by the Company, a Paying Agent, any Holder or any agent of any Holder or unless a Trust Officer with responsibility for this Indenture acquires actual
knowledge of such Event of Default in the course of performing other duties pursuant to this Indenture. 

  
 -69-

 Section 6.02 Acceleration. If an Event of Default (other than an Event of
Default specified in clause (10) or (11) of Section 6.01(a)) occurs and is continuing, the Trustee may, by written notice to the Company, or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding may,
by written notice to the Company and the Trustee, declare the principal amount of, and accrued and unpaid interest to the date of declaration on, all the Notes to be immediately due and payable. Upon such a declaration, such principal amount and
such accrued and unpaid interest shall be due and payable immediately. If an Event of Default specified in Section 6.01(a)(10) or (11) occurs, the principal amount of, and accrued and unpaid interest to the date of such occurrence on, all
the Notes shall automatically become and be immediately due and payable without any declaration, notice or other act on the part of the Trustee or any Holders of Notes. The Holders of a majority in aggregate principal amount of the Notes then
outstanding by notice to the Trustee may rescind an acceleration and its consequences if (a) all existing Events of Default, other than the nonpayment of the principal of the Notes which have become due solely by such declaration of
acceleration, have been cured or waived; (b) the rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (c) all payments due to the Trustee and any predecessor Trustee under Section 7.07
have been made. No such rescission shall affect any subsequent Event of Default or impair any right consequent thereto. 

Section 6.03 Other Remedies. 
 (a) If an Event of Default occurs and is continuing, the Trustee may, but shall not be obligated to, subject to the terms of the Intercreditor Agreement, pursue any available remedy by proceeding at law
or in equity to collect payment of the principal amount and accrued and unpaid interest on the Notes or to enforce the performance of any provision of the Note Documents. 
 (b) The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any of them in the proceeding. A delay or omission by the Trustee or any Holder in exercising any
right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No remedy is exclusive of any other remedy. All available remedies are cumulative to the extent
permitted by applicable law. 
 Section 6.04 Waiver of Defaults and Events of Default. Subject to
Sections 6.07 and 9.02, the Holders of a majority in aggregate principal amount of the Notes then outstanding by notice to the Trustee may waive an existing Default or Event of Default and its consequences, except an uncured Default or Event of
Default in the payment of the principal of or any accrued but unpaid interest on any Note or any Default or Event of Default in respect of any provision of the Note Documents which, under Section 9.02, cannot be modified or amended without the
consent of the Holder of each Note affected. When a Default or Event of Default is waived, it is cured and ceases. 

Section 6.05 Control by Majority. The Holders of a majority in aggregate principal amount of the Notes then outstanding may
direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on it. However, the Trustee may refuse to follow any direction that conflicts with law or this

  
 -70-

 
Indenture, the Security Documents or the Intercreditor Agreement, that the Trustee determines in good faith may be unduly prejudicial to the rights of another Holder or the Trustee, or that may
involve the Trustee in personal liability unless the Trustee is offered security or indemnity satisfactory to it; provided, however, that the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with
such direction. 
 Section 6.06 Limitations on Suits.

(a) A Holder may not pursue any remedy with respect to the Note Documents (except actions for payment of overdue principal or interest)
unless: 
 (1) the Holder gives to the Trustee written notice of a continuing Event of Default; 

(2) the Holders of at least 25% in aggregate principal amount of the then outstanding Notes make a written request to the
Trustee to pursue the remedy; 
 (3) such Holder or Holders offer to the Trustee reasonable security or indemnity
to the Trustee against any loss, liability or expense; 
 (4) the Trustee does not comply with the request within
60 days after receipt of the request and the offer of security or indemnity; and 
 (5) no direction inconsistent
with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in aggregate principal amount of the Notes then outstanding. 
 (b) No Holder of a Note shall have any right under any provision of the Note Documents to affect, disturb, or prejudice the rights of another Holder of a Note or to obtain a preference or priority over
another Holder of a Note. 
 Section 6.07 Rights of Holders to Receive Payment. Notwithstanding any other
provision of this Indenture, the right of any Holder of a Note to receive payment of the principal of and interest on the Notes held by such Holder, on or after the respective due dates expressed in the Notes and this Indenture (whether upon
redemption, repurchase, or otherwise) and to bring suit for the enforcement of any such payment on or after such respective due dates, is absolute and unconditional and shall not be impaired or affected without the consent of the Holder,
provided that a Holder shall not have the right to institute any such suit for the enforcement of payment if and to the extent that the institution or prosecution thereof or the entry of judgment therein would, under applicable law, result in
the surrender, impairment, waiver or loss of the Lien of any of the Note Documents upon any property subject to such Lien. 

Section 6.08 Collection Suit by Trustee. If an Event of Default described in clause (1) or (2) of
Section 6.01(a) occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust against the Company or another obligor on the Notes for the whole amount owing with respect to the Notes and such
further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel. 

  
 -71-

 Section 6.09 Trustee May File Proofs of Claim. Subject to the terms of the
Intercreditor Agreement, the Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel) and the Holders allowed in any judicial proceedings relative to the Company (or any other obligor on the Notes), its creditors or its property and shall be entitled and empowered to
collect and receive any money or other property payable or deliverable on any such claims and to distribute the same, and any Receiver in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in
the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel,
and any other amounts due the Trustee under Section 7.07, and to the extent that such payment of the compensation, reasonable expenses, disbursements and advances in any such proceedings shall be denied for any reason, payment of the same shall
be secured by a lien on, and shall be paid out of, any and all distributions, dividends, money, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of
reorganization or arrangement or otherwise. Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to, or, on behalf of any Holder, to authorize, accept or adopt any plan of reorganization, arrangement, adjustment
or composition affecting the Notes or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 
 Section 6.10 Priorities.
 (a) If the Trustee collects any money or
property pursuant to this Article VI, it shall, subject to the terms of the Intercreditor Agreement, pay out the money or property in the following order: 
 (1) First, to the Trustee for amounts due under Section 7.07; 

(2) Second, to Holders for amounts due and unpaid on the Notes for the principal amount, and interest, as applicable,
ratably, without preference or priority of any kind, according to such respective amounts due and payable on the Holders’ Notes; 
 (3) Third, to such other Person or Persons, if any, to the extent entitled thereto; and 
 (4) Fourth, the balance, if any, to the Company. 
 (b) The Trustee may fix a
record date and payment date for any payment to Holders pursuant to this Section 6.10. 
 Section 6.11 Undertaking
for Costs. In any suit for the enforcement of any right or remedy under the Note Documents or in any suit against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may require the filing by any party
litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to
the merits and good faith of the claims or defenses made by the 

  
 -72-

 
party litigant. This Section 6.11 does not apply to a suit made by the Trustee, a suit by a Holder pursuant to Section 6.07, or a suit by Holders of more than 10% in aggregate principal
amount of the Notes then outstanding. This Section 6.11 shall be in lieu of Section 315(e) of the TIA and such Section 315(e) is hereby expressly excluded from this Indenture, as permitted by the TIA. 

Section 6.12 Restoration of Rights and Remedies. If the Trustee or any Holder has instituted any proceeding to enforce any
right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such
proceedings, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding
has been instituted. 
 Section 6.13 Rights and Remedies Cumulative. No right or remedy herein conferred upon or
reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or
now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 

Section 6.14 Delay or Omission Not Waiver. No delay or omission of the Trustee or of any Holder of any Note to exercise any
right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Subject to the terms of the Intercreditor Agreement, every right and remedy
given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be. 

ARTICLE VII 

TRUSTEE 

Section 7.01 Obligations of Trustee. 
 (a) If an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this Indenture and use the same degree of care and skill in its exercise
as a prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. 
 (b) Except during
the continuance of an Event of Default: 
 (1) the Trustee need perform only those duties as are specifically set
forth in this Indenture and no others; and 
 (2) in the absence of bad faith on its part, the Trustee may
conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, 

  
 -73-

 
upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture. The Trustee, however, shall examine any certificates and opinions which by any
provision hereof are specifically required to be delivered to the Trustee to determine whether or not they conform to the requirements of this Indenture, but need not confirm or investigate the accuracy of mathematical calculations or other facts
stated therein. 
 This Section 7.01(b) shall be in lieu of Section 315(a) of the TIA and such Section 315(a) is
hereby expressly excluded from this Indenture, as permitted by the TIA. 
 (c) The Trustee may not be relieved from liability
for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that: 

(1) this paragraph does not limit the effect of Section 7.01(b); 

(2) the Trustee shall not be liable for any error of judgment made in good faith by a Trust Officer, unless it is proved
that the Trustee was negligent in ascertaining the pertinent facts; and 
 (3) the Trustee shall not be liable
with respect to any action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 6.05. 
 This Section 7.01(c) shall be in lieu of Sections 315(d)(1), 315(d)(2) and 315(d)(3) of the TIA and such Sections are hereby expressly excluded from this Indenture as permitted by the TIA.

 (d) No provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers unless the Trustee shall have received adequate security or indemnity in its opinion against potential costs and liabilities incurred by it
relating thereto. 
 (e) Every provision of this Indenture that in any way relates to the Trustee is subject to
subsections (a), (b), (c) and (d) of this Section 7.01. 
 (f) The Trustee shall not be liable for interest
on any money received by it except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 

Section 7.02 Rights of Trustee.
 (a) Subject to Section 7.01: 
 (1) The Trustee may rely
conclusively on any document reasonably believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document. 

  
 -74-

 (2) Before the Trustee acts or refrains from acting, it may require an
Officers’ Certificate, an Opinion of Counsel or both, which shall conform to Section 13.04(b). The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officers’ Certificate or Opinion
of Counsel. 
 (3) The Trustee may act through its agents and shall not be responsible for the misconduct or
negligence of any agent (other than an agent who is an employee of the Trustee) appointed with due care. 
 (4)
The Trustee shall not be liable for any action it takes or omits to take in good faith which it reasonably believes to be authorized or within its rights or powers. 

(5) The Trustee may consult with counsel of its selection, and the advice or opinion of such counsel as to matters of law
shall be full and complete authorization and protection in respect of any such action taken, omitted or suffered by it hereunder in good faith and in accordance with the advice or opinion of such counsel; provided, however, that such
action taken, omitted or suffered by the Trustee does not constitute willful misconduct or negligence. 
 (6) The
Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security
or indemnity satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. 
 (7) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent,
order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall
determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or attorney at the sole cost of the Company, and shall incur no liability or additional
liability of any kind by reason of such inquiry or investigation. 
 (8) The Trustee shall not be deemed to have
notice of any Default or Event of Default unless a Trust Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a Default is received by the Trustee at the Corporate Trust Office, and such
notice references the Notes and this Indenture. 
 (9) The rights, privileges, protections, immunities and
benefits given to the Trustee, including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, including, without limitation as Paying Agent, Registrar and
Collateral Agent, and to each agent, custodian and other Person employed to act hereunder. 
 (10) In no event
shall the Trustee, including in its capacity as Paying Agent, Registrar or Collateral Agent or in any other capacity hereunder, be liable under or in 

  
 -75-

 
connection with this Indenture for indirect, special, incidental, punitive or consequential losses or damages of any kind whatsoever, including but not limited to lost profits, whether or not
foreseeable, even if the Trustee has been advised of the possibility thereof and regardless of the form of action in which such damages are sought. 
 (11) The permissive rights of the Trustee to do things enumerated in this Indenture shall not be construed as a duty unless so specified herein. 

Section 7.03 Individual Rights of Trustee. The Trustee in its individual or any other capacity may become the owner or
pledgee of Notes and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. However, the Trustee is subject to Sections 7.10 and
7.11 and TIA Sections 310(b) and 311. 
 Section 7.04 Trustee’s Disclaimer. The Trustee makes no representation
as to the validity or adequacy of the Note Documents. It shall not be responsible for any statement in the Notes other than its certificate of authentication. 
 Section 7.05 Notice of Default or Events of Default. If a Default or an Event of Default occurs and is continuing and if it is known to a Trust Officer of the Trustee, the Trustee shall mail
to each Holder of a Note notice of such Default or Event of Default (unless the same has been cured) within 90 days after it occurs or, if later, within 15 days after it becomes known to a Trust Officer of the Trustee. However, the Trustee may
withhold the notice if and for so long as a committee of its Trust Officers in good faith determines that withholding notice is in the interests of Holders of Notes, except in the case of a Default in payment of the principal of or interest on any
Note when due. This Section 7.05 is in lieu of section 315(b) of the TIA and such provision is expressly excluded from this Indenture as permitted by the TIA. 
 Section 7.06 Reports by Trustee to Holders. 
 (a) If a report is
required by TIA Section 313, within 60 days after each May 15, beginning with the May 15 following the date of this Indenture, the Trustee shall mail to each Holder of Notes a brief report dated as of such May 15 that complies
with TIA Section 313(a). If required by TIA Section 313, the Trustee also shall comply with TIA Sections 313(b)(1), (b)(2), (c) and (d). 
 (b) A copy of each report at the time of its mailing to Holders of Notes shall be mailed to the Company and, to the extent required by the TIA, filed with the SEC, and each stock exchange, if any, on
which the Notes are listed. The Company shall notify the Trustee in writing whenever the Notes become listed on any stock exchange or listed or admitted to trading on any quotation system and any changes in the stock exchanges or quotation systems
on which the Notes are listed or admitted to trading and of any delisting thereof. 
 Section 7.07 Compensation and
Indemnity. 
 (a) The Company shall pay to the Trustee from time to time such compensation (as agreed to from time to time by
the Company and the Trustee in writing) for its services (which compensation shall not be limited by any provision of law in regard to the 

  
 -76-

 
compensation of a trustee of an express trust). The Company shall reimburse the Trustee upon request for all reasonable disbursements, expenses and advances incurred or made by it. Such expenses
may include the reasonable compensation, disbursements and expenses of the Trustee’s agents and counsel. 
 (b) The Company
and the Guarantors shall indemnify the Trustee or any predecessor Trustee (which for purposes of this Section 7.07 shall include its officers, directors, employees and agents) for, and hold it harmless against, any and all loss, liability or
expense including taxes (other than taxes based upon, measured by or determined by the income of the Trustee), incurred by it in connection with the acceptance or administration of its duties under this Indenture or any action or failure to act as
authorized or within the discretion or rights or powers conferred upon the Trustee hereunder including the reasonable costs and expenses of the Trustee and its counsel in defending (including reasonable legal fees and expenses) itself against any
claim or liability in connection with the exercise or performance of any of its powers or duties hereunder. The Trustee shall notify the Company promptly of any claim asserted against the Trustee for which it may seek indemnity. The Company and the
Guarantors need not pay for any settlement effected without their prior written consent, which shall not be unreasonably withheld or delayed. 
 (c) The Company and the Guarantors need not reimburse the Trustee for any expense or indemnify it against any loss or liability incurred by it resulting from its gross negligence, willful misconduct or
bad faith. 
 (d) To secure the Company’s and the Guarantors’ payment obligations in this Section 7.07, the
Trustee shall have a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by the Trustee. The obligations of the Company and the Guarantors under this Section 7.07 shall survive the satisfaction
and discharge of this Indenture or the resignation or removal of the Trustee. 
 (e) When the Trustee incurs expenses or renders
services after an Event of Default specified in clause (10) or (11) of Section 6.01(a) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law. The
provisions of this Section shall survive the termination of this Indenture. 
 Section 7.08 Replacement of
Trustee. 
 (a) The Trustee may resign by so notifying the Company. The Holders of a majority in aggregate principal amount
of the Notes then outstanding may remove the Trustee by so notifying the Trustee and the Company and may appoint a successor Trustee. 
 (b) If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee. The resignation or removal of a Trustee
shall not be effective until a successor Trustee shall have delivered the written acceptance of its appointment as described below. 
 (c) If a successor Trustee does not take office within 45 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least 10% in principal amount of the
Notes then outstanding may petition any court of competent jurisdiction for the appointment of a successor Trustee at the expense of the Company. 

  
 -77-

 (d) If the Trustee fails to comply with Section 7.10, any Holder may petition any court
of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 
 (e) A successor Trustee
shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee and execute and deliver an
instrument transferring to such successor Trustee all the rights, powers and trusts of the retiring Trustee, subject to the rights set forth in Section 7.07, and be released from its obligations (exclusive of any liabilities that the retiring
Trustee may have incurred while acting as Trustee) hereunder, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee under this Indenture. A
successor Trustee shall mail notice of its succession to each Holder. 
 (f) A retiring Trustee shall not be liable for the acts
or omissions of any successor Trustee after its succession. 
 (g) Notwithstanding replacement of the Trustee pursuant to this
Section 7.08, the Company’s obligations under Section 7.07 shall continue for the benefit of the retiring Trustee. 
 Section 7.09 Successor Trustee by Merger, Etc. If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business (including the
administration of this Indenture) to, another corporation, the resulting, surviving or transferee corporation, without any further act, shall be the successor Trustee; provided such transferee corporation shall qualify and be eligible under
Section 7.10. Such successor Trustee shall promptly mail notice of its succession to the Company and each Holder. 

Section 7.10 Eligibility; Disqualification. 
 (a) The Trustee shall always satisfy the requirements of paragraphs (1), (2) and (5) of TIA Section 310(a). The Trustee (or its parent holding company) shall have a combined capital
and surplus of at least $100.0 million as set forth in its most recent published annual report of condition. If at any time the Trustee shall cease to satisfy any such requirements, it shall resign immediately in the manner and with the effect
specified in this Article VII. The Trustee shall be subject to the provisions of TIA Section 310(b). In addition, if the Trustee is a corporation included in a bank holding company system, the Trustee, independently of such bank holding
company, shall meet the capital requirements of the TIA set forth in Section 310(a)(2). Nothing herein shall prevent the Trustee from filing with the SEC the application referred to in the penultimate paragraph of TIA Section 310(b).

 (b) If the Trustee has or acquires a conflicting interest within the meaning of the TIA, the Trustee shall either eliminate
such interest or resign, to the extent and in the manner provided by, and subject to the provisions of, the TIA and this Indenture. 

  
 -78-

 Section 7.11 Preferential Collection of Claims Against Company. The Trustee
shall comply with TIA Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated therein. 

ARTICLE VIII 

LEGAL DEFEASANCE AND COVENANT DEFEASANCE 
 Section 8.01 Option to Effect Legal Defeasance or Covenant Defeasance. The Company may at any time, at the option of the Board of Directors evidenced by a resolution set forth in an
Officers’ Certificate, elect to have either Section 8.02 or 8.03 hereof be applied to all outstanding Notes upon compliance with the conditions set forth below in this Article VIII. 

Section 8.02 Legal Defeasance and Discharge. Upon the Company’s exercise under Section 8.01 hereof of the option
applicable to this Section 8.02, the Company and each of the Guarantors will, subject to the satisfaction of the conditions set forth in Section 8.04 hereof, be deemed to have been discharged from their obligations with respect to all
outstanding Notes (including the Note Guaranties) on the date the conditions set forth below are satisfied (hereinafter, “Legal Defeasance”). For this purpose, Legal Defeasance means that the Company and the Guarantors will be deemed to
have paid and discharged the entire Indebtedness represented by the outstanding Notes (including the Note Guaranties), which will thereafter be deemed to be “outstanding” only for the purposes of Section 8.05 hereof and the other
Sections of this Indenture referred to in clauses (1) and (2) below, and to have satisfied all their other obligations under the Note Documents (and the Trustee, on demand of and at the expense of the Company, shall execute proper
instruments acknowledging the same), except for the following provisions which will survive until otherwise terminated or discharged hereunder: 
 (1) the rights of Holders of outstanding Notes to receive payments in respect of the principal of or interest on such Notes, when such payments are due, from the trust referred to in Section 8.04
hereof; 
 (2) the Company’s obligations with respect to such Notes under Article II and
Section 4.02 hereof; 
 (3) the rights, powers, trusts, duties and immunities of the Trustee hereunder and
the Company’s and the Guarantors’ obligations in connection therewith; and 
 (4) this
Article VIII. 
 Subject to compliance with this Article VIII, the Company may exercise its option under this
Section 8.02 notwithstanding the prior exercise of its option under Section 8.03 hereof. 
 Section 8.03
Covenant Defeasance. Upon the Company’s exercise under Section 8.01 hereof of the option applicable to this Section 8.03, the Company and each of the Guarantors will, subject to the satisfaction of the conditions set forth in
Section 8.04 hereof, be released from each of their obligations under the covenants contained in Sections 4.07 through 4.21 hereof (other than their obligations under clause (i) of Section 4.14 in respect of preservation of the

  
 -79-

 
corporate existence of the Company) and Article X hereof with respect to the outstanding Notes on and after the date the conditions set forth in Section 8.04 hereof are satisfied
(hereinafter, “Covenant Defeasance”), and the Notes will thereafter be deemed not “outstanding” for the purposes of any direction, waiver, consent or declaration or act of Holders (and the consequences of any thereof) in
connection with such covenants, but will continue to be deemed “outstanding” for all other purposes hereunder (it being understood that such Notes will not be deemed outstanding for accounting purposes). For this purpose, Covenant
Defeasance means that, with respect to the outstanding Notes and Note Guaranties, the Company and the Guarantors may omit to comply with and will have no liability in respect of any term, condition or limitation set forth in any such covenant,
whether directly or indirectly, by reason of any reference elsewhere herein to any such covenant or by reason of any reference in any such covenant to any other provision herein or in any other document and such omission to comply will not
constitute a Default or an Event of Default under Section 6.01(a) hereof, but, except as specified above, the remainder of this Indenture and such Notes and Note Guaranties will be unaffected thereby. In addition, upon the Company’s
exercise under Section 8.01 hereof of the option applicable to this Section 8.03, subject to the satisfaction of the conditions set forth in Section 8.04 hereof, clauses (3), (4) and (5) of Section 6.01(a) hereof
(in each case to the extent pertaining to a Default under any of Sections 4.07 through 4.21 hereof (other than a Default under clause (i) of Section 4.14 in respect of preservation of the corporate existence of the Company) or
Article X hereof) and clauses (6), (7), (8) and (9) of Section 6.01(a) hereof will not constitute Events of Default. 
 Section 8.04 Conditions to Legal or Covenant Defeasance. In order to exercise either Legal Defeasance under Section 8.02 or Covenant Defeasance under Section 8.03 hereof: 

(1) the Company must irrevocably deposit with the Trustee, in trust, for the benefit of the Holders, cash in U.S. dollars,
non-callable Government Securities, or a combination thereof, in such amounts as will be sufficient, in the opinion of a nationally recognized investment bank, appraisal firm, or firm of independent public accountants, to pay the principal of and
interest on the outstanding Notes on the stated date for payment thereof or on the applicable Redemption Date, as the case may be, and the Company must specify whether the Notes are being defeased to such stated date for payment or to a particular
Redemption Date; 
 (2) in the case of an election under Section 8.02 hereof, the Company must deliver to
the Trustee an Opinion of Counsel confirming that: 
 (A) the Company has received from, or there has been
published by, the Internal Revenue Service a ruling; or 
 (B) since the date of this Indenture, there has been a
change in the applicable federal income tax law, 
 in either case to the effect that, and based thereon such Opinion of Counsel
shall confirm that, the Holders of the outstanding Notes will not recognize income, gain or loss for federal income tax purposes as a result of such Legal Defeasance and will be subject to federal income tax on the same amounts, in the same manner
and at the same times as would have been the case if such Legal Defeasance had not occurred; 

  
 -80-

 (3) in the case of an election under Section 8.03 hereof, the Company
must deliver to the Trustee an Opinion of Counsel confirming that the Holders of the outstanding Notes will not recognize income, gain or loss for federal income tax purposes as a result of such Covenant Defeasance and will be subject to federal
income tax on the same amounts, in the same manner and at the same times as would have been the case if such Covenant Defeasance had not occurred; 
 (4) no Default or Event of Default shall have occurred and is continuing on the date of such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such
deposit (and any similar concurrent deposit relating to other Indebtedness), and the granting of Liens to secure such borrowings); 
 (5) such Legal Defeasance or Covenant Defeasance will not result in a breach or violation of, or constitute a default under, any material agreement or instrument (other than this Indenture and the
agreements governing any other Indebtedness being defeased, discharged or replaced) to which the Company or any of the Guarantors is a party or by which the Company or any of the Guarantors is bound; 

(6) the Company must deliver to the Trustee an Officers’ Certificate stating that the deposit was not made by the
Company with the intent of defeating, hindering, delaying or defrauding any creditors of the Company or others; and 
 (7) the Company must deliver to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent relating to the Legal Defeasance or the Covenant Defeasance
have been complied with. 
 The Collateral will be released from the Liens securing the Note Obligations, as provided in
Section 10.03, upon a Legal Defeasance or Covenant Defeasance in accordance with the provisions of this Section 8.04. 

The Trustee shall hold in trust the U.S. dollars and Governmental Securities deposited with it pursuant to this Section 8.04 and
shall apply all money held by the Trustee in trust to the payment of the principal of and interest on the Notes in accordance with this Indenture and the Notes. 
 Section 8.05 Repayment to Company. Subject to applicable abandonment property laws, any money held by the Trustee in trust for the payment of the principal of or interest on any Notes and
remaining unclaimed for two years after such principal or interest has become due and payable shall be paid to the Company on its request; and the Holder of such Notes will thereafter be permitted to look only to the Company for payment thereof, and
all liability of the Trustee with respect to such trust money will thereupon cease; provided, however, that the Trustee, before being required to make any such repayment, shall at the expense of the Company cause to be published once,
in the New York Times and The Wall Street Journal (national edition), notice that such money remains unclaimed and that, after a date specified therein, which will not be less than 30 days from the date of such notification or publication, any
unclaimed balance of such money then remaining will be repaid to the Company. 

  
 -81-

 Section 8.06 Reinstatement. If the Trustee is unable to apply any U.S. dollars
or non-callable Government Securities in accordance with this Article VIII by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, then the Company’s and
the Guarantors’ obligations under the Note Documents will be revived and reinstated as though no deposit had occurred pursuant to this Article VIII until such time as the Trustee is permitted to apply all such money in accordance with this
Article VIII; provided, however, that, if the Company makes any payment of principal of or interest on any Notes following the reinstatement of its obligations, the Company will be subrogated to the rights of the Holders of such
Notes to receive such payment from the money held by the Trustee. 
 ARTICLE IX 

AMENDMENTS; SUPPLEMENTS AND WAIVERS 
 Section 9.01 Without Consent of Holders. The Trustee or Collateral Agent (as the case may be) and the Company may amend or supplement any of the Note Documents, and the Collateral Agent and
other counterparties thereto may amend or supplement the Intercreditor Agreement, without notice to or consent of any Holder of a Note as provided in Section 10.03(e) or for the purpose of: 

(a) evidencing a successor to the Company or a Guarantor and the assumption by that successor of the Company’s or such
Guarantor’s obligations under the Note Documents; 
 (b) adding to the Company’s or Guarantors’ covenants for the
benefit of the Holders or surrendering any right or power conferred upon the Company or any Guarantor; 
 (c) allowing any
Person to guarantee the Notes; 
 (d) evidencing and providing for the acceptance of the appointment of a successor trustee in
accordance with Article VII; 
 (e) complying with the requirements of the SEC in order to effect or maintain the
qualification of this Indenture under the TIA, as contemplated by this Indenture or otherwise; 
 (f) complying with the
provisions of any securities depositary, clearing agency, clearing corporation or clearing system, or the requirements of the Trustee or Registrar, relating to transfers and exchanges of the Notes pursuant to this Indenture; 

(g) curing any ambiguity, omission, defect or inconsistency or correcting or supplementing any defective provision contained in the Note
Documents or the Intercreditor Agreement; 

  
 -82-

 (h) modifying any other provisions of the Note Documents or the Intercreditor Agreement in
any manner that will not adversely affect the rights of the Holders in any material respect; 
 (i) making, completing or
confirming any grant of Collateral permitted or required by this Indenture or any of the Security Documents; and 
 (j)
releasing any Collateral from the Liens securing the Note Obligations pursuant to the terms of this Indenture, any of the Security Documents or the Intercreditor Agreement. 
 Section 9.02 With Consent of Holders. 
 (a) The Trustee or Collateral
Agent (as the case may be) and the Company may amend or supplement any of the Note Documents, and the Collateral Agent and other counterparties thereto may amend or supplement the Intercreditor Agreement, in each case with the written consent of the
Holders of at least a majority in aggregate principal amount of the Notes then outstanding. However, subject to Section 9.04, without the written consent of each Holder affected, an amendment, supplement or waiver may not: 

(1) alter the manner of calculation or rate of accrual of interest on any Note or change the time of payment of any
installment of interest on any Note; 
 (2) make any of the Notes payable in money or securities other than that
stated in the Notes; 
 (3) change the Stated Maturity of any Note or provide that any Note may be redeemed prior
to the Final Maturity Date at the option of the Company other than as described in Section 3.01(a) and (b); 

(4) reduce the principal amount or Redemption Price payable (as applicable) with respect to any of the Notes, or the
amount payable upon purchase pursuant to this Indenture or any Note; 
 (5) impair the right of the Holder of any
Note to receive payment of principal of or interest on such Note on or after the due dates therefor or to institute suit for the enforcement of any payment on or with respect to such Note; 

(6) make any change in this Article IX; or 

(7) release any Guarantor from any of its obligations under its Note Guaranty or this Indenture, except in accordance with
the terms of this Indenture. 
 In addition, any amendment or supplement to the provisions of this Indenture or any Security
Document that has the effect of releasing all or substantially all of the Collateral from the Liens securing the Note Obligations, except in accordance with the terms of this Indenture, any Security Document or the Intercreditor Agreement, will
require the consent of the Holders of at least 66-2/3% in aggregate principal amount of the Notes then outstanding. 

  
 -83-

 Without limiting the forgoing provisions of this Section 9.02(a), the Holders of a
majority in aggregate principal amount of the Notes then outstanding may, on behalf of all the Holders of the Notes, (i) waive compliance by the Company or any Guarantor with the restrictive provisions of the Note Documents, and (ii) waive
any past Default or Event of Default under this Indenture and its consequences, except an uncured failure to pay when due the principal amount of or accrued and unpaid interest on the Notes or the Redemption Price, or in respect of any provision
which under the Note Documents cannot be modified or amended without the consent of the Holder of each outstanding Note affected. 
 (b) It is not necessary for the consent of the Holders of Notes under this Section 9.02 to approve the particular form of any proposed amendment, supplement or waiver, but is sufficient if such
consent approves the substance thereof. 
 (c) After an amendment, supplement or waiver under this Section 9.02 becomes
effective, the Company shall promptly mail to the Holders affected thereby a notice briefly describing the amendment, supplement or waiver. Any failure of the Company to mail such notice, or any defect therein, shall not, however, in any way impair
or affect the validity of any such amendment, supplement or waiver. 
 Section 9.03 Compliance with Trust Indenture
Act. Every amendment to or supplement of this Indenture or the Notes shall comply with the TIA as in effect at the date of such amendment or supplement. 
 Section 9.04 Revocation and Effect of Consents. Until an amendment, supplement or waiver becomes effective, a consent to it by a Holder is a continuing consent by the Holder and every
subsequent Holder of a Note or portion of a Note that evidences the same debt as the consenting Holder’s Note, even if notation of the consent is not made on any Note. However, any such Holder or subsequent Holder may revoke the consent as to
its Note or portion of a Note if the Trustee receives the notice of revocation before the date the amendment, supplement or waiver becomes effective. After an amendment, supplement or waiver becomes effective, it shall bind every Holder of a Note.

 Section 9.05 Notation On or Exchange of Notes. If an amendment, supplement or waiver changes the terms of a Note,
the Trustee may require the Holder of the Note to deliver it to the Trustee. The Trustee may place an appropriate notation on the Note about the changed terms and return it to the Holder. Alternatively, if the Company or the Trustee so determines,
the Company in exchange for the Note shall issue and the Trustee shall authenticate a new Note that reflects the changed terms. 

Section 9.06 Trustee to Sign Amendments, Etc. The Trustee or Collateral Agent (as the case may be) shall sign any amendment
or supplemental indenture authorized pursuant to this Article IX if the amendment or supplemental indenture does not adversely affect the rights, duties, liabilities or immunities of the Trustee or Collateral Agent. If it does, the Trustee or
Collateral Agent (as the case may be) may, in its sole discretion, but need not sign such amendment or supplemental indenture. In signing or refusing to sign such amendment or supplemental indenture, the Trustee or Collateral Agent (as the case may
be) shall be entitled to receive and, subject to Section 7.01, shall be fully protected in relying upon, an Officers’ 

  
 -84-

 
Certificate and Opinion of Counsel stating that such amendment or supplemental indenture is authorized or permitted by this Indenture. The Company may not sign an amendment or supplemental
indenture until the Board of Directors approves it. 
 Section 9.07 Effect of Supplemental Indentures. Upon the
execution of any supplemental indenture under this Article IX, this Indenture shall be modified in accordance therewith, and such supplemental indenture shall form a part of this Indenture for all purposes; and every Holder of Notes theretofore
or thereafter authenticated and delivered hereunder shall be bound thereby. 
 Section 9.08 Payment for Consent.
Neither the Company nor any of its Subsidiaries will, directly or indirectly, pay or cause to be paid any consideration, whether by way of interest, fee or otherwise, to any Holder of any Notes for or as an inducement to any consent, waiver or
amendment of any of the terms or provisions of this Indenture or the Notes unless such consideration is offered to be paid or is paid to all Holders of the Notes that consent, waive or agree to amend in the time frame set forth in the solicitation
documents relating to such consent, waiver or amendment. 
 ARTICLE X 

COLLATERAL AND SECURITY 
 Section 10.01 Security Interest. 
 (a) The due and punctual payment of
the principal of and interest on the Notes when and as the same shall be due and payable, whether on an interest payment date, at maturity, by acceleration, repurchase, redemption or otherwise, and interest on the overdue principal of and interest
(to the extent permitted by law) on the Notes and performance of all other Obligations of the Company and the Guarantors to the Holders of Notes or the Trustee under this Indenture and the Notes, including, without limitation, the Note Guaranties,
according to the terms hereunder or thereunder (collectively the “Note Obligations”) are secured as provided in the Security Documents. Each Holder of Notes, by its acceptance thereof, consents and agrees to the terms of the Security
Documents (including, without limitation, the provisions providing for foreclosure and release of Collateral) as the same may be in effect or may be amended from time to time in accordance with their terms and the terms of this Indenture. Wells
Fargo Bank, N.A. shall initially act as Collateral Agent and shall be authorized to appoint co-collateral agents as necessary in its sole discretion. Pursuant to such authority, the Collateral Agent hereby appoints PNC Bank, National Association, as
co-collateral agent to act as mortgagee for the benefit of the holders of the Note Obligations and the Priority Lien Obligations under any mortgages on real property located in the State of Minnesota that are granted by the Company pursuant to
Section 4.18(c) hereof. Each Holder of Notes, by its acceptance of Notes, and the Trustee direct the Collateral Agent (directly or through co-collateral agents) to enter into the Security Documents and to perform its obligations and exercise
its rights thereunder in accordance therewith, subject to the terms and conditions thereof and of this Indenture and the Intercreditor Agreement. The Company will deliver to the Trustee copies of all documents delivered to the Collateral Agent (or
any co-collateral agent) pursuant to the Security Documents, and will do or cause to be done all such acts and things as may be required by the provisions of this Indenture 

  
 -85-

 
and the Security Documents to assure and confirm to the Collateral Agent (or any co-collateral agent) the security interest in the Collateral contemplated by this Indenture and the Security
Documents or any part thereof, as from time to time constituted, so as to render the same available for the security and benefit of this Indenture and of the Notes. 
 (b) The Company will comply with the provisions of TIA §314. 

Section 10.02 Intercreditor Agreement. This Article X and the provisions of each Security Document are subject to the
terms, conditions and benefits set forth in the Intercreditor Agreement. Each Holder of the Notes, by its acceptance of the Notes (a) directs the Trustee and Collateral Agent to enter into the PNC Intercreditor Agreement and to perform their
obligations and exercise their rights thereunder in accordance therewith, subject to the terms and conditions of this Indenture, (b) further directs the Trustee and Collateral Agent, if any Indebtedness of the Company or any Guarantor under any
Credit Facility other than the Credit Agreement has been designated by the Company in an Officers’ Certificate delivered to the Trustee and Collateral Agent as “Priority Lien Debt” for purposes of this Indenture, to, at the request of
the Company, enter into an Additional Intercreditor Agreement with the agent or other representative of the holders of such Indebtedness designated pursuant to the terms of the documents governing such Credit Facility and to perform their
obligations and exercise their rights thereunder in accordance therewith, subject to the terms and conditions of this Indenture, (c) consents to the subordination of Liens provided for in any Intercreditor Agreement and (d) agrees that it
will be bound by, and will take no actions contrary to, the provisions of any Intercreditor Agreement. The foregoing provisions are intended as an inducement to the lenders under the Credit Agreement to extend credit to the Company and certain of
its Subsidiaries, and such lenders and each other present and future holder of Priority Lien Obligations are intended third party beneficiaries of such provisions and the provisions of the Intercreditor Agreement. 

Section 10.03 Release of Liens in Respect of Notes. 
 (a) The Collateral Agent’s (and any co-collateral agent’s) Liens upon the Collateral will no longer secure the Notes outstanding under this Indenture or any other Note Obligations, and the right
of the Holders of the Notes and holders of such other Note Obligations to the benefits and proceeds of the Collateral Agent’s (and any co-collateral agent’s) Liens on the Collateral, and the obligations of the Company and each Guarantor or
other Restricted Subsidiary of the Company under the Security Documents, will automatically terminate and be discharged: 
 (1) upon satisfaction and discharge of this Indenture in accordance with Article XII hereof; 
 (2) upon a Legal Defeasance or Covenant Defeasance of the Notes in accordance with Article VIII hereof; 
 (3) upon payment in full and discharge of all Notes outstanding under this Indenture and all other Note Obligations that are outstanding and due and payable at the time the Notes are paid in full and
discharged; 

  
 -86-

 (4) in whole or in part, with the consent of the Holders of the requisite
percentage of Notes in accordance with Article IX hereof; and 
 (5) if and to the extent required by of the
Intercreditor Agreement. 
 (b) If any assets or rights of the Company, any Guarantor or any other Restricted Subsidiary of the
Company constituting a part of the Collateral are sold or otherwise disposed of to a Person that is not (either before or after giving effect to such transaction) the Company or a Restricted Subsidiary of the Company, such assets or rights shall be
automatically released from the Liens securing the Note Obligations and the right of the Holders of the Notes and holders of the other Note Obligations to the benefits and proceeds of the Collateral Agent’s (or any co-collateral agent’s)
Liens on such assets or rights will automatically terminate and be discharged, provided that, subject to the terms of the Intercreditor Agreement, the Net Proceeds of such sale or disposition are applied in accordance with Section 4.10
hereof. 
 (c) If Equity Interests in any Guarantor or other Restricted Subsidiary of the Company are sold or otherwise disposed
of (including by way of consolidation or merger) to a Person that is not (either before or after giving effect to such transaction) the Company or a Restricted Subsidiary of the Company, the Liens on the assets and rights of such Guarantor or other
Restricted Subsidiary securing the Note Obligations will be automatically released and the rights of the Holders of the Notes and the holders of the other Note Obligations to the benefits and proceeds of the Collateral Agent’s (or any
co-collateral agent’s) Liens on such assets and rights, and the obligations of such Guarantor or other Restricted Subsidiary under the Security Documents, will automatically terminate and be discharged, provided that, subject to the
terms of the Intercreditor Agreement, the Net Proceeds of such sale or other disposition are applied in accordance with Section 4.10 hereof and, to the extent applicable, the Company complies with Article V hereof. 

(d) If all Priority Liens on any assets or rights of the Company, any Guarantor or any other Restricted Subsidiary of the Company
securing the Priority Lien Obligations are released (other than in connection with the payment in full of such Priority Lien Obligations and the termination or expiration of all commitments, if any, to extend credit that would constitute Priority
Lien Obligations), the Liens on such assets or rights securing the Note Obligations will also be automatically released and the right of the Holders of the Notes and holders of other Note Obligations to the benefits and proceeds of the Collateral
Agent’s (or any co-collateral agent’s) Liens on such assets or rights will automatically terminate and be discharged (provided that, if Priority Liens are at any time thereafter granted on such assets or rights to secure Priority
Lien Debt, the Company shall promptly take or cause the applicable Guarantor or other Restricted Subsidiary to take such actions as may be reasonably required to grant to the Collateral Agent (or a co-collateral agent) a second priority Lien
(subject to Priority Liens and Permitted Prior Liens) on such assets or rights to secure the Note Obligations). 
 (e) Upon
release of the Collateral, or any portion thereof, from the Liens securing the Notes and other Note Obligations, in each case in accordance with the provisions of this Section 10.03, all right, title and interest of the Collateral Agent (or any
co-collateral agent) therein shall thereupon cease and, at the written request of the Company and at the Company’s cost and expense, the Collateral Agent (or such co-collateral agent) (i) shall execute such

  
 -87-

 
instruments as the Company may reasonably request to evidence such release of record and (ii) if the Collateral so released is in the possession of the Collateral Agent (or such
co-collateral agent), shall deliver such Collateral to the Company. 
 (f) The release of any Collateral from the terms of this
Indenture will not be deemed to impair the security under this Indenture in contravention of provisions hereof if and to the extent the Collateral is released pursuant to the terms hereof. To the extent applicable, the Company will comply with TIA
§314(d) relating to the release of property or securities subject to the Lien of the Security Documents. Any certificate or opinion required by TIA §314(d) may be made by an Officer of the Company except in cases where TIA §314(d)
requires that such certificate or opinion be made by an independent Person, which Person will be an independent engineer, appraiser or other expert selected by the Company. Notwithstanding anything to the contrary in this paragraph, the Company will
not be required to comply with all or any portion of TIA §314(d) if it determines, in good faith based on advice of counsel, that under the terms of TIA §314(d) and/or any interpretation or guidance as to the meaning thereof of the SEC and
its staff, including “no action” letters or exemptive orders, all or any portion of TIA §314(d) is inapplicable to the released Collateral. 
 Section 10.04 Collateral Agent. 
 (a) The Collateral Agent (directly or
through co-collateral agents) will hold and, subject to the terms of the Intercreditor Agreement, will be entitled to enforce all Liens on the Collateral created by the Security Documents. 

(b) The Collateral Agent will not be obligated to do any of the following in the absence of the written direction of the Trustee or the
Holders of a majority in principal amount of the Notes then outstanding (as certified to by the Trustee): 
 (1)
to act upon directions purported to be delivered to it by any Person; 
 (2) to foreclose upon or otherwise
enforce any Lien; or 
 (3) to take any other action whatsoever with regard to any or all of the Security
Documents or the Liens created thereby or the Collateral. 
 (c) Subject to the terms of the Intercreditor Agreement and
Article VII, the Collateral Agent is authorized and empowered to institute and maintain such suits and proceedings as it may deem expedient to protect or enforce the Liens on the Collateral or the other rights under the Security Documents to
which the Collateral Agent is a party or to prevent any impairment of Collateral by any acts that may be unlawful or in violation of such Security Documents or this Indenture, and such suits and proceedings as the Collateral Agent may deem expedient
to preserve or protect its interests and the interests of the Holders in the Collateral, including power to institute and maintain suits or proceedings to restrain the enforcement of or compliance with any legislative or other governmental
enactment, rule or order that may be unconstitutional or otherwise invalid if the enforcement of, or compliance with, such enactment, rule or order would impair the Liens or other rights under such Security Documents or hereunder or be prejudicial
to the interests of Holders or the Collateral Agent. 

  
 -88-

 (d) Notwithstanding any provision to the contrary contained elsewhere in this Indenture, the
Security Documents or the Intercreditor Agreement, the Collateral Agent shall not have any duties or responsibilities hereunder, nor shall the Collateral Agent have or be deemed to have any fiduciary relationship with the Trustee, any Holder or any
Guarantor, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Indenture, the Security Documents or the Intercreditor Agreement or otherwise exist against the Collateral Agent. Without
limiting the generality of the foregoing sentence, the use of the term “agent” in this Indenture with reference to the Collateral Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency
doctrine of any applicable law. Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties. Except as expressly otherwise provided
in this Indenture, the Collateral Agent shall have and may use its sole discretion with respect to exercising or refraining from exercising any discretionary rights or taking or refraining from taking any actions which the Collateral Agent is
expressly entitled to take or assert under this Indenture, the Security Documents and the Intercreditor Agreement. 
 (e) The
Collateral Agent shall have no obligation whatsoever to the Trustee or any of the Holders to assure that the Collateral exists or is owned by the Company or any Guarantor or is cared for, protected, or insured or has been encumbered, or that the
Collateral Agent’s Liens have been properly or sufficiently or lawfully created, perfected, protected, maintained or enforced or are entitled to any particular priority, or to determine whether all of the Company’s or any Guarantor’s
property constituting Collateral intended to be subject to the Lien and security interest of the Security Documents has been properly and completely listed or delivered, as the case may be, or the genuineness, validity, marketability or sufficiency
thereof or title thereto, or to exercise at all or in any particular manner or under any duty of care, disclosure, or fidelity, or to continue exercising, any of the rights, authorities, and powers granted or available to the Collateral Agent
pursuant to this Indenture, any Security Document or the Intercreditor Agreement, it being understood and agreed that in respect of the Collateral, or any act, omission, or event related thereto, the Collateral Agent may act in any manner it may
deem appropriate, in its sole discretion given the Collateral Agent’s own interest in the Collateral and that the Collateral Agent shall have no other duty or liability whatsoever to the Trustee or any Holder as to any of the foregoing.

 (f) No provision of this Indenture, the Intercreditor Agreement or any Security Document shall require the Collateral Agent
(or the Trustee) to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or thereunder or to take or omit to take any action hereunder or thereunder or take any action at the
request or direction of Holders (or the Trustee in the case of the Collateral Agent) if it shall have reasonable grounds for believing that repayment of such funds is not assured to it. 

Section 10.05 Further Assurances. Subject to and to the extent consistent with the Intercreditor Agreement and the terms of
the Security Documents, upon the reasonable request of the Collateral Agent at any time and from time to time, the Company and each of the Guarantors shall promptly execute, acknowledge and deliver such documents and instruments, and take such other
actions, as shall be reasonably required by the Collateral Agent to create, perfect, protect, assure or enforce the Liens granted or intended to be granted by the Security Documents. 

  
 -89-

 Section 10.06 Insurance. 

(a) The Company and the Guarantors shall: 
 (1) keep their properties insured at all times by financially sound and reputable insurers; 
 (2) maintain such other insurance, to such extent and against such risks (and with such deductibles, retentions and exclusions), including fire and other risks insured against by extended coverage, as is
reasonably comparable to companies in the same or similar businesses operating in the same or similar locations, including public liability insurance against claims for personal injury or death or property damage occurring upon, in, about or in
connection with the use of any properties owned, occupied or controlled by them; and 
 (3) maintain such other
insurance as may be required by law. 
 (b) Upon the request of the Collateral Agent, the Company and the Guarantors will
furnish to the Collateral Agent information as to their property and liability insurance carriers. Holders of Notes, as a class, will be named as additional insureds on all material liability insurance policies of the Company and the Guarantors, and
the Collateral Agent (or a co-collateral agent, as applicable) will be named as second lender loss payee, with 30 days’ notice of cancellation or material change, on all property and casualty insurance policies of the Company and the
Guarantors. 
 Section 10.07 Impairment of Security Interest. The Company will not, and will not permit any of its
Restricted Subsidiaries to, take or knowingly or negligently omit to take any action, which action or omission would reasonably be expected to have the result of materially impairing the security interest with respect to the Collateral for the
benefit of the holders of the Note Obligations, except as expressly permitted by the Note Documents. 
 ARTICLE XI 

NOTE GUARANTIES 

Section 11.01 Guaranty. 
 (a) Subject to this Article XI, each of the Guarantors hereby, jointly and severally, unconditionally guarantees to each Holder of a Note authenticated and delivered by the Trustee and to the Trustee
and its successors and assigns, irrespective of the validity and enforceability of this Indenture, the Notes or the obligations of the Company hereunder or thereunder, (i) that the principal of and interest on the Notes will be promptly paid in
full when due, whether at maturity, by acceleration, redemption or otherwise, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder will be promptly paid in full or performed, all in accordance with the terms
hereof and thereof, and (ii) in case of any extension of time of payment or renewal of any Notes or any of such other obligations, that the same shall be promptly paid in full when due or performed in accordance with the terms of the extension
or renewal, whether at stated maturity, by acceleration or otherwise. 

  
 -90-

 Failing payment when due of any amount so guaranteed or any performance so guaranteed for
whatever reason, the Guarantors will be jointly and severally obligated to pay the same immediately. Each Guarantor agrees that this is a guarantee of payment and not a guarantee of collection. 

(b) The Guarantors hereby agree that their obligations hereunder are unconditional, irrespective of the validity, regularity or
enforceability of the Notes or this Indenture, the absence of any action to enforce the same, any waiver or consent by any Holder of the Notes with respect to any provisions hereof or thereof, the recovery of any judgment against the Company, any
action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or defense of a guarantor. Each Guarantor hereby waives diligence, presentment, demand of payment, filing of claims with a court in
the event of insolvency or bankruptcy of the Company, any right to require a proceeding first against the Company, protest, notice and all demands whatsoever and covenants that, except as otherwise provided in this Indenture, this Note Guaranty will
not be discharged except by complete performance of the obligations contained in the Notes and this Indenture. 
 (c) If any
Holder or the Trustee is required by any court or otherwise to return to the Company, the Guarantors or any custodian, trustee, liquidator or other similar official acting in relation to either the Company or the Guarantors, any amount paid by
either to the Trustee or such Holder, this Note Guaranty, to the extent theretofore discharged, will be reinstated in full force and effect. 
 (d) Each Guarantor agrees that it will not be entitled to any right of subrogation in relation to the Holders in respect of any Obligations guarantied hereby until payment in full of all Obligations
guaranteed hereby. Each Guarantor further agrees that, as between the Guarantors, on the one hand, and the Holders and the Trustee, on the other hand, (1) the maturity of the Obligations guaranteed hereby may be accelerated as provided in
Article VI hereof for the purposes of this Note Guaranty, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the Obligations guaranteed hereby, and (2) in the event of any declaration of
acceleration of such Obligations as provided in Article VI hereof, such Obligations (whether or not due and payable) will forthwith become due and payable by the Guarantors for the purpose of this Note Guaranty. The Guarantors will have the
right to seek contribution from any non-paying Guarantor so long as the exercise of such right does not impair the rights of the Holders under the Note Guaranties. 
 (e) Each Note Guaranty shall remain in full force and effect and continue to be effective should any petition be filed by or against the Company for liquidation or reorganization, should the Company
become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of the Company’s assets, and shall, to the fullest extent permitted by law, continue to be
effective or be reinstated, as the case may be, if at any time payment and performance of the Notes are, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee on the Notes or Note
Guaranties, whether as a “voidable preference,” “fraudulent transfer” or otherwise, all as though such payment or performance had not been made. In the event that any payment or any part thereof is rescinded, reduced, restored or
returned, the Notes shall, to the fullest extent permitted by law, be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned. 

  
 -91-

 (f) In case any provision of any Note Guaranty shall be invalid, illegal or unenforceable,
the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

(g) Each payment to be made by a Guarantor in respect of its Note Guaranty shall be made without set-off, counterclaim, reduction or
diminution of any kind or nature. 
 (h) Each Guarantor acknowledges that it will receive direct and indirect benefits from the
financing arrangements contemplated by this Indenture and that the guarantee and waivers made by it pursuant to its Note Guaranty are knowingly made in contemplation of such benefits. 

Section 11.02 Limitation on Guarantor Liability. Each Guarantor, and by its acceptance of Notes, each Holder, hereby confirms
that it is the intention of all such parties that the Note Guaranty of such Guarantor not constitute a fraudulent transfer or conveyance for purposes of Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or
any similar federal or state law to the extent applicable to any Note Guaranty. To effectuate the foregoing intention, the Trustee, the Holders and the Guarantors hereby irrevocably agree that the obligations of such Guarantor will be limited to the
maximum amount that will, after giving effect to such maximum amount and all other contingent and fixed liabilities of such Guarantor that are relevant under such laws, and after giving effect to any collections from, rights to receive contribution
from or payments made by or on behalf of any other Guarantor in respect of the obligations of such other Guarantor under this Article XI, result in the obligations of such Guarantor under its Note Guaranty not constituting a fraudulent transfer
or conveyance. 
 Section 11.03 Execution and Delivery of Note Guaranty. 

To evidence its Note Guaranty set forth in Section 11.01 hereof, each Guarantor hereby agrees that a notation of such Note Guaranty
substantially in the form attached as Exhibit B hereto will be endorsed by such Guarantor on each Note authenticated and delivered by the Trustee. 
 Each Guarantor hereby agrees that its Note Guaranty set forth in Section 11.01 hereof will remain in full force and effect notwithstanding any failure to endorse on each Note a notation of such Note
Guaranty. 
 If an officer of a Guarantor whose signature is on this Indenture or on any notation of the Note Guaranty no longer
holds that office at the time the Trustee authenticates the Note on which a notation of the Note Guaranty is endorsed, the Note Guaranty will be valid nevertheless. 
 The delivery of any Note by the Trustee, after the authentication thereof hereunder, will constitute due delivery of the notation of Note Guaranty endorsed on such Note on behalf of the Guarantors.

  
 -92-

 Section 11.04 Guarantors May Consolidate, etc., on Certain Terms. 

(a) Except for a Guarantor whose obligations under its Note Guaranty are to be released as provided in Section 11.05(a) hereof, no
Guarantor may consolidate with or merge with or into (whether or not such Guarantor is the surviving Person) another Person, other than the Company or another Guarantor, unless: 

(1) the Person (if other than such Guarantor) formed by or surviving any such consolidation or merger expressly assumes
all the obligations of that Guarantor under (i) its Note Guaranty pursuant to a supplemental indenture, executed and delivered to the Trustee, and (ii) to the extent applicable, the Security Documents pursuant to supplements thereto,
executed and delivered to the Collateral Agent; 
 (2) after giving effect to such transaction, no Default or
Event of Default exists; and 
 (3) the Company shall have, at or prior to the date of such consolidation or
merger, delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that such consolidation or merger complies with this Section 11.04 and, if a supplemental indenture and/or supplements to Security Documents
are required in connection with such transaction, such supplemental indenture and/or supplements comply with this Section 11.04, and that all conditions precedent herein provided for relating to such transaction have been complied with.

 The foregoing clause (2) shall not apply to any merger or consolidation of a Guarantor with or into any Subsidiary of the Company that
is not a Guarantor. 
 (b) Upon any consolidation of a Guarantor with, or merger of a Guarantor into, any other Person in
accordance with Section 11.04(a), the successor Person formed by such consolidation or into which such Guarantor is merged shall succeed to, and be substituted for, and may exercise every right and power of, such Guarantor under the Note
Documents with the same effect as if it had been named as a Guarantor therein. Such successor Person thereupon may cause to be signed any or all of the Note Guaranties to be endorsed upon all of the Notes issuable hereunder which theretofore shall
not have been signed by the Company and delivered to the Trustee. All the Note Guaranties so issued will in all respects have the same legal rank and benefit under this Indenture as the Note Guaranties theretofore and thereafter issued in accordance
with the terms of this Indenture as though all of such Note Guaranties had been issued at the date of the execution hereof. 

Section 11.05 Releases. 
 (a) In the event the Equity Interests of any Guarantor is sold or otherwise disposed of (including by way of consolidation or merger) to a Person that is not (either before or after giving effect to such
transaction) the Company or a Restricted Subsidiary of the Company, then such Guarantor will be automatically released and relieved of any obligations under its Note Guaranty, provided that, subject to the terms of the Intercreditor
Agreement, the Net Proceeds of such sale or other disposition are applied in accordance with Section 4.10 hereof and, to the extent applicable, the Company complies with Article V hereof. 

  
 -93-

 (b) Upon designation of any Restricted Subsidiary that is a Guarantor as an Unrestricted
Subsidiary in accordance with the terms of this Indenture, such Guarantor will be automatically released and relieved of any obligations under its Note Guaranty. 
 (c) Upon Legal Defeasance or Covenant Defeasance in accordance with Article VIII hereof or satisfaction and discharge of this Indenture in accordance with Article XII hereof, each Guarantor will
be automatically released and relieved of any obligations under its Note Guaranty. 
 Any Guarantor not released from its
obligations under its Note Guaranty as provided in this Section 11.05 will remain liable for the full amount of principal of and interest on the Notes and for the other obligations of such Guarantor under this Indenture as provided in this
Article XI. 
 ARTICLE XII 
 SATISFACTION AND DISCHARGE OF INDENTURE 
 Section 12.01 Satisfaction and
Discharge of Indenture. This Indenture shall cease to be of further force and effect, and the Trustee, on demand of and at the expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture,
when either: 
 (A) all Notes theretofore authenticated and delivered (other than (i) Notes which have been
destroyed, lost or stolen and which have been replaced or paid as provided in Section 2.07 and (ii) Notes for whose payment money has theretofore been deposited in trust and thereafter repaid to the Company as provided in
Section 12.03) have been delivered to the Trustee for cancellation; or 
 (B) all Notes not theretofore
delivered to the Trustee for cancellation, 
 (i) have become due and payable, 

(ii) will become due and payable at the Final Maturity Date within one year, or 

(iii) are to be called for redemption within one year under arrangements reasonably satisfactory to the Trustee for the
giving of notice of redemption by the Trustee in the name, and at the expense, of the Company; 
 provided, in the case of
clause (B), that 
 (1) the Company or any Guarantor has deposited with the Trustee or a Paying Agent (other
than the Company or any of its Affiliates) as trust funds in trust for the purpose of and in an amount sufficient to pay and discharge in respect of all Notes not theretofore delivered to the Trustee for cancellation, the principal thereof and
interest thereon to the date of such deposit (in the case of Notes which have become due and 

  
 -94-

 
payable) or to the Final Maturity Date or Redemption Date, as the case may be. In the event that the Company exercises its right to redeem the Notes as provided in Article III, the Company
shall have the right to withdraw its funds previously deposited with the Trustee or Paying Agent pursuant to the immediately preceding sentence; 
 (2) the Company or any Guarantor has paid or caused to be paid all other sums payable hereunder by the Company; and 
 (3) the Company has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein relating to the satisfaction and discharge of this
Indenture have been complied with. 
 The Collateral will be released from the Lien securing the Note Obligations as provided in
Section 10.03 upon a satisfaction and discharge in accordance with the provisions of this Section 12.01. 

Section 12.02 Application of Trust Money. Subject to the provisions of Section 12.03, the Trustee or a Paying Agent
shall hold in trust, for the benefit of the Holders, all money deposited with it pursuant to Section 12.01 and shall apply the deposited money in accordance with this Indenture and the Notes to the payment of the principal of and interest on
the Notes. 
 Section 12.03 Repayment to Company. 

(a) The Trustee and each Paying Agent shall promptly pay to the Company upon request any excess money (1) deposited with them
pursuant to Section 12.01 and (2) held by them at any time. 
 (b) The Trustee and each Paying Agent shall, subject to
applicable abandonment property laws, pay to the Company upon request any money held by them for the payment of principal or interest that remains unclaimed for two years after a right to such money has matured; provided, however, that
the Trustee or such Paying Agent, before being required to make any such payment, may at the expense of the Company cause to be mailed to each Holder entitled to such money notice that such money remains unclaimed and that after a date specified
therein, which shall be at least 30 days from the date of such mailing, any unclaimed balance of such money then remaining will be repaid to the Company. After payment to the Company, Holders entitled to money must look to the Company for payment as
general creditors unless an applicable abandoned property law designates another person. 
 Section 12.04
Reinstatement. 
 (a) If the Trustee or any Paying Agent is unable to apply any money in accordance with
Section 12.02 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, then the Company’s and the Guarantors’
obligations under this Indenture, the Notes and the other Note Documents shall be revived and reinstated as though no deposit had occurred pursuant to Section 12.01 until such time as the Trustee or such Paying Agent is permitted to apply all
such money in accordance with Section 12.02; provided, however, that if the Company has made any payment of the principal of or interest on any Notes because of the 

  
 -95-

 
reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Notes to receive any such payment from the money held by the Trustee or such Paying Agent.

 (b) If pursuant to the last sentence of Section 12.01(a)(1), the Company withdraws its previously deposited funds as a
result of its exercise of its redemption right, the Company’s obligations under this Indenture and the Notes shall be revived and reinstated as though no deposit has occurred pursuant to Section 12.01. 

ARTICLE XIII 

MISCELLANEOUS 

Section 13.01 Trust Indenture Act Controls. If any provision of this Indenture limits, qualifies or conflicts with the duties
imposed by any of Sections 310 to 317, inclusive, of the TIA through operation of Section 318(c) thereof, such imposed duties shall control. 
 Section 13.02 Notices. Any demand, authorization notice, request, consent or communication shall be given in writing and delivered in person or mailed by first-class mail, postage prepaid, or
by guaranteed overnight courier, addressed as follows or transmitted by facsimile transmission (confirmed by delivery in person or mail by first-class mail, postage prepaid, or by guaranteed overnight courier) to the following facsimile numbers:

 If to the Company and/or any Guarantor, to: 
 Hutchinson Technology Incorporated 
 40 West Highland Park Drive NE 

Hutchinson, Minnesota 55350-9784 
 Attention: Investor Relations 
 Fax: (320) 587-1810 

if to the Trustee, to: 
 Wells Fargo Bank, National Association 
 MAC N9311-110 

625 Marquette Avenue 
 Minneapolis, Minnesota 55479 
 Attention: Hutchinson Administrator 

Such notices or communications shall be effective when received. 

The Company, any Guarantor or the Trustee by notice to the other may designate additional or different addresses for subsequent notices
or communications. 
 Any notice or communication mailed to a Holder of a Note shall be mailed by first-class mail or delivered
by an overnight delivery service to it at its address shown on the register kept by the Primary Registrar. 

  
 -96-

 Failure to mail a notice or communication to a Holder of a Note or any defect in it shall
not affect its sufficiency with respect to other Holders of Notes. If a notice or communication to a Holder of a Note is mailed in the manner provided above within the time prescribed, it is duly given, whether or not the addressee receives it.

 If the Company mails any notice to a Holder of a Note, it shall mail a copy to the Trustee and each Registrar and Paying
Agent. 
 Notwithstanding any other provision of this Indenture or any Note, where this Indenture or any Note provides for
notice of any event (including any notice of redemption or repurchase) to a Holder of a Global Note (whether by mail or otherwise), such notice shall be sufficiently given if given to the Depositary as such Holder (or its designee) pursuant to the
standing instructions from the Depositary or its designee. 
 Section 13.03 Communications by Holders with Other
Holders. Holders of Notes may communicate pursuant to TIA Section 312(b) with other Holders of Notes with respect to their rights under this Indenture or the Notes. The Company, the Trustee, the Registrar and any other person shall have the
protection of TIA Section 312(c). 
 Section 13.04 Certificate and Opinion as to Conditions Precedent.
(a) Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee at the request of the Trustee: 

(1) an Officers’ Certificate stating that, in the opinion of the signers, all conditions precedent (including any
covenants, compliance with which constitutes a condition precedent), if any, provided for in this Indenture relating to the proposed action have been complied with; and 

(2) an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent (including any
covenants, compliance with which constitutes a condition precedent) have been satisfied. 
 (b) Each Officers’ Certificate
and Opinion of Counsel with respect to compliance with a condition or covenant provided for in this Indenture shall include: 
 (1) a statement that the person making such certificate or opinion has read such covenant or condition; 
 (2) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; 

(3) a statement that, in the opinion of such person, he or she has made such examination or investigation as is necessary
to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

  
 -97-

 (4) a statement as to whether or not, in the opinion of such person, such
condition or covenant has been complied with; 
 provided, however, that with respect to matters of fact an Opinion of Counsel may
rely on an Officers’ Certificate or certificates of public officials. 
 Section 13.05 Record Date for Vote or
Consent of Holders of Notes. The Company (or, in the event deposits have been made pursuant to Section 12.01, the Trustee) may set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action
by vote or consent authorized or permitted under this Indenture, which record date shall not be more than 30 days prior to the date of the commencement of solicitation of such action. Notwithstanding the provisions of Section 9.04, if a record
date is fixed, those persons who were Holders of Notes at the close of business on such record date (or their duly designated proxies), and only those persons, shall be entitled to take such action by vote or consent or to revoke any vote or consent
previously given, whether or not such persons continue to be Holders after such record date. 
 Section 13.06 Rules by
Trustee, Paying Agent and Registrar. The Trustee may make reasonable rules (not inconsistent with the terms of this Indenture) for action by or at a meeting of Holders. Any Registrar or Paying Agent may make reasonable rules for its functions.

 Section 13.07 Legal Holidays. A “Legal Holiday” is a Saturday, Sunday or a day on which state or
federally chartered banking institutions in New York, New York, Chicago, Illinois or Minneapolis, Minnesota are authorized or obligated to close. If a payment date is a Legal Holiday, payment shall be made on the next succeeding day that is not a
Legal Holiday, and no interest shall accrue for the intervening period. If a Regular Record Date is a Legal Holiday, the record date shall not be affected. 
 Section 13.08 Governing Law. This Indenture and the Notes shall be governed by, and construed in accordance with, the internal laws of the State of New York. 

Section 13.09 No Adverse Interpretation of Other Agreements. This Indenture may not be used to interpret another indenture,
loan or debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture. 
 Section 13.10 No Recourse Against Others. All liability described in paragraph 15 of the Notes of any director, officer, employee or shareholder, as such, of the Company hereby is waived
and released by each of the Holders. 
 Section 13.11 Successors. All agreements of the Company in this Indenture
and the Notes shall bind its successor. All agreements of the Trustee in this Indenture shall bind its successor. All agreements of each Guarantor in this Indenture will bind its successors, except as otherwise provided in Section 11.05 hereof.

 Section 13.12 Multiple Counterparts. The parties may sign multiple counterparts of this Indenture. Each signed
counterpart shall be deemed an original, but all of them together represent the same agreement. 

  
 -98-

 Section 13.13 Separability. If any provisions in this Indenture or in the Notes
shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 Section 13.14 Table of Contents, Headings, Etc. The table of contents, cross-reference sheet and headings of the Articles and Sections of this Indenture have been inserted for convenience of
reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 
 Section 13.15 Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of
the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the “Specified Courts”), and each party hereto, and each Holder of a Note by
its acceptance thereof, irrevocably submits to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or
rule of court) to such party’s or Holder’s address set forth or referred to in Section 13.02 above shall be effective service of process for any such suit, action or other proceeding brought in any such court. Each party hereto, and
each Holder of a Note by its acceptance thereof, irrevocably and unconditionally waives any objection to the laying of venue of any such suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees
not to plead or claim in any such court that any such suit, action or other proceeding has been brought in an inconvenient forum. 
 [SIGNATURE PAGE FOLLOWS] 

  
 -99-

 IN WITNESS WHEREOF, the parties hereto have hereunto set their hands as of the date and year
first above written. 
  

			
	HUTCHINSON TECHNOLOGY INCORPORATED
		
	By:	 	 /s/ David P. Radloff

		 	Name: David P. Radloff
		 	Title: CFO
	
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,
 solely as Trustee hereunder and not in its individual capacity

		
	By:	 	 /s/ Richard Prokosch

		 	Name: Richard Prokosch
		 	Title: Vice President

  

			
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,
 solely as Collateral Agent hereunder and not in its individual capacity

		
	By:	 	 /s/ Richard Prokosch

		 	Name: Richard Prokosch
		 	Title: Vice President

 [Signature Page to Indenture] 

  

 EXHIBIT A 
 [FORM OF FACE OF NOTE] 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER
USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS
REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS
AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN CERTIFICATED FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.* 
  

	*	This legend should be included only if the Note is issued in global form. 

  
 A-1

 HUTCHINSON TECHNOLOGY INCORPORATED 

8.50% Senior Secured Second Lien Notes due 2017 
  

					
	No. [            ]	  		  	CUSIP:                     

 Hutchinson Technology Incorporated, a Minnesota corporation, promises to pay to
                     or registered assigns the principal amount of
                    ($        )[, as such amount may be adjusted in accordance with the Schedule of Exchanges
of Interests in the Global Note attached hereto,]* on January 15, 2017. 
 This Note shall bear interest as specified on
the other side of this Note. 
 Additional provisions of this Note are set forth on the other side of this Note. 

Dated: 
 [SIGNATURE PAGE
FOLLOWS] 
  

	*	The reference to the Schedule of Exchanges of Interests in the Global Note should only be included if the Note is issued in global form. 

  
 A-2

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	HUTCHINSON TECHNOLOGY INCORPORATED
		
	By:	 	  

		 	Name:
		 	Title:

 Dated: 

Trustee’s Certificate of Authentication: This is one of the 
 Notes referred to in the within-mentioned Indenture. 
 WELLS FARGO BANK, NATIONAL ASSOCIATION,

 solely as Trustee hereunder and not in its individual capacity 

 

			
	By:	 	  

		 	Authorized Signatory

  
 A-3

 [FORM OF REVERSE SIDE OF NOTE] 

HUTCHINSON TECHNOLOGY INCORPORATED. 
 8.50% SENIOR SECURED SECOND LIEN NOTES DUE 2017 
  

	1.	INTEREST 

 Hutchinson Technology
Incorporated, a Minnesota corporation (the “Company”, which term shall include any successor corporation under the Indenture hereinafter referred to), promises to pay interest on the principal amount of this Note from
                    or from the most recent Interest Payment Date (as defined below) to which interest has been paid or duly provided for at the rate
of 8.50% per annum. The Company shall pay interest semiannually on January 15 and July 15 of each year (each an “Interest Payment Date”), commencing
                    . Each payment of interest will include interest accrued through the day before the relevant Interest Payment Date (or Redemption
Date, Purchase Date or Change of Control Payment Date, as the case may be). Cash interest will be computed on the basis of a 360-day year comprised of twelve 30-day months. 
 No sinking fund is provided for the Notes. 
  

	2.	METHOD OF PAYMENT 

 The Company
shall pay interest on this Note to the Person who is the Holder of this Note at the close of business on January 1 or July 1, as the case may be (each, a “Regular Record Date”), next preceding the related Interest Payment Date.
Payment of the principal of and interest on this Note shall be made at the office or agency of the Company maintained for that purpose at the Corporate Trust Office of the Trustee in such coin or currency of the United States of America as at the
time of payment is legal tender for payment of public and private debts; provided, however, that at the option of the Company payment of interest may be made through the Paying Agent by check mailed to the address of the Person
entitled thereto as such address appears in the Registrar; provided further that a Holder of Notes in an aggregate principal amount in excess of $2.0 million will be paid interest on such Notes by wire transfer in immediately available
funds at the election of such Holder if such Holder has provided wire transfer instructions to the Trustee at least 10 Business Days prior to the Interest Payment Date. Any wire transfer instructions received by the Trustee will remain in effect
until revoked by the Holder. 
  

	3.	PAYING AGENT AND REGISTRAR 

Initially, Wells Fargo Bank, National Association (the “Trustee”, which term shall include any successor trustee under the
Indenture hereinafter referred to) will act as Paying Agent and Registrar. The Company may change any Paying Agent or Registrar without notice to the Holder. The Company or any of its Subsidiaries may, subject to certain limitations set forth in the
Indenture, act as Paying Agent or Registrar. 

  
 A-4

	4.	INDENTURE, LIMITATIONS 

 This
Note is one of a duly authorized issue of Notes of the Company designated as its 8.50% Senior Secured Second Lien Notes Due 2017 (the “Notes”), issued under an Indenture dated as of
            , 2012 (together with any supplemental indentures thereto, the “Indenture”), between the Company and the Trustee. The terms of this Note include those stated in the
Indenture and those required by or made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended, as in effect on the date of the Indenture. This Note is subject to all such terms, and the Holder of this Note is referred to
the Indenture and said Act for a statement of them. Capitalized terms used in this Note shall have the meanings assigned to them in the Indenture unless otherwise indicated. 
 The Notes and other Note Obligations are secured on a second priority basis (subject to Priority Liens and Permitted Prior Liens) by Liens on substantially all of the assets (other than Excluded Assets)
of the Company, subject to the terms of the Indenture, the Security Documents and the Intercreditor Agreement. 
 If, after the
date of this Indenture, the Company or any Restricted Subsidiary of the Company forms or acquires any Domestic Subsidiary that is a Wholly Owned Restricted Subsidiary, the Notes will be guaranteed by such Domestic Subsidiary and the Notes and other
Note Obligations will be secured on a second priority basis (subject to Priority Liens and Permitted Prior Liens) by Liens on substantially all of the assets (other than Excluded Assets) of such Domestic Subsidiary, subject to the terms of the
Indenture, the Security Documents and the Intercreditor Agreement. 
 If, after the date of the Indenture, any Restricted
Subsidiary that is not a Guarantor guarantees or provides credit support for (other than by granting Liens on its assets) any Priority Lien Obligations, the Notes will be guaranteed by such Restricted Subsidiary, subject to the terms of the
Indenture. 
 If, after the date of the Indenture, the Priority Lien Debt is secured by Liens on any assets of the Company or
its Restricted Subsidiaries not theretofore subject to a Priority Lien (other than Rule 3-16 Excluded Assets, but including any other Excluded Assets), the Notes and other Note Obligations will be secured on a second priority basis (subject to
Priority Liens and Permitted Prior Liens) by Liens on such assets, subject to the terms of the Indenture, the Security Documents and the Intercreditor Agreement. 
  

	5.	REDEMPTION AT THE OPTION OF THE COMPANY 

 The Company may at any time on any one or more occasions redeem all or a part of the Notes, upon not less than 30 nor more than 60 days’ notice, at a redemption price equal to 100% of the principal
amount of the Notes redeemed, plus the Applicable Premium as of, and accrued and unpaid interest on the principal amount of the Notes redeemed to, the Redemption Date. 
 “Applicable Premium” means, with respect to any Note on any Redemption Date, the excess of: (a) the present value at such Redemption Date of (i) the principal amount of the Note
redeemed plus (ii) all required interest payments due on such principal amount from such 

  
 A-5

 
Redemption Date through January 15, 2017 (excluding accrued but unpaid interest to the Redemption Date), computed using a discount rate equal to the Treasury Rate as of such Redemption Date
plus 50 basis points; over (b) the principal amount of the Note redeemed. 
 Unless the Company defaults in the payment of
the Redemption Price, interest will cease to accrue on the Notes or portions thereof call for redemption on the applicable Redemption Date. 
  

	6.	NOTICE OF REDEMPTION 

 Notice of
redemption, as set forth in Section 3.03 of the Indenture, will be mailed by first-class mail at least 30 days but not more than 60 days before a Redemption Date to each Holder of Notes to be redeemed at its registered address. Notes in
denominations larger than $2,000 may be redeemed in part, but only in whole multiples of $1,000 in excess thereof. On and after the Redemption Date, subject to the deposit with the Paying Agent of funds sufficient to pay the Redemption Price, such
Notes or portions of them called for redemption will cease to be outstanding, whether or not the Note is delivered to the Paying Agent, and the rights of the Holder in respect thereof shall cease (other than the right to receive the Redemption
Price). 
  

	7.	CHANGE IN CONTROL AND SALE OF ASSETS 

 Upon the occurrence of (a) a Change in Control, each Holder shall have the right to require the Company to repurchase all or part of such Holder’s Notes at a purchase price in cash equal to 101%
of the principal amount of the Notes repurchased plus accrued and unpaid interest on such principal amount to the date of purchase, and (b) an Asset Sale, the Company may be obligated to make an offer to purchase the Notes from the Holders with
Excess Proceeds of such Asset Sale at a purchase price equal to 100% of the principal amount of such Notes plus accrued interest on such principal amount to the date of purchase; all as provided in, and subject to the terms of, the Indenture.

  

	8.	DENOMINATIONS, TRANSFER, EXCHANGE 

The Notes are in registered form, without coupons, in denominations of $2,000 principal amount and integral multiples of $1,000 principal
amount in excess thereof. A Holder may register the transfer of or exchange Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay any
taxes or other governmental charges that may be imposed in relation thereto by law or permitted by the Indenture. 
  

	9.	PERSONS DEEMED OWNERS 

 The
Holder of a Note may be treated as the owner of it for all purposes. 
  

	10.	UNCLAIMED MONEY 

 Subject to
applicable abandonment property laws, if money for the payment of principal or interest remains unclaimed for two years, the Trustee and any Paying Agent will pay the 

  
 A-6

 
money back to the Company at its written request, subject to applicable unclaimed property law and the provisions of the Indenture. After that, Holders entitled to money must look to the Company
for payment as general creditors unless an applicable abandoned property law designates another person. 
  

	11.	AMENDMENT, SUPPLEMENT AND WAIVER 

Subject to certain exceptions, the Note Documents and the Intercreditor Agreement may be amended or supplemented with the consent of the
Holders of at least a majority in aggregate principal amount of the Notes then outstanding, and an existing Default or Event of Default and its consequence or compliance with any provision of the Note Documents and the Intercreditor Agreement may be
waived in a particular instance with the consent of the Holders of a majority in aggregate principal amount of the Notes then outstanding. Without the consent of or notice to any Holder, the Company and other counterparties thereto may amend or
supplement the Note Documents and the Intercreditor Agreement to, among other things, cure any ambiguity, defect or inconsistency or make any other change that does not adversely affect the rights of the Holders in any material respect. 

 

	12.	SUCCESSOR ENTITY 

 When a
successor entity assumes all the obligations of its predecessor under the Note Documents in accordance with the terms and conditions of the Indenture, the predecessor entity shall be released from those obligations. 

 

	13.	DEFAULTS AND REMEDIES 

 Events of
Default are set forth in the Indenture. If an Event of Default (other than an Event of Default resulting from certain events of bankruptcy or insolvency as described below) occurs and is continuing, the Trustee may, by notice to the Company, or the
Holders of at least 25% in aggregate principal amount of the Notes then outstanding may, by notice to the Company and the Trustee, declare the principal amount of, and accrued and unpaid interest to the date of declaration on, all the Notes to be
immediately due and payable. Upon such a declaration, such principal amount and such accrued and unpaid interest shall be due and payable immediately. Certain events of bankruptcy or insolvency are Events of Default and shall result in the Notes
being immediately due and payable without any declaration or other act on the part of the Trustee or any Holders of Notes. The Holders of a majority in aggregate principal amount of the Notes then outstanding by notice to the Trustee may rescind an
acceleration and its consequences if (a) all existing Events of Default, other than the nonpayment of the principal of the Notes which have become due solely by such declaration of acceleration, have been cured or waived; (b) the
rescission would not conflict with any judgment or decree of a court of competent jurisdiction; and (c) all payments due to the Trustee and any predecessor Trustee under the Indenture have been made. No such rescission shall affect any
subsequent Event of Default or impair any right consequent thereto. Holders may not enforce the Note Documents except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before it enforces the Note Documents. Subject
to certain limitations, Holders of a majority in aggregate principal amount of the Notes then outstanding may direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders notice of any continuing Default or Event
of Default 

  
 A-7

 
(except a Default in payment of principal or interest) if and so long as it determines that withholding notice is in their interests. The Company is required to file periodic certificates with
the Trustee as to the Company’s compliance with the Indenture and knowledge or status of any Default or Event of Default. 
  

	14.	TRUSTEE DEALINGS WITH THE COMPANY 

Wells Fargo Bank, National Association, the initial Trustee under the Indenture, in its individual or any other capacity, may make loans
to, accept deposits from and perform services for the Company or an Affiliate of the Company, and may otherwise deal with the Company or an Affiliate of the Company, as if it were not the Trustee. 

 

	15.	NO RECOURSE AGAINST OTHERS 

 A
director, officer, employee or shareholder, as such, of the Company or any Guarantor shall not have any liability for any obligations of the Company or the Guarantors under any Note Documents nor for any claim based on, in respect of or by reason of
such obligations or their creation. The Holder of this Note by accepting this Note waives and releases all such liability. The waiver and release are part of the consideration for the issuance of this Note. 

 

	16.	AUTHENTICATION 

 This Note shall
not be valid until the Trustee or an authenticating agent manually signs the certificate of authentication on the other side of this Note. 
  

	17.	ABBREVIATIONS AND DEFINITIONS 

Customary abbreviations may be used in the name of the Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants
by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST 
 (= Custodian) and UGMA (= Uniform
Gifts to Minors Act). 
 All terms defined in the Indenture and used in this Note but not specifically defined herein are
defined in the Indenture and are used herein as so defined. 
  

	18.	INDENTURE TO CONTROL; GOVERNING LAW 

 In the case of any conflict between the provisions of this Note and the Indenture, the provisions of the Indenture shall control. This Note and the Indenture shall be governed by, and construed in
accordance with, the laws of the State of New York. 
  

	19.	INTERCREDITOR AGREEMENT 

Anything herein to the contrary notwithstanding, the liens and security interests securing the obligations evidenced by this Note and the
exercise of any right or remedy with respect thereto are subject to the provisions of the PNC Intercreditor Agreement and any Additional Intercreditor Agreement. In the event of any conflict between the terms of the PNC Intercreditor Agreement and
this Note, the terms of the PNC Intercreditor Agreement shall govern and 

  
 A-8

 
control. In the event of any conflict between the terms of any Additional Intercreditor Agreement and this Note, the terms of such Additional Intercreditor Agreement shall govern and control.

  
 A-9

 ASSIGNMENT FORM 
 To assign this Note, fill in the form below: 
 I or we assign and transfer this
Note to 
  
  

(Insert assignee’s social security or tax I.D. number) 

 
  
  

 
  

 
 (Print or type assignee’s
name, address and zip code) 
 and irrevocably appoint 
  

 
 agent to transfer this Note on the books of the
Company. The agent may substitute another to act for him or her. 
  

							
		 		 		 	Your Signature
				
	Date:	 	  
	 		 	  

		 		 		 	(Sign exactly as your name appears on the other side of this Note)
			
	*Signature guaranteed by:	 		 	
				
	By:	 	  
	 		 	

  
  

	*	The signature must be guaranteed by an institution which is a member of one of the following recognized signature guaranty programs: (i) the Securities Transfer
Agent Medallion Program (STAMP); (ii) the New York Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program acceptable to the Trustee. 

  
 A-10

 OPTION OF HOLDER TO
ELECT PURCHASE 
 If you want to elect to have this Note purchased by the Company pursuant to
Section 4.10 or 4.15 of the Indenture, check the appropriate box below: 
  

					
	  ̈ Section 4.10
	  		  	 ̈ Section 4.15

 If you want to elect to have only part of the Note purchased by the Company pursuant to Section 4.10
or 4.15 of the Indenture, state the amount you elect to have purchased: 

$             

 

									
	Date:	 		 		 		 	
					
		 		 		 	 Your

Signature:
	 	  

		 		 		 		 	(Sign exactly as your name appears on the face of this Note)
					
		 		 		 	Tax	 	
	Signature	 		 		 	Identification	 	
	Guarantee*:	 		 		 	No.:	 	

  

	*	Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to the Trustee). 

  
 A-11

 SCHEDULE OF EXCHANGES OF
INTERESTS IN THE GLOBAL NOTE* 
 The following
exchanges of a part of this Global Note for an interest in another Global Note or for a Certificated Note, or exchanges of a part of another Global Note or Certificated Note for an interest in this Global Note, have been made: 

 

									
	 Date of Exchange
	 	Amount of
decrease in
Principal Amount
of this Global Note	 	Amount of increase
in 
Principal
Amount of this
Global Note	 	Principal Amount
of this Global 
Note
following such
decrease
(or
increase)	 	Signature of
authorized 
officer
of Trustee or
Custodian
		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  

	*	This schedule should be included only if the Note is issued in global form. 

  
 A-12

 EXHIBIT B 
 FORM OF NOTATION OF GUARANTY 
 For value received, each Guarantor (which term
includes any successor Person under the Indenture) has, jointly and severally, unconditionally guaranteed, to the extent set forth in and subject to the provisions of the Indenture dated as of
            , 2012 (the “Indenture”) among Hutchinson Technology Incorporated (the “Company”), the Guarantors party thereto and Wells Fargo Bank, N.A., as trustee (the
“Trustee”), the due and punctual payment of the principal of and interest on the Notes, whether at maturity, by acceleration, redemption or otherwise, and the due and punctual performance of all other obligations of the Company to the
Holders or the Trustee under the Notes or the Indenture, all in accordance with the terms of the Indenture. The obligations of the Guarantors to the Holders of Notes and to the Trustee pursuant to the Note Guaranty and the Indenture are expressly
set forth in Article XI of the Indenture and reference is hereby made to the Indenture for the precise terms of the Note Guaranty. Each Holder of a Note, by accepting the same, agrees to and shall be bound by such provisions. 

Capitalized terms used but not defined herein have the meanings given to them in the Indenture. 

 

			
	[NAME OF GUARANTORS]
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 B-1

 EXHIBIT C 
 FORM OF SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSEQUENT GUARANTORS 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of
                    , among                     
(the “Guarantying Subsidiary”), a subsidiary of Hutchinson Technology Incorporated (or its permitted successor), a Minnesota corporation (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to
herein) and Wells Fargo Bank, N.A., as trustee under the Indenture referred to below (the “Trustee”). 
 W I T N E S S
E T H 
 WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the “Indenture”),
dated as of             , 2012 providing for the issuance of 8.50% Senior Secured Second Lien Notes due 2017 (the “Notes”); 

WHEREAS, the Indenture provides that under certain circumstances the Guarantying Subsidiary shall execute and deliver to the Trustee a
supplemental indenture pursuant to which the Guarantying Subsidiary shall unconditionally guarantee all of the Company’s obligations under the Notes and the Indenture on the terms and conditions set forth in the Indenture (the “Note
Guaranty”); and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and
deliver this Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the Guarantying Subsidiary and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to
them in the Indenture. 
 2. AGREEMENT TO GUARANTY. The Guarantying Subsidiary
hereby agrees to provide an unconditional guarantee on the terms and subject to the conditions set forth in the Note Guaranty and in the Indenture including but not limited to Article XI thereof. 

4. NO RECOURSE AGAINST OTHERS. No director, officer, employee or shareholder,
as such, of the Guarantying Subsidiary will have any liability for any obligations of the Company or the Guarantors under the Note Documents or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder
of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. 

  
 C-1

 5. NEW YORK LAW TO GOVERN. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED
IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK. 
 6. COUNTERPARTS. The parties may sign any
number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 7. EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof. 

8. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the
validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guarantying Subsidiary and the Company. 

  
 C-2

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed and attested, all as of the date first above written. 
  

					
	 Dated:             ,
	  		 	
		
		  	[GUARANTYING SUBSIDIARY]
			
		  	By:	 	  

		  		 	Name:
		  		 	Title:
		
		  	[COMPANY]
			
		  	By:	 	  

		  		 	Name:
		  		 	Title:
		
		  	WELLS FARGO BANK, N.A., as Trustee
			
		  	By:	 	  

		  	Authorized Signatory

  
 C-3

 EXHIBIT D 
 FORM OF PRIVATE PLACEMENT LEGEND 
 Each Restricted Certificated Note shall bear
the following legend (the “Private Placement Legend”) on the face thereof unless otherwise agreed by the Company and the Holder thereof or if such legend is no longer required as contemplated by Section 2.12(d) of the Indenture:

 THIS NOTE (OR ITS PREDECESSOR) WAS ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES
SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND THIS NOTE MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS NOTE IS HEREBY NOTIFIED THAT
THE SELLER OF THIS NOTE MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER. 
 THE HOLDER OF THIS NOTE AGREES FOR THE BENEFIT OF THE COMPANY AND THE GUARANTORS THAT (A) THIS NOTE MAY BE OFFERED, RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (I) SO LONG AS SUCH SECURITY IS
ELIGIBLE FOR RESALE PURSUANT TO RULE 144A, IN THE UNITED STATES TO A PERSON WHOM THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) IN A TRANSACTION MEETING THE REQUIREMENTS
OF RULE 144A, (II) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 904 UNDER THE SECURITIES ACT, (III) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY RULE 144
THEREUNDER (IF AVAILABLE), (IV) PURSUANT TO ANY OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, OR (V) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH OF CASES (I) THROUGH
(IV) IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND THE OTHER REQUIREMENTS OF THE INDENTURE APPLICABLE TO RESTRICTED NOTES, AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY
ANY PURCHASER OF THIS NOTE FROM IT OF THE RESALE RESTRICTIONS REFERRED TO IN (A) ABOVE. NOTWITHSTANDING THE FOREGOING, THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THIS
NOTE, PROVIDED THAT NO SUCH PLEDGE SHALL AFFECT THE REQUIREMENTS OTHERWISE APPLICABLE TO THE TRANSFER OF THE NOTE IN ACCORDANCE WITH THE TERMS OF ANY SUCH PLEDGE, NOR SHALL ANY SUCH PLEDGE AFFECT THE MAINTENANCE OF THIS LEGEND ON THIS NOTE.

  
 D-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]